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The diverse functions of the MDM2 oncoprotein in growth control and 
tumourigenesis are managed through coordinated regulation of its discrete 
domains induced by both extrinsic and intrinsic stimuli. A picture of MDM2 is 
immerging where structurally discrete but interdependent functional domains 
are linked through changes in conformation. However compelling insights 
into how this process is carried out have been hindered by inadequate 
information on the structure and conformation of the full-length protein.  
The data presented indicates that the C-terminal RING domain of MDM2, 
primarily responsible of the E3 ubiquitin ligase activity of the protein, has 
other intriguing functions. The binding of ATP within the RING domain, 
triggers conformational changes of MDM2 and its main interaction partner – 
p53. This in effect promotes efficient binding of the p53 tumour suppressor to 
specific DNA promoter sequences. Moreover, results presented in this thesis 
demonstrate a novel role for the RING domain of MDM2 in determining the 
conformation and activity of its N-terminal hydrophobic cleft, the key target of 
anticancer drugs designed to activate the function of p53 tumour suppressor 
protein. Specific modulations within the RING domain, affecting Zinc 
coordination are synonymous with increased binding affinity of the 
hydrophobic pocket to the transactivation domain of p53 resulting in a gain of 
MDM2 transrepressor function thus leading to a decrease in p53-dependant 
gene expression. ThermoFluor measurements and size exclusion 
chromatography show that changes in the RING motif lack an effect on the 
overall integrity of the MDM2 protein. The intrinsic fluorescence 
measurements manifest that these changes generate long range 
conformational transitions that are transmitted through the core/central acidic 
domain of MDM2 resulting in allosteric regulation of the N-terminal 
hydrophobic pocket. Such RING generated conformational changes result in 
the relaxation of the hydrophobic pocket. Additionally, it is shown that the 
cooperation between the RING and the hydrophobic cleft in MDM2 has 
implications in the efficiency of binding of anticancer drugs such as Nutlin by 
MDM2. Cooperation between the RING and hydrophobic domain of MDM2 to 
regulate function demonstrates an allosteric relationship and highlights the 
need to study MDM2 in a native conformation. In essence the presented data 
demonstrates that the complex relationship between different domains of 





• Gain insight into the allosteric regulation of MDM2 protein.  
 
• Focus on a key functional domain of MDM2 - the C-terminal RING 
domain, as a potential regulator of structure and function, of the whole 
protein. 
 
• Illustrate intrinsic chaperone function of MDM2 on its main interacting 
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The experimental observations of cancers and cancer cells developed during the 
second half of the nineteenth and the first half of the twentieth century, indicated that 
tumours were nothing more than normal cell populations which had become rogue. 
Moreover, many tumours seemed to be composed of descendants of a single cell that 
had crossed the line from a physiologically normal state to malignancy and 
proceeded to spawn myriad offspring constituting neoplastic masses. 
The fundamental abnormality resulting in the development of cancer is the continual 
unregulated proliferation of cancer cells. Rather than responding appropriately to the 
signals that control normal cell behaviour, these cells grow and divide in a dynamic 
manner, forming tumour foci. Tumours can be either benign (localized, non-
invasive) or malignant (invasive, metastatic), invading normal tissues and organs and 
eventually spreading throughout the body. The metastases spawned by malignant 
tumours are responsible for almost all deaths from cancer.  The generalized loss of 
growth control facilitated by genome instability of these cells is exhibited in the net 
result of accumulated abnormalities in multiple cell regulatory systems and is 
reflected in several aspects of cell behaviour that distinguish cancer cells form their 
untransformed counterparts. 
 
Cancer can result from abnormal proliferation of virtually all cell types in the human 
body, hence there are more than a hundred distinct types of cancer, which vary 
considerably in rate of development, behaviour and response to treatment.  Most 
common human cancers are of epithelial origin – the carcinomas. These can be 
classified into two categories; squamous cell carcinomas arise from epithelia that 




Chapter 1                                                                                                   Introduction 
 
 3 
1.2 Tumour suppressors and oncogenes 
 
Cancers result from alternations in critical regulatory genes that control cell 
proliferation, differentiation and survival. Studies of tumour viruses revealed that 
specific genes (called oncogenes) are capable of inducing cell transformation, 
thereby providing the first insights into the molecular basis of cancer. In other words 
an oncogene is a gene that, when mutated or expressed at high levels, helps turn a 
normal cell into a cancer cell. The inability to find tumour viruses in the majority of 
human cancers (80%) during the Nixon anti-cancers campaign left the research field 
with one major theory of how most human cancers arise (mid 1970s); namely that 
carcinogens act as mutagens and function by mutating vital, endogenous to the 
human genome, growth-controlling proto-oncogenes into oncogenes. This hypothesis 
fuelled by an avalanche of scientific data provided a simple and powerful 
explanation of how the proliferation of cells is driven. The proteins encoded by the 
proto-oncogenes participate in various ways in receiving and processing growth-
stimulatory signals that originate in the extracellular environment. When these genes 
suffer mutation, the flow of the signal becomes deregulated. Instead of emitting them 
in carefully controlled bursts, the oncoproteins release a steady stream of growth-
stimulating signals, resulting in the unrelenting proliferation associated with cancer 
cells. 
When one applies logic to a functioning control signalling system, the conclusion can 
be drawn that process promoting components must be counterbalanced by others that 
oppose this process. Biological systems, which by far are the most complex 
signalling arrays known to man, seem to follow this logic as well.  The tumour 
suppressor genes constitute a large group of genes that specify protein products 
mediating diverse cell-physiologic functions. These proteins operate in all parts of 
the cell, and there is only one shared attribute that allows their inclusion in this gene 
grouping; in one way or another each one of these genes functions to reduce the 
likelihood that clinically detectable tumour will appear in one of the body’s tissues.  
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1.3 The p53 tumour suppressor protein  
 
The year 2009 celebrates the 30th anniversary of the discovery of p53. The p53 
protein was initially discovered as a protein interacting with the oncogenic T antigen 
from SV40 virus (DeLeo et al., 1979; Kress et al., 1979; Lane and Crawford, 1979; 
Linzer and Levine, 1979; Linzer et al., 1979; Melero et al., 1979). 
Since then three decades of intense investigation have produced a progressively 
sharper image of why the p53 tumour suppressor protein is so important for cancer 
protection. Upon the infliction of almost any cellular stress this normally short-lived 
protein accumulates and gains full competence in transcriptional activation. The p53 
transcriptional programme includes the activation of a number of cell cycle inhibitors 
leading to temporary growth arrest and pro-apoptotic proteins, which results in 
apoptosis or irreversible proliferate arrest, the later is also known as senescence.  
 
In essence the p53 tumour suppressor protein is a transcription factor, which 
regulates cellular response to stress, abnormal cell proliferation and DNA damage 
(Fuster et al., 2007; Romer et al., 2006; Sharpless and DePinho, 2002; Vogelstein et 
al., 2000). Over 50% of human tumours possess mutated TP53  (Hollstein et al., 
1999), moreover the inactivation of p53 function leads to cellular transformation 
(Hollstein et al., 1991; Levine et al., 1991). Interestingly, oncogenic mutations of 
TP53 are localized mostly in the DNA Binding Domain (DBD, p53 residues 102-
292) (Petitjean et al., 2007) of p53. This domain is responsible for physical contact 
with specific DNA sequences that reside in promoters of p53 controlled genes and 
obey the rules of the specific consensus sequence (el-Deiry et al., 1992). The DBD 
can be rendered incapable of binding to such sequences by distinct mechanisms. 
Some changes caused by TP53 mutations are known to cause a destabilization of its 
structure (class II or “structural” mutants, some of which affect the binding of the 
zinc atom, important for the DNA binding domain structure) while others directly 
disrupt its DNA contact (class I or “contact” mutants) (Bullock et al., 2000; Cho et 
al., 1994) (Figure 1.1). The N-terminal part of the p53 protein is divided into two 
transcription-inducing regions within distinct target gene specificity (residues 1-40 
and 41-63) (Venot et al., 1999) and the proline rich region (residues 64-97). These 
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domains are responsible for recruitment of cell’s transcriptional machinery elements 
to p53 responsive promoters, activation or suppression of which plays the most 
prominent role in p53-dependent anti-tumour response (Laptenko et al., 2006). The 
N-terminal p53 domain is also a site of extensive, regulatory post-translational 
modifications as well as binding of p53 modulating molecules, such as MDM2 or 
viral proteins (May and May, 1999). The C-terminal part of p53 contains two other 
domains. The physiologically relevant form of p53, efficiently binding specific DNA 
sequences, is a tetramer (McLure and Lee, 1998). The oligomerization domain 
(residues 323-356), which is relatively well structured, is responsible for 
tetramerization of p53. The extreme C-terminal domain (res. 363-393) is important 
for regulation of p53 activity, by being modified with phosphate and acetyl groups as 
well as possessing its own, unspecific DNA binding activity. Most of the data 
gathered so far suggests that this domain inhibits the specific p53 DNA-binding 
activity, and its post-translational modifications or short-DNA contacts play an 
important, although not exclusive, role in activation of otherwise latent p53 
molecules (Laptenko et al., 2006). Interestingly, the functional importance of N- and 
C-terminal p53 domains is not mirrored by the number of human tumour mutations 
detected in TP53 gene regions encoding those domains (BOX 1) (Petitjean et al., 
2007). Recently a provocative hypothesis has been suggested that mutational changes 
in the DBD – much more frequent in tumours than in any other p53 region – are not 
only inactivating p53 and acting in the dominant negative manner on wt p53 
monomer/dimer molecules, but additionally allow to obtain new, oncogenic target 
gene and interaction specificities by a gain-of-function mechanism (Strano et al., 
2007). Moreover, p53 may also be rendered inactive by other cellular events, such as 
the sequestration of wild-type p53 in the cytoplasm, due to the increased nuclear 
export (Stommel et al., 1999a; Stommel et al., 1999b), association of p53 with 
cytoplasmic proteins (Wadhwa et al., 2002) or degradation induced by ubiquitination 
mediated by the MDM2 E3 ubiquitin ligase (Moll and Petrenko, 2003).  
Numerous superlatives such as  “Guardian of the genome”, “Cellular Gatekeeper” 
and “Policeman of the oncogenes” (Efeyan and Serrano, 2007) are attributed to p53 
for its role in the suppression of human tumour development. Nevertheless from a 
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Figure 1.1 Domain localization of p53 mutations in human tumours
 
(A) Diagram representing the distribution and frequency of single nucleotide substitutions in TP53 gene 
codons found in human cancers (according to November 2007 and 2008 edition of IACR TP53 mutation 
database http://www-p53.iacr.fr) fitted against p53 protein domains. Vertical bars indicate the 
percentage of all 20828 single nucleotide substitutions in the database. Codons (corresponding to 
amino acid position within the protein primary structure) most frequently changed are additionally 
numbered. Roman numerals in the p53 domain organisation diagram represent evolutionary conserved 
motifs. 
(B) The structure of the DNA binding domain (DBD) of p53 bound to target DNA sequence; (PDB id: 
1TSR - Cho et al., 1994) p53 residues 96-289 shown as a ribbon model with secondary structure 
specific colours. Additionally six marked residues (presented as spheres) correspond to the most 
frequently changed in human tumours (see panel A). Ariginines 248,273 coloured in blue are 
responsible for direct contact of the DBD with the DNA, while amino acid residues coloured in purple 
are important for stabilization of the DBD structure conformation, which allows binding to 
tumour-suppresive p53 target gene promoters. 
A
B
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instability (Bell et al., 2002; Canadillas et al., 2006) and being largely unstructured 
(Bell et al., 2002). Around the physiological temperature range of a human body 
(35°C – 42°C), even the most structured part of purified wild-type p53 - the DBD - 
unfolds, adopts an inactive misfolded conformation and aggregates at a relatively 
high rate (Butler and Loh, 2006; Hansen et al., 1996; Muller et al., 2004). Whether 
this feature of the protein is directly required for p53’s role as an important control 
node in the network of a cellular reaction to stress, remains an open question. 
Nevertheless this intrinsic p53 instability is evolutionary conserved (Canadillas et al., 
2006; Veprintsev et al., 2006).  
The wild-type native form of p53, in spite of its relative instability under 
physiological conditions, has sufficient affinity for specific DNA sequences that 
reside in p53 controlled gene promoters (Dearth et al., 2007). In the reaction to 
stresses, such as ionizing radiation, UV and hypoxia, misregulated intracellular-
signalling caused by oncogenes,  p53 is activated, stabilized and imported into the 
nucleus, where it promotes or represses transcription of genes whose products induce 
cell cycle arrest, DNA repair or apoptosis (Figure 1.2) (Balint and Vousden, 2001). 
Under stress conditions the half-life of the p53 protein is extended due to reduced 
degradation. Under non-stress conditions, the level of p53 in the cells is mainly 
regulated at the post-translational level by MDM2 (Haupt et al., 1997; Honda et al., 
1997; Kubbutat et al., 1997; Li et al., 2003), additionally recent data suggest that this 
focal regulator of p53 also has a controlling effect on the translation of the tumour 
suppressor (Candeias et al., 2008b). In recent years the direct role of p53 post-
translational modifications in the p53 activation has been the subject of much debate, 
since several studies questioned the essential role of phosphorylation (Ashcroft et al., 
1999; Ashcroft and Vousden, 1999; Blattner et al., 1999) or acetylation (Krummel et 
al., 2005) in p53 stabilization and induction. At the same time the more subtle role 
for p53 acetylation has been discovered, governing the long unknown mechanism of 
decision-making between p53-dependent cell-cycle arrest and apoptosis (Sykes et al., 
2006; Tang et al., 2006). Other p53 regulatory mechanisms involve its interaction 
and competition with paralogues – p63 and p73 (Li and Jin, 2007), as well as with 
recently discovered protein products of alternative translation initiation and splicing 
of p53 mRNA (Bourdon et al., 2005; Yin et al., 2002).  
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As being the most frequently tumour-associated molecule in humans, p53 is an 
obvious target of potential anti-cancer therapies. Since in most tumours wt p53 is 
altered by mutations or otherwise inactivated, strategies based on overproduction of 
wt p53 have had a limited efficiency (Roth et al., 1996). A potentially more effective 
p53-related anti-cancer therapy requires methods that would attempt to inhibit gain-
of-function and dominant-negative properties of oncogenic p53 variants (often 
referred to as “mutant p53” for short), and even more importantly, the reconstitution 
of wild-type structure and function to inactivated p53 (Selivanova and Wiman, 
2007). However, it is also apparent that in healthy cells there must be a set of 
mechanisms that keep wild-type p53 in a state required for activation of its target 
genes. These mechanisms have to deal with conformation and stability maintenance  
of the  p53 DNA binding domain structure, prone to unfolding even at 37°C. 
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Figure 1.2 The p53 network
 
The p53 tumour suppressor protein is an important node in the vast  cellular network response to 
genome damage and other forms of stress. A simplified view of known components is presented above. 
Stress induction upon the cell is the first stage of p53 activation, which leads to increased p53 stability 
and affinity towards target gene promoters. Target gene expression regulated by p53 most of all to cell 
cycle arrest and/or apoptosis. Each process is controlled by protein products of several p53 induced 
genes, which modulate the progression of a given process (examples listed). The p53 protein is also 
suggested to undertake transcription-independent actions to accomplish tasks such as DNA repair or 
inhibition of angiogenesis and apoptosis. A principal feedback loop between MDM2 and p53 restrains 
this network thus supervising the accuracy and timing of the p53 response. The localization of p53 in 
the centre of this key cellular signalling network has its advantages and disadvantageous. While its 
existence facilitates the coordination of the multiplex stress response process, it also exposes the cell 
to the danger of being unable to perform this process if the central network node is deactivated.   
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1.4 MDM2 - MOUSE DOUBLE MINUTE 2 HOMOLOG 
 
It is well established that under numerous forms of cellular stress, activation of the 
p53 pathway leads to a protective outcome ensuring tissue integrity. Nevertheless, 
cellular proliferation and differentiation is indispensable for tissues to maintain their 
proper structure and function. It follows that in the absence of stress signals, there is 
a requirement to keep p53 under tight control. 
Around a decade after the discovery of the TP53 gene and the tumour suppressor 
protein it encodes, another crucial discovery was made. That was the discovery of 
MDM2 one of the numerous target genes activated by p53. However, unlike other 
p53 target gene products, the MDM2 protein does not act downstream of p53 to 
mediate the biological effects of this tumour suppressor. Rather it interacts with p53 
itself and regulates its function in a number of ways. At the present time the 
scientific community considers MDM2 as the major cellular antagonist of p53. 
 
1.4.1 Identification of the MDM2 protein and its Biological Function 
 
The murine double minute 2 (mdm2)1 (Fakharzadeh et al., 1991) was originally 
identified as one of three genes ( mdm1, 2, and 3) which were overexpressed greater 
than 50-fold by amplification in the spontaneously transformed mouse cell line 
BALB/c (3T3-DM).  The mdm2 genes were located on small, acentromeric 
extrachromosomal nuclear bodies, called double minutes, which were retained, by 
the cells only if they provided a growth advantage. A cDNA library was constructed 
using RNA from these cells and cDNA clones were isolated representing sequences 
that are amplified and overexpressed in these 3T3-DM cells. From the results of 
Northern- and Southern-blot analyses, it was concluded that these cDNAs 
represented two distinct genes, which were designated mdm-1 and mdm-2. Using 
                                                 
1 The abbreviations used throughout this thesis are MDM2, human gene and oncogene, MDM2, 
human protein and isoform; mdm2, mouse gene; Mdm2, mouse protein.   
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DNAs from a panel of Chinese hamster-mouse somatic cell hybrids together with in 
situ hybridization protocols for gene mapping studies, it was found that these DM-
associated, amplified DNA sequences originate from mouse chromosome 10, region 
C1-C3. Sequences homologous to mdm-1 and mdm-2 are present in the genomes of 
several species examined, including that of man (Cahilly-Snyder et al., 1987).  
The gene product of the mdm2 gene was later shown to be responsible for 
transformation of NIH3T3 and Rat2 cells when overexpressed (Cahilly-Snyder et al., 
1987; Fakharzadeh et al., 1991). In summary, the data presented in these two initial 
publications supports the conclusion that mdm2 represents an evolutionarily 
conserved gene with tumourigenic potential and a predicted role in mechanisms of 
cellular growth control.  
 
1.4.1.1 MDM2 and tumourigenesis 
 
Not long after the identification of the mdm2 gene, the reason for its transformation 
potential was discovered.  The protein product of this gene was shown to be a 
cellular phosphoprotein, with an apparent molecular mass of 90 kDa (Mdm2), which 
forms a tight complex with the tumour suppressor p53 and inhibits p53-mediated 
transactivation (Momand et al., 1992).  
At the same time, MDM2 gene amplification was observed in human sarcomas that 
retained wild-type p53. To determine whether the MDM2 protein plays a role in 
human cancer, Oliner and colleagues have cloned the human orthologueue of the 
mdm2 gene and showed that the recombinant derived human MDM2 protein binds 
p53 in vitro (Oliner et al., 1992). Moreover, they mapped the MDM2 gene to 
chromosome 12q13-14 (later the exact position of the gene was shown to be at 
12q14.3-q15 distal to CDK4 and flanked by Genethon microsatellites D12S80 and 
D12S83 (Mitchell et al., 1995)). Strikingly this position appeared to be altered in 
many sarcomas (Mandahl et al., 1989; Meltzer et al., 1991; Turc-Carel et al., 1986) 
with the MDM2 gene amplified in over a third of 47 sarcomas, including common 
bone and soft tissue forms. Amplification of the MDM2 gene is also present in 
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oesophageal carcinomas (Shibagaki et al., 1995), gliomas, anaplastic astrocytomas 
(Reifenberger et al., 1993; Reifenberger et al., 1994), and neuroblastomas (Corvi et 
al., 1995). Interestingly, up regulation of the MDM2 protein in cancer cells can also 
be achieved through enhanced translation of mRNA, independent of gene 
amplification (Landers et al., 1997; Landers et al., 1994). More recent data have 
shown that a naturally occurring polymorphism (SNP309) within the MDM2 
promoter leads to an increase in MDM2 mRNA and protein in human populations 
(Bond et al., 2004).  
In essence, amplification of the MDM2 gene is observed in a variety of human 
tumours. At least 5-10% of all human tumours possess inappropriate MDM2 
overexpression, due to either gene amplification or transcriptional and post-
transcriptional mechanisms (Daujat et al., 2001b; Juven-Gershon and Oren, 1999; 
Momand et al., 2000).  
 
These pioneering studies were the cornerstone of the hypothesis that overexpression 
of MDM2 was another mechanism by which the cell could inactivate p53 in the 
process of transformation. Whereas this hypothesis is clearly valid, transformation is 
more complex. Some tumours contain both high levels of MDM2 and mutations in 
the p53 gene. The reasons for disrupting two components of the same pathway are 
unclear but suggest that MDM2 may have other growth-promoting functions.  
 
1.4.2 Gene Structure and Function 
 
Both the mdm2 gene and its human orthologueue MDM2 consist of 12 exons that can 
generate many protein isoforms. Interestingly over 40 different splice variants of 
MDM2 transcripts have been identified both in tumours and normal tissues in mice 
and humans alike (for review see (Bartel et al., 2002)). In humans, MDM2-A and 
MDM2-2B are the major splice variants that delete exons 4-9 and 4-11, respectively. 
Neither of these two end protein products contain the p53-binding motif (Figure 1.3). 
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MDM2-2B also known as MDM2-ALT1, interacts with full length MDM2 and 
sequesters it into the cytoplasm (Evans et al., 2001).  
The human gene, similar to the murine orthologueue, contains two different promoter 
regions, the second of which is responsive to p53. These two promoters in end 
generate two proteins, the full-length p90 (of apparent molecular mass 90 kDa 
estimated by SDS PAGE) and a shorter p76 (of apparent molecular mass 76 kDa) at 
an internal ATG (Olson et al., 1993; Perry et al., 1993; Saucedo et al., 1999). The 
p76 isoform is missing part of the p53-binding domain (Figure 1.3) and it can act as a 
dominant negative inhibitor of the full length MDM2 protein. 
1.4.3 Protein Structure 
 
The human full length MDM2 protein is a 491-amino acid long polypeptide (Figure 
1.3 Panel B).  This multi-domain protein comprises of; i) a hydrophobic cleft at its 
N-terminus, ii) a central acid domain and, iii) a C-terminal RING finger domain.  
As the ability of MDM2 to inactivate p53 relies on a direct physical interaction 
between the two proteins, this is carried out through the NH2 terminal 100 amino 
acids of the MDM2 protein with an alpha helix present in the NH2 transactivation 
domain of p53 (Kussie et al., 1996a). Conformation and hydrophobicity appear to be 
two critical requirements for this key interaction to occur. Other motifs include a 
nuclear localization signal and a nuclear export signal. These signals are believed to 
shuttle the protein back and forth between the cytoplasm and the nucleus, thus 
providing yet another means by which p53 activity is tightly regulated (Freedman 
and Levine, 1998; Roth et al., 1998). The authors postulate that mutation of the 
nuclear export signal (NES) in MDM2 abolishes its ability to shuttle p53 to the 
cytoplasm for degradation. Similarly, blocking CRM-1 mediated nuclear export of 
NES-containing proteins with leptomycin B leads to nuclear accumulation and 
increased steady-state levels of p53 and MDM2 (Freedman and Levine, 1998; 
Stommel et al., 1999a). Therefore these findings suggest that, whether p53 shuttles 
out of the nucleus autonomously (Tao and Levine, 1999a; Zhang and Xiong, 2001) 
or in an MDM2-mediated fashion (Boyd et al., 2000; Geyer et al., 2000; Stommel et 























Figure 1.3 Structure of the MDM2 gene and protein 
 
(A) The MDM2 gene consists of 12 exons and two p53 responsive elements (p53 RE) in intron I. Two 
promoters are highlighted by arrows. Full-length MDM2 (p90 - migrating on an SDS PAGE as a 90kDa 
species) is translated from the first start codon ATG in eon III and the short form, p76 is translated from 
the second ATG in exon IV.  Two major aternative splice variants in the human genes MDM2-A and 
MDM2-B are shown these have exons IV-IX and IV-XI deleted respecitevely. 
 
(B) Primary structure of the full length human MDM2 491 amino acid  isoform (p90). p53 binding - 
primary ineraction site with p53 protein, NLS- Nuclear localization signal, NES- Nuclear export signal, 
NoLS- Nucleolar localization signal ZN - Zinc finger domain, RING- ring-finger domain. The numbers 
above the diagrams denote amino acid numbers and roman numerals are exon numbers. 
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The central acidic domain of MDM2 is necessary for interaction with ribosomal 
proteins L5 (Dai et al., 2006; Marechal et al., 1994), L11 (Lohrum et al., 2003; 
Zhang et al., 2003) and L23 (Dai et al., 2004) (Jin et al., 2004) and with p300/CBp 
(CREB-binding protein). Recently this domain was found to contribute to the 
MDM:p53 interaction by constituting a secondary interaction site with the tumour 
suppressor, highlighting an allosteric mode interaction between the two proteins 
(Shimizu et al., 2002; Wallace et al., 2006). Downstream of the acidic domain is a 
zinc finger domain (a conserved interaction module that binds DNA, RNA, proteins 
or small molecules) a site of cancer associated missense mutations leading to limited 
interaction with the mentioned L5 and L11 proteins, retention of the mutated protein 
in the nucleus and decreased regulatory potential on p53 (Lindstrom et al., 2007). 
The RING domain is at the C-terminus of the MDM2 polypeptide. The RING finger 
domain is a subtype of zinc-finger domain found in a numerous mammalian proteins 
(more than 300-RING finger genes have been identified in the human genome). The 
true potential of the RING finger motif was realised around ten years ago. Before 
that no specific function had been ascribed to the RING finger beyond a role in 
dimerization of several proteins. In was not until 1999/2000 (ten years post the 
discovery of MDM2) that numerous reports from laboratories studying diverse 
biological processes have led to the realization that RING finger proteins play a 
critical role in the ubiquitin mediated proteasome degradation pathway by facilitating 
the transfer of ubiquitin both to heterologous substrates as well as to the RING finger 
proteins themselves. Eukaryotic proteins can be differentially modified through 
attachment to various small molecules and proteins. One such modification is 
conjugation to ubiquitin, which controls a broad range of physiological processes 
(Hochstrasser, 2009). These include the regulations of interaction of a given protein 
with other macromolecules, for example binding to the proteasome or recruitment to 
chromatin.  The RING domain present in MDM2 renders it biochemically active as 
an E3 ubiquitin ligase (Fang et al., 2000), is a site of nucleotide binding by the 
protein (Poyurovsky et al., 2003) and mediates MDM2 interaction with RNA 
(Candeias et al., 2008a; Elenbaas et al., 1996; Naski et al., 2009). 
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1.4.4 p53-dependent functions of MDM2  
 
1.4.4.1 Mouse Model 
 
The importance of Mdm2 and p53 was elucidated through elegant mouse genetics 
(Jones et al., 1995; Montes de Oca Luna et al., 1995). Mice lacking the mdm2 gene 
are early embryonic lethal and die before implantation. The phenotype is completely 
rescued by concomitant deletion of p53, strongly suggesting an important genetic 
dependence between these two genes in murine development. It is thought that the 
lethality of mdm2 knockout is caused by inappropriate p53-dependent apoptosis due 
to the hypoxic embryonic environment. Therefore, in order for p53 to accumulate 
and become highly active in response to stress, the autoregulatory loop must be 
interrupted so that p53 can escape Mdm2 regulation. Nevertheless one must 
remember that despite the fact that mouse gene knockout technology is a powerful 
tool in regards to gene crosstalk/interdependence, at the same time it might provide 
an over simplistic model, as no dosage dependent interactions of protein complexes 
can be studied. 
In regards to Mdm2 and the physiological consequences of its down regulation in 
mice, intriguing results were obtained a few years post the mdm2 knockout studies 
(Mendrysa et al., 2003; Mendrysa et al., 2006; Mendrysa and Perry, 2000). By 
crossing animals containing either wild-type, hypomorhic or null mdm2 alleles a set 
of lines expressing a range of Mdm2 protein levels was generated. These mice 
expressing sub-physiological levels of Mdm2 were later crossed with mice that 
carried a mutated APC allele (these animals are predisposed to developing intestinal 
adenomas). The results showed that even a subtle (∼20%) decrease of Mdm2 levels 
led to a significant reduction in intestinal adenoma formation, while further down- 
regulation of Mdm2 ( to ∼30% of wild type) reduced the number of such tumours by 
a factor of  >16 (Mendrysa et al., 2003). The observed anti-tumour response 
mediated by heightened p53 activity did not coincide with an overall increase in p53 
protein levels, leading the authors to conclude that in normal tissues, Mdm2 
primarily regulates the activity of p53 and may have only minimal effects on p53 
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protein stability. Further speculation was made that the two canonical activities 
towards p53 - repression and degradation (detailed below) are independently 
regulated both in a tissue specific manner as well as following stress response.  
To conclude these findings, one may state that small amounts of Mdm2 are sufficient 
for maintenance of overall p53 levels and moreover lead to increased p53 response, 
while only a near or complete loss of Mdm2 would result in overall accumulation of 
the p53 protein and consequently lead to extensive cell death and embryonic lethality 
in the organism. 
 
1.4.4.2 Transrepression of p53 transcriptional activity 
 
MDM2 mediated regulation of p53 is carried out on several levels. Despite their 
complexity and divergence i.e. trafficking out of the nucleus, control of binding to 
chromatin, post-translational modifications with mono- and polyubiquitin (Brooks 
and Gu, 2006; Pickart, 2004), all of them rely of the fact that these two proteins 
directly interact and form a complex. Initially the interaction was shown to result in 
the inhibition of p53-mediated transcriptional activity (Chen et al., 1995; Momand et 
al., 1992; Oliner et al., 1993). MDM2 within its N-terminus possesses a structural 
motif that can house p53’s transcriptional activation domain (TAD), via induced fit 
and hydrophobic interactions. This results in MDM2 mediated concealment of the 
p53 TAD from critical transcription initiation proteins; consequently leading to an 
transcriptionally inactive p53-MDM2 complex (Chen et al., 1993; Lin et al., 1994; 
Oliner et al., 1993; Picksley et al., 1994). Moreover, MDM2 has been shown to 
inhibit p53-mediated transcription not only masking its TAD, but also through a 
direct repressor effect on basal transcription from p53-responsive promoters (Leng et 
al., 1995; Thut et al., 1997). Domain mapping of MDM2 had shown that residues 50-
222 bind to the 34K subunit of TFIIE (member of the general transcription 
machinery) independent of p53. Other studies have mapped the interaction of MDM2 
with general transcription factor TFIID, TAFII250/CCG1 and TBP through RING 
finger and acidic domains respectively (Leveillard and Wasylyk, 1997). Recent 
studies have shown that MDM2 induces monoubiquitination of histones surrounding 
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the p53-response elements resulting in transcriptional repression (Minsky and Oren, 
2004).  
In essence one may conclude that these combined activities of MDM2 assure 
efficient inactivation of p53-dependent transcription by MDM2. 
 
1.4.4.3 The ubiquitin/proteasome pathway of protein degradation  
 
The abundance of many cellular proteins must be tightly controlled in response to a 
variety of physiological signals. This is done by two highly controlled processes; 
protein synthesis and protein degradation. The foundations of the 
ubiquitin/proteasome pathway started to emerge in the early 1980s (Ciechanover et 
al., 1980; Hershko et al., 1980; Hershko et al., 1983), with experimental data aimed 
at understanding why intracellular proteolysis measured as the release of amino acids 
from intact cells, requires metabolic energy (Simpson, 1953). At present the bulk of 
scientific data gathered since these early experiments supports the notion that the 
ubiquitin/proteasome pathway is the principal mechanism for turnover of normal 
short-lived proteins in mammalian cells. A protein substrate intended for proteolytic 
degradation needs to be targeted. This usually requires the covalent attachment of a 
ubiquitin polymer, containing at least four tandemly conjugated ubiquitin moieties 
(Ciechanover et al., 2000; Thrower et al., 2000) onto the protein destined for 
degradation. One ubiquitin molecule is initially linked via its C-terminal glycine to 
the ε-amino side chain of a lysine present in the target protein; a second ubiquitin 
molecule is then linked to Lys48 of the first ubiquitin, and the process is repeated a 
number of times. This multi-step mechanism involves a sequential cascade of 
activating (E1), conjugating (E2) and ligase (E3) enzymes. The E1 enzyme activates 
ubiquitin in an ATP dependent manner to synthesize ubiquitin C-terminal adenylate, 
which then serves as an enzyme bound substrate for the formation of an E1-ubiquitin 
thiol ester (Hershko et al., 1982; Hershko et al., 1983)(Figure 1.4). The ubiquitin 
molecule is then transferred to a ubiquitin conjugating enzyme (E2) through a thiol 
ester bond. An ubiquitin-protein ligase (E3) specifically attaches ubiquitin to the 
target protein. The presence of multiple substrate-linked ubiquitins recruits 
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transporter proteins shuttling the tagged protein moiety to the 26S proteasome This is 
a 2.5 MDa complex that in an ATP dependent manner unfolds the substrate 
polypeptide chain translocates it into an interior chamber where peptide bond 
hydrolysis occurs to produce small peptides (Baumeister et al., 1998). Ubiquitin is 
spared from degradation through its release from the substrate by deubiquitinating 
enzymes (Hershko et al., 1980). Thus, there are two independent reasons why ATP is 
required for intracellular proteolysis; to activate the ubiquitin C terminus in 
preparation for conjugation and to support the proteasome’s substrate unfolding and 
translocation activities (Figure 1.4) (Pickart, 2001).  
To date only a few E1 enzymes have been identified to be encoded by the human 
genome. Interestingly humans have more than 30 different E2s. As E3 ligases are 
primarily responsible for substrate recognition their numbers are the highest (exact 
number not known in the region 500-1000 (Hicke et al., 2005).  
 
E3 ubiquitin ligases from a mechanistic standpoint, can be categorized into two 
groups (Figure 1.5); those that utilize a covalent mechanism – HECT domain E3s 
(ubiquitin is covalently bound to a E3 before being transferred to the target protein) 
and those that do not bind ubiquitin directly but rather form a scaffold for specific 
transfer of ubiquitin from an E2 to the target protein - (RING, U-box, PHD, F-box 
domain E3s).  The representatives of the latter group can be single multi-domain 
polypeptides (CHIP, MDM2) or large multiprotein complexes (SCF, ECV, Cul4) in 
which each subunit is a member of a distinct protein family and each bearing a 
different function in the assembled complex (SKP1-CUL1-F-box composing the SCF 











































































Figure 1.4 Overview of the ubiquitin proteasome system
 
Protein degradation through the Ubiquitin Proteasome System (UPS) is a highly regulated process 
involving several consecutive steps. 
(A) The first step in the cascade is the activation of ubiquitin (Ub) by an ubiquitin-activating enzyme 
(E1). This step of the ubiquitination cascade requires ATP binding to the ATP-binding cleft of E1. This 
process can be subdivided into three major sub-steps: (a) ubiquitin adenylate formation (b) rapid cis 
transfer of the E1-bound ubiquitin molecule from AMP to active site cysteine in E1 (c) second round of 
adenylate formation to yield a fully loaded enzyme. 
(B) The ubiquitination conjugation cascade. The ubiquitin conjugating enzyme (E2) is recruited to the 
E1 which is followed by transfer of the activated ubiquitin from the active cysteine of E1 to the catalytic 
cysteine in E2.  The next step of efficient transfer of ubiquitin molecules to specific lysines of the 
substrate protein (S) is carried out by a class of enzymes called ubiquitin ligases (E3). These generally 
provide a scaffold for the formation of a S~E3~E2-Cys-Ub complex.
(C) The ‘marked for death’ polyubiquitinated substrate is released from the E3. The modified substrate 
is shuttled to the proteasome, where in an ATP dependent manner the polyubiquitin tagged protein is 
unfolded, the ubiquitin chains are recycled through  proteasome associated ubiquitin hydrolases. The 
unfolded polypeptide is threaded into the proteasome chamber, where protease active sites are 
located. 
(Adapted from Nalepa et al., 2006 and Pickart 2004)
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1.4.4.4 Polyubiquitin chains are diverse 
 
It should be kept in mind that protein ubiquitination is not exclusively synonymous 
with protein degradation. Protein ubiquitination has over the past years emerged as 
complex network matched in intricacy by the eukaryotic kinome (Adhikari and 
Chen, 2009). Indeed, proteins devoted to ubiquitin conjugation, deconjugation and 
recognition constitute one of the largest families in the proteome. Thus this post-
translationalmodification is involved in a broad spectrum of cellular processes 
(Pickart, 2001). Monoubiquitination has been implicated in a number of degradation-
independent processes, including endocytosis, virus budding and transcriptional 
silencing via attachment of ubiquitin moiety to histones leading to chromatin 
remodelling (Ciechanover and Brundin, 2003; Fingerman and Briggs, 2004; Sun and 
Allis, 2002).  
The enzymes involved in the covalent conjugation of ubiquitin to specific protein 
substrates also promote the formation of long polyubiquitin chains through lysine 
residues in ubiquitin. Pioneering studies using yeast genetics showed that Lys48-
linked polyubiquitin chains are the principal targeting signal for proteasomal 
degradation (Chen et al., 1996; Spence et al., 1995). Unconventional ubiquitin chains 
(through the other remaining lysines within ubiquitin; Lys11, Lys27, Lys29, Lys33) 
attached to proteins, although much more scare, could target proteasomal 
degradation in vivo (Jin et al., 2008). 
Moreover, the role of Lys63-linked polyubiquitin chains in DNA repair and stress 
response, has been proposed (Pickart, 2000; Spence et al., 1995). Further studies 
demonstrated the role of Lys63-polyubiquitin chains in kinase activation and vesicle 


































Figure 1.5 The ubiquitin proteasome pathway
 
(A) The ubiquitin cascade is pyramidal in design. A single E1 activating enzyme transfers ubiquitin to 
roughly three dozen E2s, which function together with several hundred different E3 ubiquitin ligases to 
ubiquitinate thousands of protein substrates. 
 
(B) Several classes of ubiquitin ligases are known so far. Single RING E3 ligases bear all the necessary 
domains for their activity within one polypeptide stretch. HECT E3 ubiquitin ligases which in contrast to 
the others  form a covalent bond with ubiquitin during polyubiquitination of their target proteins. Multi- 
subunit RING-finger E3 ubiquitin ligases here are exemplified by the SCF complex. This multiprotein E3 
ligase consists of a scaffolding cullin molecule, a RING-finger-containing subunit (RBX1 or RBX2), 
which functions as a docking site for E2 enzymes, and a substrate specificity module - F-box, which 
binds substrates. 
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1.4.4.5 MDM2 is a RING finger E3-Ubiquitin Ligase 
 
Originally identified as a transrepressor of p53 mediated transcription, MDM2 was 
subsequently shown to control the steady state levels of p53 in unstressed cells by 
acting as a RING finger domain E3-ubiquitin ligase (Fang et al., 2000; Honda and 
Yasuda, 2000), which results in the polyubiquitination of p53 and subsequent 26S 
proteasomal degradation. Additionally, MDM2 has been shown to control its own 
abundance and activity within the cell via auto ubiquitination (Fang et al., 2000; 
Honda and Yasuda, 2000). This process as well as the E3 ubiquitin ligase activity on 
target proteins other than MDM2 is believed to be regulated by the quaternary 
structure of the active E3 complex and may involve interactions with the paralogue 
of MDM2 – MDM4 (MOUSE DOUBLE MINUTE 4 HOMOLOG) (Jackson and 
Berberich, 2000) (Stad et al., 2001) (Gu et al., 2002; Iwakuma and Lozano, 2003).  
 
The enzymatic process of covalent ubiquitin attachment by the E3 ligase onto an 
amino group within a lysine residue cannot be explained by a simple enzyme 
substrate complex kinetics. Upon complex formation of MDM2 with p53, several 
conformational shifts occur within the intradomains for both of the proteins, 
providing a basis for allosteric crosstalk of p53 binding sites within MDM2 (Wallace 
et al., 2006). Despite the discovery of several other p53 specific E3 ubiquitin ligases 
such as Pirh2, COP-1 and CHIP, Arf-BP1 (Brooks and Gu, 2006), to date MDM2 is 
still believed to be the principal physiological antagonist of p53, acting to curb the 
pool of active p53 transcription factor in unstressed cells. 
 
MDM2 was also found to differentially catalyze mono-ubiquitination and poly-
ubiquitination of p53 in a dosage-dependent manner (Li et al., 2003).  Mono-
ubiquitination is believed to be predominant in the presence of low levels of MDM2, 
whereas high levels promote poly-ubiquitination and nuclear degradation of p53. 
Moreover, mono-ubiquitinated p53 protein was shown to localize within the 
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cytoplasm and it has been suggested that mono-ubiquitination of p53 modulates the 
tetramerization of the transcription factor, unmasking the nuclear export signal 
(Stommel et al., 1999a).  This data tempted the scientific field to hypothesize that 
these distinct post-translational modes of action of MDM2 on p53 are exploited 
under different physiological conditions. For example, MDM2-mediated poly-
ubiquitination and nuclear degradation may play a critical role in suppressing p53 
function during the later stages of the DNA damage response or rather when MDM2 
is malignantly overexpressed (Shirangi et al., 2002; Xirodimas et al., 2001b). On the 
other hand, MDM2-mediated mono-ubiquitination and subsequent cytoplasmic 
translocation of p53 may represent an important means of p53 regulation in 
unstressed cells, where MDM2 is maintained at low levels. Despite the logical 
grounds for this hypothesis there are still a few avenues, which are vexing. Namely, 
what happens to the mono-ubiquitinated p53 moiety in the cytoplasm? Does it 
undergo further poly-ubiquitination and proteasome mediated degradation by a novel 
E3 or E4 (p300) enzyme complex, or rather does it surpass degradation by being 
retained at low levels in an inactive oligomeric complex in association with abundant 
molecular chaperones (King et al., 2001; Zylicz et al., 2001; Zylicz and Wawrzynow, 
2001)? As ubiquitination like all other post-translational modifications is reversible, 
this p53 state upon a signalling shift in the cell could be reactivated via an 
appropriate deubiquitinating enzyme (Brooks et al., 2007a; Brooks et al., 2007b). 
Moreover, movement of p53 into the cytoplasm may be important for transcriptional-
independent functions of p53 such as the interaction with mitochondrial proteins in 
the apoptosis response (Chipuk and Green, 2004; Chipuk et al., 2004; Marchenko et 
al., 2007; Mihara et al., 2003).   
 
1.4.4.6 Involvement in translational control 
 
The MDM2 oncoprotein has a direct effect on the abundance of the p53 protein in 
the cell. MDM2 has been shown not only to control the cellular levels of p53 through 
ubiquitination but also has been shown to induce and repress its synthesis. MDM2 
induces translation of the p53 mRNA from two alternative initiation sites, giving rise 
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to full-length p53 and another protein with a relative molecular mass of 
approximately 47 kDa. This translation induction requires MDM2 to interact directly 
with the nascent p53 polypeptide (Yin et al., 2003). Moreover this MDM2 mediated 
induction of p53 synthesis is not due to an increase in p53 mRNA levels, yet as the 
authors propose through increased p53 mRNA translation efficiency.  This is shown 
by elegant experiments indicating that MDM2 is recruited to active polyribosomes 
by the nascent p53 N-termini, resulting in cis regulation of p53 mRNA translation. In 
other words for MDM2 to induce efficient p53 translation it has to interact with p53 
while it is still on the ribosome.  
Interestingly, the p53 mRNA region encoding the MDM2-binding site interacts 
directly with the RING motif of MDM2. This complex renders the MDM2 
oncoprotein transiently impaired as an E3 ubiquitin ligase and results in the 
promotion of p53 mRNA translation (Candeias et al., 2008b; Naski et al., 2009).   
The RNA binding and the E3 ubiquitin ligase domain of MDM2 overlap, indicating 
that the two functions of MDM2 to control p53 abundance have evolved in parallel. 
Based on this the role of MDM2 as a positive regulator of p53 activity is starting to 
emerge. Another recent study shows MDM2 as an inhibitor of p53 translation (Ofir-
Rosenfeld et al., 2008).  The authors report that MDM2 decreases p53 translational 
levels by binding, via the acidic domain, and subsequently catalyzing 
polyubiquitination of L26 ribosomal protein. This protein has been shown to bind 
p53 mRNA and augment its translation.  
This apparent contradiction of MDM2 action on p53 translation can be understood 
when one considers the mechanism in more depth. First of all one is dealing with two 
different types of regulation. In the case where MDM2 binds to p53 mRNA we are 
dealing with a direct (in cis) positive mode of action. In the later case the control is 
indirect as MDM2 limits the pool of a positive effector catalyzing p53 translation.   
Moreover different domains within MDM2 govern these interactions. The direct 
binding of p53 mRNA is facilitated by the RING domain, whereas L26 binding by 
MDM2 is carried out by the acidic domain. Furthermore, as the authors discuss, the 
level of L26 ubiquitination appears to impact only a minor, presumably functionally 
distinct, subpopulation of L26.  
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Numerous interactions of MDM2 through the acidic domain with ribosomal proteins 
have been reported. The oncoprotein interacts with the components of the large 
ribosomal subunit - L5 protein (Dai and Lu, 2004; Marechal et al., 1994) as well as 
with several other ribosomal proteins like L11, L23, S7 (Jin et al., 2004; Lindstrom 
et al., 2007; Lohrum et al., 2003; Zhang et al., 2003). For these cases, such binding, 
is thought to sequester MDM2 and inhibit p53 protein polyubiquitination resulting in 
the increase of transcriptionally active p53 pool (Dai and Lu, 2004). 
All these recent discoveries highlight additional points of MDM2 mediated 
regulation of p53, showing the involvement of MDM2 not only in the degradation of 
the tumour suppressor but also in its synthesis. 
 
1.4.4.7 Feedback loops 
 
A variety of studies have identified numerous positive and negative loops in the p53 
pathway (Harris and Levine, 2005). Each of these loops bases on a circuit of 
components composed of proteins whose activities or rates of synthesis are 
influenced by the activation of p53, and this in turn results in the alteration of p53 
activity in the cell.  
 
Those that involve MDM2 in them will be discussed below: 
One of the foremost-characterized target genes of p53 is the MDM2 gene. It binds to 
two adjacent p53-responsive elements located at an intronic, highly conserved p53 - 
dependent promoter (P2) within the MDM2 gene (Zauberman et al., 1995a), and 
promotes the initiation of transcription. The resulting MDM2 protein possesses E3 
ubiquitin ligase activity towards p53, resulting in targeting it for proteasomal 
degradation [for review see (Michael and Oren, 2003)], yet at the same time has a 
positive effect on p53 translation efficiency (Candeias et al., 2008b; Naski et al., 
2009). In such circumstances MDM2 and p53 are linked through an autoregulatory 
feedback loop in which p53 induces MDM2 transcription and MDM2 in the end 
targets p53 for degradation (review by Michael and Oren, 2002). Several 
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mechanisms are in place to modulate the p53-MDM2 pathway during times of 
cellular stress. Under these conditions p53 synthesis is increased, and MDM2–
dependent degradation of p53 is inhibited. These mechanisms include p14 ARF 
binding to MDM2 (Kamijo et al., 1998; Pomerantz et al., 1998b). 
 
1.4.4.7.1 p14 ARF  
 
The p14 ARF (also referred to as p14/19 ARF) protein binds to MDM2 and inhibits  
its ubiquitin ligase activity increasing the levels of p53 protein in the cell (Honda and 
Yasuda, 1999). The transcription of the p14 ARF gene is positively regulated by 
E2F-1 (Zhu et al., 1999) and beta-catenin (Damalas et al., 2001) and negatively 
regulated by p53. The active p53 protein positively regulates the transcription of 
ubiquitin ligase Siah-1 (Fiucci et al., 2004), which in turn acts to degrade beta-
catenin protein (Iwai et al., 2004). Beta-catenin levels can positively regulate 
p14ARF, which in turn is a suppressor of MDM2 leading to higher levels of p53. 
Siah-1 thus connects the Wnt-beta-catenin-APC pathway to the p53 pathway.  
 
1.4.4.7.2 Retinoblastoma protein 
 
The Retinoblastoma protein (Rb) is found in a complex with MDM2 and p53 in cells, 
resulting in high p53 activity and enhanced apoptotic function (Xiao et al., 1995). 
High levels of active E2F-1 not bound to Rb switch the p53 response from G1 arrest 
to apoptosis. Both Rb and MDM2 are phosphorylated and inhibited by the 
CDK2/CycE complex. When p53 is activated, it stimulates the synthesis of the 
p21CIP1/WAF1 protein, inhibitor of CDK2/CycE activity. This in turn acts on the 
Rb/MDM2 complex that promotes p53 activity and apoptosis. 
Upon DNA damage both MDM2 and p53 are modified by the ATM protein kinase 
(Chang et al., 2008; Chehab et al., 1999; Craig et al., 1999; Maya et al., 2001; Shieh 
et al., 1997). This leads to subsequent binding of the p300 co-activator and further 
acetylation of p53 in its C-terminal region (Shimizu and Hupp, 2003). This results in 
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the increase of the steady-state level of the p53 and consequential surge in the 
expression of more than a hundred p53 target genes, including those involved in cell 
cycle arrest, senescence and apoptosis (Michael and Oren, 2002). 
 
1.4.4.7.3 CyclinG/PP2A complex 
 
Another p53 responsive gene is cyclin G.  It is transcribed to high levels upon p53 
activation in various cell lines (Bates et al., 1996; Okamoto and Beach, 1994; 
Yardley et al., 1998; Zauberman et al., 1995b). The Cyclin G protein forms a 
complex with PP2A phosphatase, rendering it active and mediating 
dephosphorylation of MDM2 (Okamoto et al., 2002). Phosphorylation of MDM2 by 
Cdk2/CycA (Zhang and Prives, 2001) inhibits its activity, thus the PPA/CycG 
phosphatase complex acts oppositely, which in the end leads to a decrease of p53 
activity. This loop acts both on the basal level of p53, and on higher levels activated 
upon stress induction (Okamoto et al., 2002).  
 
1.4.4.7.4 Ubiquitin Ligases 
 
Apart from MDM2 several other E3 ubiquitin ligases have been identified; COP1 , 
Pirh2, CHIP, ARF-BP1. These, apart from CHIP and ARF-BP1, similarly to MDM2 
form an autoregulatory loop resulting in lower p53 activity (Dornan et al., 2004a; 
Dornan et al., 2004b; Leng et al., 2003). The genes encoding these proteins are 
transcriptionally activated by p53.  
 
1.4.5 p53-independent functions of MDM2 
 
For a tumour to overexpress MDM2 and inactivate p53 would seem redundant, 
unless MDM2 has other functions. The MDM2 oncoprotein also possesses numerous 
Chapter 1                                                                                                   Introduction 
 
 29 
p53-independent activities, which contribute to the development of tumours where 
MDM2 is overexpressed.  
 
1.4.5.1 Evidence in tumours and cell lines 
 
MDM2 overexpression occurs mostly by gene amplification possibly caused by 
polymorphism at the mdm2 promoter sequence (Bond et al., 2004) for review see 
also (Daujat et al., 2001a; Ganguli and Wasylyk, 2003; Zhang et al., 2005b). Human 
cancers with non-functional p53 and amplification of MDM2 have poor prognosis 
(Cordon-Cardo et al., 1994; Dworakowska et al., 2004). MDM2 also confers a 
growth advantage to cells without p53 and pRb, overcoming G1-cell cycle arrest 
induced by p107 (Dubs-Poterszman et al., 1995).  
Transgenic mice with a wild-type MDM2 gene are predisposed to spontaneous 
tumour formation in a p53 -/- background, and have a high incidence of lymphoma 
and sarcoma (Jones et al., 1998). More than forty MDM2 isoforms have been 
detected in human cancers (Bartel et al., 2004). Interestingly, splice variants lacking 
the p53-binding domain were identified in human and murine tumours and 
subsequently shown to promote transformation in vitro and tumour development in 
vivo (Harris, 2005). Furthermore synonymous mutants were shown to be associated 
with high-grade and late-stage human cancer (Liang et al., 2004; Steinman et al., 
2004).  
 
1.4.5.2 p53-independent activation of MDM2 expression  
 
To add to the complexity of MDM2 regulation, it must be stated that its gene 
expression is regulated by additional mechanisms independent of p53. MDM2 
expression profile during development has been shown to be independent of p53 in 
different organs (Leveillard et al., 1998). MDM2 expression increases following 
FGF-2 treatment in cells (Bates et al., 1998). The MDM2 promoter has been shown 
to be a target of the MAPK kinase pathway, thus upregulation of Ras during normal 
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cell signalling or through mutation can induce increase of MDM2 functions (Ries et 
al., 2000).  
 
1.4.5.3 MDM2 Interactome 
 
Although the published data indicates that elevated levels of MDM2 contribute to 
tumour development independently of p53, the biochemical mechanism of oncogenic 
activity of MDM2 remains elusive. Indeed, though MDM2 interacts with proteins 
fulfilling a variety of cellular functions (p300, pRb, Numb, MTBP, DNA polymerase 
ε, PML, Tip60, YY1, IGF-IR, GR/ER, AR, HIF-1, p73, NF-κB, PSP-95, ARF, E2F1, 
TBP, TAFII250, Sp1, ribosomal proteins, TSG 101, Ras-GAP binding proteins, 
p21CIP1/WAF1), the biological significance of these multiple interactions remains to be 
explained. It should be stressed that not all MDM2 interacting proteins are targeted 
for proteasome-dependent degradation, hence not all involvement of MDM2 protein 
can be explained by its E3 ubiquitin ligase activity. 
It is not the intention to directly elaborate on each and everyone member of the 
above-listed MDM2 protein interactors, though it is informative when one sub-
categorizes this group into sets of proteins involved in major cellular pathways; cell 
cycle (Rb, E2F1/DP1, p21CIP1/WAF1, PML, MTBP, TGF-β1), differentiation (Numb), 
DNA synthesis (DNA Polymerase ε), ribosome biosynthesis (L5, L11, L23 
ribosomal proteins, 5SrRNA), transcription (TBP, TAFII250, p300, NFκB). 
Of note is the fact that not all of the MDM2 interactions mentioned fall in the 
tumourigenesis promoting category. The physical interaction between human DNA 
polymerase ε is of particular interest. Initially established by a yeast two hybrid 
screen has been confirmed by in vitro binding of the proteins isolated either from 
E.coli or insect cells and co-immunoprecipitation from cell culture (Vlatkovic et al., 
2000). Further analysis mapped the interaction motif within MDM2 to the  N-
terminal 166 amino acids, in addition to binding this region is essential for induced 
activation of DNA polymerase ε. The proposed roles of this enzyme include DNA 
repair, recombination, replication, damage sensing and chromatin remodelling. In 
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response to DNA damage, MDM2 may mediate a beneficial process that allows the 
polymerase to associate with repair/recombination proteins.  
Additionally a link between MDM2 and cyclin A, a regulator of cell cycle, has been 
reported. This particular cyclin is important for a cell to enter S phase. MDM2 was 
shown to regulate the expression of cyclin A, indirectly through interaction with 
component of the general transcription factor family. MDM2 binds TAFII250 
through its C-terminal RING domain. Basal levels of MDM2 activate cyclin A 
transcription, whereas high levels of MDM2 inhibit the process (Leveillard and 
Wasylyk, 1997).  
 
 
1.4.5.4 MDM2 mediated ubiquitination of other proteins  
 
Although the enzymatic E3 ubiquitin ligase activity of MDM2 is considered 
primarily in terms of p53, it can also catalyse the addition of ubiquitin moieties to 
other proteins. Growing evidence indicates that a subpool of proteins within the 
MDM2 interactome can be regulated by its ligase activity.  
 
1.4.5.4.1 β-arrestins 
G-protein-coupled receptors (GPCRs) constitute a vast family of signalling 
molecules. They are shown to have fundamental roles in regulation of a variety of 
cellular functions including, cell growth, differentiation and metabolism. This is due 
to their signalling transduction potential from myriad extracellular signalling 
mediators (hormones, neurotransmitters, chemokines, environmental stimuli etc.) to 
intracellular effector pathways. A key feature that occurs upon the activation of these 
receptors is the negative feedback loop activation that prevents potentially harmful 
effects resulting from persistent activation of signal pathways. This regulatory loop is 
maintained by G-protein-coupled receptor kinases (GRKs), which upon agonist 
binding to the receptor, mediate phosphorylation of the intracellular fragment of the 
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receptor. This is followed by translocation to the cell membrane of β-arrestins – 
negative-regulators of GPCRs. Two known paralogues namely, β-arrestin 1 and 2 
were shown to bind to the phosphorylated agonist bound GPCR and facilitate 
uncoupling and internalisation of the receptor in effect leading to desensitization of 
the cell to a given signal (Ma and Pei, 2007).  
MDM2 is known to participate in this regulatory negative feedback loop, moreover 
its E3 ubiquitin ligase activity is key. The ligase binds to β-arrestins and catalyzes 
their ubiquitination, which leads to receptor internalization (Shenoy et al., 2001). For 
the ubiquitination reaction to occur two points need to be met, agonist occupancy on 
the GPCR and GRK-mediated phosphorylation of his receptor, ensuring β-arrestin 
displacement to the vicinity of the receptor. The region within MDM2 mediating 
physical interaction with β-arrestin was roughly mapped to amino acids 161-321 
(Shenoy et al., 2001), which in part encompasses the acid domain of MDM2. 
MDM2-catalysed ubiquitination of β-arrestin is required for the internalization of the 
GPCR. Moreover, the receptor itself was shown to be polyubiquitinated, which can 
be mediated by MDM2, though the oncoprotein is not essential, as other E3 ligases 
can catalyse this reaction (Shenoy and Lefkowitz, 2003). Ubiquitination of β-arrestin 
and of the receptor appears to serve different functions in regulating the life cycle of 
the receptor. β-arrestin ubiquitination is required for receptor internalization, whereas 
direct receptor ubiquitination leads to proteasomal degradation  (Shenoy et al., 2001; 
Strous and Schantl, 2001).  
The β-arrestin mediated recruitment of MDM2 to the proximity of the receptor 
complex has additional features worth mentioning. First, a G-protein-coupled 
receptor kinase, namely GRK2 was found, through a series of elegant experiments, 
as an additional target of MDM2 E3 ligase activity (Salcedo et al., 2006). Secondly, 
these series of events dramatically affects subcellular localization of MDM2. The E3 
ligase in resting cells is distributed primarily in the nucleus, where it carries out 
transcriptional regulation of p53. Upon ligand induced activation of the GPCR, the 
formation of the cytoplasmic complex is stimulated which contains MDM2, β-
arrestin, and the receptor, thus MDM2 for some time is retained in distinct 
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compartment than the p53 transcription factor. Hence this flux may directly stimulate 
p53 transcriptional activity (Ma and Pei, 2007).  
 
1.4.5.4.2 FOXO4 
The Forkhead box O (FOXO) class of transcription factors are involved in the 
regulation of several cellular responses including cell cycle progression and 
apoptosis. These proteins additionally act as transcription factors and affectors of 
ageing in model organisms (van der Horst and Burgering, 2007; Wolff and Dillin, 
2006; Wolff et al., 2006). 
Additionally FOXOs and p53 are remarkably similar within their spectrum of 
regulatory proteins (van der Horst and Burgering, 2007). Hence, it may come to no 
surprise that MDM2 was found be an active E3 ubiquitin ligase towards FOXO4 
(Brenkman et al., 2008). The ligase was shown to catalyse monoubiquitination of 
FOXO4 induced by hydrogen peroxide treatment. Increase in proteasomal 
degradation of the targeted protein post modification was not observed, in contrast 
the attachment of monoubiquitin to the target protein, as mentioned earlier is thought 
to be linked to regulated compartmental trafficking within the cell.  
 
1.4.5.5 Genome instability affected by MDM2 
 
Maintenance of genome integrity and stability is paramount in maintaining myriad 
pathways that cooperate to ensure that the genome remains intact and mutations are 
not passed on to daughter cells.  
Data supports the notion that MDM2 is a prominent node regulating genome stability 
ultimately leading to cellular transformation [for comprehensive reviews see (Bouska 
and Eischen, 2009a, b)]. Overexpression of human MDM2 in murine fibroblasts led 
to centrosome amplification, which resulted in chromosome instability (Carroll et al., 
1999). Subsequently transgenic Mdm2 expression in mammary epithelial cells 
caused polyploidy in mice independent of the status of p53 (Lundgren et al., 1997).  
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Cell culture based studies indicate that MDM2 overexpression drives cell-cycle 
progression and increases the percentage of cells entering S-phase (Bond et al., 2005; 
Lundgren et al., 1997; Sdek et al., 2005). This in part is due to p53 inhibition. 
Nevertheless p53 independent activities of MDM2 should be acknowledged as well, 
namely MDM2 mediated disruption of the Rb-E2F1 control axis (Sdek et al., 2004).  
The MDM2 oncoprotein also regulates proteins involved in DNA repair and cell 
cycle control. Therefore MDM2-overexpressing cells are doubly disadvantaged 
because they would have less time to repair their DNA rendering the process less 
efficient, making accumulation of mutations even more likely.  
Nevertheless MDM2’s oncogenic potential was contradicted by several experimental 
findings; G1 cell cycle arrest induced by MDM2 driven cyclin A depletion (Zhou et 
al., 2005) is of note. Furthermore, MDM2 mediated activation of DNA polymerase ε 
is also in direct contradiction of the dogma.  
p21CIP1/WAF1 (a cyclin-dependent kinase inhibitor blocking G1/S phase transition) is 
another provoking example. The classical studies have clearly shown that MDM2 
negatively regulates the levels of p21 expression through a p53 dependent pathway. 
Moreover, evidence has also emerged that MDM2 regulates p21 expression 
independently of p53. MDM2 can directly bind p21 leading to p21-C8 proteasome 
subunit association and a subsequent decrease in p21 protein levels (Jin et al., 2003; 
Zhang et al., 2004b). Despite this p21 transcription driven by a p53 paralogue – p63 
was considerably enhanced by MDM2 in Saos2 tumour cells (Calabro et al., 2002). 
Another p53 paralogue – p73 that is capable of inducing transcription of many p53 
responsive genes, was shown to be stabilized by MDM2 (Ongkeko et al., 1999).   
 
MDM2 activity has also been shown to correlate directly to the induction of 
apoptosis in a cell and context specific manner.  MDM2 overexpression in medullary 
thyroid carcinoma cells, lacking functional p53, induced an increase in E2F-1 
expression. E2F-1 dependent transcriptional activity sensitized the cells to gamma-
radiation induced apoptosis (Dilla et al., 2002). Cancers can evade treatment-induced 
apoptosis by upregulating NFκB, a heterodimeric anti-apoptotic transcription factor. 
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In rhabdamyosarcoma cell line in which the NFκB pathway is constitutively active 
alongside with mutant p53 expression, MDM2 overexpression led to suppression of 
cell growth and increased apoptosis (Cheney et al., 2008).  
 
1.4.6 Regulation of MDM2 protein activity 
 
Post-translational modification of eukaryotic proteins governs their functional output 
in the cellular environment or in the extracellular matrix.  
Post-translational mechanisms acting on the MDM2 protein not only regulate its 
intrinsic enzymatic activity in response to cellular stresses, but also govern its 
subcellular localization, differentiate between substrate-ubiquitination and auto-
ubiquitination, and last but not least integrate the stress response with mechanisms 
mediating cell survival.  
 
1.4.6.1 Interacting proteins 
 
Numerous protein interactors other than p53, exert a regulatory effect on MDM2, 
both in light of the p53-MDM2 autoregulatory feedback loop, and its p53-
independent activities.  
 
1.4.6.1.1 Nucleophosmin  
Nucleophosmin (NPM) is a nucleolar phosphoprotein that acts as a molecular 
chaperone for ribosome assembly and protein transport, shuttling between the 
nucleolus and cytoplasm also being essential for centrosome duplication (Okuda et 
al., 2000). It has been reported that MDM2 binds to NPM in a p53-independent 
manner, both in vitro and in cell culture (Kurki et al., 2004). The NPM binding 
region was mapped to the p53 binding domain and the RING-finger domain of 
MDM2. Upon UV stress an increase of the MDM2-NPM complex is observed 
mediating p53 sumoylation and leading to the stabilization of the tumour suppressor 
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(Kurki et al., 2004).  Moreover MDM2 overexpression was shown to be induced by 
NPM in a p53 -/- background (Saos cells). As described earlier within this particular 
cellular context MDM2 was shown to upregulate the transcriptional activity of p63, 
yielding an increase in p21 levels (Calabro et al., 2002). Although the exact 
mechanism of NPM activity on MDM2 is yet to be elucidated, given the data 




Merlin is one of the numerous proteins involved in control of cell growth and 
differentiation (Morrison et al., 2001). Its tumour suppressor function has been 
implicated by studies in the mouse model. Germ line heterozygous nf2 (gene 
encoding Merlin) mutant mice develop a variety of aggressive malignancies with 
metastatic properties (Kim et al., 2004). Merlin, by direct interaction with MDM2 
induces auto-ubiquitination and degradation of the latter. This in effect augments 
cellular death induced by doxorubicin in lung cancer cells with wild-type p53.  
 
1.4.6.1.3 p300 
The p300 protein and its homologue CREB-binding protein (CBP) were shown to 
co-activate p53 in response to DNA damage via acetylation (Grossman, 2001). 
MDM2 was shown to interact with the p300 transcriptional co-activator (Ito et al., 
2001; Jin et al., 2002; Kobet et al., 2000; Wang et al., 2004). The result of this 
interaction is quite complex. It involves the effects of p300 on p53 and MDM2 
protein turnover and MDM2 synthesis. It was shown that p300 is required by p53 to 
induce the transcription of the MDM2 gene. Moreover, inhibition of p300 results in 
p53 stabilization and apoptosis (Thomas and White, 1998). In agreement with this 
observation it was subsequently shown that CBP/p300 and MDM2 play a synergistic 
role in the regulation of p53 stability. In unstressed cells, CBP/p300, p53 and MDM2 
form a ternary complex that mediates p53 turnover (Grossman et al., 1998). 
Interestingly, further data postulate that p300 is the major enzyme catalyzing p53 
Chapter 1                                                                                                   Introduction 
 
 37 
poly-ubiquitination, whereas MDM2 mediates only multiple mono-ubiquitin 
attachment to p53 (Grossman et al., 2003).  
Under stress conditions, such as DNA damage, the following model is proposed. The 
p53 protein becomes stabilized and activated by phosphorylation at multiple sites, 
leading to a dramatic decrease in MDM2 affinity for the tumour suppressor. 
Enhanced recruitment of CBP/p300  to p53 follows, leading  to acetylation within the 
C-terminal regulatory domain of p53 (Appella and Anderson, 2001) (Bode and 
Dong, 2004; Dornan et al., 2003; Xu, 2003). Site-specific phosphorylation of p53 
and MDM2 alike determine the preferential binding of the coactivator complex by 
the tumour suppressor while at the same time impairing the MDM2-p53 interaction 
(Shimizu and Hupp, 2003). 
 
1.4.6.1.4 ARF 
The INK4a-ARF locus (CDKN2A in humans) encodes two intimately linked but 
distinct tumour-suppressor proteins, p16INK4a and p14ARF (p19ARF in mouse) that 
indirectly govern the activities of retinoblastoma protein (RB) and the p53 
transcription factor [for a thorough review see (Sherr, 2006)].  
The p14ARF protein from now on referred to as ARF is believed to be prominent 
player in tumour surveillance as it was shown to protect p53 from MDM2 mediated 
degradation (Chin et al., 1998; Kamijo et al., 1998; Pomerantz et al., 1998a; Saporita 
et al., 2007; Zhang et al., 1998). As a result of this antagonizing effect of ARF on 
MDM2, the p53 transcription factor is stabilized and its activity is increased.  ARF 
induced p53 stabilization is though to be mediated by sequestration of MDM2 into 
the nucleolus, thus due to distinct compartment localization, the interaction between 
the tumour suppressor and the E3 ubiquitin ligase will not occur (Pomerantz et al., 
1998a; Tao and Levine, 1999b).  




1.4.6.1.5 MDM4  
MDM4 (also referred to as MDMX)  was identified in 1996 as a p53-binding protein, 
which is structurally and functionally related to MDM2 (Shvarts et al., 1996a)  
This MDM2 paralogue contains an N-terminal p53 binding domain, a central Zinc-
finger motif and a RING-finger motif located in the C-terminus. Nevertheless unlike 
MDM2, MDM4 is not an active E3 ubiquitin ligase for p53.  
Its role as another critical regulator of p53 emerged with studies on MMD4 knockout 
mice displaying embryonic lethality that was prevented with parallel p53 gene 
deletion (Finch et al., 2002; Migliorini et al., 2002). Intriguingly, MDM2 and MDM4 
are non-redundant, mutually dependent regulators of p53, as each regulator is 
normally unable to compensate for the loss of the other.   
Similar to MDM2, MDM4 can bind to the transactivation domain of p53, thus 
limiting its transcriptional activity by restricting access to essential transcription co-
activators, and presumably basal transcription machinery (Marine and Jochemsen, 
2005).  
Structural studies are beginning to unravel the MDM2-MDM4-p53 regulation 
mechanism. MDM4 has been shown to heterodimerize with MDM2 via the RING 
domain present in both of the proteins and a crystal structure of such a complex has 
recently been solved (Linke et al., 2008). The authors propose that MDM4 regulates 
p53 abundance by modulating the levels and activity of MDM2. Dimerization, 
mediated by the conserved C-terminal RING domains of both MDM2 and MDM4, is 
critical to this activity. Numerous reports indicate that MDM4 regulates MDM2 
activity on p53 in cell based models, although initially contradictive, a consensus is 
starting to emerge showing that the MDM2:MDM4 protein abundance ratio is key in 
the decision fork leading to p53 stabilization or degradation and/or MDM2 turnover. 
(Gu et al., 2002; Kawai et al., 2007; Okamoto et al., 2005; Stad et al., 2001).  
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1.4.6.1.6 Protein Kinases 
 
A number of stress response and cell cycle regulatory kinases have been shown to 
interact and phosphorylate several sites within MDM2 in a cellular context. The 
general outcome of these modifications is the destabilization of the p53-MDM2 
interaction. Further details on the known phosphorylation sites and the mediating 




MDM2 protein is an active E3 ubiquitin ligase mediating the transfer of ubiquitin to 
substrates such as p53 tumour and others such as NUMB, IRF-2, beta arrestin 
(Juven-Gershon et al., 1998; Pettersson et al., 2009; Shenoy et al., 2001). Moreover 
MDM2 is able to catalyze auto-ubiquitination, thus regulating its own abundance in 
the cell (Fang et al., 2000; Honda et al., 1997). 
It is worth to note that while sites of ubiquitination have been clearly mapped to a 
cluster of lysine residues in the C-terminal regulatory domain of p53 (Rodriguez et 
al., 2000) and the DNA binding domain as well (Chan et al., 2006), the identities of 
the auto-ubiquitination sites in MDM2 have so far been only proposed to lie within 
the α-helix of the ββαβ super-secondary structure fold of the C-terminal RING 
domain of MDM2 (Linke et al., 2008).  
Specificity in the transfer of ubiquitin to p53 and MDM2 itself is thought to be 
dictated by the RING domain, as the substitution of this domain with a heterologous 
RING finger permits auto-ubiquitination but abolishes ubiquitination of p53 (Fang et 
al., 2000). The balance between auto- and substrate-ubiquitination of MDM2 is 
modulated physiologically by post-translational modifications, including 
sumoylation, phosphorylation and acetylation.  
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1.4.6.3 Sumoylation  
 
Reversible modification of a number of proteins involved in gene expression by a 
small ubiquitin-like modifier, SUMO, has profound effects on the activity of the 
protein. This modification has been shown to affect protein stability/turnover, 
localization, protein-protein interaction and DNA binding potential. The addition of 
SUMO to lysyl ε-amino groups in target proteins occurs through an enzyme cascade, 
analogous to that of the ubiquitination machinery.  
The site of SUMO modification has been mapped in MDM2 to lie within the stretch 
of amino acid residues 134-212, this region contain the Lys182 as well as Lys136,146,185 
(Miyauchi et al., 2002; Xirodimas et al., 2002).  
There are at least two models elucidating MDM2 sumoylation. One proposes the 
SUMO moiety is attached to MDM2 as it enters the nucleus, because RanBP2 is a 
part of the nuclear pore, and further sumoylated by PIAS proteins within the nucleus 
itself (Miyauchi et al., 2002). The second model postulates that conjugation of 
SUMO to MDM2 is promoted by ARF (Xirodimas et al., 2002). This is of particular 
interest as it diminishes MDM2 mediated degradation of p53 and is consistent with 
the notion that SUMO and ubiquitin modifications may be mutually exclusive and/or 
antagonistic (Meek and Knippschild, 2003). This suggests that SUMO modification 
of MDM2 can differentially modulate the outcome of MDM2 E3 ubiquitin ligase 
activity in a manner that favours p53 accumulation. This is a stress responsive 
switch, as UV irradiation has been shown to decrease the interaction between MDM2 
and Ubc9 (SUMO E3 ligase), resulting in the loss of MDM2 sumoylation 




If one considers the primary structure of MDM2 in terms of amino acid residue 
abundance, almost 20% of the total amino acids building MDM2 are either serine or 
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threonine residues. Two major clusters of phosphorylation sites have been mapped 
and are located at the N-terminal and the central acidic domains of MDM2.  
1.4.6.4.1 DNA-PK 
The DNA-activated protein kinase (DNA-PK) is a member of the 
phosphatidyloinositol 3-kinase (PI3-K) family, which includes ATM (ataxia 
telangiectasia-mutated) and ATR (ATM and Rad3-related) protein kinases. DNA-
PK, ATM, and ATR share many substrates and are each targeted toward a SQ core 
motif in the target protein.  
Of eight potential DNA-PK targets in MDM2, Ser17 site is of particular interest. This 
site has been shown to be phosphorylated in vitro (Mayo et al., 1997b) and although 
this phosphorylation site in physiological (in vivo) context has yet to be confirmed, 
the significance of it on p53 MDM2 interaction/complex formation is prominent.  
This is due to the proximity of the serine to the ordered hydrophobic cleft of MDM2 
(amino acids 25-109) which accommodates the BOXI  (part of the transactivation 
domain) domain of p53. It has been reported the residues (16-24) preceding the 
hydrophobic pocket of MDM2 form a flexible lid /pseudo substrate motif (McCoy et 
al., 2003). This labile polypeptide, due to its location, has great potential for 
intramolecularly controlling MDM2 affinity towards p53 by selectively blocking or 
enhancing the access to the hydrophobic pocket of MDM2, which constitutes the 
major p53 interaction site. Furthermore, it can be deduced from the information 
given above, Ser17 lies within this region and is part of a consensus DNA-PK, ATM 
site (SQ motif). In vitro phosphorylation of this site has been shown to diminish the 
p53-MDM2 complex (Mayo et al., 1997a).  
 
1.4.6.4.2 ATM 
MDM2 was shown to be rapidly phosphorylated in an ATM–dependent manner in 
response to specific DNA-damaging agents (Khosravi et al., 1999). Subsequent 
studies indicated that ATM phosphorylates MDM2 on Ser395 in vitro and in cell 
culture based assays (Maya et al., 2001). The phosphorylated form of MDM2 was 
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shown to decrease control activity over p53 indicating a reduction of the affinity 
towards the interacting partner. 
 
1.4.6.4.3 PI3-K/Akt Pathway 
In response to the activation of lipid PI3-K kinase with its appropriate second 
messenger phospatydyloinositol(3,4,5)-triphosphate (PIP3), by upstream growth 
factor and cytokine binding to plasma membrane receptors, the down stream effect 
ensues which involves the activation of Akt kinase by phosphorylation. Once 
activated this kinase is released from the cytoplasmic envelope and is free to interact 
with potential targets, one of which is MDM2. The Akt phospho-acceptor sites in 
MDM2 have been mapped to Ser166 and Ser186, these two amino acids lie in close 
proximity of the NES and NLS and evidence suggests that phosphorylation of these 
residues by Akt stimulates entry of MDM2 into the nucleus (Mayo and Donner, 
2001; Zhou et al., 2001). Moreover, MDM2 phosphorylated at Ser166,186 was shown 
to have decreased binding to its negative regulator ARF (Blattner et al., 2002). In 
addition, the modulation of MDM2 by the PI3-K/Akt pathway by Insulin growth 
factor 1 receptor stimulation (member of the G protein coupled receptors, described 
previously in this introduction) alters G protein receptor kinase 2 (GRK2) 
degradation and augments the cellular levels of the kinase, putting forward a new 
mechanism for controlling GRK2 activity (Salcedo et al., 2006).  
 
1.4.6.4.4 c-Abl Tyrosine Kinase 
The ABL proto-oncogene encodes a protein tyrosine kinase, capable of shuttling 
between the cytoplasm and nucleus. The cytoplasmic c-Abl is involved in mediating 
the response to growth and survival signals, whereas nuclear c-Abl plays a pivotal 
role in mediating apoptosis.  
MDM2 was shown to associate with c-Abl both in vitro and in the nuclei of cultured 
cells leading to the phosphorylation of MDM2 at multiple sites (Goldberg et al., 
2002).  Of these the key phosphorylation site was identified to be Tyr394. Upon 
phosphorylation of MDM2 by c-Abl, the activity of the former to down-regulate p53 
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has been shown to decrease dramatically, keeping in line with the model that this 
modification contributes to the promotion of p53 induced apoptosis.  
 
1.4.6.4.5 CDK2-cyclinA  
The role of MDM2 in cell cycle regulation is at multiple levels. Taking aside the p53 
dependent actions and direct, p53 independent, interaction with p21WAF1/CIP1. MDM2 
protein was shown to regulate the levels of cyclin A protein. The latter in complex 
with CDK2 (Cyclin dependent kinase), phosphorylates MDM2 at Thr216 (Zhang and 
Prives, 2001) in effect leading to a decrease in the MMD2-p53 interaction and an 
increase of association of ARF to MDM2.  
1.4.6.4.6 CK2 
The CK2 protein kinase phosphorylates MDM2 at Ser269 and although this 
modification occurs physiologically. Its direct effect, apart from a minor increase in 
MDM2 mediated p53 turnover, is yet to be discovered (Dumaz et al., 2001; Gotz et 
al., 1999; Guerra et al., 1997).  
 
1.4.6.4.7 Multisite phosphorylation of the acidic domain 
The acidic domain of MDM2 is centrally located in the primary structure of the 
protein and contains several structural elements that contribute to the interaction with 
p300, ARF, Rb, some ribosomal proteins. A cluster of phosphorylation sites has been 
shown to reside within the acidic domain (Ser 240-262) (Blattner et al., 2002; Hay 
and Meek, 2000). The published data suggest that that this cluster of residues is 
normally phosphorylated in the cell under non-stress conditions, nevertheless the 
kinases involved in this process still remain to be identified. Functionally, however, 
based on site directed mutagenesis studies, this modified cluster may significantly 
contribute to MDM2 mediated turnover of p53.  
As in the case of many post-translational modifications, phosphorylation is a 
reversible process. Dephosphorylation of the acidic domain in agreement with other 
sites is thought to play a role in the network of events mediating stress responses and 
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p53 induction. It was shown that key phospho-serine residues in the acidic domain 
are dephosphorylated in response to ionizing radiation in a manner that clearly 
precedes p53 accumulation (Blattner et al., 2002).  
 
1.4.6.5 Acetylation  
MDM2 was reported to be a target for acetylation (Wang et al., 2004). MDM2 is 
acetylated in vitro and in tissue based experiments by CREB-binding protein (CBP) 
and to a lesser extent by p300.  Acetylation occurs primarily within the RING 
domain of the protein, moreover the native fold of this structural motif is key for this 
post-translational modification to occur. Furthermore the authors have shown that the 
acetylation-mimicking mutant of MDM2 (Lys466/467Glu) is impaired to promote p53 
ubiquitination as well as auto-ubiquitination (Wang et al., 2004).  
Acetylation of the p53 transcription factor generally regarded as important 
component of the activation cascade of the protein in response to various stress 
stimuli. Thus, regulated acetyltransferase activity may contribute to the p53 response 
through a dual mechanism, involving simultaneous activation of p53 and inactivation 
of its regulator MDM2.  
 
1.4.7 Intrinsic chaperone activity of MDM2 
 
If one considers the plethora of research data published in regards to MDM2 there 
are several findings that indicate MDM2 as having similar activity to those described 
for molecular chaperones. Namely, binding to nascent polypeptide chain (Yin et al, 
2002), activation of transcription factors E2F1, p63 (Martin et al, 1995; Calabro et 
al, 2002), protection and activation of DNA polymerases (Asahara et al, 2003), 
involvement in ribosome assembly (Marechal et al, 1994), (Hartl and Hayer-Hartl, 
2002).  
Molecular chaperones are defined as a vast class of structurally unrelated proteins 
that assist in correct non-covalent assembly of other polypeptide-containing 
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structures, but which are not components of these assembled structures when they are 
performing their normal biological functions (review Ellis, 1993).  Through 
controlled binding and release cycles, chaperones facilitate the correct fate of 
polypeptides bearing non-native conformation. Recently it was shown that the Hsp90 
molecular chaperone, in an ATP-dependent reaction, retains p53 in a conformation 
that allows binding to a specific promoter sequence (Walerych et al., 2004).  
 
Given that MDM2 protein can bind ATP, interact with the Hsp90 chaperone, has a 
significant  role in the activation of transcription factors, protection and activation of 
DNA polymerases, involvement in ribosome assembly and nascent p53 protein 
biosynthesis, the experimental data in this thesis shows MDM2 protein to possess an 
intrinsic molecular chaperone activity.  
 
1.5 Targeting the MDM2-p53 interaction for cancer therapy 
 
The p53 protein is a stress responsive transcription factor that is intimately involved 
in myriad surveillance networks that monitor genome status, dynamically respond to 
variation in gene expression and changes in the extracellular matrix composition. 
These are in place to govern cellular function and integrity, moreover preventing the 
cell from neoplastic transformation. The importance of the p53 node in these 
networks is highlighted by the fact that it is either mutated or inactivated roughly half 
of human tumours. For those human cancers that retain wild-type p53, its activity is 
disabled by alternative mechanisms, in part mediated by MDM2 overproduction.  
Given the fact that MDM2 is considered to be the chief negative regulator of p53, 
several therapeutic strategies aimed at liberating the tumour suppressor from MDM2 
are analysed, all in principle focus on restoring p53 activity, which in effect is 
expected to limit tumourigenesis. 
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1.5.1 Proof of principle 
 
The data provided by mouse knockout and knockdown models have clearly shown 
the genetic interdependence of p53 and MDM2. Basing on the on the fact that 
decreased sub-physiological levels of the MDM2 protein in a p53 wild-type 
background are beneficial for the organism to resist tumour formation. Early studies 
through the use of biological reagents have validated MDM2 as a potential drug 
target (Bottger et al., 1997b; Picksley et al., 1994; Wasylyk et al., 1999). Transient 
RNA interference gene knockdown techniques utilized a decrease of MDM2 
abundance in the cell, thus facilitating pronounced p53 activation leading to growth 
arrest and/or apoptosis (Tortora et al., 2000; Zhang et al., 2005a). Moreover, 
microinjection of MDM2 specific antibodies as well as introduction of scaffold 
attached competitive peptides, disrupted the p53:MDM2 protein interaction, ensuing 
an increase of the p53 tumour suppressor response. These biological reagents 
provided proof of concept for the activation of p53 by targeting MDM2.  
 
1.5.2 Inhibition of MDM2 E3 ligase activity 
 
Biochemically, the MDM2 protein should be regarded as an enzyme. By providing a 
discrete platform for the interaction of the target protein – p53 with the E2 
conjugating enzyme, it increases the rate at which the ubiquitin transfer reaction 
reaches equilibrium. This is a simplified view, nevertheless it does provide grounds 
to consider this RING finger E3 ubiquitin ligase as a drug discovery target. In theory 
there are two potential approaches to block MDM2s E3 ubiquitin ligase activity. One 
is to develop molecules that disrupt the interaction between the RING finger and the 
E2 protein. The other is to disrupt the interaction between the ubiquitination 
substrate-p53 and the substrate interaction domain on the E3-MDM2. These two 
approaches differ greatly by the specificity of action - the first one, aims at 
extinguishing MDM2 E3 ligase activity irrespective of the ubiquitination substrate, 
whereas the later focuses purely on the MDM2:p53 primary interaction site.  
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Small molecule inhibitors of E3 enzymes are still in the preliminary stage, to date 
only a few compounds have been reported to decrease MDM2s E3 ubiquitin ligase 
activity. Through in vitro based enzyme chemical screening assays, three inhibitors 
were identified belonging to chemically distinct classes (benzosulfonamides, ureas, 
imidazolones) , each with the potency in the micromolar range (Lai et al., 2002). 
These three compounds were synonymous in selective inhibition of MDM2 E3 ligase 
activity, with little or no effect on other enzymes of the ubiquitination cascade. The 
mode of action of these three compounds is mutually exclusive indicating a common 
site of interaction within MDM2, which still remains to be identified. Moreover they 
showed a non-competitive profile with respect to the major substrate – p53. 
Surprisingly these molecules did not inhibit MDM2 mediated auto-ubiquitination.  
Another class of small molecules (HLI98) was reported to inhibit the E3 ubiquitin 
ligase activity of MDM2  (IC50 20-50 µM range) leading to p53 dependent activation 
of transcription in cell models (Yang et al., 2005). Nevertheless the authors underline 
the preliminary nature of their findings, as cellular induced toxicity was observed and 
also unspecific inhibitory effects on structurally and mechanistically unrelated E3 
ubiquitin ligases (HECT domain E3s) was acknowledged. Further, optimization of 
these inhibitors to increase their potency and selectivity is required to assess the 
potential of this p53-activating strategy.  
 
1.5.3 Blocking the interaction between p53 and MDM2 
 
1.5.3.1 Competitive inhibitors targeted to bind MDM2 
 
MDM2 is unable to downregulate p53 if prevented from interacting with it. For a 
small molecule to function effectively as an inhibitor of protein-protein interaction it 
must fulfil two interdependent key requirements: affinity and specificity (Vassilev, 
2004).  From a structural standpoint the primary p53-binding interface in MDM2 
looks inviting for experimental drug design. This is due to the existence of a well-
defined open p53-binding pocket on the MDM2 polypeptide into which exogenous 
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low molecular weight compounds could preferentially bind, therefore diminishing 
the physiological p53:MDM2 interaction. Whether these potential drugs act simply 
as competitive inhibitor and/or have a diminishing effect on the ubiquitination state 
of p53, is open for discussion. This is due to the allosteric mechanism by which 
MDM2 catalyzes ubiquitination of p53 and shall be discussed in further detail in 
appropriate parts of this thesis.  
The set of inhibitors falling within this category, both small molecule and peptide 
based, have been steadily increasing for almost a decade now. Early members of this 
group represented diverse chemotypes and although shown satisfactory inhibition of 
tumour cell proliferation in vitro, they failed (with a few exceptions) to reproduce 
satisfactory potency in vivo (for review see (Dudkina and Lindsley, 2007).   
Through extensive biochemical fine mapping, of the primary interaction site 
comprising the N-terminal amphipatic peptide fragment of p53 and the N terminus of 
MDM2, a potent 12 amino acid peptide inhibitor (later in this thesis described in 
more detailed and referred to as the 12.1 peptide) was discovered (Bottger et al., 
1996). The offspring of this discovery were peptide antagonists shown to posses 
binding affinities over 1700-fold greater than the protoplast (Garcia-Echeverria et al., 
2000). 
Historically, members of the first set of small non-peptidic molecular p53:MDM2 
inhibitors were the 4-phenyl-piperazine derivatives. These molecules were developed 
based on the class of peptide inhibitors described above. The architectural scaffold 
for their design, capitalized on the biochemical and crystallographic data regarding 
the mode of binding between MDM2 and p53.  With the aid of structure based 
design and computational chemistry the following classes of molecules were 
proposed: 
 α-helicetical mimetics (Chen et al., 2005b; Kutzki et al., 2002; Orner et al., 
2001; Orner et al., 2002)  
 Norcamphane derivatives (Zhao et al., 2002) 
 Chalone derivatives (Stoll et al., 2001; Stoll et al., 2000) 
 Bisarylsulfonomides (Vassilev, 2005; Zheleva et al., 2003) 
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 Isoindolinone scaffold derivatives (Hardcastle et al., 2005; Hardcastle et 
al., 2006) 
 Benzodiazepinediones (Raboisson et al., 2005) (Parks et al., 2005; Zhang et 
al., 2004a) 
 Quilinol Derivatives (Lu et al., 2006) 
 Spiro-oxindoles (Ding et al., 2005; Ding et al., 2006)  
 Cis-imidazolines (Nutlins) (Ambrosini et al., 2007; Vassilev, 2004, 2005, 
2007; Vassilev et al., 2004) 
 
The list above should be considered as representative, as it is not exhaustive. Nor 
should all of the list components be considered as potential drug leads. The point to 
acknowledge is the fact that all of these compounds exploded onto the scientific field 
in less than a decade post the year 2000. This is extremely encouraging as this 
pyramid of compounds shows increasing levels of potency. This is achieved through 
the increase in p53 ligand spatial mimicry, binding affinity – decrease of IC50 (the 
last four underlined classes of molecules representing IC50 in the nM range), 
specificity/selectivity and most important bioavailability.  
 
1.5.3.2 Compounds binding to p53 and reactivating its function 
 
A forced chemical induced activation of the p53 tumour suppressor may offer a 
therapeutic benefit for tumourigenesis decrease in the patient. Given that this protein 
is retained in the patient in a genetically non-mutated state, this in principle could be 
achieved through the mentioned above classes of anti-MDM2 compounds.  
RITA (reactivation of p53 and induction of tumour cell apoptosis) is small molecule 
compound (2,5-bis-(5-hydroxymethyl-2thienyl)furan) initially discovered in the 
National Cancer Institute Anticancer Drug Screen (Issaeva et al., 2004). RITA is 
structurally and functionally unrelated to the previously described classes of 
compounds, as it does not seem to bind MDM2. Instead it is believed to bind the N 
terminus of p53 and prevents the recognition of p53 by MDM2 (Issaeva et al., 2004), 
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although no structural data depicting this is available at the moment. Interestingly, 
RITA seems to prevent p53 from interacting with other regulatory proteins such as 
PARC and p300 (Grinkevich et al., 2009; Issaeva et al., 2004). The RITA -stabilized 
p53 is transcriptionally active as it can promote transcription of downstream effector 
genes (Issaeva et al., 2004), moreover it slows down the growth of human tumour 
xenogrfts in mice in a dose dependent manner, although the oral bioavailability of 
this compound still remains to be confirmed.  
 
The pharmacological rescue of p53 transcription factor function up to this point 
relied on one key point that the reader should be reminded of. The protein in question 
needed to be in a wild-type/non mutated form. 
 
PRIMA-1 (p53 reactivation and induction of massive apoptosis) this is another 
prominent small molecule compound (2,2-bis-(hydroxymethyl)-1-
azabicyclo[2,2,2]octan-3-one) discovered through screening of chemical libraries in 
cell based assays (Bykov et al., 2002b).  
This compound and its methylated version PRIMA-1MET were shown to effectively 
induce p53 downstream transcription targets in human cancer cells. Systematic 
administration of PRIMA-1 and PRIMA-1MET inhibits human xenograft tumour 
growth in mice (Bykov et al., 2002a) (Bykov and Wiman, 2003; Foster et al., 1999). 
Elegant in vitro studies have shown that PRIMA-1 can preserve the physiological 
transcriptionally active conformation of the tumour suppressor under stress 
conditions. Moreover, PRIMA-1 restores mutant p53 function. Transcription 
dependent and independent induction of apoptosis facilitated by mutant p53 (H175R) 
in combination with drug treatment was shown (Bykov et al., 2002b; Chipuk et al., 
2003; Zache et al., 2008). The molecular mechanism by which PRIMA-1 exerts it 
function on p53 was recently published (Lambert et al., 2009). The authors 
demonstrated that PRIMA-1 within the cell is converted to reactive products that can 
modify thiol groups, namely the cysteine residues in the core domain of p53. These 
residues represent a nucleophile profile and thus can be alkylated by the drug in 
question. The presented results indicate that covalent modification of one or several 
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cysteine residues in the core domain of the transcription factor is responsible for 
restoring the wild-type p53 conformation. 
 
1.5.4 Drug leads applied in synergy  
 
Given the plethora of potential drug leads aimed at restoring p53 function, one 
question is in need of answering, that is whether combinatorial use of the 
pharmacophores will show a synergistic antitumour effect. The grounds for such 
studies seem logical, as the molecules have been shown to attack different facets of 
the MDM2-p53 recognition process (for review see (Nalepa et al., 2006)). 
Surprisingly however, very little work has been done in this field. Although PRIMA-
1 was tested in combination with commonly used anticancer drugs showing 
promising results. Namely, combined treatment with cisplatin (DNA alkylator) 
PRIMA-1MET resulted in synergistic induction of tumour cell apoptosis and inhibition 
of human tumour xenografts in mice (Bykov et al., 2005). No studies yet have been 
performed to consider the recently identified broad panel (Nutlins, spiro-oxindoles, 
RITA, PRIMA-1) of possible pharmacological synergism between each other and/or 
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2.1 General Reagents 
 
Chemicals and reagents were supplied by Sigma unless stated otherwise. Tissue 
culture reagents including Dulbecco/Vogt modified Eagle's minimal essential 
medium (DMEM), Roswell Park Memorial Institute medium (RPMI 1640), McCoy's 
5A medium, penicillin/streptomycin solution, trypsin- EDTA free solution and 
Lipofectamine™2000 were supplied by Invitrogen unless otherwise stated, while 
fetal bovine serum (FBS) was supplied by Autogen Bioclear. 
 
2.2 General Lab Equipment 
 
Fluroskan (Ascent FL), PowerwaveXSTM microplate reader (Bio-Tek), were used to 
read 96-well plates. DNA concentrations were measured using a NanoDrop® 
spectrophotometer. SDS PAGE was carried out using Biorad Protean II mini-gel 
system.  X-ray films were developed using a Mediphot 937 developer. Sorvall RC-
5C plus and Eppendorf 5415R were used for all centrifugations.  
 
2.3 Cell Culture 
2.3.1 Cell lines and Media 
Cells were incubated at the recommended temperature and humidity (see table 
below) in incubators supplied by Hera. The following table lists the various cell lines 
used, their origin, optimum growth conditions and culture media.  













Human (lung – metastatic 
site lymph node), non-







1% (v/v) P/S 
HCT-
116wt 









1% (v/v) P/S 
A375 



















1% (v/v) P/S 






1% (v/v) P/S 






1% (v/v) P/S 
Table 2.1 Cell lines used.  
 
Abbreviation key: RPMI – Roswell Park Memorial Institute 
         DMEM – Dulbecco’s Minimal Essential Medium 
         FBS – Fetal Bovine Serum 
         P/S – Penicillin/Streptomycin 
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2.3.2 Subculturing, storage and recovery of cells 
 
Freezing media 
50 % (v/v) Fetal bovine serum 
10 % (v/v) DMSO 
40 % (v/v) Tissue culture media (depending on cell line)  
 
Cells were subcultured 2-3 times per week in 10 cm diameter culture dishes in sterile 
conditions and split to a maximal dilution of 1/10. The media was discarded and the 
cells were washed with sterile phosphate buffered saline (PBS). 1x Trypsin-EDTA 
solution (0.5 ml/ 10 cm diameter culture dishes) was added and the cells were placed 
in the incubator until the cells started to detach from the culture dish. The cells were 
taken up into media (9.5 ml/ 10 cm diameter culture dishes) and then split 1:10 into 
new culture dishes with fresh media (10 ml/ 10 cm diameter culture dishes).  
Cells were kept in liquid nitrogen for long-term storage. To prepare cells for storage 
a 10 cm diameter culture dish with confluent cells was trypsinised and the cells 
collected by centrifugation (1000 rpm, 5 min, 4 ºC). The cell pellet was gently 
resuspended in 4 ml freezing media and transferred to cryotubes (Nunc) at 1 ml/ 
tube. The cells were frozen down slowly in NalgeneTM Cryo 1 ºC freezing containers 
and then transferred to liquid nitrogen.  
To recover the cells the tubes were thawed quickly at 37 ºC and the cells transferred 
to a culture dish containing fresh media. The media was changed the following day 
and the cells were left to grow until they were confluent before being subcultured for 
the first time 
 
2.3.3 Transient transfections  
 
Cells were seeded out onto 6-, 24well plates or 10 cm2 plates 24 h prior to 
transfection with/without antibiotics and grown to 80-90 % confluency. The cells 
were transfected with plasmid DNA using LipofectmineTM 2000 (Invitrogen) 
according to manufacturer’s handbook. DNA was trasfected at a ratio of 1:1 using 
Chapter 2                                                                                  Materials and Methods 
 
 57 
LipofectamineTM 2000. Cells were then incubated at 37°C overnight before they were 
harvested or subjected to chemical treatment or stress. 
 
2.4 Microbiological Techniques 
All microbiological techniques were carried out under aseptic conditions. Standard 
code of practice in line with health and safety regulation was employed. 
2.4.1 Escherichia Coli - bacterial Strains 
 
DH5α — [F– (φ80dΔ(lacZ)M15) recA1 endA1 gyrA96  thi-1 hsdR17(rk– mk– ) 
supE44 relA1 deoR Δ(lacZYA-argF)U169] 
 
BL21 (DE3)  — [F– ompT hsdS (rB– mB– ) dcm+ gal I (DE3) endA The] 
 
BL21 (DE3) CodonPlus – RP (Stratagene) — F– ompT hsdS (rB– mB– ) dcm+ 
gal I (DE3) endA Hte [argU proL Camr]   
 
BL21 Rozetta —(Stratagene) [F– ompT hsdS(rB– mB–) dcm+ Tetr gal ë(DE3) 
endA metA::Tn5(kanr)Hte [argU proL Camr]] 
 
BL21 pLys — (Stratagene)  [F– ompT hsdS(rB– mB –) dcm+ Tetr gal ë(DE3) 
endA Hte [pLysS Camr]] 
 
BL21 Ril — (Stratagene)  [F– ompT hsdS(rB– mB–) dcm+ Tetr gal endA Hte 
[argU ileY leuW Camr]] 
 
2.4.2 Growing bacterial cultures 
 
Luria-Bertani  (LB) broth  
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1 % (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaCl 
Sterilised by autoclaving at 121 °C for 20 min 
 
Selective antibiotics used 
Ampicillin (Sigma) at 100 µg/ml 
Kanamycin at 100 µg/ml  
Tetracyclin at 100 µg/ml 
 
5 ml LB media (containing a selective antibiotic if required) was inoculated with a 
colony of bacteria from a stock plate or from a glycerol stock and incubated for 
several hours overnight at 37 °C (225 rpm). This starter culture was then transferred 
to 200 ml LB media (containing antibiotics if appropriate) and incubated under the 
same conditions overnight. Culture flask capacities were at least 5x the volume of the 
culture being grown to allow for aeration. 
 
2.4.3 Glycerol stocks 
 
Glycerol stocks of bacterial cells were prepared by adding 0.15 ml of sterile glycerol 
to 0.85 ml of liquid bacterial culture in a cryovial (Nunc) and snap frozen. The cells 
were stored at –70 °C. 
2.4.4 Agar bacterial culture dishes 
 
LB agar 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaCl  
1.5 % (w/v) Agar, granulated 
Sterilised by autoclaving at 121 °C for 20 min. 




LB agar was liquefied by means of heat provided by microwave oven. When the agar 
was hand warm (at body temperature) it was poured into 90 mm diameter Petri 
dishes (Sterilin) and left to cool. If antibiotic selection was required, the antibiotic 
was added to the agar immediately before pouring. The culture dishes were stored at 
4 °C for no longer than one month. Prior to use the plates were dried at 37 °C for 1 h.  
 
2.4.5 Preparation of competent cells  
 
Heat shock method 
Transforming buffer 1 (TFBI) 
30 mM Potassium acetate 
100 mM RbCl 
10 mM CaCl2 
50 mM MnCl2 
15 % (v/v) Glycerol 
Adjust to pH 5.8 with acetic acid and 
sterilise by filtration. 
Transforming buffer 2 (TFBII) 
10 mM MOPS 
75 mM CaCl2 
10 mM RbCl2 
15 % (v/v) Glycerol 
Adjust to pH 6.5 with KOH and sterilise 




A starter culture of E.coli DH5α cells was set up by transferring a colony of bacteria 
from a stock-plate to 2 ml of LB in a 15 ml sterile tube. The culture was incubated 
overnight at 37 °C and with agitation. This culture was diluted 1/100 in 200 ml of LB 
and incubated at 37 °C at 225 rpm until the OD600nm lay within 0.3-0.5. The cells 
were collected by centrifugation (10 min, 8000 rpm, 4 °C) and resuspended in ice-
cold 80 ml of TFBI buffer at 2/5 of the original 200 ml culture volume. After 10 min 
of incubation on ice the cells were again centrifuged (5 min, 2500 rpm, 4 °C) and 
gently resuspended in 8 ml of TFBII buffer at 1/25 of the original 200 ml culture 
volume. The cells were incubated on ice for 15 min and 200 µl aliquots were added 
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to pre-chilled microcentrifuge tubes. The aliquots were snap frozen on dry ice and 
stored at –70 °C.  
 
2.4.6 Transformation of bacteria 
 
2.4.6.1 Heat shock method 
 
100 µl of E.coli DH5α competent cells were defrosted on ice and mixed with 0.1-0.5 
µg of plasmid DNA. The cells were incubated on ice for 30 min and heat-shocked at 
42°C for 1 min. Following another 5 min incubation on ice, 1 ml LB media was 
added and the culture was incubated at 37 °C at 225 rpm for 30 min in a 15 ml sterile 
tube. Cells were then plated onto LB agar bacterial culture dishes containing 
selective antibiotic where appropriate and incubated overnight at 37 °C.  
 
2.5 Molecular Biology Methods 
 
2.5.1 Plasmid DNA 
 
Amplification of plasmid DNA – A single colony of bacteria containing the plasmid 
required was used to inoculate a starter culture of 5 ml of LB containing selective 
antibiotic and incubated at 37 °C at 225 rpm for 4-8 h in a 50 ml sterile tube. The 
starter culture was then transferred to a larger 100 ml liquid bacterial culture and 
incubated overnight at 37 °C at 225 rpm in a 500 ml flask.  
Purification of plasmid DNA – Cells from the culture grown for amplification of 
plasmid DNA were collected by centrifugation at 6000 rpm for 20 min at 4 °C. 
Plasmid DNA was isolated using Qiagen MaxiTM and MiniTM prep kits according to 
manufacturer’s instructions. The DNA was resuspended in nuclease-free dH2O and 
stored at -20 °C.   
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Quantification of plasmid DNA – The concentration of plasmid DNA was 
determined by spectrophotometry at 260 nm using the PowerwaveXSTM Microplate 
Spectrophotometer (Bio-Tek). Plasmid DNA was diluted 1/100 and 100 µl volumes 
were added to wells of a 96-well UV-StarTM Plate (Greiner), using 100 µl dH2O as a 
blank control. 50 µg/ml DNA gives an OD260nm of 1 A thus DNA concentrations 
could be calculated. The plate reader software (KCJuniorTM) was adjusted for a 1 cm 




2.5.2.1 Preparation of cell lysates 
 
Cell lysis  
 
0.1 % or 1 % Triton X-100 lysis buffer 
50 mM HEPES pH 7.6 
0.1 mM EDTA 
150 mM NaCl 
1x protease inhibitor mix* 
0.1 % or 1 % (v/v) Triton X-100 
10 mM NaF 
Stored at -20 ºC in aliquots. 
2 mM DTT (add prior to use) 
 
Urea lysis (Denaturing) buffer 
7 M Urea 
0.1 M DTT 
0.05 % (v/v) Triton X-100 
25 mM NaCl 
25 mM HEPES pH 7.6 
Buffer prepared just prior to use. 
NP40 Lysis Buffer 
1% NP40 
25 mM HEPES-KOH, pH 7.6 
0.4 M NaCl 
5 mM DTT 
120 nM okadaic acid 
1x Protease Inhibitor mix* 
 
*10x Protease inhibitor mix 
10 µg/ml Leupeptin 
SDS sample buffer (SB) 
5 % (w/v) SDS 
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4 µg/ml Aprotinin 
2 µg/ml Pepstatin 
1.2 mM Benzamidine 
10 µg/ml Soya bean trypsin inhibitor 
400 µg/ml Pefabloc 
1 mM EDTA 
Stored at -20 ºC in aliquots.  
25 % (v/v) Glycerol 
125 mM Tris pH 6.8 
0.02 % (w/v) Bromophenol blue 
DTT (1 M) added to buffer (1 DTT : 4 
SB) prior to use 
 
Cells were washed with cold PBS, scraped with 150 µl of PBS into microcentrifuge 
tubes and then centrifuged at 5000 rpm for 5 min at 4 ºC. The supernatant was 
removed and cell lysis buffer was added in excess of the cell pellet (50-100 µl per 
well in a 6-well plate). The cells were resuspended by pipeting the cell lysis buffer 
up and down several times. Samples were then incubated on ice for 20 min. The cell 
lysate was centrifuged at 13000 rpm for 2 min and the supernatant was recovered. 
The cell pellet was recovered and lysed further by resuspending it in 200 µl of SDS 
sample buffer and heated at 95 ºC for 5 min. Samples were then sonicated 
(Soniprep150TM, MSE) twice for 10 sec (Level 2-3), snap-frozen in liquid nitrogen 
and stored at -70 ºC. 
 
2.5.2.2 Protein precipitation 
 
Trichloroacetic acid (TCA) was used to precipitate protein and concentrate protein 
samples using the following method. 2 % deoxycholate (DOC) was added to the 
samples to a final concentration of 0.02 % and incubated at room temperature for 15 
min. 24 % TCA was added to a final concentration of 8 % and incubated on ice for 1 
hr. The precipitated proteins were pelleted by centrifugation at 13,000 g for 10 min at 
4 oC. The supernatant was removed and the pellet washed with 200 µl ice cold 
acetone to remove residual TCA. The protein pellet was air dried for 1 – 2 min 
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before resuspending in either urea lysis buffer or 4 x SDS sample buffer (4 % SDS, 
250 mM Tris-HCl pH 6.8, 10 mM EDTA, 0.2 M DTT, 1% Bromophenol blue). 
 
2.5.2.3 Protein quantification  
 
Protein concentrations were determined using the BCATM Assay kit (Pierce, Perbio 
Science) in a 96-well plate measuring absorbance at 562 nm with the 
PowerwaveXSTM Microplate Spectrophotometer (Bio-Tek). Read-outs were 
converted to concentrations using the standard curve generated from the BSA 
standards and adjusted by the dilution factor.  
Protein concentration of individual samples was also carried out by means of 
Bradford Assay supplied from BioRad. The assay was carried out according to the 
instruction manual supplied by the manufacturer. Bovine serum albumin (BSA) was 
used as the protein standard in order to plot the standard curve. The reaction was 
carried out on 96 well microtitre plates. The absorbance for the protein-dye 
complexes was measured at λ= 595nm by means of KC-Junior microplate reader. 
 
2.5.3 Preparation of gels and separation of proteins by SDS-PAGE 
Running buffer  
192 mM Glycine 
25 mM Tris 
0.1 % (w/v) SDS 
Separating gel – 10%  (per 5 ml) 
30 % Acrylamide mix*  1.7 ml 
1.5 M Tris (pH 8.8)  1.3 ml 
10 % SDS  0.05 ml 
10 % Ammonium peroxidisulphate  0.05 ml 
TEMED (Sigma)  0.002 ml 
dH2O  1.9 ml 
Separating gel – 15 %  (per 5 ml) 
30 % Acrylamide mix*  2.5 ml 
1.5 M Tris (pH 8.8)  1.3 ml 
10 % SDS  0.05 ml 
Stacking gel – 5 %  (per 1 ml) 
30 % Acrylamide mix*  0.17 ml 
1.5 M Tris (pH 6.8)  0.13 ml 
10 % SDS  0.01 ml 
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10 % Ammonium peroxidisulphate  0.05 ml 
TEMED (Sigma) 0.002 ml 
dH2O  1.1 ml 
10 % Ammonium peroxidisulphate  0.01 ml 
TEMED (Sigma)  0.001 ml 
dH2O  0.68 ml 
* Acrylamide mix (National Diagnostics; Ultrapure Protogel) consists of 30 % (w/v) 
acrylamide and 0.8 % (w/v) bis-acrylamide. 
 
SDS-polyacrylamide gels at acrylamide concentrations of 8%, 10 % or 15 % were 
prepared [described by Laemlli et al (1970)] using a MiniProtean3TM (Bio-Rad) blot. 
The separating gel was left to polymerise and overlaid with water to straighten the 
top of the gel. The water was then removed and the stacking gel with a 
polyacrylamide concentration of 5 % was added together with a 10- or 15-well comb, 
which was also left to polymerise. The combs were removed and the wells were 
washed out with Running buffer.  
SDS sample buffer was added to the cell lysates containing between 25-50 µg of 
protein in a ratio of 1:1 (v/v) and samples were heated at 95 ºC for 5 min prior to 
loading. 5 µl of pre-stained protein standards (Bio-Rad) were loaded in the first well 
as size markers. Proteins were separated by electrophoresis in Running buffer at 100-
170 V until the Bromophenol blue dye front reached the bottom of the gel.  
2.5.4 Detection of fractionated protein  
Gels were removed from the glass plates and the stacking gel was discarded. 
Coomassie brilliant blue staining 
Destain 1 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
 
Destain 2 
7.5 % (v/v) Methanol 
10 % (v/v) Acetic acid 
Coomassie brilliant blue stain 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
0.2 % (w/v) Coomassie Blue R-250 
 
 
Gels were transferred to a dish containing Destain 1 for >5 min and then placed into 
another dish containing Coomassie Blue Stain. The duration of the staining 
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procedure depended on the strength of the staining required (5 min to 12 h) and in 
some cases the stain was preheated to 45 ºC to increase staining even further. Gels 
were then placed in a dish containing Destain 2. A folded tissue was used to absorb 
excess dye and Destain 2 was renewed as needed. Destaining was performed until 
the bands became visible and the background staining was removed. Gels were air-
dried in between DryEase MiniCellophaneTM sheets (Invitrogen) in a DryEase 




10x PBS (Phosphate-Buffered Saline) 
1.37 M NaCl 
0.1 M Na2HPO4 
0.027 M KCl 
0.018 M KH2PO4 
Adjust pH to 7.4 with HCl 
 
PBS+Tween (PBST) 
1x PBS + 0.1 % (v/v) Tween 20 
 
ECL Solution 1 
100 mM Tris pH 8.5 
2.5 mM Luminol stock 
0.4 mM p-Coumaric acid 
 
ECL Solution 2 
100 mM Tris pH 8.5 
0.02 % (v/v) H2O2 
Solutions stored at 4 ºC in the dark.  
Transfer buffer 
192 mM Glycine 
25 mM Tris 




The separated proteins were transferred electrophoretically to PROTRANTM 
nitrocellulose transfer membranes (Schleicher & Schuell Biosciences) in tanks with 
agitated Transfer buffer and an ice block to control the temperature. Electroblotting 
was carried out at constant 100 V for 1 h or at constant 20 mA overnight. After 
transfer of proteins the membranes were washed in PBST and stained with black ink 
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(Pelikan) diluted in PBST (1/100) for 10-15 min. Membranes were washed again in 
PBST to remove the excess stain and non-specific antibody binding was blocked by a 
1 h incubation in buffer A - PBST + 5 % (w/v) dried skimmed milk (PBST5M; 
Marvel) + 0.5% (w/v) BSA. The membranes were then incubated with the primary 
antibody in buffer A for 1 h at RT (or overnight at 4 ºC). Following 5x 5 min washes 
in PBST, the appropriate secondary antibody (conjugated to horse radish peroxidase; 
DAKO) diluted 1/1000 – 1/2000 in buffer A, was added to the membrane and 
incubated for 1 h at RT. Membranes were again washed for 5x 5 min with PBST and 
specific bands were detected by enhanced chemiluminescence (ECL). Membranes 
were overlaid with ECL solution 1 and 2 (mixed 1:1) for 1 min, blotted dry and 
exposed to HyperfilmTM ECL (Amersham Biosciences), which was then developed. 
 






2.5.6.1 Primary antibodies 
Table 2.2 List of primary antibodies used in this study. 
 
2.5.6.2 Secondary antibodies 
 
Secondary antibodies were sourced from DAKO and HRP-conjugated forms of 
Rabbit α-Mouse IgG; Swine α-Rabbit IgG; Rabbit α-goat IgG; Rabbit α-sheep IgG 
were used. 
 
Target kDa Clonality Supplier Dilution 
β - actin 42 Mouse Monoclonal Abcam 1:5000 
GAPDH  35 Mouse Monoclonal Santa Cruz 1:10000 
IRF-1 (C-20) 48 Mouse Monoclonal BD 1:1000 
MDM2 (2A9) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
MDM2 (2A10) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:2000 
MDM2 (4B2) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
MDM2 (3G5) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
MDM2 (SMP 14) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
BAX 21 Mouse Monoclonal  1:1000 
p21 (Ab-1) 21 Mouse Monoclonal Oncogene 1:1000 
p53 (DO1) 53 Mouse Monoclonal 
Moravian 
Biotechnology 1:5000 
p53 (DO12) 53 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
p53 (CM-1) 53 Rabbit Polyclonal 
Moravian 
Biotechnology 1:1000 
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2.5.7 Stripping Membranes 
Stripping buffer 
50 mM Tris pH 6.8 
2 % (w/v) SDS 
100 mM β-mercaptoethanol 
 
Antibodies bound to membranes were removed by stripping when the blots needed to 
be re-probed. The stripping buffer was heated to 50 ºC in a water bath and added to 
the membrane. The blot was kept at 50 ºC in the water bath for 15-30 min with 
occasional agitation. The membrane was rinsed multiple times with PBS and was 
then immunoblotted as described above.  
2.6 Clonning and Site Directed Mutagenesis (SDM) 
2.6.1 Polymerases 
Hot-start Taq polymerase amplification  
PCR Master mix/reaction  Cycling conditions  
1xPCR buffer (Qiagen)  
1mΜ dNTPs (Promega)  
0.1µM forward and reverse primers  
1µg DNA template  
HotstarTaqTM DNA polymerase 
5units/reaction (Qiagen)  
ddH2O up to a final volume of 50 µl  




Annealing: 53.6°C for 
30sec,  
Elongation:72°C for 1min  
Cycle to step 2 x30 times,  
72°C x 5min.  
4 °C for t∞  
 
In order to ensure maximum yield of amplification for each product, different 
annealing times, varying from 50-70°C, along with elongation times between 30sec-
3min, were tried. 100ng of DNA template were used as initial concentration.  
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2.6.2 PFU polymerase reaction  
 
PFU® Turbo amplification was used instead of Taq polymerase for site directed 
mutagenesis because of its high thermostability and 3' to 5' exonuclease proof-
reading activity that enables the polymerase to correct nucleotide-misincorporation 
errors. This means that Pfu DNA polymerase-generated PCR fragments will have 
fewer errors than Taq-generated PCR inserts. All reactions performed in a DNA 
Engine DyadTM machine.  
 
2.6.3 Agarose gel electrophoresis  
 
50x TAE (Tris-Acetate EDTA)  6x DNA loading buffer  
2M Tris pH 6.8,  
0.1M Na2EDTA.2H2O  
4% Acetic acid (v/v)  
Adjust pH to 8.5  
0.25% Bromophenol blue (w/v)  
0.25% Xylene cyanol (w/v)  
15% Ficoll 400 (w/v)  
 
TAE buffer was diluted (50x) to 1x and 1% (w/v) ultrapure agarose was added. The 
PCR Master mix/reaction  
 
Cycling conditions  
1x cloned PFU® buffer (Stratagene)  
1mΜ dNTPs (Promega)  
0.5mM MgCl2 (Qiagen)  
0.1µM forward and reverse primers  
5% (v/v) DMSO  
1µg DNA template  
PFU® Turbo DNA polymerase 2.5 
units/reaction (Stratagene)  
ddH2O up to a final volume of 50 µl  




Annealing: 53.6°C for 
30sec,  
Elongation:72°C for 1min  
Cycle to step 2 x30 times,  
72°C x 5min.  
4 °C for t∞  
Chapter 2                                                                                  Materials and Methods 
 
 70 
solution was heated in a microwave oven until the agarose is completely dissolved 
and left to cool down to handwarm under the hood. Ethidium Bromide EtBr was 
added to a final concentration of 5% (w/v). The solution was then poured into a 
horizontal electrophoresis gel tray with a 10-well or bigger comb inserter and left to 
solidify. When solid, the agarose gel was submerged in a horizontal electrophoresis 
tank filled in 1xTAE buffer. DNA loading buffer (6x) was added to the samples (3µl 
of site-directed mutagenesis DNA or 10µl of PCR amplified DNA) to 1x and then 
loaded onto the gel. 1kb DNA ladder was also loaded at 5µl volume. Electrophoresis 
at 100V at room temperature followed till adequate separation was achieved and then 
the bands were visualized by UV light using a CHEMI Genius2 BioImaging 
SystemTM (Syngene) and the GenesnapTM tool with an ethidium bromide filter and 
transilluminator. The images were captured with a Sony UP-D895MD. 
 For cloning the DNA was extracted from the gel using a DNA gel 
purification kit from Qiagen. 
 
2.6.4 Restriction enzyme digestion and Ligation of DNA in the appropriate 
vector 
 
Restriction enzyme digestion of the vector and the DNA-insert is required after PCR 
amplification. The restriction endonucleases recognize specific sequences to digest. 
As far as the insert is concerned the adequate restriction enzymes were chosen 
according to the Multiple Cloning Site (MCS) of the vector to be inserted in.  
Restriction digests were performed to manufacturers protocol (New England Bio-
labs). 




Ligation reaction  Formula for the vector:insert ratio  
1x Ligation Buffer (10x Promega)  
10-100ng vector DNA  
xng insert  
10units of T4 ligase (10u/µl , Promega) 
ddH2O up to 10µl  
µg of vector x size of insert (Kb) x ratio insert  
size pf vector (Kb) vector  
 
After digestion the vector plasmid and the DNA-insert were ready to be ligated. The 
above reaction was incubated at 4 °C in Eppendorf tubes, overnight. For each 
ligation different ratios insert:vector were applied each time, varying between 3:1 
and 10:1, according to the size of the insert when compared to the vector.  
 
2.6.5 Site-directed mutagenesis and Cloning 
 
2.6.5.1 Primer design  
 
Cloning primers were designed with a length of around 20-30 bp spaced over the 
beginning or end of the MDM2 open reading frame with restriction sites or a 
homologous recombination site incorporated into them.  
Oligonucleotides were purchased from Sigma-Aldrich, de-salt purified for cloning 
























Table 2.3 Cloning Primers. 
2.6.5.2 Site-directed mutagenesis 
 
Primers containing the desired mutations were designed according to the quidelines 
in the QuikChangeTM Site-Directed Mutagenesis Kit Manual (Stratagene). 
Oligonucleotides were purchased from Sigma-Aldrich de-salt purified and were 
reconstituted in nuclease-free ddH2O. Site-directed mutagenesis was carried using 
the QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene) was applied 
according to manufacturer’s instructions. After mutant strand synthesis reaction, 1 µl 
of DpnI restriction enzyme (10U/µl) was added to the amplification reaction and 
mixed. The reaction mixture was centrifuged for 1 minutes and incubated at 37oC for 
up to 4 hours to digest the parental (non-mutated) dsDNA. After incubation, 2 µl of 





























to Alanine  
5’CCTTTTCTTTAGCTTCTTTGCCGCTGTAAAGCAGG
CCATAAGATGTCC 3’  
































































































Table 2.4  Site Directed Mutagenesis Primers 
 
2.6.6 Sequence analysis of plasmid DNA 
 
All sequence analysis was performed by the Sequencing Unit at the MRC Human 
Genetics Unit, Edinburgh. The sequencing reactionset up to final volume of 10µl 
containing 2 µl of BigDye® Terminator 3.1 (Applied Biosystems), 3.2 pmol of 
primer, 1x BigDye Sequencing buffer (Applied Biosystems), 150 ng of DNA 
template and nuclease-free ddH2O was assembled. The sequencing reaction was 
thermal-cycled using cycling parameters according to the manufacturer’s 
instructions.  
The sequenced DNA was then precipitated by mixing the reaction with 30 µl of 100 
% (v/v) ethanol and 2.5 µl of 125 mM EDTA. Following vortexing, the reaction was 
incubated at room temperature for 15 minutes. After centrifuging at 13000 rpm for 
20 minutes, the solution was removed and precipitated DNA was microcentrifuged 
for 20 seconds. Residual ethanol was removed before 30 µl of 70 % (v/v) ethanol 
was added to the precipitated DNA and centrifuged at 13000 rpm for 5 minutes. The 
ethanol was removed before the precipitated DNA was microcentrifuged for 20 
seconds. Residual ethanol was removed and the precipitated DNA was left to air-dry 
before sequence-analysed. 
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2.7 Protein Purification 
2.7.1 His-purification 
Cultures were grown and induced with 0.5mM IPTG for 3 hours at 20 °C. After 
induction the cells were pelleted and resuspended in 10ml of lysis buffer (20mM Tris 
pH8, 150mM NaCl, 0.1% NP-40, 10% glycerol, 10mM MgCl2), sonicated and spun 
down.  The supernatant was added to 250ul of Ni-NTA agarose beads (Qiagen) 
washed in PBS, and incubated for 1 hour at 4oC.  Supernatant was removed, leaving 
enough to transfer beads to a small column and washed 6x with lysis buffer + 40mM 
imidazole.  Protein was then eluted in 14 fractions of 0.5 ml using lysis buffer plus 
250mM imidazole.  All fractions were run out on an 18% gel.  Peak fractions were 
then pooled and loaded onto an equilibrated fast flow Q-column (GE Healthcare) and 
eluted off with a high salt concentration. 
 
2.7.2 Native protein Purification. Isolation of MDM2 species form E.coli 
 
Wild-type human MDM2 was overexpressed in E.coli BL-21 RIL DE3 strain at 20 
ºC for 3 hours after induction with 0.5 mM IPTG. Cells were harvested by 
centrifugation at  8 000 g for 10 min and snap frozen in liquid nitrogen. The bacterial 
pellet was lysed in buffer A: (100 mM Tris-HCl pH 8.0, 200 mM KCl, 10% glycerol, 
1 mM PMSF, 5 mM Mg (CH3COO)2, 5 mM DTT,  1 mM benzamidine, protease 
inhibitor cocktail EDTA free (Roche),  1 tablet per 50 ml of buffer A)  containing 1 
mg/ml lysozyme for 1.5 hours at 4ºC with frequent stirring followed by 2 minutes at 
37ºC and an additional 15 minutes at 4ºC. Afterwards the suspension was centrifuged 
at 100 000 g for 1 hour at 4°C.  Under these lysis conditions most of the desired 
protein was insoluble and localized within the pellet after centrifugation.  Extraction 
of the MDM2 protein from the cell pellet was carried out overnight at 4ºC with 
constant shaking. The following extraction buffer (B) was used: 25 mM Tris-HCl pH 
7.6, 1.2 M KCl, 5 mM Mg(CH3COO)2, 1% Triton X-100, 5 mM DTT, 10% sucrose, 
1 mM PMSF, 1 mM benzamidine, protease inhibitor tablets. Following 
centrifugation (100 000g for 1 hour at 4°C ) the supernatant was collected, dialysed  
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into buffer (C): 25 mM HEPES-KOH pH 7.3, 1 M (NH4)2SO4, 1 M KCl,  5% 
glycerol, 2 mM DTT, 1 mM PMSF. Following two hour dialysis the sample was 
loaded onto a Butyl-Sepharose column (Amersham) equilibrated with the same 
buffer. The protein, which bound to the column, was eluted using a linear gradient of 
decreasing ionic strength and increasing glycerol concentration. The fractions 
containing MDM2 protein were pooled and loaded onto a Q-Sepharose column 
equilibrated with buffer (D): 25 mM HEPES pH 7.6, 50 mM KCl,  10% glycerol, 2 
mM DTT, 1 mM PMSF.  The flow through from the column was immediately loaded 
onto a SP-Sepharose column equilibrated with buffer D. The bound proteins were 
eluted by means of a linear salt gradient (from 50 mM to 800 mM KCl in buffer D). 
Fractions containing MDM2 protein were pooled, frozen in liquid nitrogen and kept 
at -80 ºC for further experiments. 
An analogous method was used to isolate MDM2K454A, MDM2C464A, MDM2C478S, 
MDM2I440A  from E.coli. 
Human recombinant p53 was purified essentially as described by (Nichols and 




2.8.1 p53 DNA binding assay 
 
The DNA binding activity of p53 was quantified by EMSA (Electrophoretic Mobility 
Shift Assay; gel-shift). Indicated amount of human recombinant p53 was diluted in 
the final volume of 5 µl or 7 µl of EMSA buffer: 25 mM Hepes pH 7.5, 5% glycerol, 
100 mM KCl, 10mM MgCl2, and 3 mM DTT. Samples were supplemented 
optionally with constant increasing amounts of MDM2  and/or BSA and  ATP (for 
exact amounts used see Figure descriptions). Such samples were then incubated at 4 
ºC  to 50ºC for the indicated time in a thermocycler. The activation step followed that 
included addition of 15 µl or 13 µl mix containing: 1x EMSA buffer, 0.2 MDPM of 
32P labeled specific DNA sequence (below), 1 µg of unspecific 44-bp dsDNA 
(sequence below, usage based on (Anderson et al., 1997)) and 100ng of the antibody 
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pAb421 (Ab-1; Oncogene). 20 µl samples with the specific DNA were afterwards 
incubated for 5 min at room temperature (RT), loaded onto a 4% native 
polyacrylamide TB gel and electrophoresed at 15mA for 2h at 4°C. Gels were dried 
and exposed to the phosphoimager screen and scanned by STORM phosphoimager 
(Amersham).  
For p53 activated by CKII, the activation mix was made, containing per every 4 µl of 
volume: 50ng p53, 7U of CKII (Calbiochem), 0.3 U of creatine kinase, 150mM of 
phosphocreatine (ATP regeneration system; Roche), 5 mM of ATP and 1x EMSA 
buffer. CKII activation was done for 30 min at 25ºC and then each 4 µl of CKII 
activation reaction was supplemented separately with Hsp90/BSA in 1xEMSA buffer 
up to 5 µl. Afterwards, 1h incubation step either at 4ºC or 37oC was performed, 
followed by addition of 15µl DNA mix without the antibody.  Electrophoresis was 
performed as described above.  
For testing the unspecific p53-DNA binding activity, 0.2 MDPM of unspecific, 
radiolabeled 44-bp dsDNA (below) was used per 1 sample instead of labeled 
promoter-derived sequence in the activation step. The remaining part of the 
experiment was performed as mentioned before for specific DNA but no additional 
unlabeled DNA, antibody or CKII was used in this case.  
DNA sequences used in EMSA (annealed from complementary ssDNA to form 
dsDNA): 
CON (artificial p53-binding “consensus”) sequence: 
5’-AGCTTAGACATGCCTAGACATGCCTA-3’ 
WAF1 promoter derived sequence:  
5'-TGGCCATCAGGAACATGTCCCAACATGTTGAGCTCTGGCA-3',  





BAX promoter derived sequence: 




Unspecific, 44-bp DNA:  
5'-GCTTCGAGATGTTCCGAGAGGCGAATGAGGCCTTGGAACTCAAG-3',  
Sequences were annealed to form double stranded DNA in a thermocycler using 
following program: 5min 94ºC, 5min 50ºC, 4ºC. Presence of the dsDNA was tested 
with a 16% polyacrylamide TB gel electrophoresis. Sequences used in the EMSA 
assay were labeled with the T4 Polynucleotide Kinase (PNK; Fermentas) as 
described in the producer’s manual. 2-week long series of experiments was 
performed using DNA radioactivity determined at this point. This allowed the same 
amounts of specific DNA per reaction but caused differences in overall intensity of 
results, as radioactivity of sequences decreased due to the isotope half-life. Image 
Quant TL software (Amersham) was used to adjust intensities of obtained images to 
a comparable background to signal ratio. 
In most described experiments the pAb421 antibody was used to activate p53 for 
specific DNA-binding, despite without it p53 clearly binds the promoter-derived 
DNA specifically in the presence of short, unspecific dsDNA included as a 
competitor in the activation mix. This is in agreement with earlier reports (Anderson 
et al., 1997). However, in the presence of pAb421 the binding is increased and bands 
more suitable for quantitative analysis, while overall result outcome remains 
unchanged (data not shown). 
 
2.8.2 Enzyme Linked Immunosorbent Assay (ELISA)  
 
A 96-well microtiter plate (Corning Inc.) was coated with purified p53 (50ng per 
well) diluted in 0.1 M Na2HCO3, pH 8.6-9.2, and incubated overnight at 4 °C. An 
analogous approach was undertaken when the experiment required an anchoring 
anitobody to be coatedonto wells. Each well was washed 6x with PBS containing 
0.1% Tween 20 (PBS-T) followed by incubation for 1 h at room temperature with 
gentle agitation in PBS-T supplemented with 3% bovine serum albumin. The wells 
were washed 6x with PBS-T prior to incubation with appropriate amounts of purified 
MDM2WT and the desired mutants diluted in PBS-T 3% bovine serum albumin for 1 
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h at room temperature.  For competition ELISA’s a fixed concentration of 100ng 
MDM2 was used with a titration of appropriate inhibitor added at the same time.  
After 1 h incubation the plate was washed again 6x with PBS-T and incubated with 
MDM2 specific abtibody 2A10 (1:1000 in PBS-T 3% BSA) for 1 h at room 
temperature.  For peptide ELISA’s plate was coated with streptavidin overnight, 
washed 6x with PBS-T and biotinylated peptides were added for 1 hour followed by 
addition of MDM2.   Following a further 6x washes with PBS-T wells were 
incubated with secondary rabbit anti mouse horseradish peroxidase antibodies 
followed by further washing and ECL. The results were quantified using Fluoroskan 
Ascent FL equipment (Labsystems) and analyzed with Ascent Software version 2.4.1 
(Labsystems).    
 
Peptides BOXIa, BOXIb, BOXVa, and BOXVb were from Chiron Mimetopes and 
Nutlin3a from Alexis Biochemicals 
BOXIa Biotin-SGSGPPLSQETFSDLWKLLP  
BOXIb (12.1peptide) Biotin-SGSGMPRFMDYWEGLN  





2.8.3 In Vitro Ubiquitination Assay 
 
Human recombinant p53 (100ng) purified from E.coli was incubated in a 20 µl 
reaction volume containing 1x ubiquitination buffer (UB): 50 mM Tris pH 7.6, 100 
mM KCl, 10 mM MgCl2, 2 mM DTT, 0.07 units of creatine kinase, 10 mM creatine 
phosphate, 5 mM ATP, 6 µg ubiquitin (human recombinant purified from E. coli or 
from Boston Biochem.), 50 nM E1 ubiquitin activating enzyme  (rabbit/human 
recombinant), 1.5 µM E2  conjugating enzyme - UbcH5a (mouse/human 
recombinant), 3-150 nM E3- human recombinant MDM2WT, MDM2K454A , 
MDM2C464A or MDM2C478S, .  The reactions were incubated at 30ºC-37ºC for 10 
min-2 hours. Afterwards they were terminated with SDS-sample buffer with 
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Dithiotreitol (DTT) and the reaction products were fractioned by SDS-PAGE (8-
10%). Transfer to a nitrocellulose/PVDF film followed and standard immunoblot 
blot detection was carried out using anti p53 DO-1 antibody. 
 
Master Mix: 
366µl  H2O  
10µl  1M HEPES (pH8) 
2.4µl  1M MgCl2 
2µl     10% Triton X-100 
0.2µl  1M DTT 
6µl      0.2M ATP 
0.4µl  1M Benzamidine 
3.2µl  10mg/ml Ubiquitin 
 
2.8.4 In vivo ubiquitination assay 
 
H1299 cells were seeded onto 6 well plates.  When the cells reached 80-90% 
confluency they were transfected by means of lipofectamine™ 2000 reagent with the 
total amount of DNA for all wells kept constant at 4 µg. These 4 µg consisted of 1 
µg of pCNA3.1 p53 wt, 0.5-2 µg pcDNA3.1 MDM2 wt or the K454A , C464A, 
C478S mutants along with 0.5 µg of pCMV His-Ub plasmid. The DNA mixtures, 
with appropriate controls were made up accordingly for each well to be transfected 
with the addition of pCDNA3.1 empty vector  the make up the 4µg were necessary.  
The proteasome inhibitor MG132 (CalBiochem) was added to final concentration of 
10 µM per well for four hours prior to harvesting.  
Twenty four hours post transfection, the cells were washed twice in ice-cold PBS 
before being scraped and collected in 1 ml of  ice-cold PBS. At this step the cells 
were divided into two fractions: 200 µl fraction which was to be directly lysed in 
NP-40 lysis buffer and assayed via western blot (transfection control) 800 µl fraction 
which was to be used in the ubiquitination assay. 
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Both fractions were centrifuged at 5000rpm 4ºC for 5min and snap frozen in liquid 
nitrogen. 
Stock solutions used in the procedure described below 
 
Buffer A 
6 M Guanidium-HCl 
94.7 mM Na2HPO4 
5.3 mM NaH2PO4 
10 mM Tris-HCl, pH8.0 
10 mM β-mercaptoethanol 
(Buffer made up to desired volume pH adjusted to pH8.0) 
 
Lysis Buffer 
Buffer A supplemented with 5 mM Imidazole 
 
Buffer B 
8 M Urea 
94.7 mM Na2HPO4 
5.3 mM NaH2PO4 
10 mM β-mercaptoethanol 




8 M Urea 
22.5 mM Na2HPO4 
77.5 mM NaH2PO4 
10 mM Tris-HCl pH8.0 
10 mM β-mercaptoethanol 
(Buffer made up to desired volume pH adjusted to pH6.3) 
 
 








Buffer C supplemented with 0.1% Triton X-100 
 
Elution Buffer 
0.2 M Imidazole 
5% SDS 
150 mM Tris-HCl pH 6.8 
10% Glycerol 
0.7 M β-mercaptoethanol 
 
The thawed pellet (800µl) was lysed in 1 ml of freshly prepared lysis buffer by 
pipetting up and down using fine tip liquid pipette. The lysate was transferred to 15 
ml falcon tube  containing additional 4 ml of lysis buffer and 75 µl of Ni2+-NTA 
agarose beads (Qiagen). The falcon tubes were placed on a rotating table for 4 hours 
or O/N at 4ºC.  
The beads were collected by centrifugation at 2000 rpm for 4 minutes and the 
supernatant was carefully removed or aspirated off. The beads were washed with 
750µl of Buffer A and transferred to eppendorf tubes. The beads were washed with 
750 µl of each of the Buffers B-E for 15 minutes at room temperature on a rotating 
table. After each wash a 4min centrifugation step at 2000 rpm followed.  
Following this the beads were incubated with 75 µl of Elution Buffer for 30 minutes 
at room temperature on a rotating table.  The beads were collected by centrifugation 
at 13000 rpm for 5 minutes and the supernatant was mixed with equal volume of 2x 
sample buffer, 40 µl of each sample were loaded on 4-12% Novex gel for analysis by 
western blot. 
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2.8.5 Dual Luciferase Reporter Assay  
 
The term ‘dual reporter’ refers to the simultaneous expression and measurement of 
two individual reporter enzymes within a single system. Typically, the 
‘experimental’ reporter is correlated with the effect of the specific experimental 
conditions, while the activity of the co-transfected ‘control’ reporter provides an 
internal control that serves as a baseline response. Normalizing the activity of the 
experimental reporter to the activity of the internal control minimizes experimental 
variability caused by differences in cell viability or transfection efficiency, thus 
greatly improving the accuracy of the assay. 
H1299 cells were seeded onto 24 well plates. Upon reaching 80-90% confluency the 
cells were transfected by means of lipofectamine™ 2000 reagent with the total 
amount of DNA for all wells kept constant at 0.8 µg. 
In all experiments focusing on transcriptional potential of desired proteins an 
optimised ratio between the ‘experimental’ reporter and the ‘control’ reporter has 
been set up in order to minimize unspecific in trans effects between promoters of 
cotransfected plasmids. 
In experiments which focused on p53-dependent transcriptional activity constant 
(30ng) pGL4.10[luc2] bearing a 44base stretch of the p21 promoter (‘experimental’ 
reporter) was mixed with 70ng of the phRL-CMV (‘control’ reporter). To this 
mixture 150ng of the pCNA3.1 p53wt, 75-550ng pcDNA3.1 MDM2 wt or the 
previously mentioned single amino acid mutants were added.  The DNA mixtures, 
with appropriate controls were made up accordingly for each well to be transfected 
with the addition of pCNA3.1 empty vector  the make up the 0.8µg total DNA  were 
necessary.  
 
Twenty four hours post transfection, the cells were washed once in ice-cold PBS and 
passively lysed with 1x Passive Lysis Buffer (supplied with the Dual-Luciferase® 
Reporter Assay System from Promega) Afterwards the Dual-Luciferase® assay was 
performed in accordance with the protocol provided by the manufacturer. The assay 
was carried out on 96 well black polypropylene plates and the luminescent signals 
were measured with the Thermo Scientific Fluoroskan Ascent Multimode Reader. 




For further immunoblot analysis the lysates were precipitated with Trichloroacetic 
acid (TCA) with Deoxycholate (DOC). Briefly DOC was added to the lysates final 
concentration of 0.02% v/v and incubated at room temperature for 15 minutes. 
Afterwards TCA was added to final concentration of 6% v/v and the samples were 
incubated at 4ºC for 1hour. The samples were spun down and the pellets were 
washed with ice-cold acetone and centrifuged once again. The air dried pellet was 
resuspended in an appropriate   volume of 1x SDS PAGE sample buffer. 
 
2.8.6 Monitoring p53 conformation in cells 
Human lung carcinoma H1299 cells were grown at 37 °C in RPMI with 10% (v/v) 
fetal bovine serum, 5% CO2. Cells were gently lysed on ice in Nonidet P-40 buffer 
(25 mM Hepes pH 7.5, 0.1% (v/v) Nonidet P-40, 150 mM KCl, 5mM DTT, 50 mM 
NaF, protease inhibitor mixture by Roche Applied Science (1 tablet was added per 
10 ml of lysis buffer)). The protein concentration of the cell lysates was quantified 
using the Bio-Rad Bradford assay kit. To estimate the amount of correctly folded p53 
in H1299 p53_/_ cell lines transfected with appropriate plasmids (pCDNA3.1 (EV)-
mock, pCDNA3.1/p53wt, pCDNA3.1/MDM2wt, pCDNA3.1/ MDM2K454A, 
pCDNA3.1/MDM2C464A, and pCDNA3.1/MDM2C478S in appropriate 
combinations), the ratio between the level of p53 captured by pAb1620 and DO-1 
was calculated. 
The ELISA procedure was carried out as follows: the wells were coated with wt-p53 
conformation-specific pAb1620 monoclonal antibody or DO-1 (both mouse origin, 
Moravian Biotechnology) at 200 ng per well in 100 mM carbonate buffer, pH 9.0, at 
4 °C for 16 h. The wells were blocked for 1 h at 17 °Cwith blocking buffer (4 mg/ml 
BSA in phosphate-buffered saline). This was followed by titration of increasing 
amounts of appropriate cell lysate diluted with the reaction buffer (25 mM HEPES, 
pH 7.3, 150 mM KCl, 5 mM DTT, 10% glycerol, 0.1% Triton X-100, 4 mg/ml BSA, 
protease inhibitor mixture). The reaction was performed for 1 h at 17 °C. Detection 
of p53 protein was carried out using the FL-393 antibody (rabbit origin, Santa Cruz 
Biotechnology) for1hat 17 °C. This was followed by the addition of anti-rabbit IgG-
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horseradish peroxidase secondary antibodies (Santa Cruz Biotechnology). Analysis 
of bound antibodies was performed by colorimetric detection with the TMB 
peroxidase kit (Bio-Rad) followed by quenching the reaction with 1 M H2SO4 and by 
absorbance measurements at 450 nm. The results obtained were plotted as a function 
of absorbance with respect to the amount of protein in question. For each particular 
case within the linear range the first derivative was calculated. The final values 
presented on the graph in Figure 3.12 represent the normalization fractions obtained 
by division of pAb1620 derivative values versus DO-1 derivative values. The data 
represent the mean from five independent experiments with a standard deviation. 
 
2.8.7 Immunoprecipitation protocol 
 
Lysis Buffer 
50mM HEPES pH 7.2 
150mM NaCl 
0.5%Tween20 
Protease Inhibitor mix (10x) 
 
Cell pellets were resuspended in 200ml of ice cold lysis buffer mixed well and 
incubated on ice for 15 minutes.  Cell debris was spun down at 10000 rpm for 20 
minutes at 4oC.  Lysate was pre-cleared with 100µl of Sephadex CL-4B beads 
(Sigma-Aldrich).  Beads were washed 3x in cold lysis buffer.   The beads were added 
to the cell lysate in a 1.7ml eppendorf tube and incubated for 40 minutes at 4oC with 
rotation. The beads were spun down at 5000 rpm and supernatant transferred to a 
new eppendorf tube and protein concentration was calculated by Bradford method. 
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2µg of specific antibody (DO-1 for p53) was added to lysate (200-800 µg) and 
incubated for 2 hrs at 4oC with rotation.  15µl of protein G beads (GE healthcare) 
were added to eppendorf tube and left to incubate for an hour.  The beads were spun 
down at 5000rpm at 4oC for 2 minutes.  Beads were washed 4x with ice cold PBS.   
The antibody-antigen complex was removed by the addition of 50µl of sample buffer 
followed by incubation at 95oC for 5 minutes.  Beads were spun at 10000 rpm for 5 
minutes and sample buffer removed.  10µl of elution was resolved on a 10% gel. 
 
2.8.8 Pulse-Labelling Assay for Measuring Protein Synthesis  
H1299 cells were seeded onto a 6 well plate, upon reaching 80-90% confluency, they 
were transiently transfected with plasmids encoding for p53 and MDM2.  Twenty 
four hours post transfection the cells were washed twice with PBS. 35S-methionine 
labelling was carried out by culturing the cells in methionine-free medium containing 
2% dialysed fetal calf serum (FCS) for 1 hour (22 µM, Merck Biosciences). Easytag 
Express Protein Labelling Mix (35S, 90 µCi; PerkinElmer) was added for 20 min or 
60min in the presence of proteasome inhibitor MG132. Afterwards the p53 protein 
was immunoprecipitated using CM-1 antibody (a gift from B. Vojtesek, Masaryk 
Memorial Cancer Institute, Brno, Czech Republic) and separated by SDS–PAGE. 
2.8.9 Tryptic digestion 
 
Wt or mutant MDM2 protein (1 µg) plus trypsin (10 ng) was incubated at 30oC in 50 
mM ammonium bicarbonate buffer for up to 30 min. Aliquots were removed and the 
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reaction stopped by the addition of SDS sample buffer and heating at 80oC for 4 min. 
The samples were analysed by on 4-12% gradient gels (invitrogen) and immunoblot.  
 
2.8.10 Intrinsic fluorescence assay 
 
Fluorescence emission spectra were recorded with the use of the SPEX 
FLUOROMAX-3 (Jobin Yvon Horiba) spectrofluorometer. The bandwidths for 
excitation and emission were set at 5nm. An excitation wavelength of 295nm was 
used. Fluorescence spectra were recorded from 320 to 450 nm in 0.5 nm steps, with 
an integration time of 1 s. Each obtained spectrum is the average of three emission 
scans minus the average of three blank (buffer) scans. All of the experiments were 
carried out at 4 °C in buffer containing: 25 mM Hepes (pH 7.5), 50 mM KCl, 5% 
(v/v) glycerol, 10µM ZnSO4 and 2mM DTT. MDM2WT , MDM2C464A , MDM2C478S 
used in this assay were initially preincubated on ice for 5 minutes at final 
concentration raging from 20nM to 1µM  (Vtotal=0.5 ml). 




2.8.11 Thermal denaturation assay 
 
To monitor protein unfolding, the fluorescent dye Sypro orange was used. Sypro 
orange is an environmentally sensitive dye. The unfolding process exposes the 
hydrophobic region of proteins and results in a large increase in fluorescence, which 
is used to monitor the protein-unfolding transition. The thermal shift assay was 
conducted in the iCycler iQ Real Time Detection System (Bio-Rad, Hercules,CA), 
originally designed for PCR. The system contains a heating/cooling device for 
accurate temperature 
control and a charge-coupled device (CCD) detector for simultaneous imaging of the 
fluorescence changes in the wells of the microplate. Solutions of 50 µl per well were 
aliquated to 96 well iCycler iQ PCR plate. They consisted of 0.5-1µM MDM2, 
25mM Hepes pH 7.6, 100mM NaCl, 2mM DTT, 4mM MgSO4 , 10x conc. Sypro 
orange dye and +/- 5mM ATP.  
The plate was heated from 20 to 95 °C with a heating rate of 0.5 °C/min.  
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3.1.1 The structure of MDM2 C2H2C4 RING  
 
In terms of how an E3 Ubiquitin Ligase mediates transfer of ubiquitin to the target 
protein two prominent classes can be distinguished. Historically the first E3 ubiquitin 
ligases to be discovered were the HECT domain E3s. Protein members of this group 
form a covalent intermediate with ubiquitin before transferring it to the target 
protein. The second group comprises of enzymes that, instead of binding directly to 
ubiquitin, rather bring the ubiquitin-bound E2 conjugating enzyme into close 
proximity to the acceptor lysine residue on the target protein and allosterically 
enhance the transfer reaction. This class comprises of RING (Really Interesting New 
Gene), U-box and PHD domain E3s. Members of both of these classes have been 
found to target the p53 tumour suppressor. It was found that p53 forms a complex 
with the HECT containing papilomavirus E6 protein and the cellular E6-AP (E6 
Associated Protein 1) (Scheffner et al., 1993) as well as the ARF-BP1 (ARF-binding 
protein 1) (Chen et al., 2005a). From the second group Pirh2 (Leng et al., 2003), 
COP1 (Dornan et al., 2004a), TOPORS (Rajendra et al., 2004), CHIP (Esser et al., 
2005b) and the main focus of this thesis MDM2 (Haupt et al., 1997; Honda et al., 
1997; Kubbutat et al., 1997) have been shown to bind and catalyse ubiquitination of  
p53. 
The MDM2 protein is by far the most studied p53-specific ubiquitin protein ligase.  
The full-length form (predominant isoform) of MDM2 is 491 amino acid residues 
long (Figure 3.1 Panel A), building a multidomain protein that contains several 
regions of high evolutionary conservation. Of these the last 60 amino acids residues 
are of particular interest in this chapter. These are critical for MDM2 to retain its E3 
ubiquitin ligase activity and were initially identified as the RING domain, based on 
protein sequence alignment (Boddy et al., 1994) (Figure 3.1 Panel A). Two zinc ions 
are essential for the proper folding and function of the MDM2 RING domain, eight 
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amino acids, six cysteine and two histidine residues coordinate the ion binding 
(Kostic et al., 2006; Linke et al., 2008) (Figure 3.1 panel B).  
Proteins bearing the RING domain portray a unique key amino acid residue sequence 
arrangement of eight strictly conserved metal binding residues, with the accepted 
consensus sequence; C-X2-C-X(9-39)-C-X-H/C-X(2-3)-C/H-X2-C-X(4-48)-C-X2-Cn 
(Freemont et al., 1991; Lovering et al., 1993). However the conservation of active 
residue spacing in MDM2 RING is different. The two zinc-binding sites are called 
C4 and H2C2 respectively (Figure 3.1 panel B). The C4 coordination site as the 
name suggests comprises of four cysteine residues; Cys438, Cys441, Cys461, Cys464. 
The second zinc binding site, H2C2,  is built up of; His452, His457, Cys475, Cys478. The 
characteristic “cross-brace” topology of the afore mentioned zinc coordinating 
ligands is illustrated schematically on Figure 3.1 panel C and is equivalent with what 
is observed in other RING/U-box bearing proteins. Moreover, the super-secondary 
structure ββαβ fold of the MDM2 RING (Figure 3.1 panel D) is also compatible with 
other members of the RING domain family. The MDM2 RING shows asymmetrical 
surface charge distribution (Figure 3.1 panel E) the bulk of the positive charge is 
located on one side of the domain, primarily due to the presence of solvent-exposed 
basic residues located in the α-helix building the ββαβ domain fold.  
When comparing the available structures of the MDM2 RING monomer from RSCB 
Protein Data Bank (http://www.rcsb.org/pdb/) (Figure 3.1 Panel F) one can see a 
high similarity of the structures with the least variable regions including zinc binding 
site I (C4) and the following α-helix, while the placement of the β-sheet and the 
second (C2H2) zinc-binding site exhibits more divergence.  The first CXXC zinc-
binding pair Cys438, Cys441 stabilizes the N-terminal region of the RING (C4) 
subunit, a stretch of seven residues bearing irregular structure follows leading to β-
strand 1 (Figure 3.2 Panel A and B). At the end of β1 His452 is present and is 
involved in zinc-binding by the second subunit (H2C2). This is followed by a short 
loop (Gly453-Lys454) leading into β2, which ends with His457. Two histidine side- 
chains extend from the ends of the antiparallel β-strands to form one side of the 
second (H2C2) zinc-binding site.  
Several RING/U-box domains are found to form homo- or heterodimers, furthermore 
specific dimer organization is proposed to be an important regulating step in 
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activating E3 ubiquitin ligase activity of these domains (Vander Kooi et al., 2006). 
Structurally BRCA1/BARD1(Brzovic et al., 2001) and Ring1b/Bmi1(Buchwald et 
al., 2006) have been shown to form heterodimers and Pirp19 and CHIP form 
homodimers (Vander Kooi et al., 2006) (Xu et al., 2006). MDM2 RING domain 
similarly was shown to structurally homo- (Figure 3.2 panel C) and heterodimerize 
with itself and its paralogue MDMX (MDM4) respectively (Kostic et al., 2006; 
Linke et al., 2008). The hydrophobic patch of each MDM2 RING monomer is the 
region employed primarily in formation of dimer interface, resulting in burial of  a 
large hydrophobic region that would be solvent exposed in a monomeric state 
(Figure 3.2 panel D). Despite the converging crystallographic and biochemical 
results highlighting the ability of the MDM2 monomer to homo- and 
heterooligomerize with its paralogue MDMX, no studies have clearly shown whether 
this is the case for the full length form of the proteins.  All the available data are 
based on purified RING subdomains of MDM2 and MDMX, and though 
informative, do not shed light on how this process is controlled and affected by 
remaining prominent subunits of the proteins. Moreover, no structural information is 
available on how the remaining protein backbone of MDM2, excluding the RING 
motif, behaves upon dimerization.  
 
3.2 Experimental Results 
 
3.2.1 Point Mutations within Key Residues building the MDM2 RING domain 
 
The C-terminal RING Domain of MDM2 is critical for its activity, each RING 
monomer shows a ββαβ fold, a small hydrophobic core and coordinates two Zn2+ 
ions which are essential for maintaining the native domain structure resulting in an 
active phenotype of the enzyme. Zinc binding is carried out by a set of eight amino 
acid residues; four cysteines and two histidines and two cysteines respectively. 
In order to study the RING domain in the context of full-length MDM2 a series of 
RING finger domain mutant constructs was generated. Two of these, Cys464A 
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(MDM2C464A) and Cys478S (MDM2C478S), introduced single point mutations into two 
independent Zn2+ coordination sites within the C2H2C4 Zinc coordinating structure 
(Kostic et al., 2006) and a third, Lys454A (MDM2K454A), is a RING domain residue 
which is not required for Zinc coordination but is essential for MDM2 to bind ATP 
(Poyurovsky et al., 2003; Wawrzynow et al., 2007a). 
The Cys464A mutation (Figure 3.3 Panel A) is located within the first zinc-binding site 
of the monomer and is one of the first to be identified as disruptive to the E3 
ubiquitin ligase potential of MDM2. This mutation, which alters the structurally 
critical zinc coordinating cysteine has been show to abolish MDM2’s enzymatic 
activity without affecting MDM2-p53 binding (Geyer et al., 2000). Mutating the last 
cysteine within the C4 coordination site proves to have its advantages, despite the 
fact that one looses a Zn2+ coordinating residue its location within the α-helix of the 
RING, (Figure 3.3 Panel B) implicates that the mutant is predicted to globally have a 
similar conformational status as its wild type counterpart. Moreover, the mutation 
has little or no effect on the local chemical exposure to the solvent (Figure 3.3 
compare panel C and D). 
The Cys478S mutation (Figure 3.4 Panel A) is located within the second zinc-binding 
site of the monomer. This mutation also alters the structurally critical zinc 
coordinating cysteine and furthermore diminishes the interaction of MDM2 with its 
paralogue MDMX (Sharp et al., 1999). This also is the last cysteine within the H2C2 
coordination site. The mutation is located within an irregular structured loop region 
of the MDM2 RING, thus its effect on the global fold of the domain is predicted to 
be minimal (Figure 3.4 panel B). The chemical nature of the mutation from cysteine 
to serine is also quite valuable here in contrast to the previous Cys464A, as here a 
sulphydryl proton donor group is replaced with a hydroxyl one. Furthermore the  
Cys478S in contrast to the Cys464A, has a prominent effect on the local chemical 
exposure to solvent (Figure 3.4 compare panel C and D). 
A Walker A or P loop motif is localized within the RING MDM2 domain (Figure 3.5 
panel A). This is a common feature of ATP/GTP binding proteins (Walker et al., 
1982). The P loop consensus sequence (GXXXXGK(T/S)) in MDM2 consists of 
G(448)CIVHGKT(455). It is highly conserved in all vertebrate MDM2 orthologues 
and is also present in the MDMX paralogue. It must be stressed that among other 
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RING/U-box E3 ubiquitin ligase proteins, MDM2 and its paralogue MDMX are 
unique for possessing this motif. Published data highlights that MDM2 preferentially 
binds ATP over GTP with a KD =13.5 µM (Poyurovsky et al., 2003). Additionally no 
ATPase activity of MDM2 has been detected (Poyurovsky et al., 2003). Mutation of 
the mdm2 ORF in the Lys454A position inhibits ATP binding by the protein but does 
not interfere with its E3 ubiquitin ligase activity (Poyurovsky et al., 2003).  
The crucial amino acids Gly453, Lys454, Thr454 of the P Walker motif are located in 
the loop between β1 strand and β2 strand of the RING domain (Figure 3.5 panel A). 
During structural and functional studies of the MDM2 RING domain it has been 
shown that Thr455 although not involved directly in zinc binding plays an important 
role in maintaining the structural and functional integrity of MDM2 (Kostic et al., 
2006; Lovering et al., 1993; Poyurovsky et al., 2003). The Thr455 is located at the 
monomer subunit interface and has contacts with several residues on the opposite 
monomer. For this reason Lys454A was mutated for the experiments in this thesis, 
nevertheless by comparing panel D and E of Figure 3.5 one can predict that mutation 
of Lys454 has a greater effect on the local structure and chemical exposure to the 
solvent, than the previously described mutations. 
 
3.2.2 MDM2 E3 Ubiquitin Ligase Activity in Cell Culture 
 
All of the above mutations were introduced into full-length MDM2 encoding 
plasmids and were transfected into two distinct cell lines in order to assay for E3 
ubiquitin ligase activity, by means of a well characterized His-tagged ubiquitin 
pulldown assay (Xirodimas et al., 2001a). This cell-culture assay system originally 
developed in 1994 (Treier et al., 1994) is very efficient for investigating MDM2-
mediated ubiquitination of p53 within a specific cell-culture background. By means 
of transient tranfection, a construct expressing modified – His6-tagged version of 
ubiquitin is introduced to a given cell line. Thus a protein undergoing ubiquitination 
is likely to be tagged with this exogenous ubiquitin protein moiety, rendering it 
possible to extract it from the cell lysate by means of His - Ni2+ affinity 
chromatography.  
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Human lung carcinoma H1299 p53-/- cells (Wang et al., 1998), which express  
limited amounts of endogenous  MDM2 (Figure 3.6) were cotransfected with a 
combination of plasmids encoding His6-ubiquitin, wild-type p53 and wild-type or 
MDM2C464A, MDM2C478S,  MDM2K454A and MDM2K454A/C478S double mutant 
respectively. Two reasons support the use of this cell line for the assay. Firstly, it is 
very easily transfected, thus allowing straightforward detection of proteins linked to 
ubiquitin. Secondly, as stated above it is deficient for p53 expression, hence resulting 
in low  levels of endogenous MDM2.  
In order to further enhance the total pool of ubiquitinated proteins within the cell 
prior to lysis, the cell culture was treated for several hours with a proteasome inhbitor 
MG132. This was followed by protein extraction under denaturating conditions (6M 
guanidium-HCl) in order to prevent deubiquitination of protein-ubiquitin conjugates 
as well as curb any non-covalent protein-protein interactions. Following protein 
extraction under denaturating conditions, His6-ubiquitinated proteins were isolated 
from the total pool by using Ni2+ - agarose beads. Eluates were separated by means 
of SDS-PAGE, and further analysed by immunoblotting.  
The results presented in Figure 3.6 show a high specificity of p53 ubiquitination 
dependent on MDM2 transfection (compare lines 3 and 5 Panel A and B Figure 3.6). 
The tumour suppressor is di-, tri-, tetra-, penta-ubiquitinated in a dose dependant 
fashion by MDM2. As this assay is more qualitative than quantitative it is difficult to 
establish whether MDM2K454A is more or less active as a ubiquitin ligase than 
MDM2WT (Figure 3.6 compare panels A and B), nevertheless the mutant shows 
considerable ligase activity which is consistent with published data (Poyurovsky et 
al., 2003). Surprisingly, p53 was also ubiquitinated when mutants within key 
cysteine residues of the MDM2 RING, MDM2C464A and MDM2C478S were transfected 
(Figure 3.6 panel C). This seams contradictory to previous published experiments, 
where these mutants are clearly described as being E3 ubiquitin ligase ‘dead’ (Geyer 
et al., 2000). However, as the H1299 cell line used in this experiment harbours, 
although at low levels, endogenous MDM2 and MDMX, the observed phenomenon 
can be explained as such. When the physiological level of MDM2 is increased by 
transient transfection one observes an increase in the ubiquitination ladder of p53. 
This may be due to the generation of heterogeneous complexes between endogenous 
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and trasfected MDM2 mutant proteins. The p53 tumour suppressor shows increase in  
ubiquitination which is dose dependent on the amount of MDM2C464A and 
MDM2C478S expressed in the cell (Figure 3.6 Panel C). Thus, the increasing protein 
pool of exogenous MDM2 mutant proteins may recruit endogenous MDM2 leading 
to formation of an active complex and visible ubiquitination of the target protein.  
To test this hypothesis a different cell line was used, namely Mouse Embryonic 
Fibroblast, which were p53 -/- , mdm2 -/-  (MEF DKO), in this case the cell 
environment is deprived of endogenous MDM2 hence p53 ubiquitination should only 
rely on the amount of MDM2 introduced by transient transfection. This is indeed the 
case; p53 is ubiquitinated only in the presence of MDM2WT and MDM2K454A  mutant 
(Figure 3.7 Panel A and C) and no visible ubiquitination was detected in the presence 
of MDM2C464A and MDM2C478S. This assay clearly shows dependence on the 
genotype of the cell line used.  The synergy of the two performed experiments hints 
that MDM2 in cells functions as an E3 ubiquitin ligase not in a monomeric state. 
Indeed the Cys464A and Cys478S mutations render the protein inert in terms of   
enzymatic activity yet still make it possible for interaction with the WT counterpart.  
 
3.2.3 Chaperone Activity of MDM2 
The p53 protein is widely recognized for its critical role in suppression of tumour 
development. Nevertheless when one considers its biophysical properties it is an 
adequate representative of a thermodynamically instable protein (Canadillas et al., 
2006) with numerous vast unstructured motifs (Bell et al., 2002). Given the 
physiological temperature that the human body maintains, even the most structured 
part of purified p53 protein – the DNA binding domain adopts inactive misfolded 
conformations and aggregates at relatively high rates (Butler and Loh, 2006; 
Canadillas et al., 2006; Hansen and Braithwaite, 1996; Muller et al., 2004). 
 
It has been shown that the Hsp90 molecular chaperone, in an ATP-dependent 
reaction, retains p53 in a conformation that allows binding to a specific promoter 
sequence at physiological temperature (Muller et al., 2004; Walerych et al., 2004). 
The authors have investigated this specific protein:DNA interaction by means of 
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numerous techniques, one of which is the Electrophoretic Mobility Gel Shift Assay 
(EMSA). This technique also known as bandshift, gelshift or gel retardation assay, 
serves to analyse the interactions of proteins with DNA. This method is based on the 
fact that unbound DNA in a non-denaturated gel exhibits a higher electrophoretical 
mobility than protein-bound DNA. The protein-bound DNA is denoted as "gel-
shifted" in respect to unbound DNA. 
The EMSA based experiments described in this section stem from the outline 
described in Figure 3.8 panel A. Briefly, a sample containing p53 alone or with other 
proteins is subjected to a pre-incubation step performed at different temperatures, 
afterwards its potency for binding a specific promoter DNA sequence is investigated.  
As shown by previously published data, p53 incubated at 17°C in vitro binds 
specifically to p53-responisve promoter sequences after activation by C-terminal 
specific p53 antibody or phosphorylation by CK2 kinase (Hupp et al., 1995) 
(Walerych et al., 2004) and lanes 1,2 in Figure 3.8 panel B. The same reaction 
performed under more physiological temperatures, i.e. 37°C, does not lead to the 
formation of a p53-consensus site DNA complex (Figure 3.8 panel B, lane 6). As 
published before, at 37°C p53 loses its correct fold which is required for efficient 
specific binding of p53 to the promoter sequence (Walerych et al., 2004). However, 
the ability of p53 to bind to a promoter sequence at 37°C is maintained in the 
presence of the Hsp90 molecular chaperone and ATP, both in vivo and in vitro 
(Muller et al., 2004; Walerych et al., 2004; Wawrzynow et al., 2007a). In the current 
study when Hsp90 molecular chaperone was substituted with MDM2 protein in this 
reaction efficient binding of p53 to the promoter sequence was observed (compare 
lanes 1-6 with 8-13 Figure 3.8 panel B). Moreover, Hsp90 and MDM2 work 
synergistically (Wawrzynow et al., 2007a). The MDM2-dependent binding of p53 to 
the promoter sequence is limited to the physiological temperature of 37°C (Figure 
3.8 panel B), hinting that under heat shock conditions other chaperones could also be 
involved in these reactions. The presence of MDM2 does not supershift the p53-
promoter DNA complex (Figures 3.8 and 3.9 Panel B), suggesting that MDM2 is 
only transiently required for p53 to adopt a DNA binding-competent conformation. 
To test this hypothesis monoclonal antibodies were used that interfered with p53-
MDM2 complex formation; 2A10 binds to two epitopes within MDM2 (postioned 
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respectively at aa 255-265 and 384-400) and 4B2 antibody recognizing the epitope in 
the N-terminus of MDM2. The presence of these antibodies during the preincubation 
of MDM2 with p53 at 37°C severely, in the case of 2A10, and partially, in the case 
of 4B2, reduced the ability of p53 to bind to the promoter sequence (Figure 3.9 Panel 
B lanes 5 and 6). Interestingly, the addition of the same antibodies after the  
preincubation of MDM2 with p53 at 37°C had no inhibitory effect on p53 binding to 
the promoter sequence (Figure 3.9 Panel B lanes 9 and 10), suggesting that at this 
stage MDM2 is no longer in the complex with p53. Moreover, the monoclonal 
MDM2- specific antibodies 4B2 or 2A10 do not change the mobility of p53-DNA 
complex which further supports the absence of MDM2 in the p53-DNA complex 
(Figure 3.9, lane 9 and 10). However, if such a reaction is conducted at 4°C, the 
monoclonal antibody supershifts the p53-DNA complex (Figure 3.9, lane 14), 
suggesting that recycling of MDM2 from the p53 complex is caused by the diffusion 
accelerated by temperature. The data presented suggest that the presence of MDM2 
is required only when p53 is preincubated at 37°C and that the p53-MDM2 complex 
dissociates after conversion of latent p53 to a transcriptionally active p53. In a 
control experiment (Figure 3.9 Panel B lane 12), we found that the addition of the 
p53-specific DO-1 antibody before and after preincubation of p53 at 37°C  leads to 
antibody-induced supershift, indicating that p53 is present in the complex with the 
promoter DNA sequence. In addition, by means of ELISA it has been shown that, 
DO-1 does not interfere with MDM2-p53 complex formation (Wawrzynow et al., 
2007a).  
 
In the absence of ATP, MDM2 interacts with p53 independent of p53 conformation, 
namely, a correct fold i.e. native-like or mutant-like fold. This situation changes 
however in the presence of ATP. The nucleotide does not significantly influence the 
affinity of MDM2 for p53 with the correct wild type conformation but has an effect 
when the wild-type conformation of p53 is abrogated (Wawrzynow et al., 2007a). 
The presence of ATP in this scenario leads to a reduction in the affinity of MDM2 
for p53. The MDM2K454A purified mutant tightly binds p53 regardless of the 
presence of ATP or the conformational status of p53. These experiments suggest that 
binding of ATP by MDM2 triggers the release of MDM2 from the MDM2-p53 
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complex only when p53 is not in a wild-type conformation. The MDM2K454A protein, 
which still possesses E3 ubiquitin ligase activity on a level comparable with wild-
type MDM2 (Figures 3.6 and 3.7), is not able to rescue p53 binding to the promoter 
sequence at 37°C (Figure 3.10). Because the MDM2K454A mutation is within the 
RING finger domain, one cannot exclude the possibility that this mutation not only 
affects the ability of MDM2 to bind ATP but in addition has other effect(s) on the 
overall conformation of the RING finger domain. However, two experimental facts 
strongly suggest that this is not the case. First, the MDM2K454A mutant protein 
possesses E3 ubiquitin ligase activity similar to MDM2 wt protein both in cell 
culture and in vitro. In fact kinetic studies show that MDM2K454A is slightly more 
enzymatically active than MDM2WT (Poyurovsky et al., 2003) (and data presented in 
Chapter 4 of this thesis). Secondly the point mutants Cys464A and Cys478S in the zinc 
binding motif that are completely inactive in the p53 ubiquitination reaction in vitro 
(Chapter 4) yet still efficiently bind ATP (Chapter 4) and are able to partially rescue 
p53 binding to the promoter DNA sequence at 37°C (Figure 3.11).  
 
3.2.4 MDM2 induces proper folding of p53 in cells 
To test the influence of MDM2 assisted p53 folding within the cell, an 
immunochemical-based assay was used that measures the affinity of conformation-
specific antibodies for p53 (Gannon et al., 1990; Shimizu et al., 2006). H1299 p53-/- 
cells were cotransfected with a combination of plasmids encoding wild-type p53 and 
wild-type or mutant proteins, MDM2K454A, MDM2C464A, and MDM2C478S. After 
gentle cell lysis, the ratio of p53 correctly folded in a wild-type conformation 
(ELISA test with pAb1620) to total p53 (ELISA test with DO-1) in cell lysate was 
measured (Figure 3.12 Panel A and B). Following normalization to the total amount 
of p53 in cells the data shows that transfection of H1299 cells with p53 alone gives 
less than 40% of wild-type conformation (Figure 3.12 Panel C). It is highly probable 
that in this case the correct folding of p53 is stimulated by the presence of other 
molecular chaperones, like the abundant Hsp90. Cotransfection of p53 with 
MDM2WT substantially stimulates the folding of p53. More than 70% of p53 was 
found in a wild-type conformation. Cotransfection of p53 with the MDM2C478S or 
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MDM2C464A mutants caused an even higher level of pAb1620 positive p53 species 
than was seen with MDM2WT . It must be stressed that in the case when MDM2WT is 
used, we are dealing with at least three effects; that is, an increase of the degradation 
of p53, an increase of the chaperone-like activity of MDM2, and folding of p53 
catalyzed by other chaperones like Hsp90. Cotransfection of cells with p53 and 
mutant MDM2K454A substantially reduces the amount of p53 found in wild-type 
conformation (Figure 3.12 panel C), indicating that the observed effect of MDM2 on 
p53 folding requires ATP and is most likely due to molecular chaperone activity of 
MDM2. 
 
3.2.5 Translation of p53 is assisted by MDM2 in an ATP dependent manner 
 
The abundance of a given protein in a cell can summarized into the following 
equation: 
Protein Abundance = Protein Synthesis – Protein Degradation. 
Theoretically if one were to apply this simplified equation to the abundance of the 
p53 tumour suppressor protein and neglected the input of stress induced signalling 
(caused by DNA Damage, UV radiation, activation of oncogenes etc) leading to a 
dramatic increase of p53 synthesis and a prominent decrease of its degradation, then 
one would surely consider the role of MDM2 oncoprotein as an advantageous 
coefficient of protein degradation.  
Nevertheless, the aim of the previous sections was to portray to the reader that 
despite its E3 ubiquitin ligase activity MDM2 has other functions. It acts as a 
molecular chaperone, both in an in vitro controlled experiment [the EMSA 
experiments described in this chapter and supplementary data (Wawrzynow et al., 
2007b)], as well as in cells where it favours the adoption of p53 wt conformation 
(Figure 3.12). 
The involvement of MDM2 in p53 folding is also supported by other in vivo findings 
where increased levels of MDM2, in the presence of protease inhibitors, increase the 
level of p53 expression, whereas mRNA levels remained unchanged (Yin et al., 
2002). Moreover, MDM2C464A had a comparable effect to its WT counterpart, 
Chapter 3                             Structure-function analysis of the MDM2 RING finger 
 
 101 
meaning that the capacity of MDM2 to regulate p53 mRNA translation is 
independent of its E3-ubiquitin ligase activity. As it has been shown, 35S-Met pulse-
labelled H1299 cells cotransfected with p53 and MDM2WT led to an increase in the 
amount of soluble 35S-Met p53 immunoprecipitated with DO-1 (Figure 3.13). 
Interestingly, when MDM2WT was substituted by MDM2K454A such an increase in the 
amount of soluble 35S-Met p53 was not observed (Figure 3.13 Panel B). One 
interpretation of this cell based assay could be that MDM2 not only increases 
translation of p53 protein (as suggested by Yin et al, 2002) but also, using its 
chaperone-like activity, maintains proper folding of the p53 polypeptide. In the 
absence of active molecular chaperones, incorrectly folded p53 protein could 
aggregate and be sequestered in various cell structures. It has been shown before that 
molecular chaperones can not only protect proteins from aggregation but also 
dissociate already existing protein aggregates (Parsell et al., 1994; Skowyra et al., 
1990; Ziemienowicz et al., 1993; Ziemienowicz et al., 1995).   
 
3.2.6 C2H2C4 MDM2 mutant proteins have a gain of transrepressor activity    
 
It has recently been shown that the E3-ubiquitin ligase activity of MDM2 requires 
interactions at both the hydrophobic pocket and the acid domain (Wallace et al., 
2006). These interactions are linked by an allosteric mechanism, where initial 
binding of p53 at the hydrophobic pocket of MDM2 favours recognition of a p53 
ubiquitination signal from its core DNA binding domain (BOX-V). These findings 
prompted one to question whether similar mechanisms linked other MDM2 domains 
and how cooperation between domains impacted on the protein’s multi-functional 
nature. The RING finger domain of MDM2 is required for both its E3 ubiquitin 
ligase and ATP-dependent chaperone activities through binding to an E2-ubiquitin 
conjugating enzyme and to ATP, respectively (Linke et al., 2008; Wawrzynow et al., 
2007a). However, whether conformational changes in the RING domain are 
transmitted to other MDM2 functional domains affecting their activity, remains 
unclear.  
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Although the introduction of the Cys mutations is sufficient to inactivate MDM2 as 
an E3-ubiquitin ligase they do not affect the overall integrity of the C-terminus as the 
Cys464A and Cys478S MDM2 mutants retain the ability to bind ATP, whilst ATP-
binding activity is lost in the Lys454A mutant (Wawrzynow et al., 2007a) (Figure 3.11 
and Figure 4. Chapter 4). Thus, mutation of Cys residues in the RING appears to 
specifically inactivate RING function during ligation of ubiquitin to target substrates 
whilst leaving other RING domain functions intact.  
The MDM2 RING finger domain mutants presented in this chapter were tested in a 
p53-dependent transcription assay in order to determine if inactivation of either its 
E3-ubiquitin ligase or ATP-binding activities affected the potential of MDM2 to 
repress p53–dependent transcription.  The ability of p53 to activate transcription was 
determined using the p53 responsive region of the WAF1/p21-promoter and an in 
silico designed p53 binding consensus promoter (cons-promoter) to drive luciferase 
expression (Figure 3.14). When p53 was transfected into H1299 cells  (p53-/-) along 
with the p21-luciferase reporter and cons-luciferase reporter a p53 specific activation 
of the promoter was detected, co-expression of MDM2WT in a dose-dependent 
manner manner led to a progressive decrease in reporter activity indicative of 
transrepression, with an I0.5 in the region of 300 ng of MDM2 plasmid (150 ng of p53 
plasmid; Figure 3.14 Panel A). All the RING mutants were expressed to a similar 
level and were able to inhibit p53-dependent transcription, however, both the Cys 
mutants displayed a gain of transrepressor function with an I0.5 of < 75 ng for 
MDM2C464A and <150 ng for MDM2C478S.  In contrast, mutation of Lys454A did not 
enhance the repressor activity of MDM2 and like the wild-type protein this mutant 
had an I0.5 of around 300 ng. Similarly, whilst a titration of p53 could overcome 
transrepression imposed by a fixed amount of wild-type MDM2 and the Lys454A 
mutant, there was a significant reduction in the ability of p53 to overcome the effects 
of the Cys464A and Cys478S mutants (Figure 3.15). This data further supports the fact 
that MDM2 E3-ubiquitin ligase activity can be fully uncoupled from its ability to 
repress p53 transcription and second, it provides evidence that the RING domain can 
modulate the activity of MDM2 as a transrepressor of p53-dependent transcription.  
Together the data presented above suggest that mutation of residues within the RING 
finger domain that directly affect MDM2 E3-ligase activity facilitate transrepression 
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of p53 transcriptional activity. In contrast, mutation of the ATP binding site in 
MDM2 (Lys454A) had no effect on transrepression of p53. 
A control experiment (Figure 3.16) where p53 was replaced with a mutant p53F19A 
protein sheds further light on the complex interaction of MDM2 with p53. The 
Phe19A mutant of p53 is transcriptionally active yet is refractory to MDM2 mediated 
ubiquitination and binding. Early crystallographic data that elucidated the 
biochemical basis of MDM2-mediated inhibition of p53 function showed that the 
amino terminal domain of MDM2 forms a deep hydrophobic cleft in which a 
fragment of the amino terminal transactivation domain (BOX-I)  of p53 binds, 
thereby becoming concealed from the transcriptional machinery (Kussie et al., 
1996a). The interacting domains show a tight key-lock configuration. The 
hydrophobic side of the amphipathic p53 α-helix (BOX-I), which is formed by amino 
acids 19-26 (of which Phe19 , Trp23 and Leu26 are the most crucial due to the fact that 
they make contact), fits deeply into the hydrophobic groove of MDM2. Accordingly 
the p53 binding mutants (of which Phe19A is a member) are resistant to degradation 
by MDM2, as the E3-ligase activity of the protein cannot be allosterically triggered 
by p53F19A. 
Co-expression of MDM2WT in the p53F19A background did not lead to a progressive 
decrease in reporter activity (Figure 3.16). Moreover co-expression of all the 
mentioned RING mutants similarly had no effect. This data suggests that the 
canonical interaction of the transactivation domain with the hydrophobic pocket in 
MDM2 is necessary for proper transrepression of p53 by the latter. Furthermore the 
Cys464 and Cys478 MDM2 mutants which showed a gain of function as inhibitors of 
p53 dependent transcription require the mentioned native interaction to have their 
effect.  
Eight amino acid residues build the C2H2C4 the two zinc coordination sites within 
the RING domain of MDM2. The proper folding of this domain is zinc-dependent 
and a native fold is required for proper E3-ubiquitin ligase activity. Disruption of any 
of the six cysteines and two histidines hinders the proper coordination of zinc by the 
MDM2 protein. Two of these mutations, namely MDM2C464A and MDM2C478S, 
showed a gain of function phenotype in the p53-dependant transcription assays. Thus 
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one was led to ask whether these mutations are unique or whether disruption of any 
of the eight critical amino acids will give a similar effect.  
The Cys438 residue builds the first C4 Zn2+ coordination site alongside with Cys441 it 
stabilizes the N-terminal region of the subunit (Kostic et al., 2006) and furthermore is 
located within a loop region (Figure 3.2 panel A) in contrast to Cys464 which is 
located roughly in the middle of the α-helix. For these reasons the Cys438 residue was 
chosen for site directed mutagenesis to Ala. The second vexing issue was the 
chemical nature of the mutation. The Cys478 residue located within the second zinc 
binding region (H2C2) was mutated to serine although it also had an apparent gain of 
transrepressor activity; this was not as prominent as the Cys464A mutation in MDM2. 
At this time the question asked was, whether a substitution of cysteine residue to 
serine residue within the first zinc binding site will have a similar effect to the one of 
the studied mutants. In other words whether a less destructive mutation of cysteine to 
serine (substitution of the sulphydryl group with a hydroxyl one within the side chain 
of the amino acid) would render a similar phenotype as the cysteine to alanine 
substitution. As expected the new mutated proteins MDM2C438A and MDM2C461S 
displayed comparable inhibitory potential (Figure 3.17 Panel B) as the studied Cys464 
and Cys478 mutants.  
 
3.2.7 Endogenous downstream targets of p53 are affected by MDM2C464A and 
MDM2C478S mutants 
 
The Dual Luciferase Reporter Assay is a powerful tool when looking at the control 
of transcriptional activity of a given protein. First of all due to the design of the assay 
one looks at the final normalized readout from limited pool of cells which underwent 
transient transfection, which usually is roughly 40% of total cells. Secondly, the 
results obtained represent the picture within the cell when it comes to initiation of 
transcription regulation. Thirdly they are quantitative and the effects observed are 
dependent on dose of the inhibitor or activator.  
Nevertheless, one can consider this as a partly artificial system where the cell acts as 
a reaction vessel, with the amount of transfected proteins being far from 
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physiological levels. Taking this into consideration the observed inhibitory potential 
of the Cys464 and Cys478 mutants seen using the luciferase reporter was assayed in a 
more physiological environment where endogenous wild type p53 was present and 
its potential to activate a downstream response could be checked at the protein level. 
In order to do this an independent human cancer cell line was chosen; the human 
breast carcinoma MCF7 cell line (details on http://www.sanger.ac.uk/genetics/CGP/CellLines/). 
It was transiently transfected with increasing amounts of MDM2WT and the two Cys 
mutants (Figure 3.18). The E3 dead phenotype of the Cys464 and Cys478 mutants 
towards p53 is in accordance with the accumulation of endogenous p53 (Figure 3.18 
Panel A). Despite this visible accumulation of p53 a significant increase in the 
amounts of the Cyclin-dependent kinase inhibitor 1A – p21 (WAF1Cip1) nor the  Bcl-
2–associated X (BAX) protein was not observed (BAX is a well characterised target 
for p53 (Miyashita and Reed, 1995)). On the contrary, levels of p21 and BAX 
decrease depending on the amount of MDM2C464A or MDM2C478S. Moreover Figure 
3.18 Panel B shows that BAX protein levels are unaffected by the expression of wt 
MDM2 at the concentrations used in the experiment (Figure 3.18 Panel B ; lanes 2-
4), however under the same conditions the MDM2C464A mutant suppressed BAX 
protein expression even at the lowest amount used (lanes 8-10), and consistent with 
the reporter assays, the MDM2C478S mutant had intermediate activity as it suppressed 
BAX protein expression when present at the highest amount (lane 7). 
 
3.2.8 Functional implications of the RING domain in MDM2 
 
RING domains have two roles in a protein. Firstly, they act as E3 ubiquitin ligases. 
Secondly, they provide a scaffold for protein-protein interactions. The number of 
RING domains implicated in ubiquitination is exponentially increasing. MDM2 is a  
RING-dependant E3 well known for its ability to regulate p53 protein degradation. 
Considering structural data one can conclude that several regions of RING domains 
have been implicated as important in E2 recognition and binding (Kostic et al., 
2006). These regions include two zinc-binding loops, between the first and second 
Zn2+ -binding residues, and some residues in the α-helix building the ββαβ fold of the 
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MDM2 RING. This data was obtained by superimposing known crystallized 
RING/U-box domains with interacting E2 ubiquitin conjugating  enzymes 
(BRCA1/UbcH5c  and c-Cbl/UbcH7 complex (Brzovic et al., 2001; Katoh and 
Katoh, 2003)) onto the MDM2 model. Although the exact number of potential 
interacting residues varies dependent on the template used, a minimal interacting 
consensus can be made. A substitution of  Ile440 with Ala was chosen to investigate 
the effect of the mutation on the activity of the MDM2 protein (Figure 3.19).  The 
MDM2I440A mutant displays a lack of E3 ubiquitin ligase activity in a cell based 
ubiquitination assay (Figure 3.19 Panel B) and in vitro (Petterson, S., et al 
unpublished results) thus being consistent with the role for this residue at the 
MDM2-UbcH5 interface. Moreover, its ability to transrepress p53 induced 
transcription is comparable to that seen for the  MDM2C464A, MDM2C478S mutants. 
Hence the gain of transrepressor function of MDM2 protein is linked with the E3-
ubiquitin ligase activity of the polypeptide. Once the latter is inactivated, either by 
disruption of the RING tertiary organization or mutations within the interface 
involved in E2-conjugating enzyme interaction, such MDM2 mutant protein adopts 
an altered global conformation rendering it a better repressor of transcription that its 
WT counterpart.  
The involvement of nucleotide binding at this stage in this process is unclear. 
Disruption of the Walker P motif topologically located within the RING domain of 
MDM2 does not disrupt the E3-ligase activity in vitro and in cell culture based 
experiments, moreover no gain of transrepressor function of p53 transcription is seen 
for the MDM2K454A (which, as shown in the later parts of this thesis, has a low 
affinity for nucleotide binding in contrast to the wild type form)  
Together the data presented above suggest that mutation of residues within the RING 
finger domain that directly affect MDM2 E3-ligase activity facilitate transrepression 
of p53 transcriptional activity. In contrast, loss of MDM2 molecular chaperone 
activity in the ATP binding mutant (Lys454A) had no effect on transrepression of p53. 
Further, the data demonstrate that MDM2 E3-ligase activity can be completely 
uncoupled from its ability to repress p53 transcription. 
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3.2.9 RNA binding does not induce a gain of transrepression function of 
MDM2 
 
The MDM2 oncoprotein possesses several other activities, which seem independent 
of its E3-ubiquitin ligase activity.  MDM2 was proposed to catalyze ribosomal 
assembly (Marechal et al., 1994), it forms a protein complex in vivo with the L5 
ribosomal protein, moreover it is found to associate with 5S rRNA (Elenbaas et al., 
1996). Truncation mutants demonstrate that amino acids 425-491 are necessary and 
sufficient for RNA binding (Lai et al., 1998). Specific RNA binding was shown to 
occur through the RING finger domain of MDM2 and does not seem to occur in a 
zinc-dependent manner (Elenbaas et al., 1996; Lai et al., 1998). Moreover this 
interaction can be abolished by a single point mutation of Gly448 (Gly446 in mouse 
Mdm2)  to serine. To test whether RNA binding, or in fact the lack of it, has control 
of MDM2 transrepression on p53 induced transcription, a Dual Luciferase 
Transcription Assay was performed (Figure 3.20 panel B) in which the transrepressor 
potential of the MDM2G448S mutant protein was compared to MDM2K454A (deficient 
in ATP binding) MDM2C464A (inactive as an E3-ligase) and MDM2WT. The data 
shows that the MDM2G448S mutant does not exhibit a gain of transrepressor function 
compared to MDM2C464A.  That being said, the MDM2G448S behaves more 
comparably to wt MDM2. This data sheds further light on the intricate organization 
of the MDM2 RING domain and mutations created within this domain are not all 
synonymous in their outcome. Only key amino acids, involved in either stabilization 
of the tertiary fold of the domain or involved in E2-RING interaction, when mutated 
render a gain of function, increased transrepressor phenotype.  
 
3.2.10 Gross deletions and extreme C-terminal truncation mutations within the 
RING domain of MDM2 have opposing effects on transrepression of p53 
 
The structural integrity of the MDM2 RING domain is required for E3-ubiquitin 
ligase activity of the protein and also is a site for homo and  hetero-oligomerization. 
Mutations within the key residues that coordinate zinc binding abolish enzymatic 
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activity of the protein, yet are stimulatory for transrepression measured by 
transcription based assays. Despite no established ATPase activity the RING is also a 
site for nucleotide binding, which acts as a positive switch for  the molecular 
chaperone properties of the protein, yet has no effect on its E3 activity. The domain 
is also necessary for RNA binding yet this interaction was shown to be zinc 
independent. Considering all of the above, a protein bearing this domain will display 
multifunctional properties. The question at hand is how will the MDM2 protein 
behave when it is lacking the RING domain? Surely E3 ubiquitin ligase activity will 
be abolished, yet this gross mutation still makes it possible for MDM2 to interact 
with p53 via the N-terminal hydrophobic pocket. As presented in Figure 3.21 Panel 
A, MDM2 lacking the RING is efficient at decreasing p53 mediated transcription, so 
efficient in fact that its I0.5 is consistent with the gain of function mutations at Cys464 
and Cys478 in MDM2. On the protein level (Figure 3.21 Panel B) the decrease of p53 
activated endogenous downstream targets such as p21 and BAX are also visible, 
though in this case the Cys mutants of MDM2 downregulate the expression of p21 
and BAX more effectively than the gross ΔRING MDM2 mutation (Panel B Figure 
3.21, compare lanes 7-10 with 15-18).  
Recent data (Poyurovsky et al., 2007; Uldrijan et al., 2007) illuminate the importance 
of the extreme C-terminal ‘tail’ residues in maintaining efficient MDM2 E3-
ubiquitin ligase activity. Loss of ubiquitin ligase function for these mutants 
correlated with the predicted failure of MDM2 to oligomerize with itself or with the 
paralogue MDMX. To test the effect of such mutations on MDM2 mediated 
transrepression of p53 transcriptional activity a series of nonsense mutations were 
generated (Figure 3.22 Panel A), resulting in the formation of four species of 
truncated forms of MDM2 protein, lengthwise different by 3 amino acids each.  
The MDM2Q480STOP nonsense mutation renders the protein inert in controlling p53 
activity (Figure 3.22 Panel B), yet the MDM2Q483STOP, MDM2V486STOP and 
MDM2V489STOP nonsense mutants are active.  This result demonstrates, that nine C-
terminal amino acid residues are dispensable for efficient repression of p53 driven 
transcription. Both the MDM2Q480STOP and MDM2Q483STOP mutants have been shown 
to be inactive as E3-ubiquitin ligases for p53 in vitro and in cell culture (Uldrijan et 
al., 2007). Co-immunoprecipation experiments showed that MDM2Q483STOP interacts 
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well with p53, yet no such data was shown for MDM2Q480STOP. How can one explain 
such a dramatic difference in transrepression between nonsense mutants 
MDM2Q480STOP and MDM2Q483STOP? One hint may be to consider the predicted space 
fill model with electrostatic potential distribution of the mutant monomers (Figure 
3.23). Although each mutant subunit is highly positively charged and the majority of 
that charge is located on one side of the molecule, a clear difference of negative 
charge distribution is visible when comparing the two mutants. Moreover a cavity is 
predicted to form for the MDM2Q480STOP mutant. As mentioned both of these C-
terminal truncations are inactive as E3 ubiquitin ligases, and the MDM2Q483STOP 
mutant has an I0.5 comparable to MDM2C464A (Figure 3.22 Panel B). This led to the 
assumption that MDM2Q483STOP resembles a similar gain of transrepressor function, 
to that of the mutants in key zinc binding cysteine residues. The nature of the mutant 
renders it inactive as an E3 ubiquitin ligase (Uldrijan et al., 2007) yet most probably 
considering its predicted structure it is still able to oligomerize.  





3.3.1 Alternative variants of MDM2 oncoprotein retain the RING domain  
 
The importance of MDM2 in the regulation of p53 protein stability and function has 
been illustrated in many systems. The RING domain is located within the C-terminus 
of the protein and contributes to numerous activities of the protein outlined in this 
chapter. To date, several reports have noted that human tumours can express 
alternatively and aberrantly spliced MDM2 variants (among the 40 identified in total) 
not found in normal tissue (for review see (Bartel et al., 2002).  
Paradoxically these mutants have the canonical N-terminal p53 binding domain 
truncated or deleted along with other central regions, yet still retain the RING 
domain. Interestingly these variants have been shown to be as oncogenic as the full 
length isoform of MDM2 (Fridman et al., 2003).  
Although the molecular basis for their oncogenic activity is not obvious from known 
structure-function relationships, it appears independent from physical association 
with p53, highlighting the p53 independent role of MDM2 in tumour development 
(Sigalas et al., 1996). 
It is important to note that alternatively and aberrantly spliced variants MDM2 
mRNAs are usually found together with full-length MDM2 transcripts. Although 
from the pool of variant transcripts not all of them are translated into proteins, to date 
at least several have been shown to interact with full-length MDM2 (Bartel et al., 
2002; Evans et al., 2001; Fridman et al., 2003) and sequester it in the cytoplasm. As 
the site for MDM2 homo- and hetero-dimerization is mapped to the RING domain of 
the monomer, this presents the domain in a new light as a necessary component 
contributing to the oncogenic potential of MDM2.  
The RING domain is primarily a scaffold for protein-protein interactions and is a key 
determinant of MDM2 E3-ubiquitin ligase activity. The Walker P motif located 
within the RING renders the protein capable of binding ATP. Additionally the RING 
finger has been implicated to be, at least in part, the site for RNA interaction (Bartel 
et al., 2002; Lai et al., 1998). Other activities ascribed to the RING include nucleolar 
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localization (Lohrum et al., 2000; Poyurovsky et al., 2003) and histone ubiquitination 
(Minsky and Oren, 2004).  All of the above modulate the end activity of the protein 
complex. Additionally key point mutations within this domain may specifically 
hinder one activity whilst others are retained.  
3.3.2 Regulatory effects of nucleotide binding by MDM2 
 
The results highlighting nucleotide bound MDM2 activity presented in this chapter 
suggest one possible scenario; upon MDM2:p53 complex formation, p53 protein 
undergoes partial unfolding (MacPherson et al., 2004; Yu et al., 2006). During stress 
conditions, e.g. UV radiation, p53 undergoes phosphorylation by CK2 (MacPherson 
et al., 2004), MDM2 dissociates from partially unfolded p53, thus allowing p53 to 
spontaneously fold.  Such repeated binding, unfolding, dissociation and folding 
reaction could lead p53 to reach a conformation of higher affinity towards its 
promoter sequence. Published cell culture based data strongly supports  the idea of 
MDM2 dissociation  following activation of p53.  Using  chromatin 
immunoprecipitation, White and colleagues (White et al., 2006) have shown that 
MDM2 localizes with latent p53 on the chromatin near P21(WAF1) and MDM2 
genes before but not after DNA damage. A transient complex of p53 with MDM2- 
and the Hsp90-molecular chaperone may be important for the decision to activate or 
degrade p53, by employing a series of post-translational modifications, like 
phosphorylation, acetylation, ubiquitination, sumoylation, neddylation and others. 
The situation where eukaryotic molecular chaperones are involved in folding and 
degradation of proteins is similar to prokaryotic Hsp100/Clp family members, where 
the ATPase subunit of  appropriate protease  at the same time is a molecular 
chaperone, and the specificity factor for the protein substrate’s degradation (Parsell 
et al., 1994; Wawrzynow et al., 1995a; Wawrzynow et al., 1995b; Wickner et al., 
1994). It is highly probable that in eukaryotes the quality-control process starts 
upstream of the 19S proteasome subunit, namely when the E3 ubiquitin ligase 
demonstrates its activity and the decision to repair or degrade the protein substrate 
occurs. This apparent contradictory mode of MDM2 as a component of the 
degradation machinery (E3 ubiquitin ligase activity) and as molecular chaperone-like 
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activity resembles a  dual-function of CHIP, a co-chaperone/ubiquitin ligase that also 
is p53 specific and targets a broad range of chaperone substrates for proteasomal 
degradation (Hohfeld et al., 2001) (Rosser et al., 2007). In addition to the fact that 
MDM2 can assist in correct non-covalent assembly of the p53-promoter complex, 
where MDM2 is not a component of this assembled structure,  MDM2 fulfils other 
molecular chaperone criteria.  The purified MDM2 protein, in an ATP-independent 
reaction, can function like the Hsp90 chaperone in protecting citrate synthase and 
firefly luciferase from aggregation [(Wawrzynow et al., 2007a) Supplementary data]. 
 
3.3.3 Activities of MDM2 on p53 can be uncoupled 
 
Recent genetic studies strongly postulate that the primary physiological role of 
MDM2 in the regulation of p53 protein levels is brought about through E3-ligase 
mediated ubiquitination (Itahana et al., 2007; Toledo and Wahl, 2006). These 
experiments were largely carried out in MEFs and developing mouse embryo’s 
where MDM2 activity has been lost, or reduced, and is therefore rate limiting. 
However, this situation is unlikely to reflect the environment encountered in most 
tumour cells. In fact current estimates suggest that MDM2 levels are elevated in  
~10% of all human tumours (Toledo and Wahl, 2006) due for example to enhanced 
translation or transcription in addition to amplification of the MDM2 gene (Ganguli 
and Wasylyk, 2003). In contrast to the studies in non-transformed mouse cell models 
mentioned above, work in tumour cells endogenously over-expressing MDM2 
protein suggests that its ability to act as a transrepressor contributes significantly to 
the impaired p53-response seen in these cells. Thus, in cells which are homozygous 
for a polymorphism (SNP309) that enhances SP1-dependent MDM2 transcription the 
MDM2 protein is found in association with p53 resulting in transcriptionally inactive 
complexes (Arva et al., 2005; Bond et al., 2004). Depletion of MDM2 by siRNA in 
these cells results in activation of p53-dependent transcription in the absence of 
increase p53 protein levels supporting the idea that, at least in some tumour cells, 
MDM2 acts predominantly as a transrepressor of p53 function (Arva et al., 2005). 
Furthermore, it has been demonstrated that tumour cells which do not have increased 
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MDM2 levels also operate an MDM2-dependent mechanism for controlling p53 
transcription in the absence of changes in p53 protein levels (White et al., 2006). 
Thus, the data presented in this chapter showing that C2H2C4 RING mutants that 
lose E3-ubiquitin ligase activity preferentially bind to p53 inhibiting its 
transactivation activity may be pertinent to the physiological environment of a 
tumour cell where MDM2 is controlling p53 activity primarily through 
transrepression.  
MDMX (also referred to as MDM4) a paralogue of MDM2 has recently emerged as  
another critical negative regulator of p53. MDM2 and MDMX share close similarity 
to two vital conserved domains: an N-terminal p53 binding domain and a C-terminal 
RING domain (Shvarts et al., 1996b). These two proteins can form a complex 
through their C-terminal domains, and although quite similar MDMX does not 
posses an intrinsic E3 ubiquitin ligase activity ((Stad et al., 2001; Tanimura et al., 
1999). On the other hand, genetic studies show that deletion of the MDMX gene 
leads to p53-dependent lethality during early embryogenesis, as is the case for mdm2  
deletion (Migliorini et al., 2002; Parant et al., 2001).  MDMX is believed to control 
p53 abundance in the cell indirectly by modulating the levels and activity of MDM2 
(Gu et al., 2002; Linares and Scheffner, 2003; Sharp et al., 1999).  The conserved C-
terminal RING domains in both MDM2 and MDMX allow homo- and hetero-
dimerization between the mentioned proteins and this is seen as a critical for the 
mentioned E3 ubiquitin ligase activity of MDM2 (Tanimura et al., 1999). While 
MDM2 RING forms dimers quite readily (Kostic et al., 2006),  heterodimers are 
believed to form preferentially resulting in reduced auto-ubiquitination of MDM2 
and increased p53 ubiquitination (Kawai et al., 2007; Linares and Scheffner, 2003; 
Sharp et al., 1999). Recent crystallographic data supports the notion (Linke et al., 
2008) and states that the structure of the MDM2/MDMX heterodimer is required to 
ubiquitinate in trans. MDMX therefore is believed to stabilize MDM2 and keep 53 
levels and activity low in healthy cells. 
Although the data presented in this chapter does not directly undermine these 
findings, another possibility may be considered. It is true that the MDM2/MDMX 
interaction ensures a low activity of p53 under non stress conditions. Yet in a tumour 
system the MDM2/MDM2 interaction may be preferential. The MDM2 Cys464 and 
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Cys478 mutants are inactive as E3 ligases in vitro (Chapter 4) yet in cell culture are 
inactive only in mdm2 -/- background. Human lung carcinoma, H1299 cells which 
possess endogenous levels of MDM2 although in low amounts, used as experimental 
background show that p53 can be ubiquitinated in a dose dependent manner by the 
mentioned RING mutants.  This implies a homodimeric complex formation in terms 
of protein MDM2/MDM2 and at the same time heterodimeric in terms of state 
MDM2WT/MDM2C464A. This hypothesis is further supported by the emerging picture 
for MDM2  RING with E2 ubiquitin conjugating enzyme interaction, where one 
subunit of the RING dimer interacts with E2 whereas the other subunit remains 
uninvolved in E2 binding (Kostic et al., 2006). Moreover, the RING dimer interface 
is independent of the E2 binding surface. Based on this, one cannot rule out the 
possibility in which MDM2C464A or MDM2C478S interact with MDM2WT, where the 
latter provides the scaffold for E2 binding and the mutants interact with the p53 
polypeptide chain.  
 
The findings presented in this chapter give an introduction to the hypothesis, which 
is expanded on accordingly, that MDM2 RING E3 ligase activity in tumour 
environment is not the only biochemical activity required to suppress p53 activity. 
Later chapters of this thesis provide further investigation elucidating the reason why 
the key mutations within the RING presented, namely Cys464 and Cys478 give rise to 
a gain of transrepressor function and may be seen as oncogenic. These mutations are 
considered in the background of the full length protein, a more logical and 
informative approach than considering the sub-domain alone.  
 
3.4 Figures 
Figure 3.1 Topology and structure of the MDM2 C2H2C4 RING domain. 
 
(A) Primary structure of the full length human MDM2 491aa isoform. The C2H2C4 RING domain spans 
from amino acid 438 to 479 is highlighted in red. The Walker P Motif located within the RING domain 
which utilizes nucleotide binding by the protein is highlighted in grey.
(B) The MDM2 C2H2C4 RING domain with the highlighted amino acids providing the scaffold for two 
zinc-binding sites.  
(C) Zinc coordination scheme of human MDM2 RING highlighting the cross brace configuration of the 
amino acids involved in coordinating two zinc atoms. 
(D) A super-secondary structure ββαβ fold in ribbon representation of a single subunit of human MDM2 
RING  (aa 429-491), with Zn2+ coordinating side chain highlighted.  
(E) Surface mapped electrostatic potential of MDM2 RING monomer. Red and blue regions represent 
localization of negative and positive charges respectively.
(F) Structural alignment of the MDM2 RING subunits (Kostic et al., 2006 and Linke et al., 2008).
This figure was prepared using PyMOL [http://www.pymol.sourceforge.net/] and structural data from Kostic et al., 2006 andLinke et 
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Figure 3.2 Structure of MDM2 C2H2C4 RING as a monomer and 
homodimer.
(A) Super-secondary structure ββαβ fold in ribbon representation of a single subunit of 
human MDM2 (aa 429-491), showing the distribution of regular secondary structure elements 
and the location of two Zn2+-binding sites highlighted by dashed lines. The MDM2 C2H2C4 
RING is an essential domain for ubiquitination of p53. The first zinc-binding site (C4) is 
formed by Cys438, Cys441, Cys461 and Cys464; the key players in the second zinc binding 
site (H2C2) are His452, His457, Cys457, Cys478.   The side chains of the zinc ligands are 
shown. Zinc ions  are shown as grey spheres.
(B) Analogous to (A) additionally highlighting the input of Zn2+ binding sites to the architecture 
and chemical composition of the space fill model.  (Carbon-white, oxygen-red, nitrogen-blue, 
sulphur-yellow)
(C) Homodimer comprising of two C2H2C4 RING subunits.
(D) Space fill model of the C2H2C4 MDM2 homodimer.









































Figure 3.3 MDM2C464A single amino acid mutation within the C4 Zn2+ binding 
site.
(A) Ribbon representation of the MDM2 RING C464A mutant. Carbon atoms of highlighted 
residues (in stick representation) coloured according to the secondary structure they build. 
Nitrogen atoms highlighted in blue and sulphur atoms in yellow. 
(B) Structural alignment of MDM2 RING C464A mutant to WT. Zn2+ ions represented as grey 
spheres, carbon atoms in white and sulphur atoms in yellow.
(C) Space fill model of the C4 Zn2+ coordination site within MDM2WT. Oxygen in red, carbon in 
white, nitrogen in blue and sulphur in yellow.
(D) Space fill model of the C4 Zn2+ coordination site within MDM2C464A mutant; analogous 
colour representation as in (C).
This figure was prepared using PyMOL and structural data from Kostic et al., 2006 and Linke et al., 2008 (file 2HDP,2VJE respectively 
RCSB PDB ).
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Figure 3.4 MDM2C478S single amino acid mutation within the H2C2 Zn2+ 
binding site.
(A)  Ribbon representation of the MDM2 RING C478S mutant. Carbon atoms of highlighted 
residues (in stick representation) coloured according to the secondary structure they build. 
Nitrogen atoms highlighted in blue and sulphur atoms in yellow, oxygen atoms in red. 
(B) Structural alignment of MDM2 RING C478S mutant to WT. Zn2+ represented as grey 
spheres, carbon atoms in white and sulphur atoms in yellow, oxygen atoms in red.
(C) Space fill model of the H2C2 Zn2+ coordination site within MDM2WT. Oxygen atoms 
highlighted in red, carbon in white, nitrogen in blue and sulphur in yellow.
(D) Space fill model of the H2C2 Zn2+ coordination site within MDM2C478S mutant; analogous 
colour representation as in (C).
This figure was prepared using PyMOL and structural data from Kostic et al., 2006 andLinke et al., 2008 (file 2HDP,2VJE respectively 
RCSB PDB ).
Chapter 3                                   Structure-function analysis of the MDM2 RING 
118
Walker A/P Motif
CVI CQGRPKNGCI VHGKTGHLMA CFTCAKKLKK RNKPCPVCR Q



































Figure 3.5 MDM2K454A single amino acid mutation within the P Walker ATP 
binding site.
(A) Topological localization of the Walker P motif within the C2H2C4 RING domain of MDM2. 
MDM2 RING domain shown in red, Walker motif highlighted in grey. Amino acids building the 
GxxxxGK(T/S) consensus are outlined respectively.
(B) Ribbon representation of the MDM2 Walker P motif mutant. Carbon atoms of highlighted 
residues (in stick representation) coloured according to the secondary structure they build. 
Nitrogen atoms highlighted in blue and sulphur atoms in yellow, oxygen atoms in red. Amino 
acids building the motif outlined respectively.
(C) Structural alignment of MDM2 Walker K454A mutant to WT. Carbon atoms in white, 
nitrogen in blue and oxygen atoms in red.
(D) Space fill model of the Walker P motif ATP binding site within MDM2WT. Oxygen atoms 
highlighted in red, carbon in white, nitrogen in blue.
(E) Space fill model of the Walker P motif ATP binding  site within MDM2K454A mutant; 
analogous colour representation as in (C).
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Figure 3.6 In vivo ubiquitination of p53 by MDM2 in H1299 cell line.
H1299 cell line was transfected with the appropriate plasmids and amounts as depicted 
above. Four hours prior to lysis the cells were treated with 10 µM proteasome inhibitor 
MG132. 24 hours post transfection the cells were lysed and His::ubiquitinated proteins were 
isolated by His::Ni2+ affinity pulldown method.
Panels A, B, C Immunoblot of p53 from p53-/- H1299 transfected with p53  and MDM2 (wt 
and mutant constructs as indicated) plus His-Ub. His-conjugated proteins were isolated using 
nickel –agarose and analysed on a 4-12% gradient gel. p53 was detected using DO-1. Top 
illustrations for all the panels represent western blots with pulled down His Ub proteins 
probed with p53 specific antibody (DO-1).The data are representative of 2 independent 
experiments. Middle and bottom illustrations for all panels  represent direct lysis blots of 
H1299 cell extracts transfected with appropriate plasmids.  
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Figure 3.7 In vivo ubiquitination of p53 by MDM2 in MEF p53 -/- mdm2 -/- 
cell line.
MEF p53 -/- mdm2 -/- cell line was transfected with the appropriate plasmids and amounts as 
depicted above. Four hours prior to lysis the cells were treated with 10 µM proteasome 
inhibitor MG132.  24 hours post transfection the cells were lysed and His::Ubiquitinated 
proteins were isolated.
Panels A, B, C Immunoblot of p53 from p53-/- mdm2-/- MEFs transfected with p53 (150 ng) 
and MDM2 (wt and mutant constructs as indicated) plus His-Ub. His-conjugated proteins 
were isolated using nickel –agarose and analysed on a 4-12% gradient gel. p53 was
detected using DO-1. The data are representative of 2 independent experiments.
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Figure 3.8 p53 binding to a p21WAF1 promoter derived sequence is 
temperature dependent, in the presence and absence of MDM2. 
(A) Schematic view of p53 EMSA following temperature gradient incubation. The p53 tumour 
suppressor was subjected to a temperature gradient in the presence or absence of MDM2 
protein for 1 hour, after which the protein mixture was preincubated with specific radiolabelled 
p21WAF1 sequence, short nonspecific double-stranded competitor DNA and an activating 
antibody (Ig 421). The separation of the protein:DNA complexes followed in an 
non-denaturating 4% acrylamide gel electrophoresis. The final result was obtained by 
overnight exposition of the dried gel  onto a phosphor-imager screen.      
(B) Human recombinant MDM2 restores p53 specific DNA binding activity, after 1h 
inactivation in a temperature gradient (4-40°C). In all the lanes where MDM2 was added to 
p53, a constant 1:10 mass ratio of p53:MDM2 was used. At a 1:10 protein mass ratio, 0.05 
µg of p53 was used (58.1 nM of the monomer) and 0.5µg of MDM2 protein (0.45 µM of the 
monomer). In order to rule out unspecific protection/chaperone effects all reactions were 
supplemented with 1 µg/µl BSA. The arrow indicates the specific position of the p53 
tetramer:p21 promoter sequence complex as shown by (Walerych et al., 2004).
A
B
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Figure 3.9 Correct non-covalent assembly of the p53 promoter complex is 
facilitated by transient interaction with MDM2.
(A) Schematic represenation of the p53 EMSA assay with indication of points when the 
specific competitor antibodies were added.
(B) MDM2 specific antibodies can competetively inhibit MDM2 p53 interaction during the 
crucial heat denaturation step of p53. The specific p53 antibody (DO-1) and MDM2 
antibodies (2A-10 or 4B-2) were added during and after the incubation of p53  with MDM2 
and ATP at 37°C, as visible above. 
A
B
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Figure 3.10 MDM2K454A  the ATP-binding mutant of MDM2 is defective in 
promoting p53 binding to the p21WAF1 promoter sequence.
The retention of DNA binding conformation for p53 incubated at 37°C is mediated by the 
presence of MDM2, moreover this reaction is ATP dependent. The MDM2K454A mutant was 
unable to maintain p53 binding to the p21 promoter sequence at restrictive temperature in 
comparison to  MDM2WT.  As indicated above, comparable amounts of the two proteins were 
used in the EMSA  assay.
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Figure 3.11 MDM2K454A  the ATP-binding mutant of MDM2 is defective in 
folding p53 protein whereas MDM2C478S the E3 Ubiquitin ligase ‘dead’ mutant 
is not. 
The retention of DNA binding conformation for p53 incubated at 37°C is mediated by the 
presence of MDM2, moreover this reaction is ATP dependent. Mutation within the Walker P 
motif responsible for ATP binding by MDM2 renders the protein inactive in folding the p53, 
when the latter is incubated at non-permissive temperature.  Mutations within the H2C2 
Zn2+ coordination site within the RING motif of MDM2 has little inhibitory effect on MDM2 
mediated folding of p53 at 37°C.














































































































































Figure 3.12 MDM2 assisted folding of p53 in cells.
In order to measure the involvement of MDM2 oncoprotein in the folding process of p53 
polypeptide H1299 p53-/- cell line was transfected with empty vector, p53 (0.5 µg) alone, and 
combinations of p53 (0.5 µg) with MDM2WT (1 µg), MDM2K454A (1 µg), MDM2C464A (1 µg), 
MDM2C478S(1 µg), respectively. 
(A) and (B) After cell lysis and the ELISA experiments, described in detail in the Material and 
Methods section, were carried out. The ratio of p53 with a wild-type conformation (pAb 1620 
reactive) with respect to the total amount of p53 (DO-1 reactive) in the cell was calculated. 
(C) MDM2WT transfection stimulates the proper folding of p53. The ATP-binding mutant of 
MDM2 (K454A) has no effect on p53 protein folding. In contrast the E3 ubiquitin ligase 
mutants of MDM2 (C464A, C478S which retain chaperone activity) stimulate the folding of 
p53 protein to an even greater extent than MDM2WT.


































































































Figure 3.13 MDM2 is involved in the induction of p53 translation.  
MDM2 interacts directly with the nascent p53 polypeptide during translation. H1299 cell line 
was transfected with empty vector, p53 (0.5µg) alone, and combinations of p53 (0.5 µg) with 
MDM2WT (1 µg), MDM2K454A (1 µg). Afterwards 35S-Methionine pulse labelling was carried out 
for 20 or 60 minutes. Following cell lysis the amount of soluble 35S-p53 present was detected 
using immunoprecipitation, SDS-electrophoresis, autoradiography and densitometry of auto-
radiograms with appropriate background correction. The total amounts of p53 folding immu-
noprecipitation were verified by means of western blot analysis. 
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Figure 3.14 Dose dependent MDM2 repression of p53 transcriptional activity 
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. Twenty four hours post transfection the Dual Luciferase Assay was performed. 
(A) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct.
(B) MDM2 effect of p53 dependent transcription was performed using the p53 consensus::luc 
construct. Each of the bars represents a mean from three independent experiments. 
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Figure 3.15 Increasing p53 transfection to overcome MDM2 transrepression.  
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. This is an inverse experiment to Figure 3.14, where  constant levels of appropriate 
plasmids encoding MDM2 were co-transfected with increasing levels of the p53 encoding 
plasmid.
Twenty four hours post transfection the Dual Luciferase Assay was performed. 
(A) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct.
(B) MDM2 effect of p53 dependent transcription was performed using the p53 consensus::luc 
construct. Each of the bars represents a mean from three independent experiments. 
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Figure 3.16 MDM2 mediated transrepression on p53F19A transcriptional 
activity
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs.Twenty four hours post transfection the Dual Luciferase Assay was performed. 
(A) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct.
(B) MDM2 effect of p53 dependent transcription was performed using the p53 consensus::luc 
construct. Each of the bars represents a mean from three independent experiments. 
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Figure 3.17 Dose dependent MDM2 repression on p53 transcriptional activity 
Mutations in other key residues building up the two Zn2+ coordination sites within the C2H2C4 
RING motif in MDM2, show similar phenotype as the studied MDM2C464A, MDM2C478S mutants.
(A) Zinc coordination scheme of human MDM2 highlighting the cross brace configuration of 
the amino acids involved in coordinating two zinc ions. The key residues which were mutated 
are highlighted in colours.
(B) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct. 
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. Twenty four hours post transfection the Dual Luciferase Assay was performed. Each 
of the bars represents a mean from three independent experiments. 
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Figure 3.18 MDM2 mediated transreppression on endogenous downstream 
transcription targets of p53.
MCF7 cell line used in this experiment harbour endogenous WT p53. The cells were only 
transfected with the plasmids encoding for MDM2WT, MDM2C464A, MDM2C478S, (0-4μg) 
respectively as depicted above. This was done in order to compare the effect of the 
mentioned mutants of MDM2 on levels and transcriptional activity of endogenous p53. Total 
DNA amount was normalized using empty vector control.
(A) (B) MCF7 cell line was transfected with appropriate amounts of plasmids.Twenty four 
hours post transfection, cells were lysed and the resulting lysate was analysed by western 
blotting for the presence of the  proteins highlighted above. 
Antibodies used for detection MDM2-2A10, p53-DO-1, BAX-mAb anti BAX, p21-Ab1.
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Figure 3.19 Mutation of  a key residue required for interaction with E2 
conjugating enzyme shows a similar gain of transrepressor function as the 
MDM2C464A, MDM2C478S mutants.
(A) Schematic representation of residues (highlighted in green) within MDM2 predicted to be 
important for E2 conjugating enzyme UbcH5 family binding (BRCA1/UbcH5c used a 
modelling template), whereas the residues highlighted in green with dark outline were 
predicted to be binding based on c-Cbl/UbcH7 used as a template.
(B) Cell based ubiquitination assay to check for E3 Ubiquitin ligase activity of the MDM2I440. 
The cells were transfected with appropriate amounts of plasmids as shown in the figure 
above. Following lysis and isolation of the His-Ub protein pool, western blot analysis was 
performed, probed with p53 specific antibody (DO-1). 
(C) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct. 
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. Twenty four hours post transfection the Dual Luciferase Assay was performed. Each 
of the bars represents a mean from three independent experiments. 
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Figure 3.20 The potential of the MDM2G448S mutant in transrepressing p53 
mediated transcription.
The G448S point mutation in MDM2 RING finger completely abolishes specific RNA binding 
by the oncoprotein.  
(A) Schematic representation of residue (highlighted in black) within MDM2 predicted to be 
imperative for specific RNA binding.
(B) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct. 
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. Twenty four hours post transfection the Dual Luciferase Assay was performed. For 
accuracy Each of the bars  represents a mean from three independent experiments. 
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Figure 3.21 The involvement of the C2H2C4 RING in MDM2 mediated    
transrepression on p53.
 
Deletion of the RING domain for MDM2 enhances the transrepression potential of the 
protein.
(A) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct. 
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. Twenty four hours post transfection the Dual Luciferase Assay was performed. Each 
of the bars represents a mean from three independent experiments. 
(B) The lysates from the Dual Luciferace Assay were TCA/DOC precipitated and analysed by 
means of Western blotting in order to assess transfection efficiency and the effect of the 
transfected MDM2 on downstream endogenous transcription targets of p53.  
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Figure 3.22 The involvement of the last 12 C-terminal aminoacids of MDM2 
in transrepression of p53 transcriptional activity.
(A) Topological graphic representation of the C-terminus of MDM2. The codons encoding 
amino acids highlighted in colour were mutated to nonsense mutations, resulting in 
premature stop in translation, yielding a truncated protein.  
(B) MDM2 effect of p53 dependent transcription was performed using the p21::luc construct. 
H1299 cell line was transfected with the appropriate amounts of plasmids as indicated on the 
graphs. Twenty four hours post transfection the Dual Luciferase Assay was performed. Each 
of the bars represents a mean from three independent experiments.
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Figure 3.23 Structure comparison of MDM2Q480STOP to MDM2Q483STOP
(A) Space fill model of MDM2Q480STOP RING. Carbon atoms building the structure are 
highlighted in white, oxygen in red, nitrogen in blue and sulphur in yellow.
(B) Space fill model of MDM2Q483STOP RING. Carbon atoms building the structure are 
highlighted in white, oxygen in red, nitrogen in blue and sulphur in yellow.
(C) Surface mapped electrostatic potential of MDM2Q480STOP RING  monomer. Red and blue 
regions represent localization of negative and positive charges respectively.
(D) Surface mapped electrostatic potential of MDM2Q483STOP RING  monomer. Red and blue 
regions represent localization of negative and positive charges respectively. 
Please note, the difference in negative charge localization and cavity formation for the 
MDM2Q480STOP mutant.
This figure was prepared using PyMOL [http://www.pymol.sourceforge.net/] and structural data from Kostic et al., 
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4.1 Molecular basis for p53:MDM2 structure complex formation 
and inhibition 
 
Gain of transrepressor-function activity driven by key Cys mutations within the 
C2H2C4 RING domain of MDM2 on p53 observed earlier, shall be further 
investigated in this chapter. This gain of function of MDM2 to transrepress p53-
dependent transcription is seen when Zinc coordinating residues are mutated, 
whereas mutation of a residue within the RING required for ATP binding has no 
effect on MDM2 mediated transrepression. To aim at elucidating this phenomenon 
on the molecular level one must consider the process of MDM2::p53 complex 
formation. 
Protein-protein interactions are ubiquitous in biological systems. They are key in all 
physiological processes occurring within living organisms such as cell growth, 
division and differentiation, intracellular signalling and apoptosis (Fotouhi and 
Graves, 2005; Fry and Vassilev, 2005). Although cell based assays are the standard 
benchmark for investigating protein-protein interactions and, given an appropriate 
assay is used, they provide powerful insights into transcriptional, translational, 
degradation rates and interacting partners of molecules of interest. The cell system 
may be too robust when considering intricate affinity of the proteins in question, 
especially when allosteric transition, and conformation modulation occurs upon 
complex formation. The (classical school of thought) canonical theory regarding 
protein-protein interactions claims that they occur over a relatively large surface 
area, on average approximately 800±200Å2 of protein surface is buried on each side 
of the interface [for full review see (Lo Conte et al., 1999)]. Nevertheless, further 
studies have shown that the surface contact area can be divided into subsets, which 
contribute to high-affinity binding, also known as the “hot spot” (Clackson and 
Wells, 1995). Such hot spots of binding free energy are a common feature of protein 
complexes. Residues building these subsets are clustered together and are surrounded 
by energetically minor residues that serve to occlude bulk solvent (Bogan and Thorn, 
1998). Several studies have reported phage-display selection of small peptides that 
bind to protein hormones or receptors (DeLano et al., 2000; Sidhu et al., 2003). 




Interestingly these randomly selected peptides bind at protein hot-spots, even though 
they were not selected for protein-protein inhibition. This suggests that protein hot-
spots located at the protein-complex interface appear to be preferred owing to their 
intrinsic conformational and chemical properties. Thus, in many cases protein-
protein recognition sites may be concentrated in a few key anchor residues bearing a 
characteristic conformational state. Basing on this, a concept of “protein-surface 
mimetics” was proposed describing the compounds (peptide analogs as well as other 
small molecules) that retain the essential functionalities and a particular three-
dimensional arrangement complimentary to the protein surface.  
Considering the MDM2::p53 complex a wealth of biochemical (Bottger et al., 
1997a), crystallographic (Kussie et al., 1996a) and genetic (Oliner et al., 1993) 
studies have provided extensive information on the primary interaction site of the 
two proteins in question. The secondary interaction site though discovered almost ten 
years later (Shimizu et al., 2002; Yu et al., 2006) is increasingly studied on as a 
determinant of MDM2 mediated p53 ubiquitination (Kawai et al., 2003; Wallace et 
al., 2006).    
The primary interaction site has been mapped to the N-terminus of p53 tumour 
suppressor. One region within the transactivation domain is highly conserved among 
diverse mammalian species (Liu et al., 2001). This region termed BOX-I (Figure 4.1 
Panel B), spans residues 13 to 26 of the polypeptide chain of p53. Interestingly this 
region is also conserved in two other p53 paralogues, p63 and p73 (Kaghad et al., 
1997; Yang et al., 1998). Several amino acid residues within the BOX-I region are 
essential for the interaction of p53 with MDM2. These key residues are  Phe19, Trp23, 
Leu26 (Figure 4.1 Panel B marked in red). The resolution of the X-ray structure of the 
MDM2 region bound to BOX-I region of p53 (Kussie et al., 1996b) (Figure 4.2 Panel 
B) revealed key features about the nature of interaction between these two proteins. 
The primary p53-binding region of MDM2 is roughly 25 Å long and 10 Å wide and 
is constituted by two pairs of α-helices, related by an approximate dyad axis of 
symmetry. The two repeats come together via their hydrophobic faces forming a 
profound groove or cleft at their interface. This deep hydrophobic cavity is the 
primary site within MDM2 where p53 binds. The stabilization of the MDM2-p53 




complex is mainly produced by anchoring of two aromatic residues and one aliphatic 
of p53 (Phe19, Trp23, Leu26) to this hydrophobic cleft. Thus, the interface relies on the 
steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 
region and the p53-MDM2 binding apparently involves only weak interactions that 
rely mostly on hydrophobicity. Interestingly the BOX-I peptide of p53, representing 
the primary interaction site to MDM2, on its own is unstructured in solution, 
according to NMR data (Botuyan et al., 1997; Dawson et al., 2003; Lee et al., 2000) 
and it adopts an amphipathic α-helical conformation as it comes in contact with the 
N-terminus of MDM2 (Figure 4.2 Panel B).   
The secondary interaction site that is contiguous with the S9-S10 linker motif located 
within the DNA binding region (BOX-V) (Figure 4.1 Panel B) of p53 interacts with 
the acid domain of MDM2. It was initially discovered by phage peptide display and 
characterized (Shimizu et al., 2002; Yu et al., 2006). Despite the fact that binding of 
the BOX-V region of p53 to the acid domain of MDM2 has a low affinity, it is key in 
determining the rate of p53 ubiquitination as it comprises part of the p53 
ubiquitination signal (Wallace et al., 2006).  
MDM2 is unable to downregulate p53 if prevented from interacting with it (Vassilev, 
2007). Therefore, inhibition of MDM2-p53 complex formation is a very desirable 
strategy for p53 activation and stabilization. As stated before, the p53-MDM2 
primary interaction site is limited to a few amino acid residues critical for successful 
interaction of the two proteins. This small number of hydrophobic groups buried in a 
deep cleft represents a relatively good example of protein-protein interactions that is 
a prime candidate for inhibition by small, drug-like ligands (Uhrinova et al., 2005). It 
is beyond the scope of this chapter to fully elucidate on the numerous groups (Details 
of which are provided in the Introduction chapter of this thesis) of competitive 
inhibitors of p53-MDM2 complex formation, thus focus will be drawn to one 
inhibitor used extensively in this chapter as a tool, namely Nutlin-3 (Figure 4.2 Panel 
A).  Nutlins (a series of cis-imidazoline analogues) were discovered by means of 
high throughput screening of a diverse set of chemical compounds that could inhibit 
p53-MDM2 binding (Vassilev et al., 2004). The inhibitory potential of these 
compounds is due to structural mimic of the three key amino acids of p53 BOX-I 




region. The imidazoline scaffold of Nutlin-3 replaces the helical backbone of the 
BOX-I peptide and is able to direct in a fairly rigid fashion (Figure 4.2 Panel C) the 
projection of three groups into the pockets within MDM2 normally occupied by 
Phe19, Trp23, and Leu26 of p53. The two haloaryl groups (chlorophenyl groups for 
Nutlin-3) overlap the position of Leu26 and Trp23, and the position of Phe19 is filled 
by the iso-propoxy group (Figure 4.2 panel C-F). Nutlins have demonstrated activity 
against p53-MDM2 complex formation with the median inhibitory concentration 
(IC50) in the range of  100-300 nM.  Remarkably, a 150-200 fold difference in 
inhibitory potential was observed between enantiomers of Nutlin-3 (Vassilev et al., 
2004). Due to their chemical nature, Nutlins were found to have good cell 
permeability, leading to activation of p53 target genes in cell based assays (Tovar et 
al., 2006). In vivo experiments with SJSA-1 osteosarcoma xenografts in nude mice 
showed that Nutlin-3 was orally bioavailable, achieving steady-state plasma levels of 
3.5 µM following 200 mg/kg bid dosing regimen and leading to 90% inhibition of 
tumour growth. The compound was well tolerated during a 20-day study at this dose. 
In line with this, Nultin-3 was found to stabilize p53 and induce cell cycle arrest and 
apoptosis in Hodgkin lymphoma (Drakos et al., 2007). These studies provided the 
first in vivo proof-of concept that activation of wild-type p53 by pharmalogical 
inhibitors of the p53-MDM2 interaction is feasible and might be exploited for cancer 
therapy (Vassilev,2007).  




4.2 Experimental results 
4.2.1 The MDM2 hydrophobic pocket but not the acid domain is required for 
efficient transrepression of p53 
 
As discussed in the introduction to this chapter, in order for p53 to be regulated by 
MDM2, the latter must bind to the tumour suppressor. Previous studies have 
suggested that the hydrophobic pocket of MDM2 is critical for its transrepressor 
activity (Lin et al., 1994; Liu et al., 2001) however these studies were carried out 
before the complexity of the interaction between MDM2 and p53 was fully 
illuminated. As the acid domain of MDM2 is now known to bind to the BOX-V 
domain of p53 (Wallace et al., 2006; Yu et al., 2006) constituting a secondary 
interaction site of the complex, MDM2 deletion mutants were used to determine 
which interactions were salient for MDM2 mediated transrepression. To investigate 
the influence of MDM2 domain structure on p53 transrepression, two discrete 
domain deletion mutants of MDM2 were used, where one or other of the two known 
p53 interacting domains had been deleted (Figure 4.3 Panel A; MDM2ΔN and 
MDM2ΔAc). MDM2ΔN prevents the interaction between the transactivation domain of 
p53 (BOX-I) and the hydrophobic pocket in the N-terminus of MDM2 (Kussie et al., 
1996b) whereas the MDM2ΔAc precludes binding of the core domain of p53 (BOX-
V) and the acid domain of MDM2 that is essential for MDM2 mediated 
ubiquitination of p53 (Wallace et al., 2006).   
When the deletion mutants were analysed in the p53-reporter assay (Figure 4.3 panel 
B) loss of the hydrophobic pocket essentially inactivated MDM2 as a transrepressor 
of p53-mediated transcription, whereas deletion of the acid domain did not have a 
major impact on this activity of MDM2.  This data suggest that the interaction 
between the acid domain of MDM2 and the BOX-V region of the p53 core domain is 
subsidiary for MDM2 mediated transrepression, whereas binding of the hydrophobic 
pocket to the BOX-I transactivation domain of p53 is absolutely required, as the ΔN 
mutant is essentially dead in this assay.  




Together with the results presented in the previous chapter one can draw a 
conclusion that the RING domain mutants that lose the ability to ubiquitinate p53 but 
gain p53 repressor activity do so, most likely, through modulation of the MDM2-
hydrophobic pocket: p53-BOX-I interaction.  
 
4.2.2 Isolation of human recombinant MDM2  
 
The cell based experiments described in Chapter 3 and above show that; the C2H2C4 
RING mutants have a gain of transrepressor activity, and that the hydrophobic 
pocket, but not the acid domain, is essential for MDM2 repressor activity 
respectively. These results suggested that the affinity of the hydrophobic pocket for 
the BOX-I domain of p53 might be sufficient to dictate the potency of MDM2 as a 
transrepressor and may also determine the efficacy of hydrophobic pocket binding 
drugs such as Nutlin-3. 
In order to confirm this hypothesis an in vitro approach was taken up to further study 
the association of full length p53 with full length MDM2 and a lateral investigation 
of p53 peptide aptamer interactions with MDM2 was carried out. 
For this approach to be fruitful, one requires for the two proteins in question to be 
purified to high homogeneity. Human recombinant p53 tumour suppressor protein 
was isolated from a prokaryotic expression system and provided, as a kind gift to the 
author, by Prof. Alicja Zylicz at the International Institute of Molecular and Cell 
Biology in Warsaw, Poland, with whom close collaboration is being upheld.  
The MDM2 oncoprotein although extensively studied due to its prominent negative 
regulator of p53 status (at the time of writing this thesis over 3500 publications 
recorded at NCBI http://www.pubmed.gov) the data regarding the biochemical 
nature of the full length protein is quite limited.  
Due to the extensively time consuming task of producing an optimized, reproducible 
MDM2 isolation protocol, which in the end provided satisfactory amounts of the 
protein, a brief description of the method shall be provided in this result chapter. 
Human recombinant MDM2 protein and all the described mutant forms were isolated 
from a prokaryotic expression system using the following method (Figure 4.4). 




Plasmid encoding human MDM2 cDNA (Midgley et al., 2000) was introduced into 
E.coli BL21 (DE3) RiL strain. In must be stressed that the open reading frame of the 
mdm2 gene introduced to the vector did not contain any regions encoding for C, or 
N-terminal tags, which could partially simplify the isolation procedure though at the 
end could prove artifactual as the intention is to study the full-length species with its  
N-terminus and the C-terminus in native surroundings. An overnight culture with 
antibiotic selection was diluted to a final volume of 10 litres. At the moment when 
the suspension reached ODλ=600nm - 0,4, the temperature that the culture was kept at 
was decreased from 30 °C to 18°C and induction followed with IPTG added at final 
concentration of 0.5 mM. After 3 hours post induction the bacterial pellet was 
collected be means of centrifugation. Delicate lysozyme/detergent lysis was 
performed on the pellet followed by brief heat shock and genomic DNA shattering. 
Centrifugation of the solution followed. Under these conditions a bulk of the desired 
protein was insoluble and localized within the pellet fraction, which falls in line with 
previously published procedures (Midgley et al., 2000). Delicate extraction with the 
use of an ionic detergent and high salt concentration carried out overnight with 
constant rotation proved fruitful in transferring a large portion of the MDM2 protein 
to soluble state. This fraction was shortly dialysed to reduce detergent concentration, 
yet retaining high anti-chaotropic salt concentration. After dialysis the sample was 
loaded onto a hydrophobic interaction chromatography (HIC) adsorbent. Protein 
binding to HIC adsorbents is promoted by moderately high concentrations of anti-
chaotropic salts, which also have a stabilizing influence on protein structure. Elution 
was achieved by a linear decrease in the concentration of salt in the adsorption 
buffer. The collected fractions containing MDM2 protein were pooled and loaded 
onto anion exchange chromatography adsorbent, the proteins passive to this 
adsorbent including MDM2 passed directly into the flow through and were 
immediately loaded onto a cation exchange chromatography adsorbent. Fractions 
containing MDM2 were eluted from the adsorbent collected by means of increasing 
ionic strength. The identical procedure, including same competent bacterial strain 
batch and adsorbents was used in order to isolate the Cys464, Cys478 and Lys454 
MDM2 mutants. Alongside the mentioned mutations several others were introduced 




into the human MDM2 ORF and the resulting mutant proteins were isolated, though 
shown (Figure 4.5 panel A) it is beyond the scope of this chapter to describe them in 
more detail.  
Human MDM2WT, MDM2K454A, MDM2C464A, and MDM2478S are presented in the 
first four lanes from the left on a Coomasie Blue stained gel (Figure 4.4 Panel A). 
Despite the apparent difference in concentration and thus purity the main band for all 
the MDM2 protein species migrates in a denaturating gel at a molecular mass 
representative of 90-100 kDa protein. This does seem controversial as the predicted 
molecular mass for human MDM2 is 55 kDa, similar results strengthened with 
immunoblotting were reported and discussed (Shimizu et al., 2002) indicating that 
despite denaurating conditions the MDM2 moiety may adopt a higher quatenerary 
structure. This indeed was investigated in the following chapter and shall be 
discussed in more detail there. As, despite all efforts, the isolated MDM2 proteins 
were heterogenic in purity. The protein concentrations were normalised and the 
quantitation was confirmed using an Enzyme Linked Immunosorbent Assay (ELISA) 
assay (Figure 4.5 Panel B). This simple procedure utilizing specific antigen (in this 
case MDM2 protein) antibody recognition is more advantageous than classical 
Bradford based concentration assay, as it confirms that the purified species is in fact 
MDM2 and  the concentration values of the proteins tested is more accurate as the 
background is non reactive with the antibody.  
 
4.2.3 Initial characterization of the isolated MDM2 
 
In order for the isolated MDM2 species to be of any use in further experiments, one 
must show that they retain specific activity in vitro. As MDM2 is the main antagonist 
of p53 and a clear physical interaction of these two proteins occurs, this property 
should be verified initially. 
A quick and efficient method at investigating protein-protein interactions is a 
modified version of the Enzyme Linked Immunosorbent Assay. The noteworthy 
features of this method are that the relatively small amounts of biological material 
(10-150 ng) used, produce reproducible and statistically significant results.  




The results showing specific binding of MDM2 to p53 and vice versa are presented 
in Figure 4.6 indicating a specific, dose-dependant complex formation. In this case a 
two-site (two-stage) capture ELISA was performed. This variation of the method 
relies on the fact that a specific antibody can be attached to microtiter wells (for 
Panel A anti p53 DO-1 antibody was attached, Panel B anti MDM2 2A10 antibody 
was attached) and serve a ligand specific anchor, binding the epitope, in this case the 
desired protein. Thus either a fixed amount of  p53 (Figure 4.6 Panel A) or MDM2 
(Panel B) is exposed to the reaction buffer containing increasing amounts the 
complementary binding partner. For both of the presented Panels in Figure 4.6, 
Albumin isolated from Bovine Serum was used as the inert, non-specific binding 
partner.  
The C-terminal RING domain of MDM2 ensues the protein to posses at least two 
distinguishable properties. The Walker P motif situated within the RING is the site of 
nucleotide binding (ATP preferentially) by the protein, additionally 8 other amino 
acids, 6 cysteines and 4 histidines provide a scaffold for zinc binding resulting in E3-
ubiquitin ligase activity of the MDM2. As presented in Chapter 3 these two 
properties by means of single amino acid substitutions can be abolished 
independently. Thus it is vital to verify if this is the case for the purified proteins. 
The Lys454 mutation to Ala in MDM2 was reported (Poyurovsky et al., 2003) to 
successfully lower the affinity for ATP. It must be noted that these results were 
obtained by investigating the GST-RING domain purified on its own and no data was 
established for the whole protein. Figure 4.7 represents data showing ATP binding 
preference for MDM2WT, MDM2K454A, MDM2C464A, MDM2C478S proteins. In this 
experiment α-32P ATP was used in order to rule out the possibility that binding 
reflected activity of a contaminating prokaryotic kinase. Two methods were used to 
assay for ATP binding by MDM2 (Figure 4.7). One relies on the fact that nucleotides 
that interact with the protein can be crosslinked to the later by means of  UV pulse 
λ=254 nm (310 µW/cm2). These complexes were precipitated from solution by 
means of TCA/DOC, extensively washed and resolved via SDS-PAGE (Figure 4.7 
Panel A). The second method exploits the binding properties of proteins to 
nitrocellulose, whereas unbound nucleotide molecules pass freely through the pores, 




bound ones are retained with the protein at the surface of the filter/membrane. Thus, 
the amount of radiolabelled ATP bound to protein can be assayed quantitavely with a 
scintillation counter (Figure 4.7 Panel B). The normalized values of ATP bound to 
MDM2 clearly indicate at least a 2-fold decrease in binding for the Lys454 mutant in 
comparison to its wt counterpart. Moreover mutations within the key Cys residues 
have no inhibitory effect on nucleotide association; in fact the MDM2C478S shows a 
slight increase in affinity for the nucleotide in comparison to the wt form. This result 
demonstrates the requirement of an intact P Walker motif for optimal nucleotide 
binding and strongly supports the notion that the two mentioned activities within the 
RING can be uncoupled.  
Next a purified assay system (Wallace et al., 2006) was used to check for the E3 
ubiquitin ligase activity of the purified MDM2 proteins. The reaction mixture 
consisted of human E1 ubiquitin activating enzyme, E2 ubiquitin conjugating 
enzyme, free ubiquitin and a target protein – human recombinant p53. The presence 
of the nucleotide in this mixture is required for E1 activity as ubiquitin conjugation is 
an energy dependant process. The only variable for the reactions presented in Figure 
4.8 was the absence or presence (in an increasing manner ) of MDM2WT and the 3 
investigated mutants. The results concur with the data presented in Chapter 3 (cell 
based ubiquitination assay done in MEFs)  where the wt protein and the ATP mutant 
(MDM2K454A) are active in acting as an E3-ligase for p53 and neither the Cys464A nor 
the Cys478S mutant were able to mediate ubiquitination of p53 (Figure 4.8 Panel B). 
In this case a non crucial mutation Lys4545A in regards to zinc coordination did not 
manifest its handicap in the above assay. Thus basing the above results combined 
with complimentary data from Chapter 3 one can postulate that the lack/decrease of 
ATP binding by MDM2 is not directly involved in modulating its ubiquitin ligase 
activity. Moreover, the MDM2K4545A mutant when compared to its wt counterpart 
when added to the reaction mixture at the lowest amount, exhibits better potential to 
attach ubiquitin adducts to p53. This observation is supported by (Poyurovsky et al., 
2003) where on a per mole basis the analogous mutant displayed significantly greater 
ability to ubiquitinate p53 (approximately 3-fold more) than did wild-type MDM2. 
Additionally the degree of repressing p53 transcriptional activity of the Lys4545A 




mutants was comparable to the wild-type protein, which is also coherent with the 
observations in cell based assays presented in Chapter 3.  
 
4.2.4 MDM2 Cys RING finger mutant proteins bind with a higher affinity to 
the transactivation domain of p53 
 
The mutations within the P Walker motif of MDM2 hinder its ATP binding potential 
yet do not display any decrease in ubiquitin ligase activity, moreover they do not 
modulate the ability of MDM2 to interact with p53 as shown by (Wawrzynow et al., 
2007a) and (Poyurovsky et al., 2003). The ability of the remaining mutant proteins 
(MDM2C464A and MDM2C478S ) to bind to full-length purified p53 was determined 
(Figure 4.9). In this assay a constant amount of full-length untagged p53, purified 
form E.coli, was captured onto microtiter wells and incubated with a titration of wt 
or mutant MDM2 protein. Following extensive washing bound MDM2 was detected 
using a monoclonal antibody (2A10). This showed that both of the MDM2 C2H2C4 
mutant proteins bound with a higher affinity to full-length p53 than did wt MDM2, 
however, consistent with its lower I0.5 in the transrepressor assays (Chapter 3), the 
Cys464A mutant bound better to p53 than the Cys478S mutant protein. 
Although the interaction between the acid domain of MDM2 and the BOX-V domain 
of p53 is not essential for MDM2 mediated transrepression (Figure 4.3) it is likely to 
play a role in binding of MDM2 to full-length p53 protein (Wallace et al., 2006) 
Binding to the isolated BOX-I domain was therefore investigated to determine 
whether the increase in affinity of the Cys464A and Cys478S mutants for full-length p53 
reflected a change in affinity for the p53 BOX-I domain. Binding of wt and the 
C2H2C4 mutant MDM2 proteins to a peptide based on the BOX-I domain of p53, or 
to an optimised hydrophobic pocket binding peptide, 12.1 (Bottger et al., 1996), was 
determined (Figure 4.10 Panel A and B ). Biotinylated BOX-I domain or 12.1 
peptide were immobilised on streptavidin coated wells and incubated with a titration 
of wt MDM2 or the two C2H2C4 mutant proteins. Consistent with the data 
presented, above showing that the mutants bind better to full-length p53, both the 
Cys464A and Cys478S proteins bound with a higher affinity to BOX-I and 12.1 than wt 




MDM2 protein. Mirroring its decreased I0.5 for transrepression seen in Chapter 3 and 
increased affinity for full-length p53 the Cys464A mutant consistently bound better to 
BOX-I or the BOX-I mimetic than the Cys478 mutant protein (Figure 4.10 A, B). Of 
note is the fact that the BOX-I mimetic the 12.1 peptide, shows 2-fold increase in 
affinity towards MDM2 than its protoplast.  
The data presented in Figure 4.10 Panel A, B suggests that the increased 
transrepressor activity of the MDM2 C2H2C4 RING mutants is dictated by an 
increase in the affinity of their hydrophobic pockets for the BOX-I transactivation 
domain of p53. Nevertheless, the data presented in the following Panels (C and D) of 
the Figure 4.10 indicate that the two Cys mutants of MDM2 further show a dramatic 
increase in affinity towards the secondary interaction site between MDM2 and p53. 
Biotinylated BOX-V domain peptide (representative of the secondary interaction site 
within p53) or Rb-1 [a fragment located within the C-terminus of the Rb protein, 
shown to interact and inhibit E3 ubiquitin ligase activity of MDM2 (Wallace et al., 
2006)] peptide were immobilised on streptavidin coated wells and incubated with a 
titration of wt MDM2 or the two C2H2C4 mutant proteins. It must be stressed that 
the interaction between MDM2 and p53 is a multi step process, and the resulting 
complex is not simply a result of additive interactions of MDM2 towards the BOX-I 
and BOX-V domain. Exposure of the secondary interaction site (BOX-V within p53) 
is dependent on the initial binding of BOX-I of p53 by MDM2. A conformational 
change follows within both of the proteins (Schon et al., 2002; Schon et al., 2004; 
Wallace et al., 2006) yielding an exposed BOX-V region. Although this exposed 
fragment of the p53 protein has a much lower affinity towards MDM2 (Figure 4.10 
Panel C, D) it is crucial for efficient ubiquitination of p53 by the oncoprotein studied. 
Considering this, one can hypothesize that the discussed Cys mutations within the 
RING may have a long range effect on the global conformation of the protein. This 
can be achieved through two possible mechanisms. Firstly, the increased affinity 
towards the BOX-I peptide by the Cys464 and Cys478 indicates a gain in 
conformational affinity of their hydrophobic cavity towards p53, this more efficient 
binding may allosterically induce both of the proteins in question to interact better 
through the secondary interaction site. Moreover, the specific Cys mutations within 




the RING of MDM2 may ‘transmit’ their effect on the hydrophobic pocket in cis 
through the central region of MDM2 encompassing the acid domain which forms the 
molecular basis within MDM2 for interacting with p53 (Shimizu et al., 2002). 
Deciphering between these two exciting possibilities shall be further solely 
investigated in the following chapter of this thesis.  
 
4.2.5 The MDM2 RING mutant proteins differ in their sensitivity to the 
hydrophobic pocket binding drug, Nutlin-3  
 
The atomic level of understanding of MDM2-p53 interaction through X-ray 
crystallography (Kussie et al., 1996b) provided strong information for structure 
mimic design of small-molecule antagonists of this interaction (Fry et al., 2005), 
such as Nutlin-3. This cis-imidazoline analogue competitively binds to the 
hydrophobic cleft of MDM2 preventing it from intact with the transactivation 
domain of p53, thus relieving the latter for its prominent tumour suppressor activity 
(Tovar et al., 2006; Vassilev, 2005, 2007; Vassilev et al., 2006).  
The ability of Nutlin-3 to inhibit the MDM2-p53 complex formation was checked 
initially by means of an ELISA based assay (Figure 4.11). Panel A represents the 
results obtained from an assay, where a constant amount of full-length untagged p53, 
purified from E.coli, was captured onto microtiter wells, increasing amounts of 
MDM2 were initially preincubated with DMSO (carrier), or fixed amounts of Nutlin-
3 (2.5-10 µM) then added onto the wells. After extensive washes the MDM2 bound 
to p53 was detected with 2A10 antibody. Panel B represents an assay where a fixed 
amount of MDM2 was preincubated with increasing amounts of Nutlin-3, after 
which the protein was added onto wells bearing the coated p53. The I0.5 =1.25 µM 
for Nutlin-3 calculated is consistent with published data (Vassilev, 2004). 
The above results indicate that in a dose dependant manner Nutlin-3 inhibits the 
purified MDM2 protein from binding to p53. 
Based on the above, the ability of Nutlin-3 to compete with BOX-I for binding to 
MDM2WT and MDM2C464A, MDM2C478S was investigated (Figure 4.12).  In this assay 
equal amounts of biotinylated BOX-I peptide were captured onto streptavidin coated 




microtitre wells and incubated with a fixed amount of wt or mutant MDM2 in the 
presence of increasing Nutlin-3 concentrations. The result of this assay demonstrated 
an apparent difference in the ability of the RING mutants to bind Nutlin-3, 
suggesting that mutations within the C2H2C4 structure have a direct influence on 
Nutlin-3 binding that is not mediated by other cellular proteins. Thus, Nutlin-3 is a 
weak inhibitor of BOX-I binding to the Cys464A mutant, relative to wild-type MDM2 
protein, with an I0.5 4-fold greater than for wt MDM2. This suggests that the Cys464A 
protein has a lower affinity for Nutlin-3 than the wild-type protein and binds with a 
higher affinity to BOX-I resulting in preferential BOX-I binding. Conversely the 
Cys478S mutant appears to bind Nutlin-3 with a higher affinity than the Cys464A and 
wt proteins. Thus, in this case Nutlin-3 competes more easily with BOX-I for binding 
to the hydrophobic pocket. In order to determine if the differences observed in 
Nutlin-3 binding are reflected in the ability of Nutlin-3 to disrupt the interaction 
between full-length p53 and MDM2 the following experiment was performed. Full-
length p53 was coated onto the microtiter well and incubated with a titration of 
MDM2 in the presence of various fixed concentrations of Nutlin-3 (Figure 4.13; 2.5, 
5 and 10 µM). Again there was a clear difference in Nutlin-3-dependent disruption of 
full-length p53 binding to the MDM2 proteins, with the p53:Cys478S mutant complex 
showing increase Nutlin-3 sensitivity compared to Cys464A. Once more this suggests 
that the Cys478S mutant has a higher affinity for Nutlin-3 than does the Cys464A 
protein. Panel D (Figure 4.13) indicates the rate of p53:MDM2 complex disruption, 
with respect to Nutlin-3 concentration, present in the system, from it a clear 
decreased sensitivity to the drug for the Cys464 mutant is visible. 
 
4.2.6 RING mutation affect the efficacy of Nutlin-3 as an inhibitor of MDM2-
mediated repression of p53 
 
The data presented above strongly favours the notion that the affinity of MDM2 
hydrophobic pocket towards p53, is dependant on the zinc binding state of the C-
terminal RING domain. Furthermore, the C2H2C4 RING mutants have a gain of 
transrepressor activity when compared to the wt protein (Chapter 3). To further 




investigate the link between hydrophobic pocket binding and RING domain function. 
Nutlin-3 was used in cell based assays as due to its chemical nature it is perfectly cell 
permeable (Vassilev, 2004; Vassilev et al., 2004).  
It has been previously suggested that Nutlin-3 most likely functions as an anticancer 
agent by affecting the ability of MDM2 to act as a transrepressor of p53 transcription 
rather than as an inhibitor of MDM2-dependent p53 ubiquitination. This hypothesis 
was based on the published results (Wallace et al., 2006) and is further supported by 
the data presented in Figure 4.14, clearly indicating that Nutlin-3 is not able to inhibit 
the ubiquitination of p53 in vitro using purified proteins (Panel A) and that the 
addition of Nutlin-3 to A375 cells (harbouring p53 WT/WT gene) does not decrease 
the number of modified p53 forms detected (Panel B). In fact one observes that an 
increase in p53 modification is proportionate to increases in total p53 protein levels 
and to the activation of p53, as assessed by an increase in p21 protein levels. 
Together these results suggest that modification of existing or newly synthesised p53 
protein continues in the presence of Nutlin-3.  
If the above hypothesis is correct one would predict that Nutlin-3 binding to MDM2 
would be sufficient to relieve transrepression imposed by both wt and E3-inactive 
MDM2 protein. Using the p53-reporter assay (introduced in Chapter 3) the ability of 
Nutlin-3 to reverse transrepression imposed by a fixed amount of wt MDM2 was 
shown (Figure 4.15). Nutlin-3 had a striking effect on the transrepressor activity of 
the Cys478S protein with p53 activity recovering to near the level seen in the absence 
of MDM2. This result lends strong support to the idea that Nutlin-3-dependent 
inhibition of MDM2 as a transrepressor occurs independently of MDM2 E3-ligase 
function and that this could be sufficient to explain the activating effect of Nutlin-3 
on p53. 
Interestingly, although Nutlin-3 was active against the Cys478S MDM2 mutant protein 
it had only weak activity against the Cys464A protein and even at 14 µM Nutlin-3 did 
not inhibit this mutant. To confirm this result a different cell based transcriptional 
assay system was employed. It investigated the ability of Nutlin-3 to overcome wt 
and mutant MDM2 imposed transrepression of p53, this time using endogenous p21, 
a downstream target of transcriptionally active p53, as a readout (Figure 4.16). An 




amount of transfected MDM2 wt and mutant constructs was chosen that gave 
maximal repression of endogenous p21 protein expression in H1299 cells, Nutlin-3 
was then added to the cells in a dose-dependent manner and the effect on p21 levels 
was determined. Quantitation of the data generated by in Figure 4.16 Panel B shows 
that Nutlin-3 can relieve transrepression imposed by both the wt and Cys478S mutant 
forms of MDM2 at the lowest concentration used (1.5 µM). However at 1.5 µM, 
Nutlin-3 had no measurable effect on the levels of p21 protein in the presence of 
MDM2C464A, in fact it required 7 µM Nutlin-3 to relieve transrepression by the 
MDM2C464A on p21 protein expression. This observation, strengthened by in vitro 
results, shows that the differential effect of Nutlin-3 is dependent on the status of the 
C2H2C4 RING structure, and suggests that the introduction of mutations that 
directly impact on RING structure can differentially impact on the affinity or 
availability of MDM2’s hydrophobic pocket for p53 BOX-I binding.  
In conclusion, although both the Cys464A and Cys478S proteins bind with a higher 
affinity to hydrophobic pocket interacting ligands than the wt protein, resulting in a 
gain of transrepressor activity they do so differentially. Thus, whereas the Cys478S 
protein binds preferentially to Nutlin-3, the Cys464A protein binds with a higher 
affinity to BOX-I resulting in differential Nutlin-3 sensitivity in the cell. Therefore, 
mutations within the C2H2C4 RING differentially affect the affinity of the 
hydrophobic pocket for distinct interacting ligands.  
 
4.3 Discussion  
 
Studies addressing how MDM2 structure supports its functional diversity have begun 
to provide insight into the protein’s conformational flexibility. Thus, a picture is 
emerging of interdependent functional domains linked through changes in 
conformation, emphasising the need to study the domain structure of MDM2 within 
the context of the whole protein. Key point mutations within the RING finger are 
fruitful in bestowing data demonstrating a cross-talk between the C-terminus and 
interactions taking place at the N-terminal hydrophobic pocket of MDM2. Therefore 




they provide a good starting point for investigating this matter further. A link 
between the hydrophobic pocket of MDM2 and its acid domain has been previously 
described (Wallace et al., 2006). There a model was presented, where occupation of 
the hydrophobic pocket promoted conformational changes in MDM2, that favoured 
acid domain binding to ubiquitination signal in the core DNA binding domain of 
p53. This allosteric mechanism promotes MDM2 function as an E3-ubiquitin ligase 
by stabilizing a low affinity interaction between the BOX-V domain of p53 and the 
acid domain of MDM2. The data presented in this chapter, and the previous chapter 
as well, adds to this model for the regulation of one domain of MDM2 through 
modulation of a second by demonstrating that the RING finger domain, and more 
specifically residues required to form the C2H2C4 RING structure, can allosterically 
modulate hydrophobic pocket interactions. In this case the result is an increase in the 
affinity of the hydrophobic pocket which produces a gain in transrepressor function 
in cells. Interestingly, mutation of Cys464 and Cys478 residues are not equivalent in 
terms of their effect on the hydrophobic pocket. Thus, although both mutants display 
increased binding to the BOX-I domain of p53, the Cys478S mutant binds Nutlin-3 in 
preference to BOX-I, whereas the Cys464A protein preferentially binds to BOX-I.   
Structural and computational analysis of the MDM2 hydrophobic pocket interaction 
with p53 has revealed that this domain has a high degree of plasticity and has 
suggested that the shape of the binding cleft can change significantly (Espinoza-
Fonseca and Garcia-Machorro, 2008; Espinoza-Fonseca and Trujillo-Ferrara, 2006a, 
b). A mechanism has been proposed where binding to the BOX-I domain of p53 
requires a progressive opening up of the binding cleft to reveal a hydrophobic 
interface. The binding of p53 then proceeds through an intermediate complex where 
the cleft gradually adopts a more open conformation eventually accommodating 
Thr18-Asp29 of BOX-I. Based on this type of study it has been hypothesised that the 
cleft has enough plasticity to allow a range of low-energy states rather than a single 
‘open’ or ‘closed’ conformation.  As a result the pocket can accommodate a range of 
peptides and small molecules that might not have any obvious structural similarity 
(Bowman et al., 2007; Espinoza-Fonseca and Garcia-Machorro, 2008; Espinoza-
Fonseca and Trujillo-Ferrara, 2006a, b; Stoll et al., 2001; Vassilev et al., 2004). It is 




likely therefore,  that the differential binding preferences of the  two Cys mutants are 
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Figure 4.1 Characterization of the MDM2-p53 interaction 
(A) Multidomain organization of MDM2 and p53. The location of highly conserved domains 
(I-V) within p53 is indicated in white roman numerals.  
(B) Topological representation of the two defined interaction sites, building the MDM2::p53 
complex. The primary structure of BOX-I and BOX-V is shown below. The crucial amino acids 
for the binding are outlined in red. Amino acids within the consesus marked as x are free for 
divergence. Peptide 12.1 presented as identified by Bottger et al., 1996. The Rb 1 peptide as 
shown above is located within the C-terminal primary structure of the Rb protein. 













Figure 4.2 Nutlin-3 structure and mode of binding to MDM2
(A) Chemical structure of Nutlin-3 (C30H30Cl2N4O4)* (B) Structural representation of the BOX-I 
peptide of p53 bound to the N-terminal binding site of MDM2 (C) Structural alignment of p53 
BOX-I (critical amino acids Phe19, Trp23, Leu26 side-chains outlined in ball and stick 
representation) with Nutlin-3 (carbon atoms represented in white, nitrogen in blue, oxygen in 
red and chlorine in green). (D) Structural alignment of solved structures showing MDM2 
bound to BOX-I domain  (in green), and MDM2 bound to Nutlin-3  (in gold).  (E), (F) Space fill 
model of the MDM2 N-terminal hydrophobic pocket bound to Nutlin-3 inhibitor (the inhibitor 
molecule represented in stick model). Colour scheme analogous to (C).
*(±)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one 
This figure was prepared using PyMOL [Warren L. DeLano "The PyMOL Molecular Graphics System." DeLano Scientific LLC, San 
Carlos, CA, USA. http://www.pymol.org] and structural data from Kussie et al., 1996 and Fry et al., 2004 (file 1YCR, 1TTV 
respectively RCSB PDB ).



































































































Figure 4.3 The hydrophobic pocket of MDM2 is essential for transrepression 
of p53 
(A) A schematic representation showing  MDM2 deletion constructs. MDM2∆N is missing the 
MDM2 hydrophobic pocket which binds the BOX-I domain of p53 and MDM2∆Ac does not 
have the acid domain which binds the BOX-V domain of p53.  
(B) H1299 cells were transfected with p53 alone (150 ng) or with a titration (75, 150, 300, 550 
ng) of MDM2WT, MDM2∆N or MDM2∆Ac plus the reporter plasmids. Total DNA was normalised 
using the vector control. Post transfection (24 h) the Dual Luciferase Assay was performed. 
The results are normalised by expressing p21 or consenus-Luciferase/Renilla activity in 
relative light units (RLU), c is the vector only control. 
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Figure 4.4 Purification scheme for isolating full length MDM2 from a 
prokaryotic expression system
Expression and Purification of Recombinant Protein—Human MDM2 wt was overexpressed 
in E. coli BL-21 RIL DE3 strain at 20 °C for 3 h after induction with 0.5 mM IPTG. Cells were 
harvested by centrifugation at 8000×g for 10 min and frozen in liquid nitrogen. Bacteria pellet 
was lysed for 1.5 h at 4 °C with frequent stirring followed by 2 min at 37 °C and an additional 
15 min at 4 °C. Afterward the suspension was centrifuged at 100,000×g for 1 h at 4 °C. Under 
these lysis conditions most of the desired protein was insoluble and localized within the pellet 
after centrifugation. Extraction of the MDM2 protein from the cell pellet was carried out 
overnight at 4 °C with constant shaking. After centrifugation (100,000×g for 1 h at 4 °C) the 
supernatant was collected and dialysed After 2 h dialysis the sample was loaded onto a 
butyl-Sepharose column (Amersham Biosciences). The protein that bound to the column was 
eluted via gradient of decreasing ionic strength and increasing glycerol concentration. The 
fractions containing MDM2 protein were pooled and loaded onto a Q-Sepharose column. The 
flow-through from the column was immediately loaded onto a SP-Sepharose column 
equilibrated with an analogous buffer as the Q-Sepharose. The bound proteins to the 
SP-column were eluted by means of ionic strength gradient. Fractions containing MDM2 
protein were pooled, frozen in liquid nitrogen and stored at -80°C for further experiments. 
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Figure 4.5 Purification of human MDM2 protein
Full-length untagged human MDM2 protein and six single point mutants were purified from 
bacterial expression system using the procedure described in the previous figure. 
(A) Coomasie Blue stained gels after SDS-PAGE representing the results from purification 
procedure, where MDM2WT and all the listed mutants were purified analogously. 10 μl of each 
sample premixed with 1X SDS Sample Buffer was loaded. 
(B) Amount standardization by ELISA. To check the accuracy of protein normalisation for the 
purified MDM2WT, MDM2K454A, MDM2C464A and MDM2C478S proteins (Standardization was 
performed for all the mutants shown in (A), whereas for the purpose of this chapter the shown 
mutants were sufficient). ELISA was performed in which a titration of MDM2 protein was 
coated onto the microtitre plate wells, following extensive washing. MDM2 protein levels were 
detected using 2A10 antibody.
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Figure 4.6 Initial quantitation of MDM2 p53 interaction 
Purified untagged full-length human MDM2 was assayed for specific interaction with purified 
untagged human p53 protein by means of ELISA. Specific antibodies for both of the proteins 
were used  to anchor one of the pair in the microtiter well.
(A) The anchoring DO1 Ab was attached to the microtiter well overnight by incubation in  
carbonate buffer (pH 9.2). BSA was used as a negative interaction control. The p53 protein 
was added in constant amount (100 ng) followed by titration of MDM2 protein, following 
extensive washing the MDM2::p53 complexes were detected with rabbit polyclonal anti 
MDM2 antibody (ab15471-Abcam).
(B) Procedure analogous to (A), with the anchoring antibody (2A10) specific for MDM2. The 
p53::MDM2 complexes were detected with rabbit polyclonal anti p53 antibody (CM1).




































Figure 4.7 ATP binding by MDM2
Binding of ATP to purified MDM2 proteins. The basis for this experiment was provided by   
Poyurovsky, et al., 2003. The major difference though is the use of full length MDM2 proteins 
instead of just the GST-RING domain. Two methods were used to assay the ATP binding 
potential of MDM2.
(A) Constant amount of MDM2WT or MDM2K454A was incubated with increasing amounts of 
α-32P ATP followed by UV crosslinking. The formed ATP-protein complexes were resolved by 
SDS-PAGE and an autoradiogram was obtained. C represents negative control where 
reaction buffer was used only. The arrow points at nucleotide bound MDM2. 
(B) MDM2 protein species preincubated with constant amounts of α-32P ATP  and filtered 
through 0.44 μm nitrocelullose membrane. The bound protein-nucleotide complexes were 
analysed by means of a scintilation counter. ATP binding ability of specific mutant proteins 
was normalized to the ability for MDM2WT. The data represents data sets  from three 
independent experiments.











Figure 4.8 MDM2 E3 ubiquitin ligase activity in vitro
(A) (B) Ubiquitination reactions were assembled with constant p53, E1, E2 and increasing 
amounts of MDM2 wt or mutant proteins as indicated. The reactions were carried out at 37ºC 
for 15 min. Ubiquitination was analysed by immunoblot using a 4-12% gradient gel, p53 was 
detected using DO1. Unmodified (p53) and ubiquitinated p53 (Ub-p53) is shown. C - 
represents the control where all the mentioned components were added omitting the E3 
ubiquitin ligase.The above data was obtained in cooperation with Erin Worrall.
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Figure 4.9 C2H2C4 mutants of MDM2 bind with a higher affinity to p53
p53 (100 ng/well) was coated onto microtitre wells and incubated with wt or mutant MDM2 as 
indicated. Following extensive washing the MDM2::p53 complexes were detected using 
2A10 antibody. The experiment shown is representative of  4 independent experiments. 
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Binding to Rb-1 peptide
Figure 4.10 C2H2C4 mutants of MDM2 bind with a higher affinity to discrete 
domains of p53
(A) BOX-I domain peptide (5 μM) was captured onto streptavidin coated wells and MDM2 
binding was detected using 2A10 and is expressed as relative light units (RLU) against 
MDM2 amount.   
(B) 12.1 peptide (5 μM) was captured onto streptavidin coated wells and MDM2 binding was 
detected using 2A10 and is expressed as relative light units (RLU) against MDM2 amount 
and incubated with wt or mutant MDM2 as indicated.  
(C) BOX-V domain peptide (5 μM) was captured onto streptavidin coated wells and MDM2 
binding was detected using 2A10 and is expressed as relative light units (RLU) against 
MDM2 amount and incubated with wt or mutant MDM2 as indicated.  
(D) Rb-1 peptide (5 μM) was captured onto streptavidin coated wells and MDM2 binding was 
detected using 2A10 and is expressed as relative light units (RLU) against MDM2 amount 
and incubated with wt or mutant MDM2 as indicated. 
The experiments shown in (A) (B) (C) (D) are representative of 4 independent experiments. 



















































Figure 4.11 Nutlin-3 inhibits the formation of the  p53::MDM2 complex in a 
dose dependent manner
(A) p53 (100 ng/well) was coated onto microtitre wells. The MDM2 protein before being 
titrated onto p53 was preincubated for 5 min with Nutlin-3 at amounts shown.  MDM2 binding 
was detected using 2A10 and is expressed as relative light units (RLU) against MDM2 
amount. 
(B) p53 (100 ng/well) was coated onto microlitre wells. Constant amount of MDM2 was 
initially preincubated for 5 min with increasing amounts of Nutlin-3 inhibitor (0-20μM), then 
added onto p53.  MDM2 binding was detected using 2A10 and is expressed as relative light 
units (RLU) against Nutlin-3 amount. 
The experiment shown in (A) (B) are representative of  2 independent experiments.






















































Figure 4.12 Nutlin-3 has a differential effect on the C2H2H4 MDM2 mutants
(A) (B) BOX-1 peptide (5 μM) was captured on streptavidin coated wells and incubated with 
the indicated form of MDM2 which had been preincubated (5 min) with a titration of Nutlin-3 
(0-20 μM). MDM2 binding was detected using 2A10 and is given as relative binding 
expressed as a percentage, where 100% binding is that measured in the absence of Nutlin-3. 
The experiment shown in (A) (B) are representative of  2 independent experiments.
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Figure 4.13 Nutlin-3 inhibition of the p53::MDM2 complex is dependant on 
the type of C2H2C4 RING mutation 
(A) (B) (C) p53 (100 ng/well) was coated onto microtitre wells and incubated with the 
indicated form of MDM2 which had been preincubated (5 min) with Nutlin-3 (0-10 μM). MDM2 
binding was detected using 2A10 and is given as MDM2::p53 complex formation in relative 
light units (RLU). The data presented is representative of three independent experiments.
(D) MDM2 p53 complex formation as a function of Nutlin-3 amount. Values for this panel were 
obtained by analyzing data sets from (A),(B) and (C), linear regression was performed within 
appropriate range, to obtain the rate of change of p53::MDM2 complex formation with respect 
to the concentration of Nutlin-3 present in the reaction mixture.
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Figure 4.14 Nutlin-3 and BOX-I Mimetics do not inhibit MDM2 E3 ubiquitin 
ligase activity on p53
(A) In vitro ubiquitination reactions were assembled with p53, E1, E2 and MDM2 in the 
presence or absence (c) of either Nutlin-3 or BOX-I peptide (0, 10, 20, 40, 60 μM). 
Ubiquitination was analysed by immunoblot using a 4-12% gradient gel, p53 was detected 
using DO1. Unmodified (p53) and ubiquitinated p53 (Ub-p53) are shown. The data are 
representative of at least 4 separate experiments. Data for this panel was obtained in 
cooperation with Dr. Susanne Pettersson.
(B) Nutlin-3 (10 μM) was added to A375 cells and they were harvested over a 24 h time 
course (0, 1, 2, 3, 4, 6, 8, 12, 24). The lysates were analysed by immunoblot using either a 
4-12% gradient gel (upper panel) or a 15% SDS PAGE gel  p53 was detected using DO1 and 
p21 using AB-1 for direct lysis. DMSO was used as a control (carrier). The p53 protein was 
immunoprecipitated with DO-1 and probed with rabbit polyclonal CM1 anitbody.   Modified 
forms of p53 are given as Ub-p53. The data are representative of 3 such experiments.
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Figure 4.15 MDM2 mediated transrepression of p53 can be decreased with 
Nutlin-3
H1299 cells were transfected with p53 alone or together with MDM2. Total DNA was 
normalised using the vector control.  After 24h Nutlin-3  was added in amounts shown above 
and the incubation continued for a further 6h.  The cells were harvested and the Dual 
Luciferase Assay was performed. The results are normalised by expressing 
p21/consensus-Luciferase/Renilla activity in relative light units (RLU). Each of the bars  
represents a mean from three independent experiments.  
(A) p21::luciferase reporter was used. 
(B) Analogous to (A) but the TP53 consensus::reporter was used.
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Figure 4.16 The efficacy of Nutlin-3 in cells is dependent on the C2H2H4 
RING
(A) H1299 cells were transfected with p53 alone (150 ng) or in addition with (400 ng) of 
MDM2wt, MDM2C464A or MDM2C478S. Total DNA was normalised using the vector control. Post 
transfection (24 h) the cells were treated with Nutlin-3 (0, 1.5, 3, 5, 14 μM) for a further 6 h, 
after which lysis and immunoblot analysis followed, MDM2 (2A10), p53 (DO1) and p21 (Ab1)  
(B) Densitometry analysis of p21 immunoblot. 
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5.1 Analytical tools used to measure protein conformational shift 
5.1.1 Size exclusion chromatography  
 
Cell culture based assays and end point kinetic measurements (ELISA) presented in 
the previous chapters highlighted an increase in affinity of the MDM2 protein to its 
major interacting target, p53. This is dependant on the integrity of the Zinc 
coordination with the RING domain of the oncoprotein. Key mutations within this 
domain (Cys464A, Cys478S) displayed preferential binding to the full length p53 
tetramer in comparison to their wild–type counterpart. Moreover the mutations were 
later shown to be non-synonymous in terms of binding to the specific MDM2::p53 
inhibitor Nutlin-3, where the MDM2C478S mutant displayed a considerably greater 
preference for the drug than the MDM2C464A protein. In order to further verify 
whether the mutations presented induce global conformational shifts involving 
intrinsic domain cross-talk within the protein as opposed to generating a non-specific 
aggregation-prone state the following techniques were employed.  
Size exclusion chromatography, also referred to as gel filtration, is a technique of 
separating molecules according to their diffusion coefficient (a constant value 
prescribed to a macromolecule which is dependant on its size and shape). In contrast 
to ion exchange or affinity chromatography, molecules do not bind to the matrix 
hence buffer composition (increasing/decreasing ionic strength, nor pH fluctuations) 
does not directly affect resolution.  
Separation of molecules by gel filtration chromatography is based on the porous 
nature of the matrix used and diffusion which applies to the solvent in the mobile 
phase and the macromolecules of interest alike. As the solute passes through the 
chromatographic bed its movement depends upon the bulk flow of the mobile phase 
and further upon the Brownian motion of the solute molecules which causes their 
diffusion both into and out of the stationary phase of the gel matrix. The separation 
in gel filtration depends on the different abilities of the various sample molecules to 
enter pores which are contained within the stationary phase. Assuming that the 
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biopolymers under investigation are properly folded and adopt a globular shape, very 
large molecules, which never enter the stationary phase, move through the 
chromatographic bed fastest. Smaller molecules, which have full or partial access to 
the gel pores, move more slowly through the column, since they spend a proportion 
of their time in the stationary phase. Molecules are, therefore, eluted in order of 
decreasing molecular size.  Gel filtration is well suited for biomolecules that may be 
sensitive to changes in pH, concentration of metal ions or co-factors. Separations can 
be performed in the presence of essential ions or cofactors, ionic and non ionic 
detergents, at low or high ionic strength. 
5.1.2 Intrinsic Fluorescence of Proteins 
 
Among biopolymers, proteins are unique in displaying useful intrinsic fluorescence. 
Three aromatic amino acids; phenylalanine, tyrosine, and tryptophan all display 
fluorescent properties. These amino acids are relatively rare in proteins. Tryptophan 
which is the dominant intrinsic fluorophore is generally present at about 1 mol% in 
proteins. This minute number of tryptophan residues most probably results from the 
metabolic expense of its synthesis. A protein may carry as little as one tryptophan 
residue facilitating interpretation of the spectral data. Thus the intrinsic fluorescence 
of tryptophan residues in proteins has been widely used in the analysis of the 
dynamics and conformational perturbations in these macromolecules. Tryptophan 
residues, within proteins that are in their native fold, may occupy different locations 
where they can be influenced by distinct environment characterized by a particular 
set of physico-chemical conditions. Tryptophan fluorescence can be selectively 
excited at 295-305 nm. The emission spectrum of the residue occurs near 350 nm 
and, in contrast to tyrosine emission, is highly dependent on the polarity and/or local 
environment. Shifts in the emission spectrum of tryptophan occur in response to 
conformational transitions, subunit association, substrate binding and denaturation. 
Tryptophan is uniquely sensitive to collisional quenching, a contact phenomenon 
where the fluorophore (tryptophan residue) and the quencher present must come in 
direct contact with each other. Tryptophan can be quenched by externally added 
quenchers (acrylamide, KI, iodoacetamides) or by nearby amino acid groups within 
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the protein(s) (Lakowicz, 2000; Lakowicz and Maliwal, 1983; Lakowicz et al., 1983; 
Lakowicz and Weber, 1973). Tyrosine emission maximum is rather insensitive to its 
local environment when compared to the tryptophan. The reason for this difference 
lies in the structure of the residues, tryptophan is a uniquely complex fluorophore 
with two low-lying isoenergetic transitions. In contrast, emission from tyrosine 
appears to occur from a single electronic state.   
The intrinsic tryptophan emission of proteins has proven quite valuable when 
studying protein folding. The sensitivity of tryptophan to its local environment 
usually results in changes in intensity or anisotropy during the folding process. The 
MDM2 oncoprotein contains 4 tryptophan residues (at positions 235, 303, 323 and 
329) all within proximity to the acid domain. (Figure 5.4 Panel A ) 
 
5.1.3 Thermal Denaturation of Proteins 
 
The denaturation of proteins, inducible by a variety of means, can be followed by 
any method sufficiently sensitive to detect conformational changes in a protein. Due 
to its simplicity and broad usage the thermal denaturation method can be used for a 
variety of purposes, such as the study of protein structure, folding and stability. For a 
vast majority of proteins, thermal denaturation is an irreversible process. 
Conformational instability of the protein is proportional to the temperature increase 
in the surrounding environment of the macromolecule/polypeptide. This change can 
be monitored by an increase in fluorescence emission. With the use of a specific 
marker/dye that has a higher quantum yield in a lower dielectric medium such as the 
one when protein unfolds exposing the hydrophobic region normally concealed 
within the folded conformation. However, after reaching a  plateau, the fluorescence 
intensity starts to decrease, due to temperature induced aggregation of the denatured 
protein dye complexes. The true power of the assay comes forth when considering 
sensitivity, a vast group of proteins within the living cell (prokaryotic and eukaryotic 
alike) have a low margin of stability (Liberek et al., 2008) or rather are in a constant 
thermodynamic equilibrium between several favourable energy states across the 
energy landscape (Dobson, 2004).Thus employment of this method in a controlled 
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test tube environment can successfully show ligand induced disruption or 
stabilization of a preferred energy state.  
5.1.4 Probing protein conformation using limited proteolysis  
 
Antibodies, a corner stone of today’s experimental molecular biology, are specific 
recognition markers provided by the immune system. They are extensively used to 
probe for endogenous changes of amount and localization of a protein molecule of 
interest. Their ability to bind with high affinity to a an epitope within the protein is 
employed in numerous variants of the immunoprecipitation assay, where multiple 
protein:antibody complexes can be selectively isolated from material of interest. 
They were shown in the previous chapters to be efficient anchoring agents 
immobilizing protein in a microtiter well and also shown to have competitive 
inhibitor properties inhibiting protein complex formation. In this chapter specific 
antibodies against the MDM2 oncoprotein will be used as regional markers. The 
epitope for an antibody may be a very short oligopeptide stretch. Bearing this in 
mind with lateral time-scaled proteolytic cleavage of the studied protein(s), the 
application of a diverse set of antibodies, may reveal valuable insights into exposed 
pockets of the protein structure. A specific advantage of limited proteolysis 
combined with molecular probes for elucidating protein structure and dynamics is 
that they can quickly provide valuable data, in contrast to other physiochemical 
techniques such as NMR or X-ray scattering that indeed provide an incomparable 
leap towards high resolution analysis, though are much more labour intensive and 
time consuming. An additional benefit of limited proteolysis is its modest 
requirements for the amount of protein sample required for investigation.(Fontana et 
al., 2004) 
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5.2 Experimental results 
5.2.1 Point mutations within the RING domain of MDM2 do not cause high 
order oligomerization of the protein  
 
It must be acknowledged that the isolated MDM2 protein species were initially 
overproduced in a heterogeneous, to the origin of the protein, prokaryotic system.  
The state of a given protein that is populated under specific conditions will depend 
on the relative thermodynamic stabilities of the different states occupied with the 
protein folding energy field (Dobson, 2004). When one considers a case where 
within a relatively short period of time, a foreign polypeptide has a rapid influx 
within the host, the latter may react inducing the formation of large oligomeric 
structures i.e. protein aggregate composed of the foreign protein. In other words 
some eukaryotic proteins expressed in bacterial systems tend to aggregate upon over-
expression.  Moreover, isolated protein bearing single point mutations disrupting key 
structural motifs may be prone to aggregation per se. Considering the method of 
MDM2 isolation and the results presented in the previous chapter one may 
hypothesize that the observed increased affinity of the Cys464A and Cys478S mutants 
of MDM2 to p53 may be explained by disruption in their global fold leading to the 
formation of a protein aggregate, bearing numerous MDM2 specific epitopes thus 
recruiting numerous MDM2 specific antibodies used in the ELISA assays as 
detectors. To address this, two approaches were undertaken. Before any p53-MDM2, 
peptide- MDM2 binding assays were performed the proteins (MDM2 and all the 
single point mutants mentioned) were normalized for their sole affinity to the anti 
MDM2 antibody itself, as presented in Chapter 4. Secondly, the isolated proteins 
were subjected to size exclusion chromatography to investigate their apparent 
molecular mass hinting at their quaternary structure. In order to estimate the 
molecular mass from the elution profile, one must use specific protein standards of 
known molecular weight and globular shape. Figure 5.1 represents elution profiles 
obtained by gel filtration of commercially available standards. The chromatograms 
show the variation of concentration (in terms of UV absorbance at A280nm) of sample 
components applied to the resin, as they elute from the column in order of decreasing 
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molecular size. Molecules that do not enter the matrix are eluted in the void volume, 
V0 as they pass directly through the column at the same speed as the flow of buffer. 
The peak of Blue Dextran, a high molecular weight polysaccharide containing a blue 
chlorotriazine dye - Cibacron Blue; is a marker of the void volume (Figure 5.1). 
Having established the elution volumes for the individual protein standards (Figure 
5.1 Panel A-C) and knowing the total volume of the column, the fraction of the 
stationary phase that is available for diffusion of a given protein species (Kav) was 
calculated (Figure 5.2). The partition coefficient was plotted over the logarithm of 
molecular weight, using linear regression an equation depicting partition coefficient 
(Kav) as a function of molecular weight was obtained.  
Under the same conditions that the protein standards were applied and eluted from 
the column, wild-type and mutant MDM2 were investigated (Figure 5.3). The 
fractions collected were analysed by immunoblotting highlighting the peak fraction 
where the MDM2 was most prominent consistent with the elution peaks of the 
chromatograms (data not shown). The elution profile considering the data presented 
in Figure 5.3 is consistent with the purified MDM2 mutants compared to the wild-
type protein. Single point mutations introduced into the RING domain of the protein 
do not induce spontaneous extensive oligomerization of the polypeptide. The 
mutations analyzed by size exclusion chromatography are equivalent, meaning that 
disruption of the zinc coordinating residues or the nucleotide binding pocket do not 
give rise to differential size species. Moreover the MDM2 peak fractions (14-16) 
estimate the protein to have a comparable mass to that seen when applied to SDS 
PAGE ≥ 90 kDa. Nevertheless one cannot conclude based on the data obtained, that 
the purified proteins are monomeric, dimeric, etc. This is because the variation of 
predicted molecular weight from sample 14 to 16 decreases from 264 to 94 kDa, 
(Figure 5.2) thus if one assumes that despite its actual molecular weight (55 kDa) the 
94 kDa species is a monomer (based on migration on SDS-PAGE) then the 264 kDa 
species would be close to a trimeric state. This apparent migration issue for MDM2 
is seen independent of the source material from which the protein in question is 
isolated, MDM2 purified from a prokaryotic expression system is synonymous in the 
SDS–PAGE migration pattern as the endogenous species from normal and 
tumourigenic mammalian cell lines. One may therefore assume, considering MDM2s 
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published propensity to dimerize that the SDS-PAGE solvent conditions (despite 
their denaturating character) are insufficient to break up the stable quaternary 
complex thus retaining the investigated protein in a dimeric form. This would explain 
its observed molecular size, when considering SDS PAGE. Moreover, the studied 
protein in a less stringent buffer composition (non-denaturating conditions) is likely 
to adopt structures of higher tetrameric order).  
Full elucidation of this fascinating avenue lies beyond the scope of this thesis. Meric 
state analysis of the human MDM2 oncoprotein should be performed employing a 
sucrose/glycerol gradient centrifugation analysis technique. 
In summary, one should be reminded that oligomeric state deciphering  of MDM2  in 
essence was not the sole purpose of the size exclusion chromatography procedure. 
Interest was focused on whether various point mutations within the RING domain 
induce destructive (high order oligomers) aggregate-prone species, and whether the 
purification system to isolate the protein of interest may induce similar unwanted 
properties. Hence this assay provides satisfactory answers to both of these questions. 
All of the purified MDM2 species have access to the porous nature of the Superose 6 
matrix and none of them elute within the void volume. Thus supporting the notion 
that increased affinity of MDM2 to p53 is dependent on the state (amino acid 
composition) of the RING domain.  
 
5.2.2 Intrinsic Fluorescence profile of MDM2 is responsive to mutations within 
its RING domain 
 
To investigate whether the Cys mutations within the RING may have a long range 
effect on the global conformation of the protein, yielding it more of an attractive 
binding partner to p53, the fluorescence properties of the isolated MDM2 species 
were investigated. Although all aromatic amino acids can contribute to protein 
fluorescence, tryptophan is the dominant intrinsic fluorophore. MDM2 contains a 
total of 4 tryptophan residues (Figure 5.4 Panel A) located in the central region of the 
protein in and around the central, acid domain. These residues will contribute 
unequally to the total emission spectrum, as emission reflects the average 
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environment surrounding a given tryptophan residue. For tryptophan in an apolar 
environment a blue-shifted (i.e. shorter value of  λmax ) spectrum is observed. Under 
native conditions this occurs for a protein when its tryptophan residues are buried 
within the core structure thus being shielded, less mobile and less exposed to energy 
dissipating interactions with other residues of the protein or buffer. As the tryptophan 
residue becomes hydrogen bonded or exposed to buffer, the emission spectrum shifts 
to longer wavelengths (i.e. red-shift) and usually is accompanied by a decrease in the 
quantum yield, due to the above mentioned interactions. Hence the variations in 
tryptophan emission are due to the structure of the protein. The emission maximum 
and quantum yield of tryptophan can vary greatly between proteins. Denaturation of 
proteins results in similar emission spectra and quantum yields for the unfolded 
protein. One might expect that proteins that display blue-shifted emission spectrum 
will have higher quantum yields (Q) or lifetimes (τ). Such behaviour is expected 
from the usual increase in quantum yield when a fluorophore is placed in a less polar 
solvent (Lakowicz et al., 1992; Lakowicz and Weber, 1973)Lakowicz, 2004 
#32489}(Gryczynski et al., 2003; Lakowicz, 2000). 
There are several factors that determine the emission for tryptophan residues; 
 Quenching by proton transfer by nearby charged amino groups 
 Quenching by electron acceptors such as protonated carboxyl groups 
 Electron transfer quenching by disulfides and amides 
 Electron transfer quenching by peptide bonds in the protein backbone  
 Resonance energy transfer among tryptophan residues 
 Tryptophan dipole moment shielding by water molecules that form the first 
solvation layer surrounding the exposed amino acid moiety on the surface of 
the protein 
For example, even a single hydrogen bond can eliminate the emission spectra of 
indole (i.e sensitivity to small changes in the local environment). The mentioned 
interactions are strongly dependent on distance especially the rate of electron transfer 
rate, which decreases exponentially with distance. The rates of electron transfer and 
resonance energy transfer can be large, so that some tryptophan residues may be 
essentially non-fluorescent. Trp-Trp resonance energy transfer can be expected in 
proteins, particularly if some of the residues display a blue shifted emission. Energy 
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resonance transfer is also possible among residues present on two monomer subunits 
building the quaternary holocomplex.  
Initial experiments were carried out to set the optimum concentration of MDM2 
showing a representative fluorescence emission spectrum within the sensitivity 
threshold of the spectrofluorometer used (Figure 5.4 Panel B). Panel C of Figure 5.4 
represents all the MDM2 species investigated in this assay. 
The following figure compares the emission fluorescence spectrum of MDM2 wt 
with the two Cys mutants (Figure 5.5 Panel A, B). For both of the mutant proteins we 
observe a red shift with λmax at 349-349.5 nm in comparison to the emission 
spectrum of the wt protein of λmax at 343 nm. Moreover the differential quenching of 
tryptophan fluorescence (difference in their quantum yield) for the two Cys mutants 
indicates that their conformation changes are not equivalent. This may not be 
attributed solely to the burial of tryptophan residues as it is also likely to reflect 
interactions with surrounding residues. In other words, changes in the fluorescence 
spectrum can arise as a result of subtle changes in the trypotophan’s 
microenvironment. The data showing differences in conformation between wt and 
mutant forms of MDM2 demonstrate that the RING domain mutations do not 
produce an equal affect on MDM2 conformation. Moreover, they are  consistent with 
differential binding affinity of the Cys464A and Cys478S mutants for  BOX-I and 
Nutlin-3 (Chapter 4). Considering the Ile440A mutation within MDM2 introduced 
initially in Chapter 3, one observes a strong correlation of its fluorescence emission 
spectrum to the wt counterpart, with an almost overlapping spectrum (Panel C Figure 
5.5) with a negligible blue-shift. As presented before the MDM2I440A  mutant shows 
an E3 ubiquitin ligase dead phenotype, most probably due to its lack of interaction 
with the E2 conjugating enzyme. Its zinc coordinating residues, within the RING 
domain, remain unaffected. This provides further evidence that disruption of the zinc 
coordination scheme within the C-terminus of MDM2 consistently affects its global 
perturbation in effect resulting in increased affinity of the N-terminal pocket of 
MDM2 towards p53 and analogous ligands. (As of writing this thesis the gel 
filtration profile of MDM2I440A was unavailable, yet performed later it showed the 
same elution profile as the wild type species). 
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The increased affinity towards the p53 BOX-I peptide by the Cys464 and Cys478 
indicates a gain in conformational affinity of their hydrophobic cavity towards p53, 
this more efficient binding may allosterically induce both of the proteins in question 
to interact better through the secondary interaction site. Moreover the specific Cys 
mutations within the RING of MDM2 may ‘transmit’ their effect on the hydrophobic 
pocket in cis through the central region of MDM2 encompassing the acid domain 
which forms the molecular basis within MDM2 for interacting with p53 (Shimizu et 
al., 2002).  
In summary, one can hypothesize whether RING generated conformational changes 
in MDM2 are transmitted to the hydrophobic pocket through the central domain. End 
point kinetic assays have shown (ELISA- presented in Chapter 4) that the two Cys 
mutations within the RING domain of MDM2 possess a higher affinity towards the 
secondary binding site represented in the form the p53 BOX-V domain peptide and 
Rb-1 peptide. As the p53 BOX-V motif itself lacks any tryptophan residues and as 
the fluorescence emission spectrum is not significant in contrast to BOX-I and its 
binding interface within MDM2 is closely located to the tryptophans of MDM2. The 
potential of the peptide was investigated in terms of a specific effect on the 
fluorescence emission spectrum of MDM2 and one of the Cys mutants (Initially the 
Cys464A was investigated) presented in Figure 5.6. The peptide was preincubated with 
the protein as shown in the figure and spectral analysis was performed. In both cases 
(MDM2WT and MDM2C464A mutants alike) the addition of the peptide in a dose 
dependent manner induces a blue shift in the spectrum with an appropriate increase 
in the quantum yield indicating a BOX-V dependent specific effect on the 
microenvironment surrounding the tryptophans within the protein. A control was 
used in this experiment (data not shown) involving a non specific tryptophan free 
peptide moiety clearly highlighting the specific nature of the BOXV :MDM2 
interaction. Comparing the spectral curves presented on Panel B, C (Figure 5.6) in 
more detail, one notices that the peptide induced blue-shift for the Cys464A mutant 
spectrum is greater in terms of wavelength change than for the wild-type form. 
Considering the fluorescence emission spectrum for the Cys464A mutant where the 
BOX-V peptide was added, one can notice a blue shift of λmax to the region 
coinciding with the longest wavelength of the wild-type protein. Addition of the 
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peptide forces the MDM2 mutant to adopt a conformation, or at least the close 
surroundings of the tryptophan residues similar to that of wild type. 
 
5.2.3 Thermal denaturation of MDM2 reveals further insights into inner 
domain cross-talk  
 
Tryptophan based intrinsic fluorescence of the isolated MDM2 proteins, presented 
above, highlights their conformational differences dependent on the integrity of the 
zinc binding motif within the MDM2 RING domain. Moreover the two Cys mutants, 
which are inactive as E3 ubiquitin ligases and show a higher degree of affinity 
towards p53 in vitro and in cell based assays, are divergent when it comes to their 
fluorescence emission spectra hinting at the diverse structure of the two proteins. To 
further peruse this notion the extent of global unfolding for the studied MDM2 
mutants was measured using a fluorescence based thermal shift/denaturation assay. 
The results presented in Figure 5.7 depict fluorescence intensity as a function of 
temperature. As mentioned in the introduction to this chapter a specific marker dye 
was used exhibiting a higher quantum yield in hydrophobic surroundings, hence as 
protein unfolding is driven by the increase in temperature, the recorded fluorescence 
will increase until reaching a plateau, following which the signal drops due to protein 
aggregation. 
Considering Figure 5.7 Panel A and B alike, one striking feature can be noticed; the 
presence of nucleotide (ATP) in the protein mixture undergoing thermal denaturation 
has a strong positive correlation to the inflection of the curve recorded, highlighting 
strong exposition of hydrophobic patches within the assayed proteins. This 
occurrence was not recorded for the behaviour of fluorescence emission spectra 
presented earlier. This exciting data is reproducible within the concentration range of 
the protein used in the assay and although exciting should still be considered as 
preliminary due to the fact the fluorescence values recorded in the presented assays 
are low. Nevertheless this avenue is open for pursuit, as the scientific field lacks any 
conclusive data that addresses conformational change of MDM2 protein upon 
interaction with the ATP nucleotide. 
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Mutations within the P Walker motif of MDM2 hinder its ATP binding potential yet 
do not display any decrease in ubiquitin ligase activity, moreover they do not 
modulate the ability of MDM2 to interact with p53. The MDM2K454A which binds 
ATP with a much lower efficiency than the wild-type isoform (shown in Chapter 4), 
displays relatively small ATP dependent differences as its denaturation profile is 
investigated in the absence or presence of the nucleotide. A different picture is seen 
for the other protein species investigated. Figure 5.7 indicates that for MDM2WT and 
the MDM2C464A (Figure 5.7 Panel B), the presence of the nucleotide induces the 
formation of a sharp transition peak. As stated, the fluorescence intensity measured is 
proportional to the exposition of hydrophobic patches by the protein. Hence ATP 
binding by the MDM2 species induces a conformational shift within the protein, 
leading to a state where the marker dye binds with higher affinity. As it shall be 
shown later the melting temperature of all the proteins in question does not vary by a 
great deal, it appears that the presence of the nucleotide has a crucial role in reaching 
the transition point. Moreover, this transition is not equally comparable for the 
proteins. Yet again the Cys464A mutant of MDM2 comes to the spotlight, showing a 
large increase of hydrophobic patch exposition, and once more the non-equivalent 
nature of the two Cys mutations is underlined (Figure 5.8 Panel A compared to 
Figure 5.7 Panel B). The MDM2C478S mutant shows a remarkably lower fluorescence 
signal in contrast to the Cys464A mutant. This phenomenon is most likely sensitive to 
the state of the zinc binding residues as the MDM2I440A mutant (having all the key 
zinc coordinating residues intact), shows a nucleotide dependent peak (Figure 5.8 
Panel B) that although higher in magnitude than the one for MDM2WT, yet still 
drastically lower than the one for MDM2C464A.  
Considering the summarized data presented in Figure 5.9 one can observe that the 
single point mutations within MDM2 alter the melting temperature of appropriate 
proteins within the interval ΔTm=1°C where MDM2WT was calculated to have the 
melting temperature of 55°C. With the Cys464A having the melting temperature at 
54°C and the Cys478S at 56°C. The differences in melting temperature recorded for 
the mutant MDM2 species do not diverge greatly from each other, yet what is 
noticeable is the differential affinity to the solvatochromatic dye to the protein 
species investigated (Figure 5.9 Panel A), with the Cys464A mutant in the lead. As all 
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of the proteins investigated were isolated from a prokaryotic expression system, one 
could argue that the samples may be differentially contaminated with an impurity 
leading to artefactual data. This most probably is not the case as the observed ATP 
‘switch’ effect is specific for MDM2 proteins bearing active Walker P motif (with 
the negative control in the form of MDM2K454A ). Moreover the final concentration of 
protein used in this assay was quite low 1 µM, and the results presented were 
repeated with further dilutions giving similar results.   
To fully capitalize and understand these results, one must analyze and consider the 
MDM2 polypeptide chain in terms of its hydrophobicity, which will be presented and 
discussed later in this chapter. 
 
5.2.4 Proteolytic digestion of MDM2 reveals conformational changes 
 
To further support the hypothesis that hydrophobic pocket affinity can be modulated 
by the RING domain, additional evidence of RING-dependent conformational 
change in full length MDM2 was sought. Partial proteolytic digestion of the protein 
combined with antibody reactivity may be useful to pinpoint regions within the 
protein that show a varying profile dependent on the mutation introduced. Limited 
proteolysis was used to probe for changes in the accessibility of trypsin cleavage 
sites in the MDM2 Cys mutants versus the wild-type protein. Trypsin (IntEnz 
Enzyme Nomenclature EC 3.4.21.4) is a serine protease that specifically cleaves at 
the carboxylic side of lysine and arginine. Restrictions to the specificity of trypsin 
occur when proline is at the carboxylic side of lysine or arginine; then the bond is 
almost completely resistant to lysis. Cleavage may also be considerably reduced 
when acidic residues are present on either side of a potentially susceptible bond 
(Bode et al., 1978; Bradshaw et al., 1970; Sanders et al., 1970). 
Purified wt or mutant MDM2 was incubated with trypsin at a ratio of 100:1 
(MDM2/trypsin) for up to 30 min, the reactions were stopped by addition of 1x SDS 
Sample buffer and the samples were then analysed by gradient SDS-
PAGE/immunoblot and cleavage fragments identified using a cocktail of MDM2 
monoclonal antibodies (Figure 5.10 Panel B). The results show that the wt protein 
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rapidly formed (within 5 min) a stable core comprising bands 1, 2 and 3 that was 
maintained throughout the course of the experiment. Although the MDM2C464A 
mutant initially formed a similar banding pattern to the wt protein, with bands 1, 2 
and 3 being detected, it was then further processed so that by 15 minutes a new stable 
pattern had emerged comprising bands 2, 3, 4 and 5 with band 1 no longer being 
detected. Consistent with earlier results the MDM2C478S mutant appeared to be 
intermediate between wt and the Cys464A protein as at 30 min all 5 bands were 
readily detected.  These results suggest that the Cys464A and Cys478S mutants have a 
different conformation to the wt protein leading to the exposure of trypsin sensitive 
cleavage sites that are not accessible in wild-type MDM2.  
The experiments presented above, using limited proteolysis and intrinsic 
fluorescence suggest that the introduction of point mutations in key RING domain 
Cys residues generates a measurable conformational change in full-length MDM2 
protein. In order to establish whether these conformational changes have a direct 
impact on the structure of the hydrophobic pocket a monoclonal antibody (3G5) was 
employed which binds to an epitope in the centre of the hydrophobic pocket (Figure 
5.11; Panel A (Bottger et al., 1997a)). With limited proteolysis and subsequent 
probing with the 3G5 antibody one can determine whether changes in the RING 
domain had an effect on the ability of mentioned antibody to bind to the hydrophobic 
pocket of MDM2. As a control for this experiment the 2A10 monoclonal antibody 
was used which has been mapped to two epitopes within the central and C-terminal 
domains of MDM2 (Figure 5.11; panel A). The results obtained with this antibody 
suggest that the core fragments identified in Figure 5.10 (in particular bands 2, 3 and 
4) are comprised largely of the central domain of MDM2 together with C-terminal 
truncations. In contrast Figure 5.11 Panel B suggests that the hydrophobic pocket is 
rapidly cleaved from the core of MDM2 and that its removal generates a fast 
migrating 3G5 reactive product (band 6). The MDM2C478S mutant appears to be more 
sensitive to this type of cleavage as 3G5 positive full-length protein is lost more 
rapidly than it is for wt MDM2. Of particular interest in this assay is the MDM2C464A 
mutant, as incubation of this protein leads to a dramatic loss of the 3G5 epitope 
suggesting that the hydrophobic pocket in this protein is more ‘relaxed’ and therefore 
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more accessible to trypsin digestion during which the 3G5 binding site (amino acids 
66-69) is cleaved leading to a loss of the epitope.  
Together the data presented in this chapter support the conclusion that the RING 
domain of MDM2 can influence the activity of the N-terminal hydrophobic pocket 
by producing long range conformational changes that are transmitted through the 
central acid core of MDM2 and which in turn lead to varying degrees of relaxation in 
the hydrophobic pocket. 
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5.3 Discussion  
The primary interaction site for p53 within MDM2 has been the focus of scientific 
attention for a number of years now, despite the plethora of crystallographic data 
showing the molecular basis of this interaction recent studies strongly suggest that 
the N-terminal hydrophobic groove is not a one state rigid entity (Espinoza-Fonseca 
and Garcia-Machorro, 2008; Espinoza-Fonseca and Trujillo-Ferrara, 2006a). 
Structural and computational analysis of the MDM2 hydrophobic pocket interaction 
with p53 has revealed that this domain has a high degree of plasticity and strongly 
suggests that the shape of the binding cleft can change significantly, underlying the 
dynamic nature of the p53::MDM2 interaction (Espinoza-Fonseca and Garcia-
Machorro, 2008; Espinoza-Fonseca and Trujillo-Ferrara, 2006a). A mechanism has 
been proposed where binding to the BOX-I domain of p53 requires a progressive 
opening up of the binding cleft of MDM2 to reveal a hydrophobic interface. An 
intermediate step is involved in p53::MDM2 complex formation, where the MDM2 
cleft gradually adopts a more open conformation eventually accommodating Thr18-
Asp29 of the p53 BOX-I domain. Based on this type of study it has been 
hypothesized that the cleft has enough plasticity to allow a range of low-energy states 
rather that a single ‘open’ or ‘closed’ conformation. As a result the pocket can 
accommodate a range of peptides and small molecules that might not have any 
obvious structural similarity (Bowman et al., 2007; Espinoza-Fonseca, 2005; 
Espinoza-Fonseca and Garcia-Machorro, 2008; Espinoza-Fonseca and Trujillo-
Ferrara, 2006a; Stoll et al., 2001; Vassilev, 2004). It is likely therefore that the 
differential binding preferences of the two Cys mutants investigated are a result of 
different degrees of cavity accessibility. This hypothesis is supported by data 
showing that although the Cys464A, Cys478S mutant proteins both adopt a different 
stable conformation from the wild-type protein and that their conformation is not 
equivalent. The intrinsic fluorescence of tryptophan residues within the central 
domain of the Cys478S mutant is quenched relative to the Cys464A mutant suggesting 
that they are more solvent exposed and/or are involved in additional interactions with 
nearby residues. One can imagine that these two proteins can be in a slightly 
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different conformation that brings the residue closer or further from a quenching 
group such as other aromatic residues.  
Another plausible notion, though in need of further investigation, is the possible 
resonance energy transfer between aromatic molecules present in two separate 
monomers of the protein holocomplex. The RING domain within MDM2 has been 
shown as the site of dimerization (Kostic et al., 2006; Linke et al., 2008; Maki, 
1999). Resonance energy transfer is likely to occur due to the fact that a spectral 
overlap exists between absorption and emission spectra for all of the fluorescent 
amino acid residues; Phe, Tyr, Trp. Proteins exhibiting monomeric/dimeric 
transitions during their life cycle such as interferon-γ, display resonance energy 
transfer between residues within different subunits of the complex (Boteva et al., 
1996). Furthermore site directed mutagenesis studies of  proteins bearing several 
tryptophan residues highlights the  fact that fluorescence resonance energy transfer 
can occur also within discreet subunits building the holocomplex of the protein 
(Meagher et al., 1998). Thus, the lower quantum yield in the fluorescence emission 
spectrum of MDM2C478S can be attributed to a divergence in its conformational state 
in comparison to the MDM2WT and the other Cys mutants MDM2C464A. Size 
exclusion chromatography presented in this chapter indicates that all of the 
investigated proteins posses similar properties, hence a decrease in the quantum yield 
observed for the MDM2C478S mutant in comparison to the fluorescence emission 
spectra for all the other investigated MDM2 proteins cannot be easily explained by 
differences in the quaternary structure of this mutant. Moreover data presented in 
Chapter 3, focusing on cell based ubiquitination assays, suggest that the mutant is 
able to hetero-dimerize (with endogenous wild-type MDM2) giving rise to 
ubiquitinated p53 species in a cell based system.  
To date no structural data is available regarding the full length MDM2 protein giving 
relative distances between the numerous domains within the macromolecule. The 
spectral data provided by the fluorescence emission spectra of the discussed Cys 
MDM2 mutants does not directly postulate that the substitution of cysteine 
physically affects the environment of the tryptophan molecules topologically located 
within the central part of the protein, thus affecting its spectral properties. What it 
does illuminate is the fact that structural cross talk between domains is possible. This 
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is strongly supported by the experimental data presented in Figure 5.6, where the 
addition of the p53 BOX-V domain peptide (representing the secondary interaction 
site within p53 binding to the acid domain of MDM2), shifts the spectrum of the 
MDM2C464A mutant to that of MDM2WT. The BOX-V peptide::MDM2 Cys464A 
interaction thus forces the protein to revert back to the conformation of the wild type 
species.  
Experimental data from MDM2 thermal denaturation analysis further supports this 
notion. This assay measures protein unfolding as the propensity of a given protein to 
expose its hydrophobic surface dependent on environmental temperature influx.  In 
light of the proposed hydrophobic collapse model for polypeptides, the process of 
protein folding leading to the native protein conformation consist of an early step 
which is the rearrangement of the nascent polypeptide to a compact collapsed 
structure (Brylinski et al., 2006; Dill et al., 1995). Hydrophobic collapse ensues the 
formation of a molten globule therefore constituting an early step in the folding 
pathway. The energy state of the molten globule is lower than that of the denatured 
state, yet higher than that of the native state - that is, within the energy landscape 
well of the folding funnel (Borgia et al., 2008) but not yet close to the energy 
minimum. This is believed to occur prior to the formation of secondary structures 
and native contacts present in the tertiary structure of the protein. Forced reversal of 
this process induced by energy increase to the system by means of temperature flux, 
gives rise to the to the exposition of the hydrophobic core consisting of nonpolar 
aromatic and aliphatic amino acid residues.  
The hydrophobic profile of human MDM2 protein was investigated by means of 
readily available in silico algorithms, giving each amino acid within the primary 
structure of the protein a numerical value (score) directly proportional to its 
hydrophobic nature.  Four independent sets of score matrices were used to obtain a 
synergy depicting hydrophobic hot spots within MDM2 (Figure 5.12). High scores 
were noted for residues building the N-terminal binding site for p53, a small central 
region, and the residues within the C-terminus topologically within the RING 
domain. Thus, the increase of hydrophobic exhibition by MDM2 induced by 
nucleotide (ATP) addition to the reaction can be explained not only by 
conformational changes in and around the site of nucleotide binding the RING 
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domain, but also by differential involvement of the other hydrophobic sites located 
further away within the protein. Currently it is unknown whether there is a 
preference for which hydrophobic patch to be exposed earlier than the other, hence 
all of them should be should be taken to account as contributors to the denaturation 
profile of MDM2. What one can conclude from the presented data is that mutations 
within key Cys residues of the RING alter the denaturation profile of the protein in 
comparison to the wild-type species. Again the mutations do not give an equivalent 
phenotype, where the Cys464A mutant is seen to have a significantly larger exposition 
of hydrophobic residues over the wild-type protein and the Cys478S mutant displays a 
decrease. This cannot be solely explained by a differential exposition of the residues 
within the N-terminal hydrophobic cavity of MDM2 as other parts of the protein 
have similar qualities, and as shown in the previous two chapters both of the mutants 
display a preferential affinity towards p53. What it does show is that substitutions 
within key residues of the RING domain perturb the polypeptide backbone in which 
they are present differentially. Moreover, this technique once again shows that 
discrete functions within the RING domain can be uncoupled. As the shape of the 
melting curves was dependent on the presence of ATP in the sample undergoing 
denaturation, and no such effect was observed for the MDM2K454A mutant with 
impaired nucleotide binding ability.  
  
Limited proteolysis experiments can be successfully used to probe for 
conformational features of proteins. It has been demonstrated that the sites of limited 
digestion along the polypeptide chain of a protein are characterized by enhanced 
backbone flexibility, implying that proteolytic probes can pinpoint the local sites of 
conformational fluctuation in a protein chain (Fontana et al., 2004). 
Further evidence for a difference in the conformation of the hydrophobic cleft 
dependent on the status of the RING domain comes from the use of the 3G5 
monoloclonal antibody to probe for differences in conformation following limited 
tryptic digestion. This antibody recognises an epitope in the hydrophobic pocket of 
MDM2 where residues 66LYDE69 are essential but not sufficient for binding i.e 
peptides containing the LYDE motif but not other surrounding residues are not 
sufficient for antibody recognition (Bottger et al., 1997a). The LYDE motif maps to 
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a loop structure in the hydrophobic pocket that lies between two of the α-helical 
structures that form the BOX-I binding cavity (Figure 5.13) and is flanked by lysines 
and arginine residues that provide tryptic cut sites when exposed 
(61IMTKRLYDEKQQHIV75). The data presented in this chapter hints that the cleft is 
more accessible in the Cys464A mutant than in the wt or the Cys478S protein, 
suggesting that the cleft is more relaxed and therefore more readily accommodate the 
p53 BOX-I peptide leading to increased affinity.  
In conclusion, by generating mutations within the C2H2C4 RING domain of MDM2 
an allosteric modulation of affinity and specificity of the hydrophobic pocket is 
observed. Thus indicating the importance of the mentioned domain in native cell 
surroundings for interactions with numerous protein binding partners and small 
molecule ligands (Zn2+, ATP). The effect of which will be differential control of the 
transrepressor potential of the MDM2 oncoprotein, and efficiency of pocket binding 
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Figure 5.1 Elution profile of molecular weight standards applied to Superose® 
6 10-300 GL column
Chromatograms presented above show the variation in concentration (UV Absorbance at 
A280nm) of sample components as they elute from the column in order of their molecular size. 
Blue Dextran for all the chromatograms above was used to calculate the void volume - (V0) of 
the column. The protein standards used with partial access partial access to the pores of the 
matrix elute from the column in order of decreasing molecular size.  The molecular weight of 
the standards in a decreasing is as follows;  MW (Thyroglobulin) > MW (Ferritin) > MW 
(Catalase) > MW (Ovalbumin) > MW (Chymotrypsin). Elution volume in mililiters shown next to 
appropriate elution peak.







V0 - void volume
Vt - total column volume
Ve - elution volume
Kav - distribution coefficient 









Kav = -0.2666(logMw) + 1.0446
R2 = 0.973
Blue Dextran    








Thyroglobulin 669 2.83 11.85 0.270 
Ferritin 440 2.64 13.15 0.348 
Catalase 232 2.37 14.76 0.444 
O valbum in 44  1.64 16.86 0.571 
Chym otrypsin 25  1.40 18.85 0.690 
 
Vt [ml] Averaged-V0 [ml] V0 [ml]
Ve [ml]Mw [kDa] log Mw Kav
fractions 11 12 13 14 15 16 17 18 
m l 11 12 13 14 15 16 17 18 
K av  0.218 0.279 0.339 0.399 0.459 0.519 0 .579 0.639 
Mw  [kDa] 1256 747 445 264 157 94 56 33 
 
Figure 5.2 Molecular weight determination for fractions collected
The relationship between molecular weight [Mw] of the protein standards, and their partition 
coefficient Kav was established. The equation obtained via linear regression depicts a linear 
relationship between Kav and MW. Basing on this predicted molecular weight was calculated 
for the fractions collected upon passing through the Superose 6 column.
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Figure 5.3  Mutations within the RING of MDM2 domain do not induce 
aggregation of the purified protein species.
Equal amounts of  MDM2WT (180 μmol) and all the studied RING domain mutants were 
subjected to size exclusion chromatography.  The amount of buffer passed through the 
column was 1.5 column volume (25 mM Hepes pH 7.6 50 mM KCl 5% Glyc 10 μM ZnSO4  3  
mM DTT), 1 ml fractions were collected, void volume (V0) is indicated for each of the elution 
profiles above.  Every second fraction from the elution was analyzed by means of 10% SDS 
PAGE (50 μl of sample loaded) and visualized by immunoblotting (2A10 Ab). Arrows indicate 
the peak fractions where MDM2 was most prominent.  
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Figure 5.4 Fluorescence emission spectra of MDM2
Resolution of fluorescence emission spectra of  MDM2. Intrinsic fluorescence measured with 
295 nm excitation. For both of the graphs on the right of the figure, spectra were corrected for 
associated buffer background signals.
(A) Schematic representation of tryptophan residue localization within the primary structure 
of MDM2
(B) The quantum yield, of the emission spectrum is proportial to concentration of the 
investigated protein. Initial titration of MDM2 aimed at setting up the optimal window for 
experimentation. The spectrofluorometer used gives valid readings up to 3x106 cps. 
(C) The behaviour of the fluorescence emission spectra is dependent on key single point 
mutations within the C-terminal RING domain. 
Graphs on the left represent spectra with background buffer dependent signal, the graph on 
the right represents values corrected for that. MDM2WT shown in white, MDM2I440A in green, 
MDM2C464A in brown and MDM2C478S is depicted in blue. 
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MDM2WT (343 nm, 581134 cps)
MDM2I440A (341 nm, 551645 cps)
Figure 5.5 Resolution of fluorescence emission spectra of analysed MDM2 
mutants with regards to wild-type MDM2.
(A) (B) (C) Intrinsic fluorescence measured with 295 nm excitation. Emisssion was recorded 
from 320 to 425 nm in 0.5 nm steps, with an integration time of 1 s. The spectra were 
corrected for associated buffer background signals. Maxima are indicated with shaded boxes 
on the spectra, with corresponding wavelength. The values were calculated with 
n-polynomial based algorithm, where R2≥0.999.  MDM2WT shown in white, MDM2I440A in 
green, MDM2C464A in brown, and MDM2C478S is depicted in blue.   
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MDM2C464A +25 µM BOX-V (341.5 nm 570731 cps)
MDM2C464A +50 µM BOX-V (340 nm  620720 cps)
Figure 5.6 The contribution of the acid domain to MDM2 intrinsic 
fluorescence 
(A) (B) (C) The  protein samples analysed were preincubated without or with increasing 
amount of BOX V peptide. Intrinsic fluorescence measured with 295nm excitation. Emisssion 
was recorded from 320 to 475 nm in 0.5 nm steps, with an integration time of 1s. The spectra 
were corrected for associated protein buffer, peptide solvent  background signals. Maxima 
are indicated with shaded boxes on the spectra, with corresponding wavelength. The values 
were calculated with n-polynomial based algorithm, where R2≥0.999.  MDM2WT shown in 
white,  MDM2C464A in brown. Data presented in this figure was obtained in cooperation with Dr. 
Susanne Pettersson. 


















































































































Figure 5.7 Thermal Denaturation of MDM2
Temperature driven MDM2  unfolding transition is ATP dependent. A stepwise temperature 
gradient was used from 20 °C to 95 °C (1 °C/min steps).  A solvatochromatic dye was used 
as an indicator of protein unfolding that has a low-fluorescence quantum yield in buffer alone. 
Partitioning of the dye into melted protein results in a significant increase in fluorescence. 
Sypro Orange used as the protein dye was diluted to the final concentration of 5x.  
(A) MDM2WT and MDM2K454A mutant protein (1 µM final concentration) were incubated either 
in the presence or absence of 4 mM ATP as indicated. MDM2WT shown in white, MDM2K454A  
depicted in grey, buffer alone in black.   
(B) MDM2WT and MDM2C464A mutant protein (1 µM final concentration) were incubated either 
in the presence or absence of 4mM ATP as indicated. MDM2WT shown in white, MDM2C464A 
shown in brown.
Graphs for both Panels positioned on the left, represent fluorescence intensity measured as 
a function of temperature. Panels on the right represent the negative rate of change of 
fluorescence with respect to temperature. The minima of these functions are indicative of the 
point of inflection of the corresponding curves to the left, thus revealing the melting 
temperature of the protein sample. 






















































































































Figure 5.8 Thermal Denaturation of MDM2 continued
Temperature driven MDM2  unfolding transition is ATP dependent. A stepwise temperature 
gradient was used from 20 °C to 95 °C (1 °C/min steps).  A solvatochromatic dye was used 
as an indicator of protein unfolding that has a low-fluorescence quantum yield in buffer alone. 
Partitioning of the dye into melted protein results in a significant increase in fluorescence. 
Sypro Orange used as the protein dye was diluted to the final concentration of 5x.  
(A) MDM2WT and MDM2C478S mutant protein (1 µM final concentration) were incubated either 
in the presence or absence of 4mM ATP as indicated. MDM2WT shown in white, MDM2C478S  
depicted in blue, buffer alone in black.  
(B) MDM2WT and MDM2I440A mutant protein (1 µM final concentration) were incubated either in 
the presence or absence of 4mM ATP as indicated. MDM2WT shown in white, MDM2I440A 
shown in green.
Graphs for both Panels positioned on the left, represent fluorescence intensity measured as 
a function of temperature. Panels on the right represent the negative rate of change of 
fluorescence with respect to temperature. The minima of these functions are indicative of the 
point of inflection of the corresponding curves to the left, thus revealing  the melting 
temperature of the protein sample. 
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Figure 5.9 Thermal Denaturation of MDM2 summarized
(A) Figures represent melting transitions for MDM2 proteins indicated in the presence of 4 
mM ATP. Panels on the left represent fluorescence intensity measured as a function of 
temperature. Panels on the right represent the negative rate of change of fluorescence with 
respect to temperature. The minima of these functions are indicative of the melting 
temperature of the protein sample. MDM2WT shown in white,  MDM2C464A in brown, MDM2C478S 
in blue, MDM2I440A in green and MDM2K454A  is depicted in grey. 
(B) The calculated melting temperatures of MDM2 wild-type and all the mutants specified.
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Figure 5.10 Partial proteolytic digestion of MDM2 
(A) Schematic representation of MDM2 showing the epitopes for 3G5, 4B2, SMP14 and 
2A10 antibodies in human MDM2 protein. 
(B) Immunoblot showing wild-type or mutant forms of MDM2 following limited proteolysis with 
trypsin and SDS PAGE on a precast 4-12% gel. The blot was developed using a mixture of 
the MDM2 monoclonal antibodies 2A10, 4B2, 3G5 and SMP14. The numbers are used to 
label the banding pattern. The time points used were 0, 5, 10, 15, 20 and 30 min. Data 
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Time Time Time
Figure 5.11 Partial proteolytic digestion of MDM2 
(A) Schematic representation of MDM2 protein showing the epitopes for 3G5 and 2A10 in 
human MDM2. 
(B) Immunoblot showing wild-type or mutant forms of MDM2 following limited proteolysis with 
trypsin. Following gradient SDS PAGE and western blot transfer. The blots were developed 
using 2A10 (upper panel) and 3G5 (lower panel).  The numbers are used to label the banding 
pattern. The time points used were 0, 5, and 20 min. Data presented in this figure was 
obtained in cooperation with Prof. Kathryn Ball.




















































































Figure 5.12 Hydrophobic profile of human MDM2 
ProtScale (http://www.expasy.org/tools/protscale.html) computational analysis for MDM2 
was used to represent this profile. The normalized hydrophobicity score is  defined by a 
numerical value assigned to each type of amino acid,where 0 is the least  and 1 is the most 
hydrophobic. 
(A) - (D) Graphical representation of MDM2 hydrophobic profile where four independent sets 
of scores were used to characterize the primary structure of MDM2. 
(E) Localization of major hydrophobic amino acid stretches within the multidomain 
organization of MDM2, representing convergence of data shown in (A) - (D).


































Figure 5.13 Localization of the 3G5 antibody epitope within the MDM2 
hydrophobic pocket
Panels represent different stereoscopic views.
The MDM2 hydrophobic pocket shown in ribbon representation, coloured gold. Nutlin-3 
bound to the pocket in stick representation (carbon-grey, nitrogen-blue and oxygen-red, 
chlorine-green). The epitope of 3G5 Ab consists of 4 amino acid residues; Leu66 Tyr67 Asp68 
Glu69 highlighted in purple.
This figure was prepared using PyMOL [http://www.pymol.sourceforge.net/] and structural 
data from Fry et al., 2004 (file 1TTV  RCSB PDB ). 
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MDM2 is a multi-functional protein with numerous biochemical functions.  The 
results presented in this thesis indicate that the functions of MDM2 oncoprotein in 
growth control and tumourigenesis are managed in part through the coordination, and 
intrinsic regulation of its discrete domains.  
 
6.1 The RING finger domain – key intrinsic regulator of MDM2 
function 
 
The data in this thesis indicates that the MDM2 oncoprotein promotes p53 binding to 
responsive DNA sequences at physiological temperature. This seemingly 
contradictory role of the main p53 antagonist is supported by accumulating evidence 
indicating that degradation-independent mechanisms are crucial for both MDM2 and 
MDM4 in controlling p53 activity (Kruse and Gu, 2009). It was recently proposed 
that p53 activation in vivo requires not only stabilization and activation by post-
translational modifications but also release from a repressed state. Considering 
genetic and in vitro data alike it was suggested that p53 is intrinsically active 
(Johnson et al., 2005; Ringshausen et al., 2006), yet is repressed by key negative 
regulators, MDM2 and MDM4 (Kruse and Gu, 2009).  
Intriguingly, the ability of stress-induced, allosteric activation of unmodified p53 to 
bind sequence specific DNA (Hupp et al., 1992) was recently challenged. A 
considerable number of studies provide evidence that a significant portion of p53 is 
bound to DNA in unstressed cells (Cain et al., 2000; Kaeser and Iggo, 2002; Kim et 
al., 1999; Liu et al., 2004; Szak et al., 2001). Quantitative ChIP (chromatin 
immunoprecipitation) assays demonstrate that p53 is present at the promoters of p21 
and MDM2 genes from wild-type unstressed cells. Lessons learned from cell culture 
based studies dictate that this is facilitated by an existing pool of basal post-
translational modifications, which are significantly unregulated upon stress response 
(Appella and Anderson, 2001; Webley et al., 2000).  
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These numerous findings provide tangible support for a model in which p53 is 
capable of binding to DNA in unstressed cells but remains inactive probably due to 
repression by MDM2 and MDM4. Moreover MDM2 was shown to transiently 
localize with p53 at responsive elements and this recruitment of MDM2 to chromatin 
was postulated to keep p53 in latent form (Arva et al., 2005; Minsky and Oren, 2004; 
Ohkubo et al., 2006; White et al., 2006).  
In light of this, association of the transcription factor with the promoter can occur 
without immediate activation of a given p53-responsive gene.  The results presented 
in this thesis are coherent with this notion. They illuminate that MDM2 can elevate 
the amount of p53 bound to the promoter yet at the same time no increase of p53 
transcriptional activity is observed.  
The mode of action by which MDM2 facilitates efficient binding of p53 to the 
promoter is ATP dependent. Site directed mutagenesis studies and antibody mapping 
have confirmed the direct role of MDM2 in this process. The nucleotide is 
specifically bound by a motif located within the RING finger of MDM2, without 
interfering with the intrinsic E3 ubiquitin ligase activity of the domain. 
It has been reported that nucleotide binding by the MDM2 oncoprotein induces a 
conformational change in its structure (Poyurovsky et al., 2003). Thermal 
denaturation studies shown in this thesis concur with these observations, moreover 
the shed additional light on the nature of the conformational flux. The ATP—bound 
form of MDM2 in contrast exhibits a characteristic denaturation profile. Indicating 
nucleotide driven conformational flux of the polypeptide. Moreover conformational 
changes driven by the ligand not only exhibit themselves in the oncoprotein, but 
additionally in the tumour suppressor. Monitoring p53 conformation in a mammalian 
cell lines by specific antibodies, displays a shift towards wild-type (DNA binding) 
structural arrangement of the protein driven by MDM2 species capable of ATP 
binding.  
The discovery that MDM2, apart from its E3 ubiquitin ligase activity also possesses 
a function synonymous to that seen for molecular chaperones involved in protein 
folding and protection from aggregation raises an important question concerning the 
biological relevance of MDM2 chaperone  activity toward p53 and other substrates. 
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The global in vivo situation of p53 is very complex. The results indicate that MDM2 
promotes proper folding of p53, yet the same time MDM2 accelerates the 
degradation of the tumour suppressor. From the data presented a conclusion can be 
drawn that the activity of MDM2, in concert with a prominent p53 interacting 
molecular chaperone Hsp90 (Muller et al., 2004; Walerych et al., 2004), is required 
for shifting the conformation equilibrium of p53 to such a state where the 
transcription factor is potent to bind the promoter sequence. If such a state is not 
reached, the polypeptide is presented to the ubiquitination machinery and targeted for 
degradation (Sasaki et al., 2007). Furthermore, the results presented do not indicate 
that MDM2 is part of the complex once p53 is bound to its promoter sequence, 
indicating a transient mode of action. The fact that MDM2 can assist in correct non 
covalent assembly of the p53-promoter complex, where MDM2 is not a component 
of this assembled structure can be explained if one considers the following. The fact 
that the proteins used for the DNA binding experiments were isolated to high 
homogeneity from a prokaryotic expression system, rendering them devoid of any 
post-translational modifications, is a plausible answer. This would indicate that for a 
change from a transient interaction – ensuring efficient DNA binding, to stable 
complex on the promoter sequence – where MDM2 effectively represses p53 
activity, is driven by reversible post-translational modifications of the two proteins in 
question.  Of note are recent studies where purified proteins isolated form 
mammalian cells have confirmed the fact that MDM2 co-localizes with p53 on 
promoter sequences (Tang et al., 2008) in a fashion dependent on the acetylation 
state of p53. 
Acetylation of p53 has recently been proposed to drive its specific target gene 
activation. This p53 modification involving the covalent linkage of an acetyl group to 
a lysine residue, was shown to be elevated in response to stress, and levels of 
acetylation correlate well with p53 activation and stabilization (Ito et al., 2001; 
Knights et al., 2006; Luo et al., 2001; Luo et al., 2000; Tang et al., 2008; Vaziri et 
al., 2001). The functional consequences of p53 acetylation imply that timing of 
acetylation of different p53 regions may be important for accurate p53 regulation and 
cell fate determination. In light of this several classes of genes are outlined in regards 
to when they are activated during the p53 response; modulators of excessive p53 
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activity, genes involved in growth arrest, and the last stringently controlled genes 
involved in programmed cell death.  
 
The phenomena of biomolecular crowding present in living cells, (cytoplasm and 
nuceloplasm alike) renders it a hostile environment for proteins that display intrinsic 
conformational lability (Johansson et al., 2000; Tokuriki et al., 2004). This applies to 
p53, as it is known for its biophysical instability and is prone to conformational 
changes during its lifetime. Native conformation of p53 is essential for its biological 
activity executed in great part by its transcription factor potential. The MDM2 
oncoprotein, along with other proteins interacting with p53, may constitute an 
additional level of p53 control. 
It is known that molecular chaperones directly cooperate with ubiquitin/proteasome 
system during protein quality control in eukaryotic cells (Esser et al., 2004).  
Among other E3 ubiquitin ligases specific for p53, CHIP (carboxyl terminus of 
Hsp70-interacting protein) was shown not only to target the tumour suppressor for 
proteasome mediated degradation (Esser et al., 2005a), but also aids in maintaining 
wild-type conformation capable of binding to DNA under physiological conditions 
(Tripathi et al., 2007). These published results show that CHIP mediates regulation 
of p53 conformation and abundance. The apparent redundancy of action carried out 
by CHIP and MDM2 should be considered as an evolutionary advantage, minimizing 
the pool of latent aggregate prone forms of the tumour suppressor. 
Another intriguing open question, which remains to be fully elucidated, is whether 
p53 can be ubiquitinated by MDM2 while bound to DNA, and if so which post-
translationalmodifications both on p53 and MDM2 regulate this process. 
Although the fragment of the N-terminal transactivation domain of p53 was 
originally thought to be the predominant site of interaction with MDM2, both the 
DNA-binding domain (Kulikov et al., 2006; Shimizu et al., 2002; Wallace et al., 
2006; Yu et al., 2006) and the C-terminal domain of p53 interact with MDM2 (Tang 
et al., 2008). The presence of multiple binding sites in both MDM2 and p53 leading 
to complex formation, may suggest that there is interplay between post-
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translationalmodifications that activate p53 by stabilization and in effect release it 
form repression (Kruse and Gu, 2009).   
This discovered activity of MDM2 could also in part explain the p53-independent 
oncogenic activity of MDM2. Further results in this thesis aim to illuminate the fact 
that MDM2 can function as a transrepressor independent of its ability to ubiquitinate 
p53.  
The data presented in this thesis implies that the C-terminal C2H2C4 RING of 
MDM2 can allosterically modulate not only the affinity of the N-terminal 
hydrophobic pocket but also its specificity. This further suggests that in cells the 
binding of interacting proteins and/or ligands to the RING is likely to impact on both 
MDM2 transrepressor activity and on the efficacy of pocket binding drugs in tumour 
cells. This hypothesis is supported by data showing that binding of ligands such as 
Zinc and ATP to the RING finger domain of MDM2 generate discrete 
conformational changes in the protein (Poyurovsky et al., 2003; Shimizu et al., 
2002). In fact, it was previously shown that Zinc binding can effect the interaction of 
MDM2 with the BOX-I domain of p53; in this case Zinc binding leads to a decrease 
in BOX-I binding (Poyurovsky et al., 2003; Shimizu et al., 2002). Together with the 
data presented in this thesis, it can be concluded that modulation of the RING 
domain has the potential to both negatively and positively regulate binding of BOX-I 
to the hydrophobic pocket. As the presented Cys mutants are E3-ligase dead thus it is 
not possible to determine if C2H2C4 RING interacting factors could also promote 
MDM2 E3-ligase activity. In a similar manner as increased binding to hydrophobic 
pocket binding ligands (Nutlin BOX-I mimetics) could potentially favour acid 
domain binding to the BOX-V domain of p53 signalling ubiquitination (Wallace et 
al., 2006). Thus, it will be interesting to determine whether RING domain interacting 
factors, or modifications, such as acetylation (Wang et al., 2004), within the RING 
domain, act in a concerted manner to promote both transrepression and 
ubiquitination of p53 or whether changes in RING conformation might act as a 
switch favouring one MDM2 activity over another.  
Additionally the results in this thesis show that Nutlin does not inhibit MDM2 E3-
ligase activity neither in vitro nor in cell models. However, despite its lack of E3-
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ligase inhibitory activity Nutlin can function in cells and animal models of cancer to 
activate p53 and to elevate p53 protein levels (Vassilev, 2004; Vassilev et al., 2004). 
Evidence presented here showing that Nutlin can reverse transrepression imposed by 
both the wild-type and the Cys478S mutated form of MDM2 suggests that it functions 
primarily by relieving MDM2-imposed transrepression allowing binding to 
coactivators such as p300. This conclusion is supported by the observation that 
Nutlin promotes rapid activation of p53-dependent transcription before changes in 
p53 protein level are recorded (White et al., 2006). The fact that Nutlin is proving to 
be an effective drug in some models of human cancer provides further evidence for 


















Figure 6.1 Model for Alosteric Regulation of MDM2
 
In summary the results presented in this thesis suggest that binding of interacting proteins 
and ligands or post-translational modification within the RING domain of MDM2 (A) which 
affect RING architecture will cause conformational modulation leading to changes in the 
affinity of the hydrophobic pocket for BOX-I domain of p53 and other ligands. This can result 
in formation of a transcriptionally inactive complex (B), or based on previously published 
studies (Wallace et al., 2006), could result in a transition complex (C) where hydrophobic 
pocket binding leads the acid domain to bind to the core BOX-V site in p53 signalling p53 
ubiquitination (D).  
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Themurine doubleminute (mdm2) gene encodes an E3 ubiq-
uitin ligase that plays a key role in the degradation of p53 tumor
suppressor protein. Nevertheless recent data highlight other
p53-independent functions of MDM2. Given that MDM2 pro-
tein binds ATP, can interact with the Hsp90 chaperone, plays a
role in the modulation of transcription factors and protection
and activation of DNApolymerases, and is involved in ribosome
assembly and nascent p53 protein biosynthesis, we have evalu-
ated and found MDM2 protein to possess an intrinsic molecular
chaperone activity.MDM2can substitute for theHsp90molecular
chaperone in promoting binding of p53 to the p21-derived pro-
moter sequence. This reaction is driven by recycling of MDM2
from the p53 complex, triggered by binding of ATP to MDM2.
The ATP binding mutant MDM2 protein (K454A) lacks the
chaperone activity both in vivo and in vitro. Mdm2 cotrans-
fected in the H1299 cell line with wild-type p53 stimulates effi-
cient p53 folding in vivo but at the same time accelerates the
degradation of p53.MDM2 in which one of the Zn2! coordinat-
ing residues is mutated (C478S or C464A) blocks degradation
but enhances folding of p53. This is the first demonstration that
MDM2 possesses an intrinsic molecular chaperone activity,
indicating that theATPbinding function ofMDM2 canmediate
its chaperone function toward the p53 tumor suppressor.
The p53 tumor suppressor gene encodes a sequence-specific
transcription factor that is mutated in the vast majority of
human cancers (1). Two other paralogs of p53, namely p63 and
p73, have been identified, but the physiological functions of
each member of the p53 family appear to be rather distinct (for
review, see Refs. 2 and 3). One of the foremost characterized
target genes of p53 is themdm2 gene.MDM2protein possesses
E3 ubiquitin ligase activity toward p53 that plays a role in the
negative regulation of p53 and its degradation by the protea-
some (for review, see Ref. 4).
Through its ability to ubiquitylate p53 and target it for pro-
teasomal degradation, MDM2 plays a key role in maintaining
p53 at very low levels under non-stress conditions. In such cir-
cumstances MDM2 and p53 form a negative feedback loop in
which p53 inducesmdm2 transcription andMDM2 targets p53
for degradation (2). In stress situations, MDM2-dependent
degradation of p53 is inhibited by a variety of mechanisms,
including p14ARF binding toMDM2, phosphorylation of the C
terminus of MDM2 by the ATM kinase, stress-induced phos-
phorylation of sites in the trans-activation domain of p53, sub-
sequent binding of the p300 coactivator, and further acetylation
of p53 in its C-terminal region (5), which results in an increase
of the steady-state level of the p53 transcription factor and con-
sequential flux in the expression of more than a hundred genes,
including those involved in cell cycle arrest, senescence, and
apoptosis (2).
Recent reports indicate that apart from its initially discov-
ered RING finger-dependent enzymatic E3 ubiquitin ligase
activity, MDM2 has other functions. A hydrophobic pocket in
the N-terminal domain of MDM2 forms the basis for p53 tran-
srepression. Small molecules that bind to this pocket can
release p53 from MDM2-mediated transrepression (6). The
MDM2 protein also possesses a nucleotide binding domain
mediated by the consensus Walker P motif within the MDM2
RING domain that facilitates its nucleolar localization, but the
ATP binding activity is not required for its E3 ubiquitin ligase
activity (7). Allosteric effects within MDM2 protein involving
its interaction with both the p53 transactivation motif and the
p53 DNA binding domain can mediate p53 ubiquitylation (8).
However, the collective roles of the RING domain, the ATP
binding domain, and the hydrophobic pocket in the biological
activity of MDM2 protein remain undefined.
MDM2 protein also interacts directly with the nascent p53
polypeptide (9), which suggests an unexpected role in pro-
tein biosynthesis. In the case of full-length p53, binding of
MDM2 to anN-terminal sequence in p53 leads to its efficient
proteasomal-dependent degradation. Surprisingly, it has
been shown that the truncated version of p53, called p47,
which lacks the p53 N-terminal MDM2 binding site, is
expressed much more efficiently than full-length p53. It is
proposed that this effect is not only due to decreased p47
degradation but also increased efficiency in the translation
of p47 (9). A possible function in ribosomal biosynthesis or
in translation regulation was suggested previously by spe-
cific interaction of MDM2 with the component of the large
ribosomal subunit-L5 protein (10). MDM2 was also found to
interact with several other ribosomal proteins like L11 and
L23. Such binding that sequesters MDM2 inhibits p53 pro-
tein polyubiquitylation, resulting in its activation (11).
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MDM2 oncoprotein also possesses numerous p53-inde-
pendent activities, which contribute to the development of
tumors where MDM2 is overexpressed, mostly by gene ampli-
fication possibly caused by polymorphism at the mdm2 pro-
moter sequence (Ref. 12; for review, see also Refs. 13–15).
Human cancers with non-functional p53 and amplification of
mdm2 have poor prognosis (16). Transgenic mice with wild-
type MDM2 genes are predisposed to spontaneous tumor
formation in a p53!/! background and have a high incidence
of lymphoma and sarcoma (17, 18). More than 40 MDM2
isoforms have been detected in human cancers (19). Inter-
estingly, some of them, which do not possess a p53 binding
domain, are associated with high grade and late-stage human
cancer (20, 21).
The biochemical mechanism of oncogenic activity ofMDM2
remains elusive. Indeed, although MDM2 interacts with pro-
teins, fulfilling a variety of cellular functions (p300, pRb, Numb,
MTBP (MDM2-binding protein), DNA polymerase !, promy-
elocytic leukemia protein, Tip60, YY1, insulin-like growth fac-
tor 1 receptor, glucocorticoid receptor/estrogen receptor,
androgen receptor, hypoxia-inducible factor 1, p73, NF-"B,
PSD-95, ADP ribosylation factor, E2F1, TATA-binding pro-
tein, TAFII250, Sp1, ribosomal L5, TSG 101, Ras-GAP binding
proteins), the biological significance of these multiple interac-
tions remains to be explained (for review, see Refs. 15, 22). It
should be stressed that not all MDM2 client proteins are tar-
geted for proteasome-dependent degradation; hence, not all
involvement ofMDM2 protein can be explained by its E3 ubiq-
uitin ligase activity (13, 15).
Several findings, namely binding to a nascent polypeptide
chain (9), modulation of transcription factors (23–25), protec-
tion and activation of DNA polymerases (26), and involvement
in ribosome assembly (10), indicate that the MDM2 protein
possesses similar activities to those described for molecular
chaperones (for review, see Ref. 27). Molecular chaperones are
defined as a vast class of structurally unrelated proteins that
assists in correct non-covalent assembly of other polypeptide-
containing structures but which are not components of these
assembled structures when they perform their normal biologi-
cal functions (for review, see Ref. 28). Recently we have shown
that the Hsp90 molecular chaperone, in an ATP-dependent
reaction, retains p53 in a conformation that allows binding to a
specific promoter sequence (29). Here we describe that, in the
absence of polyubiquitylation machinery, MDM2 can work
synergistically with Hsp90, thus enhancing the binding of p53
to the promoter-derived sequence. Surprisingly, MDM2 alone
possesses ATP-dependent molecular chaperone activity
involved in folding of the p53 tumor suppressor protein. This is
the first biochemical function attributed to theATP-dependent
domain ofMDM2.We suggest that this newly discovered activ-
ity of MDM2 could not only play a role in p53 protein biosyn-
thesis but could also in part explain the p53-independent onco-
genic activity of MDM2.
MATERIALS AND METHODS
Plasmid Preparation—Human untagged MDM2 open read-
ing frame lacking the first five codons (amino acids 6–491)
inserted into a PT7.7 vector was prepared as described previ-
ously (30–32). The pT7.7MDM2K454Aplasmidwas prepared
by means of site-directed mutagenesis using the QuikChangeTM
XL site-directed mutagenesis kit from Stratagene. For mutagene-









encodingMDM2wt2 and the K454A or C478Smutant were used
for purification of MDM2 wild-type and mutant proteins from
Escherichia coli. Analogous mutations were introduced into the
MDM2 wt open reading frame subcloned into the pCDNA3.1
vector.
Expression and Purification of Recombinant Protein—Hu-
man MDM2 wt was overexpressed in E. coli BL-21 RIL DE3
strain at 20 °C for 3 h after induction with 0.5 mM isopropyl
1-thio-#-D-galactopyranoside. Cells were harvested by centrif-
ugation at 8000 " g for 10 min and frozen in liquid nitrogen.
Bacteria pellet was lysed in buffer A (100 mM Tris-HCl, pH 8.0,
200mMKCl, 10%glycerol, 1mMphenylmethylsulfonyl fluoride,
5mMMg(CH3COO)2, 5mMDTT, 1mM benzamidine, protease
inhibitor mixture EDTA free (Roche Applied Science), 1 tab-
let/50 ml of buffer A) containing 1 mg/ml lysozyme for 1.5 h at
4 °C with frequent stirring followed by 2 min at 37 °C and an
additional 15min at 4 °C. Afterward the suspension was centri-
fuged at 100,000" g for 1 h at 4 °C. Under these lysis conditions
most of the desired protein was insoluble and localized within
the pellet after centrifugation. Extraction of theMDM2 protein
from the cell pellet was carried out overnight at 4 °C with con-
stant shaking. The following extraction buffer (B) was used: 25
mM Tris-HCl, pH 7.6, 1.2 M KCl, 5 mM Mg(CH3COO)2, 1%
Triton X-100, 5mMDTT, 10% sucrose, 1mM phenylmethylsul-
fonyl fluoride, 1 mM benzamidine, protease inhibitor tablets.
After centrifugation (100,000 " g for 1 h at 4 °C) the superna-
tant was collected and dialyzed into buffer C (25 mM HEPES-
KOH, pH 7.3, 1 M (NH4)2SO4, 1 M KCl, 5% glycerol, 2 mMDTT,
1 mM phenylmethylsulfonyl fluoride). After two h dialysis the
sample was loaded onto a butyl-Sepharose column (Amersham
Biosciences) equilibrated with the same buffer. The protein
that bound to the column was eluted via gradient of decreasing
ionic strength and increasing glycerol concentration. The frac-
tions containingMDM2protein were pooled and loaded onto a
Q-Sepharose column equilibrated with buffer D (25 mM
HEPES, pH 7.6, 50 mM KCl, 10% glycerol, 2 mM DTT, 1 mM
phenylmethylsulfonyl fluoride). The flow-through from the
column was immediately loaded onto a SP-Sepharose column
equilibrated with an analogous buffer as the Q-Sepharose. The
bound proteins to the SP-columnwere eluted bymeans of ionic
strength gradient (from 50 to 800mMKCl in buffer D). Fraction
containing MDM2 protein were pooled, frozen in liquid nitro-
2 The abbreviations used are: wt, wild type; DTT, dithiothreitol; ELISA,
enzyme-linked immunosorbent assay; BSA, bovine serum albumin; pAb,
polyclonal antibody; EMSA, electrophoretic mobility shift assay.
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gen, and kept at !80 °C for further experiments. An analogous
method was used to purify MDM2 K454A and MDM2 C478S
from E. coli. Human recombinant p53 was purified essentially
as described by Nichols and Matthews (33). Hsp90 proteins
were purified as described in Walerych et al. (29).
Enzyme-linked Immunosorbent Assay (ELISA)—Investiga-
tion of the p53-MDM2 interaction was carried out using an
ELISA technique. The method was performed analogously to
the one described inWalerych et al. (29). For anchoring and/or
detection of MDM2, monoclonal 2A-10 and 4B2 antibodies
and polyclonal H-221 (Santa Cruz Biotechnology) were used,
and for p53, monoclonal DO-1 and polyclonal FL-393 (Santa
Cruz Biotechnology) were chosen. Inactivation of wt p53 was
carried out at 37 °C for 90 min. Subsequently, 200 ng of heat-
inactivated or correctly folded p53 (an aliquot of p53, reactive
with the pAb1620 antibody, which was kept at 4 °C during the
mentioned 37 °C incubation step) was coated onto ELISA plate
wells in the coating buffer (25 mM Hepes, pH 7.3, 150 mM KCl,
10 mM DTT, for 1 h at 17 °C). After washing and blocking pro-
cedurewith blocking buffer (25mMHepes, pH7.3, 100mMKCl,
2 mg/ml BSA), the anchored p53 was titrated with increasing
amounts ofMDM2 (preincubated or not with 5mMATP for 90
min) in the reaction buffer (25mMHEPES, pH 7.3, 100mMKCl,
15 mM MgCl2, 10 $M ZnSO4, 5% glycerol, 5 mM DTT, 0.1%
Triton X-100, 2 mg/ml BSA) at 17 °C for 60 min. The experi-
ment was also performedwithout Zn2# ions, and no significant
differences were observed.
p53 DNA Binding Assay—The DNA binding activity of p53
was quantified by EMSA (gel-shift) assay. The procedure of the
assaywas carried out as described inWalerych et al. (29).Minor
modifications were introduced; that is, extension of the incuba-
tion time at 37 °C to 1.5 h, and with experiments that were
based on a temperature gradient, a Biometra T Gradient Ther-
moblock was used. The samples were also supplemented not
only with Hsp90 (bovine brain or human recombinant %Hsp90
isoform) but also with human recombinant MDM2wt, MDM2
K454A, orMDM2C478S. Activation of p53was predominantly
carried out by 100 ng of the antibody pAb421 (Ab-1; Onco-
gene). However, control experiments were done with CK2 acti-
vation of p53. The specific p21 sequence was labeled, and the
competitor unspecific DNA sequence was used as described in
Walerych et al. (29).
In Vitro p53 Ubiquitylation Assay—100 ng of human recom-
binant p53 purified from E. coli was incubated in a 20-$l reac-
tion volume containing 1" ubiquitination buffer (50 mM Tris
pH 7.6, 100 mM KCl, 10 mM MgCl2, 2 mM DTT, 0.07 units of
creatine kinase, 10 mM creatine phosphate, 5 mM ATP, 6 $g
ubiquitin (human recombinant purified from E. coli or from
Boston Biochem), 50 nM E1 ubiquitin activating enzyme (rab-
bit/human recombinant), 1.5 $M E2-conjugating enzyme
UbcH5a (mouse/human recombinant), 3–150 nM E3 human
recombinantMDM2wt,MDM2K454A, orMDM2C478S. The
reactions were incubated at 37 °C for 2 h. Afterward they were
terminated with SDS sample buffer with #-mercaptoethanol,
and the reaction products were fractioned by SDS-PAGE
(8–10%). Transfer to a nitrocellulose/polyvinylidene difluoride
film followed, and standardWestern blot detection was carried
out using anti-p53 DO-1 antibody.
Tissue Culture Experiments—Human lung carcinomaH1299
cells were grown at 37 °C in RPMI with 10% (v/v) fetal bovine
serum, 5% CO2. Transient transfections were carried out as
described inDornan andHupp (34). Cells were gently lysed on ice
in Nonidet P-40 buffer (25 mM Hepes pH 7.5, 0.1% (v/v) Nonidet
P-40, 150 mM KCl, 5 mM DTT, 50 mM NaF, protease inhibitor
mixturebyRocheAppliedScience (1 tabletwas addedper 10mlof
lysis buffer)). The protein concentration of the cell lysates was
quantified using the Bio-Rad Bradford assay kit. To estimate the
amount of correctly folded p53 in H1299 p53!/! cell lines trans-
fected with appropriate plasmids (pCDNA3.1 (EV)-mock,
pCDNA3.1/p53wt, pCDNA3.1/MDM2wt, pCDNA3.1/
MDM2K454A, pCDNA3.1/MDM2C464A, and pCDNA3.1/
MDM2C478S in appropriate combinations), the ratio between
the level of p53 captured by pAb1620 andDO-1 was calculated.
The ELISA procedure was carried out as follows: the wells were
coated with wt-p53 conformation-specific pAb1620 mono-
clonal antibody or DO-1 (both mouse origin, Moravian Bio-
technology) at 200 ng per well in 100 mM carbonate buffer, pH
9.0, at 4 °C for 16 h. The wells were blocked for 1 h at 17 °Cwith
blocking buffer (4 mg/ml BSA in phosphate-buffered saline).
This was followed by titration of increasing amounts of appro-
priate cell lysate diluted with the reaction buffer (25 mM
HEPES, pH 7.3, 150 mM KCl, 5 mM DTT, 10% glycerol, 0.1%
Triton X-100, 4 mg/ml BSA, protease inhibitor mixture). The
reaction was performed for 1 h at 17 °C. Detection of p53 pro-
tein was carried out using the FL-393 antibody (rabbit origin,
SantaCruzBiotechnology) for 1 h at 17 °C.Thiswas followedby
the addition of anti-rabbit IgG-horseradish peroxidase second-
ary antibodies (Santa Cruz Biotechnology). Analysis of bound
antibodies was performed by colorimetric detection with the
TMB peroxidase kit (Bio-Rad) followed by quenching the reac-
tion with 1 M H2SO4 and by absorbance measurements at 450
nm. The results obtained were plotted as a function of absorb-
ancewith respect to the amount of protein in question. For each
particular case within the linear range the first derivative was
calculated. The final values presented on the graph in Fig. 7
represent the normalization fractions obtained by division of
pAb1620 derivative values versus DO-1 derivative values. The
data represent the mean from five independent experiments
with a standard deviation.
RESULTS
Recently we have shown that the Hsp90 molecular chaper-
one in an ATP-dependent reaction retains p53 at 37 °C in a
conformation that allows binding to a specific promoter
sequence (29). As shown by previously published data, p53
incubated at 17 °C in vitro binds specifically to promoter
sequences after activation by C-terminal-specific p53 antibody
or phosphorylation by CK2 kinase (Refs. 35 and 29 and Fig. 1A,
lane 1). The same reaction performedundermore physiological
temperatures, i.e. 37 °C, does not lead to the formation of a p53
consensus site DNA complex (Fig. 1A, lane 2). As published
before, at 37 °C p53 loses its correct fold, which is required for
efficient specific binding of p53 to the promoter sequence (29).
However, the ability of p53 to bind to a promoter sequence at
37 °C is possible in the presence of the Hsp90 molecular chap-
erone and ATP both in vivo and in vitro (Fig. 1A, lane 13, and
MDM2 Molecular Chaperone Activity
NOVEMBER 9, 2007 • VOLUME 282 • NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 32605
 at G




Refs. 29 and 36).3 Surprisingly, the substitution of Hsp90 with
MDM2 in this reaction leads to efficient binding of p53 to the
promoter sequence (Fig. 1,A, lanes 8 and 11, and B, lanes 2 and
3). Moreover, the result presented in Fig. 1A (compare lanes 5
and 6 with and lanes 11 and 12, respectively) suggests that
Hsp90 and MDM2 may work synergistically.
The experiments described in Fig. 1, A and B, were per-
formed in the absence of exogenousZn2#. Zn2# ions are known
to stabilize p53 and MDM2 structures, and the presence of
Zn2# is required for Hsp90-MDM2 complex formation (37).
To test the effect of Zn2#, we performed p53 DNA binding
experiments in the presence or absence of 10 $M ZnSO4. As
shown in Fig. 2, the presence of 10 $M Zn2# in the absence of
any chaperones slightly stabilizes p53 at 37 °C, subsequently
leading to binding to the p21 promoter in the EMSA assay (Fig.
2, lane 3). In the presence of Hsp90 and Zn2#, visibly more p53
is bound to the promoter sequence at 37 °C (Fig. 2, lane 5). The
addition of MDM2 increases p53 DNA binding activity meas-
ured in the presence of Zn2# and Hsp90 (Fig. 2, lane 7), but the
effect of Zn2# is less pronounced (compare lanes 6 and 7 in Fig.
2). Zn2# ions do not significantly change the ability of MDM2
to rescue p53 binding to the promoter sequence at 37 °C (Fig. 2,
lanes 8 and 9).
The MDM2-dependent binding of p53 to the promoter
sequence is limited to the physiological temperature of 37 °C
(Fig. 3), suggesting that under heat shock conditions other
chaperones could also be involved in these reactions. As shown
in Figs. 1 and 2, the presence of MDM2 does not supershift the
p53-promoter DNA complex, suggesting that MDM2 is only
transiently required for p53 to adopt a DNA binding-compe-
tent conformation. To provide additional evidence that the
interaction ofMDM2with p53 is indeed required for this effect,
we used monoclonal antibodies that interfered with p53-
MDM2complex formation; 2A-10 binding to the central region
of MDM2 and 4B2 antibody recognizing the epitope in the N
terminus of MDM2. The presence of these antibodies during
the preincubation of MDM2 with p53 at 37 °C severely, in the
case of 2A-10, and partially, in the case of 4B2, reduced the
ability of p53 to bind to the promoter sequence (Fig. 4, lanes
4–6). Additional controls showed that anti-MDM2 antibodies,
2A-10 and to some extent also 4B-2, directly interfere with
MDM2-p53 complex formation, as judged by using the ELISA
approach described under “Materials andMethods” (result not
shown). These data support previous findings that multido-
mains of MDM2 (at least the N-terminal domain and acidic
domain) are involved in the functional interactions with p53
(8). Interestingly, the addition of thementioned antibodies after3 D. Walerych, unpublished results.
FIGURE 1. A, synergistic activity of MDM2 and Hsp90 in p53 binding to a
specific DNA promoter-derived sequence at 37 °C. Reactions contained
0.05 $g of p53 (58.1 nM of the monomer) and were incubated for 1 h at 4 °C
(lane 1) or 1.5 h at 37 °C (lanes 2–13) without or in the presence of a con-
stant amount of Hsp90 (bovine brain) with or without 5 mM ATP and
increasing amounts of MDM2 protein as indicated. To visualize the synergistic
activity of Hsp90 and MDM2 protein, Hsp90 was added to the reaction mix-
ture at 1.7 $M (of the monomer) final concentration, and under these condi-
tions Hsp90 could only marginally restore the specific p53 binding to the
promoter sequence (compare lane 3 to control lane 13 where the final con-
centration of Hsp90 was 1.7 and 3 $M, respectively). B, MDM2 restores p53-
specific binding to the promoter sequence in a dose-dependent manner. The
p53:MDM2 mass ratio for the reactions with increasing amounts of MDM2 (for
A and B alike) is 1:8 to 1:12, which is still significantly less than the amount of
Hsp90 needed to perform a similar task. At a 1:12 protein mass ratio, 0.05 $g
of p53 (58.1 nM of the monomer) and 0.6 $g of MDM2 (0.6 $M of the mono-
mer) of the proteins was used. All shown EMSA bands in this and subsequent
figures correspond to the size of the p53 tetramer bound to the DNA, super-
shifted by the activating antibody pAb421.
FIGURE 2. The influence of zinc ions Zn2!, Hsp90, and MDM2 on the bind-
ing of p53 to the p21 promoter derived sequence. Reactions containing
0.05 $g of p53 (58.1 nM of the monomer) were incubated for 1 h at 4 °C (lane
1) or for 1.5 h at 37 °C (lanes 2–9) without or in the presence of a constant
amount of Hsp90 (bovine brain, 3 $M of the monomer), MDM2 (0.6 $M mon-
omer), 10 $M ZnSO4, and/or with 5 mM ATP. After activation of p53 by CK2, the
DNA binding assay was performed. As seen in lane 3 the presence of zinc
alone slightly stabilizes p53 at 37 °C; the effect is pronounced when Hsp90 is
added (lane 5), but dramatic evidence of stabilization can be monitored when
all three components are present together during heat inactivation of p53
(lane 7). Although both proteins, namely Hsp90 and MDM2, stabilize the wild-
type conformation of p53 separately (compare lanes 2, 4, and 8), the zinc
effect is more visible for the stabilization of p53 by Hsp90 than by MDM2
(compare lanes 4 and 5 and lanes 8 and 9). It is worth noting the additive effect
of both proteins on the stabilizing effect of p53 during protein inactivation
(lane 6).
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the activation step (activation by
pAb421 (Fig. 4) or phosphorylation
of p53 by CK2 kinase (result not
shown)) do not inhibit the ability of
p53 to bind to the promoter
sequence (Fig. 4, lane 9 and 10), sug-
gesting that on this stage MDM2 is
no longer in the complex with p53.
Moreover, the monoclonal MDM2-
specific antibodies 4B-2 or 2A-10 do
not change the mobility of p53-
DNA complex which further sup-
ports the absence of MDM2 in the
p53-DNA complex (Fig. 4, lane 9
and 10). However, if such a reaction
is conducted at 4 °C, the mono-
clonal antibody 4B-2 supershifts the
p53-DNA complex (Fig. 4, lane 14),
suggesting that recycling of MDM2
from the p53 complex is caused by
the diffusion accelerated by the
temperature. The results presented
in Fig. 4 suggest that the presence of
MDM2 is required only when p53 is
preincubated at 37 °C and that the
p53-MDM2 complex dissociates
after conversion of latent p53 to a
transcriptionally active p53. In a
control experiment (Fig. 4), we
found that the addition of the p53-
specific DO-1 antibody before (lane
8) and after preincubation of p53 at
37 °C (lane 12) leads to antibody-in-
duced supershift, indicating that
p53 is present in the complex with
the promoter DNA sequence. In
addition, using an ELISA approach,
we have shown that DO-1 does not
interfere with MDM2-p53 complex
formation (see Fig. 6A and results
not shown).
In the absence of ATP, MDM2
interacts with p53 independently of
the conformational state in which
p53 is, namely, a correct fold i.e.
native-like or mutant-like fold (pre-
incubation of p53 at 37 °C for 90
min, Fig. 5). This situation, however,
is quite different in the presence of
ATP. The nucleotide does not sig-
nificantly influence the affinity of
MDM2 to p53 with the correct
wild-type conformation but has an
effect when the wild-type confor-
mation of p53 is abrogated. Here
the presence of ATP leads to a
reduction in the affinity of MDM2
toward p53 (Fig. 5A).
FIGURE 3. p53 binding to a p21 promoter-derived sequence is temperature-dependent in the presence
and absence of MDM2. Human recombinant MDM2 restores p53-specific DNA binding activity after 1 h of
inactivation in a temperature gradient (4 – 40 °C). In all the lanes where MDM2 was added to p53, a constant
1:10 mass ratio of p53:MDM2 was used. At a 1:10 protein mass ratio, 0.05 $g of p53 was used (58.1 nM mono-
mer) and 0.5 $g of MDM2 protein (0.45 $M of the monomer). To rule out unspecific protection effects, all
reactions were supplemented with 1 $g/$l BSA.
FIGURE 4. MDM2 by transient interaction with p53 can assist in correct non-covalent assembly of the p53-
promoter complex, but MDM2 is not a component of this assembled structure. The DNA binding assay was
performed as described in Fig. 1. The activation of p53 was performed either by CK2 or pAb421. The specific p53
antibody (DO-1) and MDM2 antibodies (2A-10 or 4B-2) were added during and after incubation of p53 with MDM2
and ATP at 37 °C. As lanes 2, 8, and 12 demonstrate, the antibody DO-1 supershifts the DNA-p53 complex, whereas
the MDM2-specific antibodies do not. It is highly probable that MDM2 is not a part of the p53-DNA complex.
Moreover, these antibodies added during the incubation of p53 with MDM2/ATP at 37 °C interfere with p53-MDM2
complex formation, thus inhibiting binding of p53 to the DNA (lanes 4 – 6). This does not take place if the appropriate
MDM2 antibodies are added after the 37 °C incubation step when the appropriate p53-MDM2 interactions has already
occurred (compare lanes 5 and 6 and lanes 9 and 10). Lanes 3, 7, and 11 represent the controls of thermally denatured p53.
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As reported previously, MDM2 possesses a Walker motif
allowing it to preferentially bind ATP with KD $ 13.5 $M (7).
No ATPase activity of MDM2 was detected. Mutation of the
mdm2 gene in the K454A position inhibits ATP binding by
the protein but does not interfere with its E3 ubiquitin ligase
activity (7). As shown in Fig. 5B and 6A, the purified mutant
MDM2 K454 tightly binds p53 regardless of the presence of
ATP or the conformational status of p53. These experiments
suggest that binding of ATP byMDM2 triggers the release of
MDM2 from the MDM2-p53 complex only when the wild-
type conformation of p53 is abrogated. At the same time the
MDM2 K454A protein, which still possesses E3 ubiquitin
ligase activity on a level comparable with wild-type MDM2
(Fig. 6B), is not able to rescue p53 binding to the promoter
sequence at 37 °C (Fig. 6C). Because the MDM2 K454A
mutation is within the RING finger domain of MDM2, we
cannot exclude that this mutation not only affects the ability
of MDM2 to bind ATP but in addition has another effect(s)
on the overall structure of the RING finger domain. How-
ever, two experimental facts strongly suggest that this is not
a case. First, the MDM2 K454A mutant possesses E3 ubiq-
uitin ligase activity similar to MDM2 wt protein (Fig. 6B).
Kinetic studies show that MDM2 K454A is slightly more
active in ubiquitylation of p53.4 Second, the point mutants
MDM2 C464A and C478S in the zinc binding motif that are
completely inactive in the p53 ubquitylation reaction still
efficiently bind ATP and are able to rescue the ability of
binding of p53 to the promoter DNA sequence at 37 °C
(result not shown).
The data presented in Figs. 5 and 6 suggest that recycling of
MDM2 from the p53 complex, triggered by binding of ATP to
MDM2, is required for binding of p53 to the promoter
sequence at 37 °C. One explanation of these results could be
that the binding of MDM2 to latent p53 partially unfolds p53,
and after activation of p53 and ATP-dependent dissociation of
MDM2 from the p53-MDM2 complex, p53 spontaneously
folds to the correct conformation, allowing its binding to the
promoter DNA sequence.
To test the influence of MDM2 on correct folding of p53
within the cell, we used an immunochemical-based assay
that measures p53 affinity to conformation-specific antibod-
ies (38, 39). Human lung carcinoma H1299 p53!/! cells,
which express a limited amount of MDM2 (result not
shown), were cotransfected with a combination of plasmids
encoding wild-type p53 and wild-type or mutant proteins,
MDM2 K454A, MDM2 C464A, and MDM2 C478S. After
gentle cell lysis, the ratio of wild-type correctly folded p53
(ELISA test with pAb1620) to total p53 (ELISA test with
DO-1) in cell lysate was measured (Fig. 7). In the control
experiments we show that binding of the DO-1 antibody
does not interfere with the p53-MDM2 complex formation
(Figs. 4 and 5 and result not shown). Transfection of H1299
cells with p53 alone shows that less than 40% of p53 protein
possesses a wild-type conformation (sensitive to pAb1620
monoclonal antibody). It is highly probable that in this case
the correct folding of p53 is stimulated by the presence of
other molecular chaperones, like the abundant Hsp90.
Cotransfection of p53 wt with mdm2 wt substantially stim-
ulates the folding of p53. More than 70% of p53 was found in
a wild-type conformation. Cotransfection of p53 wt with
4 C. Stevens, S. Petterson, M. Wallace, B. Wawrzynow, A. Zylicz, M. Zylicz, and T.
Hupp, manuscript in preparation.
FIGURE 5. The effect of ATP on MDM2-p53 complex formation. Reactions
containing 200 ng of wt p53 or heat-inactivated p53 (37 °C for 90 min) were
coated onto each well of an ELISA plate. After a washing and blocking proce-
dure, the reaction with MDM2 wt (A) or MDM2 K454A (B) in the presence of 5
mM ATP or without ATP was initiated. Visualization of the complex formation
between two proteins was done using the MDM2 reactive antibody H-221
(described under “Materials and Methods”).
MDM2 Molecular Chaperone Activity
32608 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 45 • NOVEMBER 9, 2007
 at G




MDM2 C478S or C464A mutants, which are deficient in E3
ubiquitin ligase activity, caused an even higher level of
pAb1620-recognizable conformation of p53 (Fig. 7). It must
be stressed that in the case when mdm2 wt is used, we are
dealing with at least three effects; that is, an increase of the
degradation of p53 (result not shown), an increase of the
chaperone-like activity of MDM2, and folding of wt p53 cat-
alyzed by other chaperones like Hsp90. Cotransfection of
cells with plasmid-encoding wt p53 and mutant MDM2
K454A substantially reduces the amount of p53 found in
FIGURE 6. The ATP binding mutant of MDM2, which is able to bind and ubiquitylate p53, is defective in promoting p53 binding to the p21 promoter
sequence. A, purified MDM2 K454A, an ATP binding mutant, specifically interacts with human recombinant p53 similarly to wt-MDM2. An ELISA was used to
verify binding, where constant amounts of MDM2 wt or MDM2 K454A (0.1 $g) were anchored onto the well via the 2A-10 monoclonal antibody, and increasing
amounts of p53 protein were added. The secondary polyclonal antibody FL-393 was used to detect the complex formation. In a control experiment the p53
protein (0.1 $g) was anchored via the p53 antibody (DO-1) onto the well, and increasing amounts of MDM2 wt or MDM2 K454A proteins were added. The
secondary polyclonal antibody H-221 was used to detect the complex formation. A BSA titration was used as a negative control of the interaction. B, MDM2
K454A possesses E3 ubiquitin ligase activity comparable with MDM2 wt in the in vitro ubiquitylation assay. The reaction was performed as indicated and
visualized as described under “Materials and Methods.” C, p53 protein binding to the specific DNA promoter at 37 °C, mediated by MDM2, is ATP-dependent.
The MDM2 K454A mutant was not able to maintain p53 binding to the p21 promoter sequence at restrictive temperature relative to wild-type MDM2. The
EMSA assay was carried out as described under “Materials and Methods.” As indicated, comparable amounts of the two proteins were used in the EMSA and
polyubiquitylation assays.
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wild-type conformation (Fig. 7), indicating that the observed
effect of MDM2 on p53 folding is due to molecular chaper-
one activity of MDM2.
DISCUSSION
p53 is a protein of complex conformational flexibility, and it
is in an equilibrium between different functional conforma-
tions. Strongly unfolded or misfolded forms of mutant p53 can
function as gain-of-function oncogenes (40–42). Moreover,
wild-type p53 tumor suppressor protein may adopt these dif-
ferent conformations either in response to various stress con-
ditions (post-translational modifications or the direct effect of
elevated temperature), binding to DNA, or the interacting pro-
teins (for review, see Refs. 43 and 44). Some of these conforma-
tional states can be detected by p53 conformation-specific anti-
bodies (pAb1620 and pAb240) (38, 45).
It has previously been proposed that wild-type p53 protein
could be transiently associated with molecular chaperones (29,
43, 46, 47). In vitro wt p53 can interact with Hsp40 and Hsp70,
but such a complex is dissociated in the presence of Hsp90 (46).
Transient interaction of p53 with Hsp90 is required for p53
binding to its consensus promoter DNA sequence (29, 36).
When p53 is in a complex with a promoter sequence, it is no
longer in a complex with Hsp90. The presence of ATP is
required for Hsp90-dependent binding of p53 to the promoter
sequence at 37 °C. Whether Hsp90 can unfold p53 protein
actively (analogy to the Hsp100 unfoldase activity as described
in Ref. 48) or by transient binding to the conformationally flex-
ible regions of p53 is still an open question. In vivo FRET exper-
iments support the notion that the Hsp90 chaperone tran-
siently interacts with wild-type p53.3
The presence of geldanamycin, a specific Hsp90 inhibitor,
abrogates the binding of p53 to the p21 promoter sequence as
well as its transcriptional activity (29). Geldanamycin-mediated
stimulation of degradation of both wt and 175H mutant of p53
in H1299 cells coexpressing CHIP (chaperone-associated E3
ubiquitin ligase) has been shown (47). Recently we reported
that cooperation of Hsp90 with MDM2 and CHIP proteins
stimulated unfolding of the native tetramer of p53 (37). At the
same time theMDM2-dependent polyubiquitylation ofmutant
p53 is inhibited by Hsp90 (49).
In this paper we have shown that MDM2 alone, in an ATP-
dependent reaction, can substitute for the Hsp90 molecular
chaperone in promoting the binding of p53 to the p21promoter
sequence at 37 °C. The results presented here and those pub-
lished by others suggest a possible scenario depicted in Fig. 8.
After binding toMDM2, p53 protein undergoes partial unfold-
ing (50, 51). In a stress situation, after activation by protein
kinases, like CK2, after UV radiation (52), MDM2 dissociates
from partially unfolded p53, thus allowing p53 to spontane-
ously fold. Such repeated binding, unfolding, dissociation, and
folding reaction could lead p53 to reach a conformation which
has a high affinity toward its promoter sequence. Recently pub-
FIGURE 7. The involvement of MDM2 in p53 folding. The H1299 p53!/! cell
line was transfected with pcDNA3.1 empty vector, pcDNA3.1/p53 (0.5 $g)
alone, and combinations of pcDNA3.1/p53 (0.5 $g) with pcDNA3.1/MDM2 wt
(1 $g), pcDNA3.1/MDM2 K454A (1 $g), pcDNA3.1/MDM2 C478S (1 $g), or
pcDNA3.1/MDM2 C464A (1 $g). After cell lysis and the ELISA experiments
described in detail under “Material and Methods” were carried out, the ratio
of conformationally wild-type p53 (pAb1620 reactive) with respect to the
total amount of p53 (DO-1 reactive) in the cell was calculated. MDM2 wt
transfection stimulates the proper folding of p53, whereas the ATP binding
mutant of MDM2 has no effect on p53 protein folding. Both mutant proteins
deficient in E3 ubiquitin ligase activity stimulate the proper p53 folding much
better than does MDM2 wt. The final values presented on the graph represent
the normalization fractions obtained by division of pAb1620 derivative val-
ues versus DO-1 derivative values. The data represent mean from 5 independ-
ent experiments with error bars indicating a S.D.
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FIGURE 8. The dual E3-ubiquitin ligase and chaperone-like activity of the
MDM2 oncoprotein. p53 protein assembles into a tetrameric form that can
be degraded by an MDM2-dependent ubiquitylation pathway or assembled
into a wild-type conformation by an MDM2 chaperone-dependent pathway.
The factors that control the switch between these two pathways are unde-
fined. However, a single point mutation in the BOX-V containing the ubiqui-
tylation signal of p53 (8) can in vitro predispose p53 to hyperubiquitylation by
MDM2 in a cell-free coupled translation system containing molecular chap-
erones (39). It means there are direct feedback sensors that can drive p53 into
a wild-type conformation or into a hyperubiquitylated conformation. Most
research in MDM2 has been centered on its E3 ubiquitin ligase function. In the
molecular chaperone pathway, MDM2 binding to p53 induces a local confor-
mational change in p53 in the flexible BOX-V motif (50). After activation by
protein kinases (or by pAb421 in vitro), MDM2 dissociates from p53, thus
allowing p53 to spontaneously fold to a conformation that has a high affinity
toward binding to the promoter sequence. This chaperone-like reaction is
ATP-dependent and can be uncoupled from the E3 ubiquitin ligase function
of MDM2 (mutation C478S or C464A). The mutation within the mdm2 gene,
which encodes the MDM2 K454A protein with deficient binding of ATP, pre-
vents the proper folding of p53 in vitro and in vivo. Activation of p53 after DNA
damage and subsequent dissociation of MDM2 occurs on chromatin (53).
Whether polyubiquitylation and subsequent degradation of p53 also occurs
on chromatin remains still an open question (66).
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lished in vivo data strongly support the idea of dissociation of
MDM2 after the activation of p53. Using a chromatin immuno-
precipitation technique, White et al. (53) have shown that
MDM2 localizes with latent p53 on the chromatin near
p21(waf1) andmdm2 genes before but not after DNA damage.
We suggest that a transient complex of p53 with MDM2 and
Hsp90molecular chaperonesmay be important for the decision
of whether to activate or degrade p53 by employing a series of
post-translational modifications, like phosphorylation, acetyla-
tion, ubiquitylation, sumoylation, neddylation, and others. The
situation where eukaryotic molecular chaperones are involved
in folding and degradation of protein is similar to prokaryotic
Hsp100/Clp family members, whereas an ATPase subunit of
the appropriate protease at the same time is a molecular chap-
erone and the specificity factor for the protein substrates deg-
radation (Refs. 54–56; for review, see Ref. 57). It is highly prob-
able that in eukaryotes the quality control process starts
upstream of the 19 S proteasome subunit, namely when the E3
ligases demonstrate their activities and the decision to repair or
degrade the protein substrates occurs. This apparent contra-
dictory mode of MDM2 as a component of the degradation
machinery (E3 ubiquitin ligase activity) and as molecular chap-
erone-like activity resembles a dual function ofCHIP, a cochap-
erone/ubiquitin ligase that targets a broad range of chaperone
substrates for proteasomal degradation (58–60). Interestingly,
while this paper was under revision, the Cyr and co-workers
reported that CHIP alone possesses a molecular chaperone
activity (61).
In addition to the fact that MDM2 can assist in correct non-
covalent assembly of the p53-promoter complex,whereMDM2
is not a component of this assembled structure, MDM2 fulfils
other molecular chaperone criteria. The purified MDM2 pro-
tein, in an ATP-independent reaction, can function like the
Hsp90 chaperone in protecting citrate synthase and firefly
luciferase from aggregation (supplemental data). The discovery
that MDM2, besides the E3 ubiquitin ligase activity, also pos-
sesses a molecular chaperone activity involved in protein fold-
ing and protection from aggregation raises an important ques-
tion concerning the biological relevance of MDM2 chaperone
activity toward p53 and other protein substrates. The in vivo
situation of the p53 case is very complex. We observe that
MDM2 promotes p53 folding but at the same time MDM2
accelerates the degradation of p53. We propose that molecular
chaperone activities of MDM2 in concert with Hsp90 are
required for shifting the equilibrium of p53 conformation
toward such a state(s) where either p53 is potent to bind to the
promoter sequence, thus being transcriptionally active, or to be
recognized by the ubiquitylation machinery. If these and prob-
ably other chaperones are not able to shift the p53 conforma-
tional equilibrium, then p53 is directed by Hsp40 to a mul-
tichaperone complex, p53-Hsp40-Hsp70-HOP-Hsp90 (46).
Such a stable complex inhibits not only p53 degradation but
also p53 transcriptional activity. The overlapping chaperone
activities (Hsp90, MDM2, and probably others) make verifica-
tion of this hypothesis rather difficult. Nevertheless, recent
findings from other laboratories indicate that ubiquitylation
and proteasomal machinery are directly involved in transcrip-
tional regulation. Zhu et al. (62) have shown that both ubiqui-
tylation and proteasomal functions are required for efficient
transcription mediated by p53. They postulate that among E3
ubiquitin ligases driving p53 toward ubiquitylation and degra-
dation, MDM2 (besides TOPORS) cannot be excluded as a co-
activator for p53 transcriptional activity. Emerging evidence
indicates that MDM2 can modulate the activity of other tran-
scription factors (23–25). We have found that MDM2, in an
ATP-dependent reaction, stimulates unfolding of E2F1/DP1
transcription factor.4 MDM2 has been proved to be a positive
regulator of HIV transactivator Tat. MDM2 promotes ubiqui-
tylation of Tat and enhancesTat-mediated transactivation (63).
Furthermore,MDM2has been shown to recruit to the estrogen
receptor-% binding ps2 promoter (64) and modulate p63, p73,
and E2F1 transcriptional activities and protein levels (3, 24, 65).
We postulate that molecular chaperone activity of MDM2
described here could not only help to explain themechanism of
involvement of ubiquitin-proteasome system in p53-mediated
transcription (62) but also could shed new light on p53-inde-
pendent activities of MDM2 as an oncogene (15). The findings
reported in this paper that a single point mutation MDM2
K454A selectively inhibits a molecular chaperone activity of
MDM2 should help in verifications of these hypotheses.
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ATP stimulates MDM2-mediated inhibition of the
DNA-binding function of E2F1
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One of the most evolutionarily conserved and widely
recruited cellular defence pathways involves the heat-
shock stress protein family. These polypeptides, now
termed molecular chaperones, were originally classi-
fied based on differences in molecular weight, and
comprise proteins of 25, 40, 60, 70, 90 and 110 kDa
[1]. The biochemical function of molecular chaper-
ones (including HSP70 and HSP90) is thought to
revolve around the regulation of protein folding,
unfolding, intracellular transport and protein degra-
dation [2]. The biological consequences of molecular
chaperone induction in many cell types involve not
only repair of damaged polypeptides and cellular
survival after injury, but acquisition of thermotoler-
ance and protection of cells from normally lethal
levels of damage [3]. In addition, molecular chaper-
ones have also been shown to prevent drug- or radia-
tion-dependent apoptosis in cells, highlighting the
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Murine double minute 2 (MDM2) protein exhibits many diverse biochemi-
cal functions on the tumour suppressor protein p53, including transcrip-
tional suppression and E3 ubiquitin ligase activity. However, more recent
data have shown that MDM2 can exhibit ATP-dependent molecular chap-
erone activity and directly mediate folding of the p53 tetramer. Analysing
the ATP-dependent function of MDM2 will provide novel insights into the
evolution and function of the protein. We have established a system to
analyse the molecular chaperone function of MDM2 on another of its tar-
get proteins, the transcription factor E2F1. In the absence of ATP, MDM2
was able to catalyse inhibition of the DNA-binding function of E2F1.
However, the inhibition of E2F1 by MDM2 was stimulated by ATP, and
mutation of the ATP-binding domain of MDM2 (K454A) prevented the
ATP-stimulated inhibition of E2F1. Further, ATP stabilized the binding of
E2F1 to MDM2 using conditions under which ATP destabilized the
MDM2:p53 complex. However, the ATP-binding mutant of MDM2 was as
active as an E3 ubiquitin ligase on E2F1 and p53, highlighting a specific
function for the ATP-binding domain of MDM2 in altering substrate pro-
tein folding. Antibodies to three distinct domains of MDM2 neutralized its
activity, showing that inhibition of E2F1 is MDM2-dependent and that
multiple domains of MDM2 are involved in E2F1 inhibition. Dimethylsulf-
oxide, which reduces protein unfolding, also prevented E2F1 inhibition by
MDM2. These data support a role for the ATP-binding domain in altering
the protein–protein interaction function of MDM2.
Abbreviations
CHIP, carboxyl terminus of HSC70-interacting protein; E2F, E2A binding factor; GST, glutathione S-transferase; HSP, heat-shock protein;
IPTG, isopropyl thio-b-D-galactoside; MDM2, murine double minute 2; pRB, retinoblastoma protein.
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role that these proteins may play in tumour cell sur-
vival and drug resistance [4].
The molecular chaperones also form the nucleus of
a large multi-protein complex or chaperone machine
that coordinates protein folding or unfolding, protein
ubiquitination, and protein degradation in cells. Defin-
ing the components of this molecular chaperone
machine will facilitate understanding of how these pro-
teins function as survival factors in normal tissue and
cancer cells [5–7]. Of the molecular chaperones, HSP90
has elicited the most widespread interest as it is the
target of the Ansamycin class of anti-cancer agent
[2,8]. Small molecules named Geldanamycin and 17-
allylamino demethoxygeldanamycin that target the
nucleotide-binding site of HSP90 can alter the activity
of the protein, change its conformation, and sensitize
cells to death [9]. HSP90 inhibitors are currently
undergoing clinical trials, although little is known
about the mechanism of Ansamycin drug function at
the proteome level or about the HSP90 holoenzyme
protein complex in primary cancers. However, the core
HSP90 multi-protein complex [comprising HSP90,
HSP70, HSP40, HSP25 and Hsp70 ⁄Hsp90 organizing
protein (Hop)] is known to be ‘re-arranged’ in cancer
cells into a distinct biochemical complex, compared to
normal cells, suggesting a mechanism to explain the
sensitivity of cancer cells to Ansamycins [6].
In addition to controlling the assembly or degrada-
tion rates of many cellular signalling proteins, most
notably protein kinases, HSP90 can also control the
conformation and function of the tumour suppressor
protein p53. The first cellular protein shown to bind to
p53 was a member of the HSP70 family of proteins
[10], whose associations with p53 have since been
extended to include the molecular chaperones HSP40
and HSP90 [11–13]. Interactions of wild-type and
mutant p53 have been reconstituted in vitro and in cell
culture with chaperone proteins, providing biochemical
models enabling insights into the cell biology of HSP–
p53 interactions [14–16]. The relevance of the interac-
tion of mutant p53 with molecular chaperones in
tumour cells has previously been unclear, but studies
have indicated that one component of the anti-apopto-
tic function of molecular chaperones may be related to
their ability to unfold and inactivate mutant p53 pro-
tein [12,13]. Novel anti-cancer drugs that target HSP90
chaperones promote reactivation of the specific DNA-
binding function of mutant p53 in tumour cell lines by
releasing the mutant p53 from the chaperone holoen-
zyme complexes [17,18]. In this situation, drugs such
as Geldanamycin can reactivate the tumour suppressor
function of p53 and have therapeutic value. However,
more recent work has shown that HSP90 can also
facilitate wild-type p53 assembly in a positive regula-
tory mode [14,19], and that HSP90, the E3 ubiquitin
ligase MDM2 and denatured p53 form a trimeric com-
plex in cancer cell lines [19,20]. The presence of
MDM2 in this trimeric complex was the first clue that
MDM2 could be linked to HSP function, at least in
some tumour cells.
In an effort to expand on the potential protein inter-
action map of the anti-cancer drug target MDM2, we
previously utilized peptide aptamer libraries to identify
novel MDM2-binding proteins [21]. This biochemical
approach for expansion of the ‘interactome’ of a target
relies on the growing realization that many protein–
protein interactions are driven by small linear motifs,
sometimes as small as four amino acids. Of many pep-
tide interaction motifs identified for MDM2, the one
that is relevant for cancer biology is that for HSP90
[21]. MDM2 and HSP90 cooperate to unfold and inhi-
bit the DNA-binding activity of the p53 protein [21].
We further found that HSP90:MDM2 and p53 form a
complex in cancer cell lines, thus identifying a novel
multi-protein complex with the two proto-oncogenes
and p53 [21]. This complex between p53, MDM2 and
HSP90 is now known to be common in cancer cell
lines [19]. A striking discovery when analysing the
folding of p53 protein based on validated chaperone
assays [14–16] was that MDM2 possesses an ATP-
dependent molecular chaperone function on p53 [22].
This is the first biochemical function attributed to the
ATP-binding domain of MDM2, which was previously
reported to play a role in controlling MDM2 intracel-
lular localization [23]. In this paper, we extend and
analyse the role of the ATP-binding domain of MDM2
with respect to its ability to function as a protein fold-
ing factor for another key target protein, E2F1, in
order to determine whether the ATP-binding function
of MDM2 can alter the protein conformation of other
MDM2 substrates. In contrast to p53, which is posi-
tively folded by MDM2 in an ATP-dependent manner
[22], MDM2 inhibits E2F1 DNA-binding activity in an
ATP-stimulated manner. The results regarding p53 and
E2F1 interactions with MDM2 provide biochemical
insights into how polypeptide conformation can be
regulated by the ATP-binding function of MDM2.
Results
Uncoupling the E3 ubiquitin ligase from the
ATP-binding function of MDM2
Before examining whether MDM2 possesses any pro-
tein folding activity towards E2F1, we first character-
ized the interaction in an E3 ubiquitin ligase assay to
ATP stimulated inhibition of E2F1 by MDM2 C. Stevens et al.
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define the integrity of the E2F1 and MDM2 proteins
used in this assay. MDM2 protein possesses an intrin-
sic RING finger-dependent E3 ubiquitin ligase func-
tion that is important for interaction with its client
protein p53. The molecular mechanism of MDM2-
mediated ubiquitination is not well defined, but at least
two interfaces are required for MDM2 to drive ubiqui-
tination of p53: a coordinated interaction of the N-ter-
minus of MDM2 with the N-terminus of p53, and an
interaction of the acid domain of MDM2 with the
central domain of p53 [24]. Accordingly, ligands such
as the NUTLIN and BOX1 peptides from p53 do not
block p53 ubiquitination by MDM2 (Fig. 1A, lanes 2
and 4 versus lane 1), but peptide ligands such as RB1
that bind the acid domain can block MDM2 function
towards p53 (Fig. 1A, lane 3 versus lane 1).
Using the assay described above for p53, the E2F1–
MDM2 ubiquitination reaction was reconstituted using
purified proteins. Titration of MDM2 and E2F1
(Fig. 1B,C) optimized the ubiquitination assay, in
which multiple mono-ubiquitin adducts were appar-
ently linked to E2F1 protein. Using this optimized
assay, the RB1 peptide was able to inhibit MDM2-
mediated ubiquitination of E2F1 (Fig. 1D, lane 3
versus lane 1), and this was also refractory to Nutlin
(Fig. 1D, lanes 4-6 versus lane 1). Thus, MDM2-medi-
ated ubiquitination of E2F1 operates by a similar two-
site mechanism to that described for p53. The precise
docking sites for MDM2 on E2F1 that drive the dual-
site ubiquitination have not been defined.
A set of MDM2 mutants was next used to examine
the role of the RING finger domain and the ATP-
binding domain in substrate ubiquitination. As
expected, mutation of the RING finger domain at
codon 478 (MDM2-C478S) inhibited the E3 ubiquitin
ligase function of MDM2 towards p53 (Fig. 2A, lanes
8–10 versus lanes 2–4). The codon 454 mutant of
MDM2 (MDM2-K454A) that shows attenuated ATP-
binding function was marginally more active as an E3
ubiquitin ligase towards p53 (Fig. 2A, lanes 5–7 versus
2–4; quantified in Fig. 2B). Similarly, mutation of the
RING finger domain at codon 478 inhibited the E3
ubiquitin ligase function of MDM2 towards E2F1
(Fig. 2C, lanes 8–10 versus lanes 2–4), whilst MDM2-
K454A showed enhanced E3 ubiquitin ligase activity
towards E2F1 (Fig. 2B, lanes 5–7 versus 2–4; quanti-
fied in Fig. 2D). These latter data indicate that mutat-
ing the ATP-binding domain of MDM2 does not
produce widespread conformational changes that
disrupt its allosteric and multi-site E3 ubiquitin ligase
function towards substrates.
MDM2-mediated inhibition of E2F1 DNA-binding
function
Using the biochemically characterized forms of
MDM2 described above, we evaluated whether E2F1
protein can be modified by the chaperonin function of
MDM2, as described for p53 [22]. First, the specificity
of glutathione S-transferase (GST)–E2F1 DNA bind-
ing in gel-retardation assays was confirmed using a
mutant probe (Fig. 3A, lane 2 versus lane 1) and
super-shifting with antibodies specific to E2F1
(Fig. 3A, lane 3 versus lane 1). p53 and E2F1 might be
expected to be modified differently by MDM2: p53 is
thermodynamically unstable at physiological tempera-
tures [25] and is completely destabilized at 37 !C [22],
while E2F1 is relatively thermostable at 37 !C and
requires and elevated temperature to reduce its DNA-
binding function (Fig. 3J, lanes 2 and 3 versus lane 1).
In the absence of ATP, a titration of wild-type MDM2
destabilized the DNA-binding function of E2F1
(Fig. 3B, lanes 2–5 versus lane 1). Further, the
MDM2-K454A (Fig. 3B, lanes 7–10) and MDM2-
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Fig. 1. The Rb1 peptide inhibits E2F1 ubiquitination by MDM2.
Ubiquitination assays were performed as described in Experimental
procedures. The following reactions were assembled and analysed
for ubiquitination by immunoblotting: (A) p53 wild-type protein
(30 ng) was incubated in the presence of dimethylsulfoxide (DMSO)
(4.5%), BOX1 peptide (50 lM), RB1 peptide (50 lM) or NUTLIN
(50lM). (B) GST–E2F1 protein (40 ng) was incubated with increasing
concentrations of wild-type MDM2 protein for 30 min (30, 60, 120
and 180 ng, lanes 2–5). (C) Wild-type MDM2 protein (25 ng) was
incubated with increasing concentrations of GST–E2F1 protein (10,
20 and 40 ng, lanes 2–4) for 30 min. (D) Wild-type MDM2 protein
(120 ng) was incubated with GST–E2F1 protein (40 ng) in the pres-
ence of dimethylsulfoxide (4.5%), BOX1 peptide (50 lM), RB1 pep-
tide (50 lM) or increasing amounts of NUTLIN (25, 50 and 100 lM).
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as wild-type MDM2 at inhibiting the DNA-binding
function of E2F1. These data are similar to the previ-
ously reported inhibition of p53 function by the
MDM2–HSP90 complex in the absence of ATP [21].
However, as ATP stimulates MDM2 folding of p53
into an active form [22], we evaluated whether ATP
has any influence on E2F1 inhibition by MDM2. A
titration of MDM2 in the presence of ATP stimulated
the inhibitory activity of MDM2 towards E2F1
(Fig. 3D, lanes 7–10 versus lanes 2–5). This is in con-
trast to the stimulation of p53 DNA-binding function
by MDM2 by ATP [22]. The ATP dependence of
E2F1 inhibition was further confirmed using wild-type
MDM2 (Fig. 3E, lanes 6–8 versus lanes 2–4; quantified
in Fig. 3F) and MDM2-K454A: in the presence of
ATP, wild-type MDM2 induces a more pronounced
inhibition of E2F1 DNA-binding function compared
with MDM2-K454A (Fig. 3G, lanes 7–10 versus lanes
2–5; quantified in Fig. 3H). As a control, preincuba-
tion of MDM2 with E2F1 does not alter E2F1 ubiqui-
tination (Fig. 3I), indicating that the misfolding of
E2F1 by MDM2 can be uncoupled from its ubiquiti-
nation. Together, these data confirm that the ATP-
binding domain of MDM2 can modify its biochemical
function, with distinct outcomes on the DNA-binding
function of the p53 or E2F1 substrates.
Protein folding and ⁄or unfolding functions operate
through dynamic associations and dissociations. When
ATP-binding proteins are involved in these processes,
these transient interactions are in turn differentially
stabilized by ATP. For example, the ATP-dependent
stimulation of p53 DNA-binding function by MDM2
correlates with a destabilization of the MDM2–p53
complex by ATP [22] that presumably allows MDM2
to dissociate and p53 to bind to DNA. This is a classic
example of an ATP-dependent chaperonin functioning
as a ‘catalyst’. We evaluated therefore whether the
inhibition of E2F1 DNA-binding function by MDM2
correlated with its enhanced binding by MDM2 or
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Fig. 2. An MDM2 mutant deficient for ATP binding does not have impaired E3 ubiquitin ligase function towards p53 or E2F1. Ubiquitination
assays were performed as described in Experimental procedures. The following reactions were assembled and analysed for ubiquitination
by immunoblotting. (A) p53 protein (30 ng) was incubated with increasing concentrations of wild-type MDM2 protein (6.25, 12.5 and 25 ng,
lanes 2–4), MDM2-K454A (6.25, 12.5 and 25 ng, lanes 5–7) or MDM2-C478S (6.25, 12.5 and 25 ng, lanes 8–10). (B) Quantification of ubiqu-
itin adducts. (C) GST–E2F1 protein (40 ng) was incubated with increasing concentrations of wild-type MDM2 protein (6.25, 12.5 and 25 ng,
lanes 2–4), MDM2-K454A (6.25, 12.5 and 25 ng, lanes 5–7) or MDM2-C478S (6.25, 12.5 and 25 ng, lanes 8–10). (D) Quantification of ubiqu-
itin adducts.
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Fig. 3. MDM2 inhibition of E2F1 function is stimulated by ATP. DNA-binding assays were performed as described in Experimental proce-
dures. The following reactions were assembled and analysed for E2F1 DNA-binding activity. (A) Specificity of E2F1 DNA binding. GST–E2F1
protein (100 ng) was incubated with wild-type probe (lanes 1 and 3) or mutant probe (lane 2). For super-shifting, GST–E2F1 protein (100 ng)
was preincubated in the presence of E2F1 antibody KH95 (200 ng, lane 3), and DNA-binding reactions were analysed using native gel elec-
trophoresis. (B) Analysis of E2F1 DNA binding using increasing concentrations of wild-type MDM2 or K454A-MDM2. GST–E2F1 protein
(100 ng) was incubated in the presence of the indicated amounts of wild-type MDM2 protein (lanes 2–5) or MDM2-K454A protein (lanes
7–10) in the absence of ATP, and DNA-binding reactions were analysed using native gel electrophoresis. (C) Analysis of E2F1 DNA binding
using wild-type MDM2 or MDM2-C478S. GST–E2F1 protein (100 ng) was incubated in the presence of the indicated amounts of wild-type
MDM2 protein (lanes 2 and 3) or MDM2-C478S protein (lanes 5 and 6) in the absence of ATP, and DNA-binding reactions were analysed
using native gel electrophoresis. (D) Analysis of E2F1 DNA binding using increasing concentrations of wild-type MDM2 and ATP. GST–E2F1
protein (100 ng) was incubated in the presence of the indicated amounts of wild-type MDM2 protein in the absence of ATP (lanes 2–5) or in
the presence of ATP (1 mM, lanes 7–10), and DNA-binding reactions were analysed using native gel electrophoresis. (E,F) ATP stimulates
wild-type MDM2 mediated inhibition of E2F1 DNA binding. GST–E2F1 protein (100 ng) was incubated with the indicated amounts of wild-
type MDM2 protein in the absence (lanes 2–4) or presence (lanes 6–8) of ATP (1 mM), and DNA-binding reactions were analysed using
native gel electrophoresis and quantified in (F) (error bars are SD of duplicate experiments). (G,H) Analysis of E2F1 DNA binding using
increasing concentrations of wild-type MDM2 or MDM2-K454A and ATP. GST–E2F1 protein (100 ng) was incubated in the presence of the
indicated amounts of wild-type MDM2 protein (lanes 2–5) or MDM2-K454A protein (lanes 7–10) in the presence of ATP (1 mM), and DNA-
binding reactions were analysed using native gel electrophoresis and quantified in (H) (error bars are SD of duplicate experiments). (I) Prein-
cubation of MDM2 with E2F1 does not alter E2F1 ubiquitination. Ubiquitination assays were performed without preincubation of MDM2 with
E2F1 (lanes 1–3, as in Figs 1 and 2) or with preincubation with E2F1 using conditions under which MDM2 inhibits the DNA-binding function
of E2F1 (lanes 4–6). Ubiquitination reactions were carried out for the indicated durations, and linearity was observed. (J) Temperature
required to inhibit the DNA-binding function of E2F1. E2F1 was incubated at the indicated temperature, as performed for wild-type p53 [22],
and analysed for DNA binding as described in Experimental procedures.
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ATP preincubation with MDM2 actually stabilized
MDM2–E2F1 complex formation as determined using
a sandwich ELISA (Fig. 4A), and this presumably
explains why the MDM2-mediated inhibition of E2F1
DNA-binding function is stimulated by ATP. By con-
trast, ATP preincubation with E2F1 has no effect on
MDM2–E2F1 complex formation as determined using
a sandwich ELISA (Fig. 4B). In the absence of ATP,
wild-type MDM2 and MDM2-K454A exhibit a similar
affinity for E2F1 (Fig. 4C); however, ATP stimulation
of the MDM2–E2F1 complex is attenuated using the
MDM2-K454A mutant (Fig. 4D). These data provide
a correlation between ATP-stimulated MDM2 binding
to E2F1 and ATP-stimulated destabilization of the
E2F1–DNA complex by MDM2.
Further evidence for a stable interaction between
E2F1 and MDM2 was evaluated by changes in partial
proteolysis of E2F1. Increasing the duration of trypsin-
ization resulted in a relatively rapid degradation of
full-length E2F1 (Fig. 5A), with accumulation of a
relatively stable set of trypsin-resistant fragments of
lower molecular mass. Addition of MDM2 protected
E2F1 from partial proteolysis, which is suggestive of a
specific binding interaction between the two proteins
(Fig. 5A bracket). Having established that MDM2 can
inhibit E2F1 function in a DNA-binding assay, and that
both the binding reaction and the inhibition reaction
are ATP-stimulated, we developed assays to confirm
MDM2 dependence in the assay, define which domain
of MDM2 might be mediating the inhibition of E2F1,
and determine whether classic protein misfolding is the
mechanism by which E2F1 is inhibited by MDM2.
Deletion of any of three domains of MDM2 can
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Fig. 4. ATP stabilizes MDM2 binding to E2F1. ELISA assays were performed as described in Experimental procedures to quantify the
amount of MDM2 bound to E2F1 under various conditions. (A) MDM2 preincubation with ATP. Increasing amounts of MDM2 protein were
preincubated in the presence or absence of ATP (1 mM) for 20 min at room temperature prior to incubation with GST–E2F1 protein (100 ng)
adsorbed to the solid phase. The amount of MDM2 bound to E2F1 was quantified using monoclonal antibody 2A10 and expressed in relative
light units. (B) E2F1 preincubation with ATP. Various amounts of GST–E2F1 protein were preincubated in the presence or absence of ATP
(1 mM) for 20 min at room temperature prior to incubation with wild-type MDM2 protein (50 ng) adsorbed to the solid phase. The amount of
E2F1 bound was quantified using monoclonal antibody KH95 and expressed in relative light units. (C) Comparison of E2F1 binding to wild-
type MDM2 and MDM2-K454A. Increasing amounts of MDM2 protein were incubated with GST–E2F1 protein (100 ng) adsorbed to the solid
phase. The amount of MDM2 bound to E2F1 was quantified using monoclonal antibody 2A10 and expressed in relative light units. (D) Prein-
cubation of wild-type MDM2 and MDM2-K454A with ATP. Increasing amounts of MDM2 protein were preincubated in the presence of ATP
(1 mM) for 20 min at room temperature prior to incubation with GST–E2F1 protein (100 ng) adsorbed to the solid phase. The amount of
MDM2 bound to E2F1 was quantified using monoclonal antibody 2A10 and expressed in relative light units.
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these domains are required for the interaction with
multiple domains of p53 [24]. These deletion analyses
do not provide mechanistic insight into the function of
the full-length protein, and we therefore used monoclo-
nal antibodies with defined binding sites on MDM2 to
determine whether MDM2 could be neutralized as an
inhibitor of E2F1. The addition of antibodies 2A10
and SMP14, which bind to the central region of
MDM2, had the most pronounced effect on blocking
MDM2 function (Fig. 6A, lanes 3 and 5 versus lane 2),
whilst the 4B2 antibody, which binds to the N-terminal
domain of MDM2, marginally attenuated MDM2
function (Fig. 6A, lane 4 versus lane 2). The ability of
all three monoclonal antibodies to attenuate MDM2
function suggests that multiple domains of MDM2
play a mechanistic role in binding to E2F1 and alter-
ing its function in a DNA-binding assay. To ensure
that the inhibition of E2F1 DNA-binding function
is not a result of a contaminating chaperone from
Escherichia coli in the recombinant MDM2 prepara-
tion, monoclonal antibodies for HSP70 and HSP90
were used as controls (Fig. 6B, lanes 4 and 5 versus
lane 3). Together, these data show that MDM2 alone
is responsible for inhibiting E2F1 function.
The study of p53 folding by factors including chap-
erones is greatly facilitated by the existence of mono-
clonal antibodies that discriminate between folded and
unfolded p53. This has allowed the accumulation of
direct evidence that p53 can be ‘misfolded’ or ‘folded’
by MDM2 and ⁄or HSP90 [21,22]. Unfortunately no
such reagents towards E2F1 are available to facilitate
a mechanistic understanding. In order to determine
whether MDM2 protein inhibits E2F1 by ‘misfolding’,
we evaluated whether solvents that classically ‘stabilize’
protein conformation can reverse the MDM2-mediated
effect on E2F1. Specifically, dimethylsulfoxide and
glycerol have been shown to restore the proper folding
and function of mutant p53 [26,27]. Titration of the
stabilizing solvent dimethylsulfoxide (Fig. 6C,D) pre-
vented the MDM2-mediated inhibition of E2F1 func-
tion, and almost completely restored E2F1 function,
suggesting that E2F1 is in fact inhibited through
conformational ‘misfolding’ of the protein by MDM2.


























































Fig. 6. E2F1 inhibition by MDM2 is attenuated by MDM2 antibod-
ies and stabilizing solvents. DNA-binding assays were performed as
described in Experimental procedures. (A) MDM2 monoclonal anti-
bodies neutralize the ability of MDM2 to inhibit E2F1. GST–E2F1
protein (100 ng) was incubated with wild-type MDM2 protein
(375 ng, lanes 2–5) in the presence of 200 ng of the MDM2 anti-
bodies 2A10 (lane 3), 4B2 (lane 4) or SMP14 (lane 5). (B) HSP
monoclonal antibodies do not neutralize the ability of MDM2 to inhi-
bit E2F1. GST–E2F1 protein (100 ng) was incubated with wild-type
MDM2 protein (375 ng, lanes 2–5) in the presence of 200 ng of
MDM2 antibody 2A10 (lane 3), HSP70 antibody (lane 4) or HSP90
antibody (lane 5). (C) Dimethylsulfoxide (DMSO) prevents MDM2-
mediated inhibition of E2F1. GST–E2F1 protein (100 ng) was incu-
bated with wild-type MDM2 protein (375 ng, lanes 2–6) in the pres-
ence of increasing amounts of dimethylsulfoxide (1%, 2.5%, 5%
and 10%, lanes 3–6). (D) Quantification of effects of solvents on
E2F1 function in the presence of inhibitory levels of MDM2.
E2F1 E2F1 + MDM2
min Trypsin@4 °C– 2.5 5 10 15 – 2.5 5 10 15
IB E2F1
1 2 3 4 5 6 7 9 108
Protected from
proteolysis
Fig. 5. MDM2 alters the tryptic digestion pattern of E2F1. Tryptic
digestion assays were performed as described in Experimental pro-
cedures. (A) GST–E2F1 protein (100 ng) was incubated with trypsin
(50 ng) at 4 !C for the indicated times in the absence of MDM2
(lanes 2–5) or in the presence of wild-type MDM2 protein (200 ng,
lanes 7–10).
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ATP-binding domain of MDM2 plays a role in stabi-
lizing the binding to E2F1, and that this induces a mis-
folded conformation in E2F1 that is incompatible with
sequence-specific DNA binding.
Discussion
MDM2 is a multi-functional protein with biochemical
functions in: (a) transcriptional suppression by direct
contact of the activation domain of p53 and occlusion
of the coactivator p300 [28], (b) p53 degradation
through RING finger-dependent E3 ubiquitin ligase
function [29], (c) p53 ubiquitination through MDM2
acid domain docking to a conformationally flexible
region of p53 that is unfolded in human cancers
[24,30,31], and (d) ATP-dependent folding of p53
mediated by the HSP90 chaperone [22]. It is interesting
that the RING domain of MDM2 protein has an
ATP-binding motif imbedded within it: this is unique
for a RING finger domain-containing protein [23]. The
presence of a nucleotide-binding domain in a signalling
protein such as MDM2 is probably highly significant,
and suggests that cells have evolved an energy-depen-
dent stage that requires a stimulus for MDM2 func-
tion. The recent study [22] was the first to determine a
molecular function for the ATP-binding domain of
MDM2, and prompted the current study on E2F1 to
determine how widespread the effects of the ATP-bind-
ing domain are and to provide novel insights into the
evolution and function of MDM2.
The E2A binding factor (E2F) family of transcrip-
tion factors plays a central role in regulating cellular
proliferation by controlling the expression of genes
that are involved in cell-cycle progression, particularly
DNA synthesis, as well as genes that are involved in
senescence and apoptosis [32]. Regulation of E2F
activity is complex, and numerous studies have demon-
strated the importance of protein–protein interactions
as well as post-translational modifications such as
phosphorylation, acetylation and ubiquitination. Reti-
noblastoma protein (pRB) is a major regulator
of E2F1 transactivation [32], but MDM2 and MDMX
proteins have also been reported to regulate E2F1
activity.
A positive role for MDM2 in the regulation of
E2F1 was first reported by Martin et al. [33], who
showed that MDM2 binds directly to the C-terminus
of E2F1 and promotes its transcriptional activity.
Additional studies have demonstrated that the central
acidic domain of MDM2 binds to the C pocket of
pRB, resulting in a reduction in the number of pRB–
E2F1 complexes and subsequent stimulation of E2F1
transactivation [34]. Furthermore, E2F1 is reported to
be stabilized by MDM2 through a mechanism that
involves displacement of the F-box-containing protein
p45SKP2, which is the cell cycle-regulated component
of the ubiquitin protein ligase SCFSKP2 [35].
In contrast to these studies, MDM2 has been shown
to function as a negative regulator of E2F1 activity.
For example, overexpression of MDM2 blocks E2F1-
mediated accumulation of p53 and induction of apop-
tosis [36], and microinjection of neutralizing antibodies
to MDM2 or MDM2 antisense oligonucleotides
increases E2F1 protein levels [37]. Furthermore,
Loughran and La Thangue [38] demonstrated that
MDM2 promotes E2F1 degradation and antagonizes
the apoptotic properties of E2F1 in a fashion that is
dependent upon its heterodimeric partner DP1.
The opposing effects reported for MDM2 on E2F1
activity may be related to the status of p53. Treatment
of tumour cells lacking functional p53 with the small
molecule inhibitor of MDM2, Nutlin, results in E2F1
stabilization and activation. In these cells, Nutlin
inhibits the binding of MDM2 to E2F1 [39]. However,
in p53 wild-type cells, E2F1 levels and activity are
downregulated by Nutlin treatment or depletion of
MDM2 by siRNA [39]. Additionally, it has been dem-
onstrated that MDM2 induction of E2F1 transactiva-
tion is p53-dependent. MDM2 was unable to enhance
E2F1 transactivation in cells lacking p53 or the cdk
inhibitor p21, suggesting that MDM2 activation of
E2F1 occurs as a consequence of inhibition of p53
transactivation of p21 [40]. Upon overexpression of
MDM2, p53 transactivation is blocked, leading to a
reduction in p21 protein and a concomitant increase in
hyperphosphorylated pRB and E2F1 activity [40]. At
present, the relative affinities of p53 and E2F1 for
MDM2 are not known, thus the interaction of p53
with MDM2 might affect the level of active MDM2
that can regulate E2F1. Furthermore, the regulation of
E2F1 activity correlates with an MDM2-dependent
regulation of DP1 [38]. Clearly, additional studies are
required to elucidate the role that p53 ⁄MDM2 plays in
the regulation of E2F1 ⁄DP1 in vivo.
By comparing the interactions of MDM2 with p53
and E2F1 in vitro, we have defined an important bio-
chemical function for the ATP-binding domain of
MDM2 that has implications for signalling in vivo.
MDM2, as well as HSP90, is now known to play a
positive role in p53 protein synthesis and mediate
nuclear import of p53 protein [14,19]. Possibly, there-
fore, the ATP-binding domain can function to switch
MDM2 from activity as an E3 ubiquitin ligase to
activity as a ‘foldase’ that can function in cooperation
with HSP90. This p53–MDM2–HSP90 pathway
appears to be misregulated in some tumour cells, as
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unfolded mutant p53, MDM2 and HSP90 form an
inactive trimeric complex [19]. Further, MDM2–
HSP90–carboxyl terminus of HSC70-interacting pro-
tein (CHIP) can cause misfolding of p53 in vitro [21],
and CHIP can induce p53 ubiquitination in cells [41].
Binding of ATP to the ATP-binding domain of
MDM2 can also alter its interaction with the E2F1 sub-
strate, but with an outcome distinct from that for p53.
One notable difference is the apparent misfolding of
E2F1 by MDM2, which is stimulated by ATP. These
data suggest that the ATP domain has evolved to
manipulate MDM2 protein–protein interactions in a
substrate-specific manner. Presumably, the documented
MDM2-mediated regulation of E2F1 function in cells
can be modified by ATP binding, which would control
the specific activity of E2F1 in cells. Interestingly, the
MDM2-related protein MDMX has also been shown to
negatively regulate E2F1 function directly via inhibition
of DNA-binding activity and repression of transactiva-
tion [42,43]. It is possible that an MDM2–MDMX com-
plex might use the energy in ATP to misfold the E2F1
protein. Whether this misfolding is coupled to E2F1
ubiquitination remains to be determined, although we
did not see any effects of mutating the ATP-binding site
of MDM2 on E2F1 ubiquitination in vitro (Fig. 2).
In summary, this study and a recent report [22]
describe a novel function for the ATP-binding domain
of MDM2 in driving changes in protein–protein interac-
tions with client proteins in classic molecular chaperone
assays. This biochemical mechanism provides a founda-
tion from which to begin to analyse the role of the ATP-
binding domain as a modifier of transcription factors
in vivo, with the prospect of developing drugs that either
stabilize the ATP-bound conformation of MDM2 or
inhibit the ATP-bound conformation of MDM2. Deter-
mination of how these ATP agonists or antagonists of
MDM2 alter the chaperone functions of HSP90 with
current anti-HSP90 small molecules has intriguing pros-
pects for targeting the chaperone pathway in cancer.
Experimental procedures
In vitro ubiquitination assay
For the in vitro ubiquitination assay, reactions contained
25 mm Hepes pH 8.0, 10 mm MgCl2, 4 mm ATP, 0.5 mm
dithiothreitol, 0.05% v ⁄ v Triton X-100, 0.25 mm benzami-
dine, 10 mm creatine phosphate, 3.5 unitsÆmL)1 creatine
kinase, ubiquitin (1 mm), and E1 (50-200 nm), E2s (0.1–
1 lm) and E2F1–GST purified from E. coli (40 ng). Reac-
tions were initiated by the addition of purified MDM2
(120 ng). Following incubation at 30 !C, reactions were
terminated by the addition of SDS sample buffer. The reac-
tions were resolved by denaturing gel electrophoresis using
4–12% NuPAGE gels in a MOPS buffer system (Invitro-
gen, Carlsbad, CA, USA) and electro-transferred to
Hybond-C Extra nitrocellulose membrane (Amersham,
Little Chalfont, UK) followed by immunoblotting. Ubiqu-
itin adducts were quantified using Scion Image (National
Institutes of Health, Bethesda, MD, USA).
Gel retardation analysis
The E2F recognition site from the adenovirus E2A promoter
(or a mutant site) was used in all gel retardation analyses.
The following primers were used: wild-type, 5¢-GATCTAGT




The nucleotides changed in the mutant site are underlined.
For gel retardation using recombinant proteins, proteins
were combined with binding buffer (10 mm HEPES pH 7.6,
100 mm KCl, 1 mm EDTA, 4% glycerol, 0.5 mm dithiothrei-
tol), 2 lg of sheared salmon sperm DNA and 200 ng of
mutant promoter oligonucleotide to reduce the non-specific
DNA-binding activity. Antibodies for E2F1 (KH95, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), MDM2 (2A10,
4B2, SMP14 – gifts from B. Vojtesek, Masaryk Memorial
Cancer Institute, Brno, Czech Republic), HSP70 (SPA-810,
Stressgen, San Diego, CA, USA) and HSP90 (SPA-830,
Stressgen) were added, and complexes were allowed to form
at room temperature. After 15 min, 1 ng of a 32P-labelled
E2F oligomer was added for a further 20 min. Complexes
were resolved on a 4% polyacrylamide gel in 0.5· Tris-
borate EDTA (TBE) at 4 !C for 2 h (200 V), and visualized
using a STORM 840 scanner and software (Amersham).
E2F1 DNA-binding activity was quantified using Scion
Image (National Institutes of Health).
Plasmid preparation
For expression in E. coli, the human untagged MDM2
ORF lacking the first five codons (amino acids 6–491)
inserted into a PT7.7 vector was prepared as described
previously [31]. pT7.7 MDM2-K454A and MDM2-C478S
plasmids were prepared by means of site-directed mutagene-
sis using a QuickChange" XL site-directed mutagenesis kit
(Stratagene, San Diego, CA, USA). For expression in
E. coli, pCMV HA-E2F1 WT was digested with BamHI
and SacI and the resulting insert was cloned into the
pGEXKG vector (Amersham) at the same sites.
Purification of recombinant GST–E2F1 protein
Transformed BL21 bacteria (Invitrogen) were grown to
mid-logarithmic phase in 500 mL of Luria–Bertani (LB)
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broth containing the appropriate antibiotic at 37 !C. Then
protein expression was induced by the addition of 0.5 mm
(final concentration) of isopropyl thio-b-d-galactoside
(IPTG) for 4 h at 30 !C.
For GST purification, bacterial pellets were resuspended
in 10 mL NaCl ⁄Pi, 1% Triton X-100 and 0.5 mm phenyl-
methanesulfonyl fluoride on ice, and then sonicated briefly
(3 · 10 s) on ice. Bacterial debris was pelleted by centrifuga-
tion at 10 000 g for 20 min at 4 !C. A 500 lL suspension of
glutathione–Sepharose beads (50% v ⁄ v) (Amersham) that
had been pre-washed in NaCl ⁄Pi, was added to the superna-
tant and mixed with constant rotation at 4 !C for 30 min.
The suspension was washed three times with 50 mL NaCl ⁄Pi
by spinning in a bench-top centrifuge at 5000 g for 5 min at
4 !C. The GST proteins were eluted from the beads by incu-
bating the bead pellet with an equal volume of 50 mm Tris
pH 8, containing 10 mm of glutathione.
Expression and purification of recombinant
MDM2 proteins
Human untagged wild-type MDM2, MDM2-K454A and
MDM2-C478S were overexpressed in E. coli BL21 RIL
(DE3) strain at 20 !C for 3 h after induction with 0.5 mm
IPTG. Cells were harvested by centrifugation at 8000 g for
10 min. The bacterial pellet was lysed in buffer A [100 mm
Tris ⁄HCl pH 8.0, 200 mm KCl, 10% glycerol, 1 mm
phenylmethanesulfonyl fluoride, 5 mm Mg(CH3COO)2,
5 mm dithiothreitol, 1 mm benzamidine, and protease inhib-
itor cocktail, EDTA-free (Roche, Basel, Switzerland), one
tablet per 50 mL of buffer] containing 1 mgÆmL)1 lysozyme
for 1.5 h at 4 !C with frequent stirring, followed by 2 min
at 37 !C and an additional 15 min at 4 !C. The suspension
was then centrifuged at 100 000 g for 1 h at 4 !C. Under
these lysis conditions, most of the desired protein was insol-
uble and located within the pellet after centrifugation.
Extraction of the MDM2 protein from the pellet was
carried out overnight at 4 !C with constant shaking. The
following extraction buffer (B) was used: 25 mm Tris ⁄HCl
pH 7.6, 1.2 m KCl, 5 mm Mg(CH3COO)2, 1% Triton
X-100, 5 mm dithiothreitol, 10% sucrose, 1 mm phenyl-
methanesulfonyl fluoride, 1 mm benzamidine, and protease
inhibitor tablets. Following centrifugation (100 000 g for
1 h at 4 !C), the supernatant was collected, and dialysed
into buffer C [25 mm Hepes-KOH pH 7.3, 1 m (NH4)2SO4,
1 m KCl, 5% glycerol, 2 mm dithiothreitol, 1 mm phenyl-
methanesulfonyl fluoride]. After dialysis for 2 h, the sample
was loaded onto a butyl-Sepharose column (Amersham)
equilibrated with the same buffer. The protein that bound
to the column was eluted via gradient of decreasing ionic
strength and increasing glycerol concentration. The frac-
tions containing MDM2 protein were pooled and loaded
onto a Q-Sepharose column equilibrated with buffer D
(25 mm Hepes pH 7.6, 50 mm KCl, 10% glycerol, 2 mm
dithiothreitol, 1 mm phenylmethanesulfonyl fluoride). The
flowthrough from the column was immediately loaded onto
an SP-Sepharose column equilibrated with buffer D. The
proteins bound to the SP column were eluted by means of
an ionic strength gradient (50–800 mm KCl in buffer D).
Fractions containing MDM2 protein were pooled, frozen in
liquid nitrogen and stored at )80 !C.
Immunoblotting
Samples were resolved by denaturing gel electrophoresis
using 4–12% NuPAGE gels in a MOPS buffer system
(Invitrogen) and electro-transferred to Hybond-C Extra
nitrocellulose membrane (Amersham), blocked in NaCl ⁄Pi,
10% non-fat milk for 30 min, then incubated with primary
antibody overnight at 4 !C in NaCl ⁄Pi, 5% non-fat milk,
0.1% Tween-20. After washing (3 · 10 min) in NaCl ⁄Pi,
Tween-20, the blot was incubated with secondary horserad-
ish peroxidase-conjugated anti-mouse IgG (DAKO, Glost-
rup, Denmark; 1 : 5000) for 1 h at room temperature in
NaCl ⁄Pi, 5% non-fat milk, 0.1% Tween-20. After washing
(3 · 10 min) in NaCl ⁄Pi, Tween-20, proteins were visualized
by incubation with ECL reagent (Pierce, Rockford, IL,
USA).
ELISA
For ELISA, a 96-well plate (Corning Incorporated,
Schiphol-Rijk, Netherlands) was coated with purified E2F1
protein or wild-type MDM2 protein diluted in 0.1 m
Na2HCO3 pH 8.0 and incubated overnight at 4 !C. Each
well was washed six times with NaCl ⁄Pi containing 0.1%
Tween-20 (PBS-T), followed by incubation for 1 h at room
temperature with gentle agitation in PBS-T supplemented
with 3% BSA. The wells were then washed six times with
PBS-T prior to incubation with purified E2F1 or MDM2
protein in the absence or presence of ATP, 10 mm creatine
phosphate, 3.5 unitsÆmL)1 creatine kinase, diluted in PBS-
T ⁄ 3% BSA for 1 h at room temperature. After 1 h incuba-
tion, the plate was washed again six times with PBS-T and
incubated with antibody specific to E2F1 (KH95) or
MDM2 (2A10) for 1 h at room temperature. After a fur-
ther six washes with PBS-T, secondary horseradish peroxi-
dase-conjugated anti-mouse IgG was added to wells,
followed by further washing, and enhanced chemilumines-
cence assays were performed. The results were quantified
using Fluoroskan Ascent FL equipment (Labsystems,
Helsinki, Finland) and analysed with ascent software
version 2.4.1 (Labsystems).
Tryptic digestion
Purified GST–E2F1 protein (100 ng) was incubated with or
without purified MDM2 protein (200 ng) in the presence of
trypsin (50 ngÆreaction)1) at 4 !C for 2.5, 5, 10 or 15 min
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as indicated. For reactions with MDM2, proteins were
mixed and incubated for 20 min at room temperature prior
to the addition of trypsin. The reactions were resolved by
denaturing gel electrophoresis using 4–12% NuPAGE gels
in a MOPS buffer system (Invitrogen) and electro-trans-
ferred to Hybond-C Extra nitrocellulose membranes (Amer-
sham) followed by immunoblotting.
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TheMDM2oncoprotein playsmultiple regulatory roles in the
control of p53-dependent gene expression. A picture of MDM2
is emerging where structurally discrete but interdependent
functional domains are linked through changes in conforma-
tion. The domain structure includes: (i) a hydrophobic pocket at
theN terminus ofMDM2 that is involved inboth its transrepres-
sor and E3-ubiqutin ligase functions, (ii) a central acid domain
that recognizes a ubiquitination signal in the core DNA binding
domain of p53, and (iii) a C-terminal C2H2C4 RING finger
domain that is required for E2 enzyme-binding and ATP-de-
pendent molecular chaperone activity. Here we show that the
binding affinity of MDM2s hydrophobic pocket can be regu-
lated through the RING finger domain and that increases in
pocket affinity are reflected by a gain in MDM2 transrepressor
activity. Thus, mutations within the RING domain that affect
zinc coordination, but not one that inhibits ATP binding, pro-
duce MDM2 proteins that have a higher affinity for the BOX-I
transactivation domain of p53 and a reduced I0.5 for p53 tran-
srepression. An allostericmodel for regulation of the hydropho-
bic pocket is supported by differences in protein conformation
and pocket accessibility between wild-type and the RING
domain mutant MDM2 proteins. Additionally the data demon-
strate that the complex relationship between different domains
of MDM2 can impact on the efficacy of anticancer drugs
directed toward its hydrophobic pocket.
The tumor suppressor protein p53 is a transcription factor
that plays a key role in the control of pathways that protect cells
from malignant transformation (1, 2). As such, p53 is the most
frequently inactivated protein in human cancers (3). In
response to cellular stress, p53 protein levels are elevated by a
decrease in its rate of degradation, and this increase in levels is
accompanied by changes in the status of p53 post-translational
modifications. Together, elevated levels of p53 and activating
post-translational modifications induce its sequence-specific
DNA binding and transcriptional activity leading to changes in
gene expression that classically result in either cell cycle arrest
or apoptosis (4).
Under non-stressed conditions p53 is tightly controlled by
the MDM2 oncoprotein through an autoregulatory feedback
loop (5–8). MDM2 plays multiple regulatory roles in the con-
trol of p53-dependent gene expression. Originally identified as
a transrepressor of p53-mediated transcription (5, 8), MDM2
was subsequently shown to control the steady-state levels of
p53 in unstressed cells by acting as a RING finger domain E34-
ubiquitin ligase (9, 10). More recently MDM2 has also been
implicated in the control of p53 translation (11) and in addition
has been shown to possess an ATP-dependentmolecular chap-
erone activity toward p53 (12, 13). MDM2 is a multidomain
protein comprising: (i) A hydrophobic pocket at its N terminus
that binds with a high affinity to the BOX-I transactivation
domain of p53 (14). This interaction is required for both the
E3-ligase and transrepressor functions of MDM2 (15). (ii) A
central acid domain that recognizes and binds with a relatively
low affinity to a ubiquitination signal in the core of p53 (16–18).
(iii) A C-terminal C2H2C4 RING finger domain (19–21). This
domain is essential for zinc coordination and is involved in
E2-binding and the formation of RING domain dimers (22). In
addition the RING domain houses a P-Walker motif that is
required for MDM2 to act as an ATP-dependent molecular
chaperone (12, 23).
Negative regulation of p53 transcription by MDM2 involves
competition for binding to p53s N-terminal LXXLL transacti-
vation domain (BOX-I domain), thus binding of MDM2 can
occlude the binding of transcription components like the coac-
tivator p300 preventing the formation of a pre-initiation com-
plex (8, 24–27). Mutations in the p53 activation domain that
prevent MDM2 binding can attenuate MDM2-catalyzed tran-
srepression (15, 28), and peptide ligands mimicking the activa-
tion domain of p53 that bind to the N-terminal domain of
MDM2 and disrupt the MDM2:p53 protein complex in vitro
can stimulate p53-dependent gene expression in cells (27, 28).
Together these data suggest that binding of the BOX-I activa-
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required for MDM2s oncogenic functions. Recent studies have
identified a second MDM2 interaction site within the core
domain (BOX-V) of p53 (16–18, 29). The BOX-V domain
binds to the acid domain of MDM2, and, although this interac-
tion has a relatively low affinity, it is key in determining the rate
of p53 ubiquitination as it comprises part of the p53 ubiquiti-
nation signal (16).
The current study has used point mutations within critical
C2H2C4 resides of the MDM2 RING domain to uncover
cross-talk between the zinc coordinating structure and the
hydrophobic pocket of MDM2. A gain in the ability of
MDM2 to transrepress p53-dependent transcription is seen
when zinc-coordinating residues are mutated, whereas muta-
tion of a residue within the RING required for ATP binding has
no effect onMDM2mediated transrepression. Studies on puri-
fied MDM2 and p53 provide a mechanism for changes in tran-
srepressor activity by demonstrating that the C2H2C4 RING
mutants have a higher affinity for hydrophobic pocket interact-
ing ligands and proteins. Thus, the RING finger domain of
MDM2 is linked to the hydrophobic pocket through conforma-
tional changes that affect MDM2 transrepressor activity. In
addition, the efficacy of small molecules, targeted to the hydro-
phobic pocket ofMDM2, can be determined by the status of the
C2H2C4 structure.
EXPERIMENTAL PROCEDURES
Reagents and Plasmids—Antibodies used were: DO-1 (p53)
and 2A10/3G5/4B2/SMP14 (MDM2) produced in-house,
p21 was detected using AB1 (Calbiochem). Peptides, N-ter-
minal biotin-labeled plus an SGSG space (Chiron Mimo-
topes), were dissolved at 10 mg/ml in DMSO as previously
described (16). The BOX-I and 12.1 sequences are
PPLSQETFSDLWKLLP and MPRFMDYWEGLN, respec-
tively. Nutlin-3 was from Alexis Biochemicals. Ubiquitin
(U-100), UbcH5a (E2-616), and E1 (E-301) were from Boston
Biochem. pcDNA3-p53 and His-ubiquitin were a gift from
David Lane, pCMV-mycMDM2wt, pCMV-mycMDM2!N,
and pCMV-MDM2!Ac were provided by Aart Jochemsen.
pcDNA3-MDM2 with the human MDM2 cDNA was used
as a template to generate pcDNA3-MDM2C464A,
pcDNA3-MDM2C478S, and pcDNA3-MDM2K454A using
a QuikChange mutagenesis kit (Stratagene). The primers






AACCAATTCAAATGATTGTG; and C478Srev, CACAATC-
ATTTGAATTGGTTGTCTGCTTACTGGGCAGGGCTTA-
TTCC.
Cell Culture, Reporter Assays, and Immunoblots—H1299
cells were maintained in RPMI medium supplemented with 10%
(v/v) fetal bovine serumand incubatedat 37 °Cwith5%CO2.A375
cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum and incubated
at 37 °C with 10% CO2. MDM2"/"p53"/" cells were main-
tained in Dulbecco’s modified Eagle’s medium with 10% (v/v)
fetal bovine serum and 10% CO2. Upon reaching 80–90% con-
fluency the cells were transfected using Lipofectamine 2000
(Invitrogen) with the total amount of DNA for all wells kept
constant at 0.8 !g. A solution was formed with (30 ng)
pGL4.10[luc2] bearing a 44-base stretch of the p21 promoter
and with 70 ng of the phRL-CMV plus p53 and MDM2 plas-
mids as detailed in the figure legends. Twenty-four hours post-
transfection, the cells were washed once in ice-cold phosphate-
buffered saline and lysed with 1# Passive Lysis Buffer (supplied
with the Dual-Luciferase Reporter Assay System from Pro-
mega). Alternatively, Nutlin was added after 24 h (as detailed in
the figure legends), and the incubation continued for a further
6 h. Afterward the Dual-Luciferase Reporter Assay was per-
formed in accordancewith themanufacturer’s instructions. For
immunoblot analysis transfected cells were lysed in Nonidet
P-40 buffer (25 mM HEPES, pH 7.5, 0.1% (v/v) Nonidet P-40,
150mMKCl, 5mM dithiothreitol, 50mMNaF), and lysates were
separated on 4–12% NuPAGE (to detect p53 modification) or
10% SDS-PAGE and transferred to nitrocellulose (16).
Ubiquitination Assay—The in vitro assay was carried out as
previously described (16). Reactions contained 25 mM HEPES,
pH 8.0, 10 mM MgCl2, 4 mM ATP, 0.5 mM dithiothreitol, 0.05%
(v/v) Triton X-100, 0.25 mM benzamidine, 10 mM creatine
phosphate, 3.5 units/ml creatine kinase, ubiquitin (2 !g), E1
(50–200 nM), E2s (0.1–1 !M), plus p53 purified from Esche-
richia coli (100 ng) andwere initiated by the addition of purified
human MDM2 (50 ng) in the presence or absence of either
BOX-I or Nutlin as detailed in the figure legends. p53 ubiquiti-
nation in p53"/"MDM2"/" mouse embryonic fibroblasts was
determined using a previously described method (16).
Protein Binding Assays—Recombinant human full-length
untagged MDM2 proteins and p53 protein were purified from
E. coli as previously described (12, 30). For peptide and protein
binding assays the microtiter wells were adsorbed with strepta-
vidin overnight, washed 6# with phosphate-buffered saline-
Tweenwith biotinylated peptides added for 1 h alternatively the
wells were coated with purified p53 (150 ng) as previously
described (16). Following extensive washing with phosphate-
buffered saline-Tween increasing amounts of MDM2 were
added either in the absence or presence of Nutlin (as detailed in
the figure legends). Following washing (6# washes with phos-
phate-buffered saline-Tween) MDM2 was detected using the
monoclonal antibody 2A10 and a secondary rabbit anti-mouse
horseradish peroxidase antibody the wells were developed
using ECL. The results were quantified using Fluoroskan
Ascent FL equipment (Labsystems) and analyzed with Ascent
Software.
Tryptic Digestion—wt or mutant MDM2 protein (1 !g) plus
trypsin (10 ng) was incubated at 30 °C in 50 mM ammonium
bicarbonate buffer for up to 30 min. Aliquots were removed,
and the reaction was stopped by the addition of SDS sample
buffer and heating at 80 °C for 4 min. The samples were ana-
lyzed by 4–12% gradient gels (Invitrogen) and immunoblotted.
Intrinsic Fluorescence Assay—Fluorescence emission spectra
were recorded on a SPEX FLUOROMAX-3 (Jobin Yvon
Horiba) spectrofluorometer. The bandwidths for excitation
and emission were set at 5 nm, and an excitation wavelength of
295 nmwas used. Fluorescence spectrawere recorded from320
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to 450 nm in 0.5 nm steps, with an integration time of 1 s. All
experiments were carried out at 4 °C in buffer containing: 25
mM HEPES (pH 7.5), 50 mM KCl, 5% (v/v) glycerol, 10 !M
ZnSO4, and 2mMdithiothreitol.MDM2wt,MDM2C464A, and
MDM2C478S used in this assay were initially preincubated on
ice for 5 min at final concentrations raging from 20 nM to 1 !M
(Vtotal $ 0.5 ml). Each spectrum produced is the average of
three emission scans minus the average of the three blanks
(buffer) scans.
RESULTS
C2H2C4 MDM2 Mutant Proteins Have a Gain of Transre-
pressor Activity—We have recently shown that the E3-ligase
activity of MDM2 requires interactions at both the hydropho-
bic pocket and the acid domain (16). These interactions are
linked by an allosteric mechanism, with binding at the hydro-
phobic pocket favoring recognition of a p53 ubiquitination sig-
nal from its core DNA binding domain (BOX-V). This
prompted us to ask whether similar mechanisms linked other
MDM2 domains and how cooperation between domains
impacted on the proteins multifunctional nature. The RING
finger domain of MDM2 is required for both its E3-ligase and
ATP-dependent chaperone activities through binding to an
E2-ubiquitin conjugating enzyme and to ATP, respectively (12,
22). However, whether conformational changes in the RING
domain are transmitted to other MDM2 functional domains
affecting their activity remains unclear.
To study the RING domain in the context of full-length
MDM2 we first generated a number of RING finger domain
mutant constructs (Fig. 1A). Two of these, Cys464A
(MDM2C464A) and Cys478S (MDM2C478S), introduced
mutations into the C4 and H2C2 coordination sites of the
C2H2C4 structure (21), respectively, and a third, Lys454A
(MDM2K454A), is a RING domain residue, which is not
required for zinc coordination but is essential for MDM2 to
bindATP (12, 23). TheCys464Amutant was chosen because it is
the most widely studied E3-ligase-dead MDM2 RING mutant,
in addition this cysteine lies within an "-helix, and structure
predication using PyMOL suggests that mutation to Ala has
little effect on the global structure of the RING or on the extent
of solvent exposure. The Cys478S mutant is similarly predicted
to have a minimal effect on the local environment, because it
lies within an irregular loop structure. To characterize these
mutants we first determined the effect of introducing the RING
mutations on E3-ligase activity using a cell-based assay. When
p53"/"MDM2"/"mouse fibroblastswere transfectedwith p53
and MDM2 together with His-tagged ubiquitin it was demon-
strated that the Lys454A mutant retained the ability to ubiquiti-
nate p53, as determined by the isolation of His-ubiquitin-con-
jugated p53 protein (Fig. 1B), whereas, as expected, the
C2H2C4 mutants were no longer able to mediate p53 modifi-
cation by ubiquitin.Although the introduction of theCysmuta-
tions is sufficient to inactivate MDM2 as an E3-ligase, they do
not affect the overall integrity of the C terminus as we have
shown that the Cys464A and Cys478S MDM2mutants retain the
ability to bind ATP, while ATP-binding activity is lost in
the Lys454A mutant (12). Thus, mutation of Cys residues in the
RING appears to specifically inactivate RING function during
ligation of ubiquitin to target substrates while leaving other
RING domain functions intact.
The various MDM2 RING finger domain mutants were
tested in a p53-dependent transcription assay to determine if
inactivation of either its E3-ligase or ATP-binding activities
affected the ability of MDM2 to repress p53-dependent tran-
scription. The ability of p53 to activate transcription was deter-
mined using the p53-responsive region of the p21-promoter to
drive luciferase expression. When human p53 was transfected
into H1299 cells (human p53 null non-small cell lung carci-
noma cells) along with the p21-reporter a characteristic activa-
tion of the promoter was detected (Fig. 1C), coexpression of
wild-type MDM2 in a titrative manner led to a progressive
decrease in reporter activity indicative of transrepression, with
an I0.5 in the region of 300 ng of MDM2 plasmid (150 ng of p53
plasmid (Fig. 1C)). All the RING mutants were expressed to a
similar level and were able to inhibit p53-dependent transcrip-
tion, however, both the Cys mutants displayed a gain of tran-
srepressor function with an I0.5 of %75 ng for MDM2C464A
and %150 ng for MDM2C478S. In contrast, mutation of Lys454
did not enhance the repressor activity of MDM2, and like the
wild-type protein, this mutant had an I0.5 of around 300 ng.
Similarly, although a titration of p53 could overcome transre-
pression imposed by a fixed amount of wild-type MDM2 and
the Lys454A mutant, there was a significant reduction in the
ability of p53 to overcome the effects of the Cys464A andCys478S
mutants (Fig. 1D). To determine whether comparison of an
Ala-substituted Cys to a Ser-substituted Cys underlined the
apparent difference in potency of the MDM2C464A and
MDM2C478S mutants we used a second mutant from within
the C4 coordination (Fig. 1E; C461S) where we mutated Cys461
to Ser. Analysis of this mutant demonstrated that it was also
more potent than theMDM2C478Smutant. These results sug-
gest that the difference in activity of the RING mutants is
unlikely to be due primarily to the choice of the substitution
residue.
To determine if endogenous p53-responsive promoters
respond to theMDM2RING domainmutant proteins in a sim-
ilar way to that observed using p53-responsive reporter con-
structs we used BAX protein expression as a measure of its
promoter activity, because BAX is a well characterized target
for p53 (31). For this assay we used MCF7 cells because they
have a wild-type p53 pathway. Fig. 1F shows that BAX protein
levels are unaffected by the expression of wtMDM2 at the con-
centrations used in the experiment (Fig. 1F, lanes 2–4), how-
ever under the same conditions theMDM2C464Amutant sup-
pressed BAX protein expression even at the lowest amount
used (lanes 8–10), and consistent with the reporter assays, the
MDM2C478Smutant had intermediate activity, because it sup-
pressed BAX protein expression when present at the highest
amount (lane 7).
Together the data presented above suggest that mutation of
residues within the RING finger domain that directly affect
MDM2 E3-ligase activity facilitate transrepression of p53 tran-
scriptional activity. In contrast, loss of MDM2molecular chap-
erone activity in the ATP-binding mutant (Lys454A) had no
effect on transrepression of p53. Further, the data demonstrate
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that MDM2 E3-ligase activity can be completely uncoupled
from its ability to repress p53 transcription.
The MDM2 Hydrophobic Pocket but Not the Acid Domain Is
Required for Efficient Transrepression of p53—Previous studies
have suggested that the hydrophobic pocket of MDM2 is criti-
cal for its transrepressor activity (15, 28), however these studies
were carried out before the complexity of the interaction
between MDM2 and p53 was fully appreciated. Because the
acid domain of MDM2 is now known to bind to the BOX-V
domain of p53 (16, 18) we sought to use MDM2 deletion
mutants to determine which interactions were salient for
MDM2-mediated transrepression. To investigate the influence
of MDM2 domain structure on p53 transrepression we used
mutant forms of murine MDM2 where one or other of the two
known p53 interacting domains had been deleted (Fig. 2A,
MDM2!N and MDM2!Ac). MDM2!N prevents the interac-
tion between the transactivation domain of p53 (BOX-I) and
the hydrophobic pocket in the N terminus of MDM2 (14),
whereas the MDM2!Ac precludes binding of the core domain
of p53 (BOX-V) and the acid domain ofMDM2 that is essential
for MDM2-mediated ubiquitination of p53 (16).
When the deletion mutants were analyzed in the p53-re-
porter assay (Fig. 2B) loss of the hydrophobic pocket essentially
inactivated MDM2 as a transrepressor of p53-mediated tran-
scription although expressed at a similar level to the wt protein
(Fig. 2C), whereas deletion of the acid domain did not have a
major impact on this activity of MDM2. The data suggest that
the interaction between the acid domain of MDM2 and the
BOX-V region of the p53 core domain is not essential for
MDM2 mediated transrepression, whereas binding of the
hydrophobic pocket to the BOX-I transactivation domain of
p53 is absolutely required because the !Nmutant is essentially
dead in this assay. Together with data in the previous section
our results suggest that RING domain mutants that loose the
ability to ubiquitinate p53 but gain p53 repressor activity do so,
most likely, through modulation of the MDM2-hydrophobic
pocket: p53-BOX-I interaction.
RING Mutations Affect the Efficacy of Nutlin as an Inhibitor
of MDM2-mediated Repression of p53—The data presented
above establish that the hydrophobic pocket ofMDM2 is essen-
tial for transrepression of p53 (Fig. 2B) and that the ability of
MDM2 to transrepress p53-dependent transcription can be
uncoupled from MDM2 E3-ligase activity (Fig. 1C). Further-
more, the C2H2C4RINGmutants have a gain of transrepressor
activity when compared with the wt protein (Fig. 1C). To fur-
ther investigate the link between hydrophobic pocket binding
andRINGdomain functionwe used the cell-permeableMDM2
hydrophobic pocket binding molecule Nutlin as a tool
(32, 33).
We have previously suggested that Nutlin most likely
functions as an anticancer agent by affecting the ability of
MDM2 to act as a transrepressor of p53 transcription rather
than as an inhibitor ofMDM2-dependent p53 ubiquitination
(16). This hypothesis was based on observations, confirmed
here, that Nutlin is not able to inhibit the ubiquitination of
p53 in vitro using purified proteins (Fig. 3A) and that the
addition of Nutlin to A375 cells does not decrease the num-
ber of modified p53 forms detected (Fig. 3B). In fact in the
current experiments we show that an increase in p53 modi-
fication was proportionate to increases in total p53 protein
levels (see Fig. 5B, upper panel) and to the activation of p53,
as assessed by an increase in p21 protein levels (Fig. 3B, lower
panel). Together these results suggest that modification of
existing or newly synthesized p53 protein continues in the
presence of Nutlin.
If the above hypothesis is correct we would predict that
Nutlin binding to MDM2 would be sufficient to relieve tran-
srepression imposed by both wt and E3-inactive MDM2 pro-
tein. Using the p53-reporter assay the ability of Nutlin to
reverse transrepression imposed by a fixed amount of wt
MDM2 was shown to be efficient (Fig. 3C). Furthermore,
Nutlin had a striking effect on the transrepressor activity of
the Cys478S protein with p53 activity recovering to near the
level seen in the absence of MDM2. This result lends strong
support to the idea that Nutlin-dependent inhibition of
MDM2 as a transrepressor occurs independently of MDM2
E3-ligase function and that this could be sufficient to explain
the activating effect of Nutlin on p53.
Interestingly, although Nutlin was active against the
Cys478S MDM2 mutant protein it had only weak activity
against the Cys464A protein and even at 14 !M Nutlin did not
inhibit this mutant. To confirm this result using a different
assay system we looked at the ability of Nutlin to overcome
wt and mutant MDM2-imposed transrepression of an
endogenous p53 promoter using p21 protein levels as a
downstream readout for transfected p53 (Fig. 3,D and E). An
amount of transfected MDM2 wt and mutant constructs was
chosen that gave maximal repression of endogenous p21
FIGURE 1. Mutation of the C2H2C4 RING gives a gain of MDM2 transrepression. A, schematic showing the RING finger domain of MDM2. The zinc
conjugating residues are highlighted and underlined, the ATP binding site is shaded gray, and the residues picked out (above) are those that were mutated to
generate the panel of mutants studied. B, immunoblot of p53 from p53"/"MDM2"/" mouse embryonic fibroblasts transfected with p53 (150 ng) and MDM2
(wt and mutant constructs as indicated;150 and 250 ng) plus His-Ub (200 ng). His-conjugated proteins were isolated using nickel-agarose and analyzed on a
4 –12% gradient gel. p53 was detected using DO-1. The data are representative of two independent experiments. In C: upper panel, H1299 cells were trans-
fected with p53 alone (150 ng) or with a titration (75, 150, 300, 400, and 550 ng) of MDM2wt, MDM2K454A, MDM2C464A, or MDM2C478S plus the reporter
plasmids. Total DNA was normalized using the vector control, and c is a vector only control. Post transfection (24 h) the Dual Luciferase Assay was performed.
The results are normalized by expressing p21-Luciferase/Renilla activity in relative light units (RLU) and are the mean & S.D. (lower panel). Immunoblot showing
the levels of p53 with MDM2wt and mutant proteins, p53 was detected using DO-1 and MDM2 using 2A10. D, as above except that the cells were transfected
with a p53 titration (75, 150, and 300 ng) alone or in the presence of a fixed concentration of wt and mutant MDM2 as indicated (400 ng). The vector-only control
is shown as c, and total DNA was normalized as above the data are representative of two individual experiments. E, schematic depicting zinc coordination
scheme of MDM2 (left panel). The key residues that were mutated are highlighted. The histogram represents data obtained from Dual Luciferase Assay
carried out as described above, with MDM2wt MDM2C478S and MDM2C461S. F, MCF7 cells were transfected with plasmids encoding MDM2WT,
MDM2C464A, and MDM2C478S (0 – 4 !g). Total DNA amount was normalized using vector control. Twenty-four hours post transfection immunoblot
analysis was carried out, p53, MDM2, and BAX were detected using DO-1, 2A10, and anti-BAX, respectively. The results are representative of at least three
independent experiments.
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protein expression in H1299 cells (p21 levels decreased by
'80%), Nutlin was then added to the cells in a titrative man-
ner, and the effect on p21 levels was determined. Quantita-
tion of the data generated in Fig. 3D shows that Nutlin can
relieve transrepression imposed by both the wt and Cys478S
mutant forms of MDM2 at the lowest concentration used
FIGURE 2. The hydrophobic pocket of MDM2 is essential for transrepression of p53. A, a schematic showing murine MDM2 deletion constructs. MDM2 !N
is missing the MDM2 hydrophobic pocket, which binds the BOX-I domain of p53, and MDM2 !Ac does not have the acid domain, which binds the BOX-V
domain of p53. B, H1299 cells were transfected with p53 alone (150 ng) or with a titration (75, 150, 300, and 550 ng) of MDM2wt, MDM2!N, or MDM2!Ac plus
the reporter plasmids. Total DNA was normalized using the vector control. Post transfection (24 h) the Dual Luciferase Assay was performed. The results are
normalized by expressing p21-Luciferase/Renilla activity in relative light units (RLU), are the mean & S.D., and c is the vector-only control. C, immunoblot
showing the levels of mycMDM2wt and mycMDM2!N detected using 2A10 (top panel) and anti-myc antibody (bottom panel), and MDM2!Ac detected using
2A10 (top right panel).
RING Finger Domain in Control of MDM2
11522 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 17 • APRIL 24, 2009
 at G




(1.5 !M). However at 1.5 !M, Nutlin had no measurable
effect on the levels of p21 protein in the presence of
MDM2C464A, in fact it required 7 !M Nutlin to relief tran-
srepression by the Cys464A protein on p21 protein
expression.
The differential effect of Nutlin, dependent on the status of
the C2H2C4 RING structure, suggests that the introduction of
mutations that directly impact on RING structure can differen-
tially impact on the affinity or availability of MDM2’s hydro-
phobic pocket for p53 BOX-I binding.
FIGURE 3. The efficacy of Nutlin in cells is dependent on the C2H2H4 RING. A, ubiquitination reactions were assembled with p53, E1, E2, and MDM2 in the
presence or absence (c) of either Nutlin or BOX-I peptide (0, 10, 20, 40, and 60 !M). Ubiquitination was analyzed by immunoblot using a 4 –12% gradient gel, p53
was detected using DO-1. Unmodified (p53) and ubiquitinated p53 (Ub-p53) are shown. The data are representative of at least four separate experiments.
B, Nutlin (10 !M) was added to A375 cells, and they were harvested over a 24-h time course (0, 1, 2, 3, 4, 6, 8, 12, and 24 h). The lysates were analyzed by
immunoblot using either a 4 –12% gradient gel (upper panel) or a 15% SDS-PAGE gel (lower panel) p53 was detected using DO-1 and p21 using AB-1. Modified
forms of p53 are given as Ub-p53. The data are representative of three such experiments. C, H1299 cells were transfected with p53 alone (150 ng) or together
with MDM2 (400 ng) after 24 h Nutlin (0, 1.5, 3, 5, and 14 !M) was added, and the incubation continued for a further 6 h. Total DNA was normalized using the
vector control. The cells were harvested and the Dual Luciferase Assay was performed. The results are normalized by expressing p21-Luciferase/Renilla activity
in relative light units (RLU) and are the mean & S.D., and c is the vector-only control. A DMSO control is included for the Nutlin carrier. D, H1299 cells were
transfected with p53 alone (150 ng) or together with (300 ng) of MDM2wt, MDM2C464A, or MDM2C478S. Total DNA was normalized using the vector control
(c). Post transfection (24 h) cells were treated with Nutlin (0, 1.5, 3, 5, and 14 !M) for a further 6 h. Immunoblot analysis of MDM2, p53, and p21 was carried out
using 2A10, DO-1, and Ab-1, respectively. E, densitometry analysis of the p21 immunoblot; p21 levels are given as a percentage of protein detected in the
presence of p53 alone.
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MDM2Cys RING FingerMutant Proteins Bind with a Higher
Affinity to the Transactivation Domain of p53—The cell-based
experiments described above show that (i) C2H2C4 RING
mutants have a gain of transrepressor activity and (ii) the
hydrophobic pocket, but not the acid domain, is essential for
MDM2 repressor activity. These results suggested to us that the
affinity of the hydrophobic pocket for the BOX-I domain of p53
might be sufficient to dictate the potency of MDM2 as a tran-
srepressor and may also determine the efficacy of hydrophobic
pocket binding drugs such as Nutlin.
If the above hypothesis is correct we would expect the
C2H2C4RINGdomainMDM2mutant proteins to bind BOX-I
with a higher affinity than thewild-type protein. To address this
we first purified full-length untagged humanMDM2, as well as
theCys464A andCys478SmutantMDM2proteins from anE. coli
expression system. The protein concentrations were normal-
ized and the quantitation was confirmed using an enzyme-
linked immunosorbent assay (Fig. 4A). E3-ligase activity was
assayed using a purified assay system (16) and as expected
(based on the results presented in Fig. 1B), whereas the wt pro-
tein was an active E3-ligase, neither the Cys464A nor the Cys478S
mutant were able to mediate ubiquitination of p53 (Fig. 4B).
Next the ability of the proteins to bind to full-length purified
p53 was determined (Fig. 4C). In this assay a constant amount
of full-length untagged p53, purified form E. coli, was captured
onto microtiter wells and incubated with a titration of wt or
mutant MDM2 protein. Following extensive washing bound
MDM2was detected using amonoclonal antibody (2A10). This
showed that both of the MDM2 C2H2C4 mutant proteins
bound with a higher affinity to full-length p53 than did wt
MDM2, however, consistent with its lower I0.5 in the transre-
pressor assay (Fig. 1C), the Cys464Amutant bound better to p53
than the Cys478S mutant protein.
Although the interaction between the acid domain of
MDM2 and the BOX-V domain of p53 is not essential for
MDM2 mediated transrepression (Fig. 2B) it is likely to play
a role in binding of MDM2 to full-length p53 protein (16).
Binding to the isolated BOX-I domain was therefore used to
determine whether the increase in affinity of the Cys464A and
Cys478S mutants for full-length p53 reflected a change in
affinity for the p53 BOX-I domain. Binding of wt and the
C2H2C4 mutant MDM2 proteins to a peptide based on the
BOX-I domain of p53, or to an optimized hydrophobic
pocket binding peptide, 12.1 (34), was determined. Biotiny-
lated BOX-I domain or 12.1 peptide were immobilized on
streptavidin-coated wells and incubated with a titration of
wt MDM2 or the two C2H2C4 mutant proteins. Consistent
with the data presented above, showing that the mutants
bind better to full-length p53, both the Cys464A and Cys478S
proteins bound with a higher affinity to BOX-I and 12.1 than
wt MDM2 protein. Mirroring its decreased I0.5 for transre-
pression and increased affinity for full-length p53 the
Cys464A mutant consistently bound better to BOX-I or the
BOX-I mimetic (12.1) than the Cys478 mutant protein.
The data presented above suggest that the increased transre-
pressor activity of the MDM2 C2H2C4 RING mutants is
dictated by an increase in the affinity of their hydrophobic
pockets for the BOX-I transactivation domain of p53.
TheMDM2 RINGMutant Proteins Differ in Their Sensitivity
to the Hydrophobic Pocket Binding Drug Nutlin—To determine
whether the differential effect ofNutlin on theC2H2C4MDM2
mutants observed in a cellular environment represented a
quantitative difference in the affinity of the mutants for Nutlin
binding, we determined the ability of Nutlin to compete with
BOX-I for binding to MDM2. In this assay equal amounts of
biotinylated BOX-I peptide were captured onto streptavidin-
coatedmicrotiterwells and incubatedwith a fixed amount ofwt
or mutantMDM2 in the presence of increasing Nutlin concen-
trations (Fig. 5A). Consistent with the results observed in cells
(Fig. 3C) this assay demonstrated an apparent difference in the
ability of the RING mutants to bind Nutlin, suggesting that
mutations within the C2H2C4 structure have a direct influence
on Nutlin binding that is not mediated by other cellular pro-
teins. Thus, Nutlin is a weak inhibitor of BOX-I binding to the
Cys464A mutant, relative to wild-type MDM2 protein, with an
I0.5 4# higher than wt MDM2. This suggests that the Cys464A
protein has a lower affinity for Nutlin than the wild-type pro-
tein and binds with a higher affinity to BOX-I resulting in pref-
erential BOX-I binding. Conversely, the Cys478S mutant
appears to bind Nutlin with a higher affinity than the wt and
Cys464A proteins. Thus, in this case Nutlin competes more eas-
ilywithBOX-I for binding to the hydrophobic pocket. Todeter-
mine if the differences observed in Nutlin binding are reflected
in the ability of Nutlin to disrupt the interaction between full-
length p53 and MDM2 the following experiment was per-
formed. Full-length p53 was coated onto the microtiter well
and incubated with a titration of MDM2 in the presence of
various fixed concentrations of Nutlin (Fig. 5B; 2.5, 5, and 10
!M). Again there was a clear difference in Nutlin-dependent
disruption of full-length p53 binding to the MDM2 proteins,
with the p53-Cys478S mutant complex showing increased Nut-
lin sensitivity compared with the p53-Cys464A and the p53-
MDM2wt interactions. Once again this suggests that the
Cys478S mutant has a higher affinity for Nutlin than does the
Cys464A protein.
In conclusion, although both the Cys464A and Cys478S pro-
teins bind with a higher affinity to hydrophobic pocket inter-
acting ligands than the wt protein, resulting in a gain of tran-
srepressor activity (Fig. 2C), they do so differentially. Thus,
whereas the Cys478S protein binds preferentially to Nutlin, the
Cys464A protein binds with a higher affinity to BOX-I (Fig. 5)
resulting in differential Nutlin sensitivity in cells (Fig. 2C).
Moreover, mutations within the zinc coordinating structure of
the RING are not synonymous.
RING-generated Conformational Changes in MDM2 Are
Transmitted to the Hydrophobic Pocket through the Central
Domain—To support our hypothesis that hydrophobic pocket
affinity can be modulated by the RING domain, evidence of a
RING-dependent conformational change in full-lengthMDM2
was sought. Firstly, limited proteolysis was used to probe for
changes in the accessibility of trypsin cleavage sites in the
MDM2 Cys mutants verses the wt protein. Purified wt or
mutant MDM2 was incubated with trypsin at a ratio of 1:100
(protein) for up to 30 min, the samples were then analyzed by
gradient SDS-PAGE/immunoblot and cleavage fragments
identified using a mixture of MDM2 monoclonal antibodies
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FIGURE 4. C2H2C4 mutant MDM2 binds with a higher affinity to p53. A, to check the accuracy of protein normalization for the purified MDM2wt,
MDM2C464A, and MDM2C478S proteins an enzyme-linked immunosorbent assay was performed in which a titration of MDM2 protein was coated onto
the microtiter plate wells, following extensive washing, and MDM2wt and mutant protein levels were detected using 2A10. B, ubiquitination reactions
were assembled with p53, E1, E2, and MDM2 wt or mutant proteins as indicated. Ubiquitination was analyzed by immunoblot using a 4 –12% gradient
gel, p53 was detected using DO-1. Unmodified (p53) and ubiquitinated p53 (Ub-p53) is shown. C, p53 (100 ng/well) was coated onto microtiter wells and
incubated with wt or mutant MDM2 as indicated. MDM2 binding was detected using 2A10 and is expressed as relative light units (RLU) against the
MDM2 amount. The experiment is representative of three independent experiments where each condition was carried out in duplicate. In the schematic
the detecting antibody 2A10 is depicted. D, BOX-I (upper panel) or 12.1 (lower panel) peptides (5 !M) were captured onto streptavidin-coated wells, and
MDM2 binding was determined as described in C. In the schematic BOX-I/12.1 are depicted and the detecting antibody is 2A10.
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(Fig. 6B). The results show that the
wt protein rapidly formed (within 5
min) a stable core comprising bands
1, 2, and 3, which was maintained
throughout the course of the exper-
iment. Although the MDM2C464A
mutant initially formed a similar
banding pattern to the wt protein,
with bands 1, 2, and 3 being
detected, it was then further pro-
cessed so that by 15min a new stable
pattern had emerged comprising
bands 2, 3, 4, and 5 with band 1
no longer being detected. Consis-
tent with earlier results the
MDM2C478S mutant appeared to
be intermediate between wt and the
Cys464A protein as at 30 min all five
bands were readily detected. These
results suggest that the Cys464A and
Cys478S mutants have a different
conformation to the wt protein
leading to the exposure of trypsin-
sensitive cleavage sites that are not
accessible in wt MDM2.
Further support for a difference
in conformation between the RING
mutants and wt MDM2 was pro-
vided by investigating the intrinsic
fluorescence properties of the pro-
tein (Fig. 6, C and D). Although all
aromatic amino acids can contrib-
ute to protein fluorescence, trypto-
phan is the dominant intrinsic flu-
orophore.MDM2 contains a total of
four tryptophan residues (Fig. 6A)
located in the central region of the
protein, in and around the acid
domain. Because the emission
observed reflects the average envi-
ronment surrounding each individ-
ual tryptophan and the tryptophans
within MDM2 are not in identical
local environments, each of these
residues will contribute unequally
to the emission spectrum. The #max
of the emission spectrum of a tryp-
tophan will be shifted to longer
wavelengths (i.e. red-shift) if it is
involved in hydrogen bonding
and/or is exposed to buffer relative
to the lower wavelength #max (blue
shift) of a tryptophan buried within
the hydrophobic core of the protein.
Fig. 6C compares the emission fluo-
rescence spectra of MDM2 wt and
the twoCysmutants. For both of the
mutant proteins we observe a red
FIGURE 5. Nutlin has a differential effect on the C2H2H4 MDM2 mutants. A, a schematic (left panel) shows
the assay format with BOX-I peptide Nutlin and the detecting antibody in blue. Right panel, BOX-1 peptide (5
!M) was captured on streptavidin-coated wells and incubated with the indicated form of MDM2 (50 ng), which
had been preincubated (5 min) with a titration of Nutlin (!M). MDM2 binding was detected using 2A10 and is
given as relative binding expressed as a percentage where 100% binding is that measured in the absence of
Nutlin. B, p53 protein (100 ng/well) was coated onto microtiter wells and incubated with a titration of wt and
mutant MDM2 as indicated. The MDM2 had been preincubated with Nutlin (2.5, 5, and 10 !M as indicated).
MDM2 binding was detected using 2A10 and is normalized to maximal binding to p53 in the presence of
saturating amounts of each mutant in %. The experiment is representative of at least three independent
experiments where each condition was carried out in duplicate. In the schematic the detecting antibody 2A10
and Nutlin are depicted.
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FIGURE 6. Conformational differences between wt and RING domain mutants of MDM2. A, a schematic representation of MDM2 showing the
epitopes for 3G5 and 2A10; the position of the 4 tryptophan residues in MDM2 is marked. B, immunoblot showing wt or mutant forms of MDM2 following
limited proteolysis with trypsin. The blot was developed using a mixture of the MDM2 monoclonal antibodies 2A10, 4B2, 3G5, and SMP14. The numbers
are used to label the banding pattern; time points used were 0, 5, 10, 15, 20, and 30 min. The data are representative of three separate experiments.
C, resolution of fluorescence emission spectra of MDM2wt (white) and the MDM2C464A (brown) and MDM2C478S (blue) RING mutants. The spectra were
corrected for associated buffer background signals. D, maxima with corresponding wavelength of MDM2 fluorescence emission spectra. The values
were calculated with mathematical n-polynomial based algorithm, where R2 $ 0.999. E, as in B except the time course was 0, 5, and 20 min. The blots
were developed using 2A10 (upper panel) and 3G5 (lower panel). F, localization of the 3G5 antibody epitope within the MDM2 hydrophobic pocket
(pocket shown in ribbon representation, colored gold). Nutlin-3 bound to the pocket in stick representation (chlorine in green, carbon in gray, nitrogen in
blue, and oxygen in red). The epitope of 3G5 antibody consists of four critical residues; Leu66, Tyr67, Asp68, and Glu69, surrounded by trypsin cleavable Lys
and Arg residues (highlighted in purple). This figure was prepared using PyMOL (W. L. DeLano (2002) PyMOL, DeLano Scientific, San Carlos, CA), and
structural data were from file 1TTV-RCSB PDB.
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shift with #max at 349–349.5 nm in contrast to that of the wt
protein of #max at 343 nm (Fig. 6D). Moreover the differential
quenching of the emission spectrum (Fig. 6C) for the two
mutants indicates that their conformation changes are not
equivalent. Thus, the data show differences in conformation
between wt and mutant forms of MDM2 and between the two
mutants. The intrinsic fluorescence measurements are there-
fore consistent with the partial proteolytic digestion data (Fig.
6B) and with the differential binding affinity of the Cys464A and
Cys478S mutants for BOX-I and Nutlin (Figs. 4 and 5).
The experiments presented above using limited proteolysis
(Fig. 6B) and intrinsic fluorescence (Fig. 6C) suggest that the
introduction of point mutations in key RING domain Cys resi-
dues generates a measurable conformational change in full-
length MDM2 protein. To establish whether these conforma-
tional changes have a direct impact on the structure of the
hydrophobic pocket we employed a monoclonal antibody
(3G5), which binds to an epitope in the center of the hydropho-
bic pocket (Fig. 6A) (35). Using limited proteolysis we deter-
mined whether changes in the RING domain had an effect on
the ability of 3G5 to bind to the hydrophobic pocket ofMDM2.
As a control for this experiment we used the monoclonal anti-
body 2A10, which has been mapped to two epitopes within the
central and C-terminal domains of MDM2 (Fig. 6A). The 2A10
data (Fig. 6E, upper panel) suggests that the core fragments
identified in Fig. 6B (in particular bands 2–4) are comprised
largely of the central domain of MDM2 together with C-termi-
nal truncations. In contrast 3G5 (Fig. 6E, lower panel) suggests
that the hydrophobic pocket is rapidly cleaved from the core of
MDM2 and that its removal generates a fast migrating 3G5
reactive product (band 6). The MDM2C478S mutant appears
to be more sensitive to this type of cleavage, because 3G5-pos-
itive full-length protein is lost more rapidly than it is for wt
MDM2. Of particular interest in this assay is theMDM2C464A
mutant, as incubation of this protein leads to a dramatic loss of
the 3G5 epitope suggesting that the hydrophobic pocket in this
protein ismore “relaxed” and thereforemore accessible to tryp-
sin digestion duringwhich the 3G5 epitope is cleaved leading to
a loss of antibody binding.
Together the data presented in this section support the con-
clusion that the RING domain of MDM2 can influence the
activity of the N-terminal hydrophobic pocket by producing
long range conformational changes that are transmitted
through the central acid core ofMDM2 andwhich lead to vary-
ing degrees of relaxation in the hydrophobic pocket.
DISCUSSION
Studies addressing how MDM2 structure supports its func-
tional diversity have begun to provide insight into the proteins
conformational flexibility. Thus, a picture is immerging of
interdependent functional domains linked through changes in
conformation, emphasizing the need to study the domain
structure of MDM2 within the context of the whole protein. In
the current study we have used point mutations within the
RING finger domain to uncover cross-talk between the C ter-
minus and interactions taking place at the N-terminal hydro-
phobic pocket of MDM2. Our results show that RING-medi-
ated allosteric modulation of the hydrophobic pocket has
implications for bothMDM2 transrepressor activity and for the
efficacy of MDM2-targeted therapy (Fig. 7).
We previously described a link between the hydrophobic
pocket of MDM2 and its acid domain (16). In this case occupa-
tion of the hydrophobic pocket promoted conformational
changes in MDM2 that favored acid domain binding to a ubiq-
uitination signal in the core DNA binding domain of p53. This
allostericmechanismpromotesMDM2 function as an E3-ubiq-
uitin ligase by stabilizing a low affinity interaction between the
BOX-V domain of p53 and the acid domain of MDM2. The
current data add to this model for the regulation of oneMDM2
domain throughmodulation of a second by demonstrating that
the RING finger domain, and more specifically residues
required to form the C2H2C4 RING structure, can alloster-
ically modulate hydrophobic pocket interactions. In this case
the result is an increase in the affinity of the hydrophobic
pocket, which produces a gain in transrepressor function in
FIGURE 7. Model for the allosteric regulation of MDM2. Our data suggest
the binding of interacting proteins and ligands or post-translational modifi-
cation within the RING domain of MDM2 (a), which affect RING architecture,
will cause conformational changes leading to changes in the affinity of the
hydrophobic pocket for BOX-I domain of p53 and other ligands. This can
result in formation of a transcriptionally inactive complex (b), or, based on our
previous studies (16), could result in a transition complex (c) where hydropho-
bic pocket binding leads the acid domain to bind to the core BOX-V site in
p53-signaling p53 ubiquitination (d).
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cells. Interestingly, mutations of Cys464 and Cys478 residues are
not equivalent in terms of their effect on the hydrophobic
pocket. Thus, although bothmutants display increased binding
to the BOX-I domain of p53 (Fig. 4), the Cys478S mutant binds
Nutlin in preference to BOX-I, whereas the Cys464A protein
preferentially binds to BOX-I (Fig. 5).
Structural and computational analysis of the MDM2 hydro-
phobic pocket interaction with p53 has revealed that this
domain has a high degree of plasticity and has suggested that
the shape of the binding cleft can change significantly (36, 37).
A mechanism has been proposed where binding to the BOX-I
domain of p53 requires a progressive opening up of the binding
cleft to reveal a hydrophobic interface. p53 binding then pro-
ceeds through an intermediate complex where the cleft gradu-
ally adopts amore open conformation eventually accommodat-
ing Thr18–Asp29 of BOX-I. Based on this type of study it has
been hypothesized that the cleft has enough plasticity to allow a
range of low energy states rather than a single “open” or
“closed” conformation. As a result the pocket can accommo-
date a range of peptides and small molecules that might not
have any obvious structural similarity (32, 36–39). It is likely
therefore that the differential binding preferences of our two
Cys mutants are a result of different degrees of cleft accessibil-
ity. This hypothesis is supported by data showing that, although
the Cys464A and Cys478S mutant proteins both adopt a different
stable conformation from the wt protein (Fig. 6), their confor-
mation is not equivalent. The intrinsic fluorescence of trypto-
phan residues within the central domain of the Cys478S mutant
is quenched relative to those in the Cys464A mutant, suggesting
that they aremore solvent-exposed or are involved in additional
interactions with nearby residues. Further evidence for a differ-
ence in the conformation of the hydrophobic cleft dependent
on the status of the RING domain comes from the use of the
monoclonal antibody 3G5 to probe for differences in confor-
mation following limited tryptic digestion (Fig. 6E). This anti-
body recognizes an epitope in the hydrophobic pocket of
MDM2, where residues 66LYDE69 are essential but not suffi-
cient for binding, i.e. peptides containing the LYDE motif but
not other surrounding residues are not sufficient for antibody
recognition (35). The LYDE motif maps to a loop structure in
the hydrophobic pocket that lies between two of the "-helical
structures that form the BOX-I binding cleft (Fig. 6F) and is
flanked by lysine and arginine residues that provide tryptic cut
sites when exposed (61IMTKRLYDEKQQHIV75). Our data
show that the LYDE motif is more accessible in the Cys464A
mutant than in the wt or the Cys478S protein (Fig. 6F), suggest-
ing that the cleft ismore relaxed and thereforemore readily able
to accommodate the BOX-I peptide leading to an increase in
BOX-I affinity.
Our data, showing thatmutations in theC-terminal C2H2C4
RING of MDM2 can allosterically modulate not only the affin-
ity of the hydrophobic pocket but also its specificity (Fig. 5),
suggest that in cells the binding of interacting proteins and/or
ligands to the RING is likely to impact on bothMDM2 transre-
pressor activity and on the efficacy of pocket binding drugs in
tumor cells (Fig. 6). This hypothesis is supported by data show-
ing that binding of ligands such as zinc and ATP to the RING
finger domain ofMDM2 generate conformational changes (17,
23). In fact, we have previously shown that zinc binding can
affect the interaction ofMDM2with the BOX-I domain of p53;
in this case zinc binding leads to a decrease in BOX-I binding
(17, 23). Together with our current data this suggests thatmod-
ulation of the RINGdomain has the potential to both negatively
and positively regulate binding of BOX-I to the hydrophobic
pocket. As the Cys mutants used in the current study are E3-li-
gase dead, it is not possible to determine if C2H2C4 RING
interacting factors could also promote MDM2 E3-ligase activ-
ity, because increased binding to hydrophobic pocket binding
ligands could potentially favor acid domain binding to the
BOX-V domain of p53 signaling ubiquitination (16). Thus, it
will be interesting to determine whether RING domain-inter-
acting factors, or modifications, such as acetylation (40), within
the RING domain act in a concerted manner to promote both
transrepression and ubiquitination of p53 or whether changes
in RING conformation might act as a switch favoring one
MDM2 activity over another.
Recent genetic studies have suggested that the primary phys-
iological role of MDM2 is the regulation of p53 protein levels
mediated by its E3-ligase activity (41, 42). These experiments
were largely carried out in mouse embryonic fibroblasts and
developingmouse embryos whereMDM2 activity has been lost
or reduced and is therefore rate-limiting. However, this situa-
tion is unlikely to reflect the environment encountered in most
tumor cells. In fact current estimates suggest thatMDM2 levels
are elevated in'10% of all human tumors (43) due for example
to enhanced translation or transcription in addition to amplifi-
cation of the MDM2 gene (44). In contrast to the studies in
non-transformed mouse cell models mentioned above work in
tumor cells endogenously overexpressing MDM2 protein sug-
gests that its ability to act as a transrepressor contributes signif-
icantly to the impaired p53-response seen in these cells. Thus,
in cells that are homozygous for a polymorphism (SNP309) that
enhances SP1-dependent MDM2 transcription the MDM2
protein is found in association with p53 resulting in transcrip-
tionally inactive complexes (25, 45). Depletion of MDM2 by
siRNA in these cells results in activation of p53-dependent
transcription in the absence of increase p53 protein levels sup-
porting the idea that, at least in some tumor cells, MDM2 acts
predominantly as a transrepressor of p53 function (25). Fur-
thermore, it has been demonstrated that tumor cells that do not
have increased MDM2 levels also operate an MDM2-depend-
entmechanism for controlling p53 transcription in the absence
of changes in p53 protein levels (46). Thus, the data presented
here, showing that C2H2C4 RINGmutants that loose E3-ubiq-
uitin ligase activity preferentially bind to p53 inhibiting its
transactivation activity, may be pertinent to the physiological
environment of a tumor cell where MDM2 is controlling p53
activity primarily through transrepression.
Wehave shown thatNutlin does not inhibitMDM2E3-ligase
activity neither in vitro nor in cell models (Fig. 3; 16). However,
despite its lack of E3-ligase inhibitory activity Nutlin can func-
tion in cells and animal models of cancer to activate p53 and to
elevate p53 protein levels (32, 33). Evidence presented here
showing that Nutlin can reverse transrepression imposed by
both the wild-type and the Cys478S mutated form of MDM2
suggests that it functions primarily by relieving MDM2-im-
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posed transrepression allowing binding to coactivators such as
p300. This conclusion is supported by the observation thatNut-
lin promotes rapid activation of p53-dependent transcription
before changes in p53 protein level are recorded (46). The fact
that Nutlin is proving to be an effective drug in somemodels of
human cancer provides further evidence for the role of MDM2
transrepressor activity in tumor development.
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Abstract The tumor suppressor p53 has evolved a MDM2-
dependent feedback loop that promotes p53 protein deg-
radation through the ubiquitin–proteasome system. MDM2
is an E3-RING containing ubiquitin ligase that catalyzes
p53 ubiquitination by a dual-site mechanism requiring
ligand occupation of its N-terminal hydrophobic pocket,
which then stabilizes MDM2 binding to the ubiquitination
signal in the DNA-binding domain of p53. A unique
pseudo-substrate motif or “lid” in MDM2 is adjacent to its
N-terminal hydrophobic pocket, and we have evaluated the
effects of the flexible lid on the dual-site ubiquitination
reaction mechanism catalyzed by MDM2. Deletion of this
pseudo-substrate motif promotes MDM2 protein ther-
moinstability, indicating that the site can function as a
positive regulatory element. Phospho-mimetic mutation in
the pseudo-substrate motif at codon 17 (MDM2S17D)
stabilizes the binding of MDM2 towards two distinct
peptide docking sites within the p53 tetramer and enhances
p53 ubiquitination. Molecular modeling orientates the
phospho-mimetic pseudo-substrate motif in equilibrium
over a charged surface patch on the MDM2 at Arg97/
Lys98, and mutation of these residues to the MDM4
equivalent reverses the activating effect of the phospho-
mimetic mutation on MDM2 function. These data highlight
the ability of the pseudo-substrate motif to regulate the
allosteric interaction between the N-terminal hydrophobic
pocket of MDM2 and its central acidic domain, which
stimulates the E3 ubiquitin ligase function of MDM2. This
model of MDM2 regulation implicates an as yet undefined
lid-kinase as a component of pro-oncogenic pathways that
stimulate the E3 ubiquitin ligase function of MDM2 in cells.
Keywords MDM2 . p53 . Allostery . Kinase . Ubiquitination
Introduction
Reconstitution of a multicomponent ubiquitin–enzyme
reaction mechanism, including the role of E1, E2, and E3
subcomponents as well as the substrate, is a fundamental
goal in understanding the molecular events that regulate the
ubiquitin–proteasome pathway [32]. The proteins within
the E3 class of ubiquitination catalysts include among
others the HECT domain and the RING domains. Unlike
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the HECT domain containing ubiquitin ligases, the E3-
RING domain containing proteins do not form a covalent
bond with ubiquitin, but catalyze the transfer of ubiquitin
from the activated E2 to the substrate by as yet undefined
mechanisms. How E3-RING domain containing ubiquitin
ligases alter substrate conformation and drive E2 recogni-
tion of substrate are critical mechanistic goals. The pro-
oncogenic protein MDM2 is such a RING domain contain-
ing E3 ubiquitin ligase that can promote the ubiquitination
of the p53 tumor suppressor protein [44, 49], and MDM2
represents a model E3 ubiquitin ligase to evaluate the
dynamics of a multiprotein ubiquitination system.
The E3-RING domain containing ubiquitin ligase MDM2
itself has been dissected into multiple domains with specific
biochemical functions. The C-terminal RING domain in
MDM2 co-ordinates the activity of MDM2 in E2-mediated
ubiquitin transfer [22] and contains a C-terminal peptide tail
that maintains RING-domain conformation [36, 46]. The
RING domain also promotes MDM2-dependent stimulation
of p53 protein synthesis through interactions with p53
mRNA during translation [7], and RNA itself can stimulate
MDM2:p53 interactions and substrate ubiquitination [5, 6,
33]. There also is an ATP-binding motif imbedded within
the RING domain that regulates the molecular chaperone
functions of MDM2 [41, 51]. Thus, the RING domain of
MDM2 mediates biochemical functions, including E2
binding, ATP binding, and RNA binding.
In addition to the C-terminal RING domain, MDM2 also
contains an N-terminal allosteric hydrophobic pocket,
which interacts with a specific linear peptide motif in
proteins such as p53 and interferon-responsive transcription
factors [20, 33]. This hydrophobic pocket was the first
region on MDM2 that was shown to bind directly to p53
[8]. Adjacent to this N-terminal domain is an “acidic”
domain that interacts at a second binding site within a
flexible motif in the DNA binding domain of p53 [38]. The
N-terminal hydrophobic binding pocket has been targeted
by small molecules like Nutlins that can interact with
MDM2 and activate p53 function by releasing p53 from
MDM2-mediated transrepression [47]. However, such
ligands do not block p53 ubiquitination [50] as ligand
occupation of this N-terminal hydrophobic pocket forms a
positive role in MDM2 function as an E3 ubiquitin ligase.
MDM2 hydrophobic pocket occupation promotes a more
stable interaction between the internal acidic domain of
MDM2 and a ubiquitination signal in the DNA-binding
domain of p53 [50].
These data have formed a “dual-site” model of MDM2-
mediated ubiquitination of p53. Accordingly, small peptides
derived from the BOX-I domain of p53 (containing the
primary MDM2 binding site) or small molecules like Nutlin
do not block p53 ubiquitination. By contrast, peptides
derived from the BOX-V domain of p53 (containing the
ubiquitination signal in the DNA-binding domain of p53)
do inhibit MDM2 ubiquitination of p53 [50]. Allosteric
interactions within full-length MDM2 protein has been
recently examined through structure-function studies dem-
onstrating that mutation of selected amino acids in the
RING domain promotes a conformation change both in the
N-terminal domain of MDM2 as defined by proteolytic
cleavage susceptibility and in the acidic domain as defined
by elevated intrinsic tryptophan fluorescence [52]. These
latter data provided the first biophysical evidence for
allosteric interactions among the various sub-domains in
full-length MDM2 protein.
This dual-site model for MDM2-mediated ubiquitination
of p53 presumably operates due to the striking flexibility of
the N-terminal p53-binding domain in the presence of
distinct peptide ligands [37, 40, 45]. A predominant feature
of this ubiquitination reaction mechanism is that there is an
induced stabilization of the acidic domain of MDM2 to the
conformationally flexible region in the DNA-binding
domain of p53 [38, 55] when the MDM2 hydrophobic
pocket is occupied by substrate [50]. This linear peptide
motif in the DNA-binding domain of p53 (named BOX-V
motif) is normally cryptic in the folded p53 tetramer, but it
is exposed on mutant p53 in human cancers as defined
using a monoclonal antibody that binds to this peptide-
epitope on denatured p53 protein [13, 48].
This flexible BOX-V motif in the DNA-binding domain
of p53 is also a multiprotein docking site; many protein
kinases, including CHK1/2, DAPK, and CK1, interact with
this region on p53 to catalyze phosphorylation of the
transactivation domain of p53 at Ser20 [9, 23]. Destabiliz-
ing mutations in p53 that “unfold” p53 protein at the
conformationally flexible region of p53 in the BOX-V
domain enhance mutant p53 protein ubiquitination in cell
systems [39] and can induce mutant p53 degradation via
MDM2 function in murine transgenes [42]. The enhanced
degradation of mutant p53 protein by an MDM2-dependent
pathway has important implications for regulating the pro-
oncogenic functions of mutant p53 in human cancers;
indeed, most human cancers appear to have a form of
mutant p53 protein with enhanced steady-state levels [30]
and therefore has presumably evaded the normal mutant
protein degradation machinery.
In order to define further the nature of the allosteric
regulation of MDM2, we have examined the function of a
flexible and unstructured N-terminal peptide motif adjacent
to the hydrophobic pocket of MDM2. Such small flexible
peptide motifs have been postulated to be important in a
wide range of signaling proteins [27–29]. This flexible
motif in MDM2 has been called a pseudo-substrate motif or
lid. Pseudo-substrate motifs operate in a range of alloste-
rically regulated enzymes, including protein kinases and
metabolic enzymes, and have been termed intrasteric
114 J Chem Biol (2009) 2:113–129
regulatory motifs [1, 16, 17]. The pseudo-substrate motif of
MDM2 harbors a phosphorylation site whose phospho-
mimetic mutation can alter the conformation of the N-
terminal domain of MDM2 protein as defined by NMR
studies [25, 40]. This phospho-mimetic mutation was
proposed to stabilize the pseudo-substrate motif over the
hydrophobic pocket and occlude p53 binding. However,
this has not been tested experimentally. As ligands that fill
the hydrophobic pocket like Nutlin can prime MDM2 and
stimulate the MDM2 E3 ubiquitin ligase function toward
p53 [50], the role of the unphosphorylated or phosphory-
lated lid is not necessarily evident—would it function as a
positive or negative cofactor in regulating the stability of
the MDM2:p53 complex, and therefore, would it ultimately
stimulate or attenuate p53 protein ubiquitination?
In this report, we show that the flexible lid is a positive
regulatory motif that maintains the thermostability of
MDM2 and that a phospho-mimetic mutation in the
MDM2 lid stabilizes the MDM2:p53 complex. We propose
a cis-acting intrasteric mechanism to explain how phospho-
mimetic mutation of the MDM2 lid might open the
hydrophobic pocket. This results in enhanced binding of
MDM2 to the first site on p53, which in turn enhances the
allosteric interaction between the acidic domain of MDM2
and the ubiquitination signal in the DNA-binding domain
of p53. These data also highlight the growing realization
that flexible and unstructured linear peptide motifs play
critical roles in controlling protein function in signal
transduction pathways [29] and provide a biochemical
foundation to study how changes in the rates of MDM2
phosphorylation at this flexible motif regulates the E3
ubiquitin ligase function of MDM2.
Results
A phospho-mimetic mutation in the pseudo-substrate motif
stimulates the E3 ubiquitin ligase function of MDM2
MDM2 is composed of distinct ligand binding domains that
regulate its multiple functions (Fig. 1). The integration of
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Fig. 1 Four distinct modes of MDM2 function. The top panel
highlights the domain structure of MDM2, including the hydrophobic
pocket in the N-terminus [20], the acidic central domain [55], a zinc-
binding motif [56], the RING domain [18], and ATP-binding site
imbedded within the RING domain [35]. MDM2 was identified as a
protein that regulates the p53 tumor suppressor via (1) inhibition of
p53-dependent transcription [26, 43]. Germline mutations in the mdm2
promoter that result in MDM2 over-production result in enhanced
MDM2 protein in chromatin fractions, which mediates suppression of
p53 function as a transcription factor [2, 52]. The second function
identified for MDM2 involved its ability to (2, 3) catalyze p53
degradation through a ubiquitin-dependent pathway [19] [15]. This
ubiquitination function of MDM2 also involves ubiquitination and
degradation of ribosomal proteins that can normally function to
stimulate p53 protein synthesis [31]. According to the dual-site
mechanism of MDM2-mediated ubiquitination of p53 [50], two
structural changes can enhance p53 ubiquitination by MDM2: one
structural change involves (2) destabilizing missense mutations in p53
that unfolds the p53 tetramer and that can expose the ubiquitination
signal in the DNA-binding domain [38], thus enhancing p53
ubiquitination in cells [39]; the second structural change involves (3)
the lid of MDM2 whose phospho-mimetic mutation increases MDM2-
mediated ubiquitination of p53 tetramers by stabilizing the MDM2:
p53 complex (this study). Small molecules that bind to the N-terminal
hydrophobic pocket of MDM2 (Nutlins) can activate p53 [47]
presumably by inhibiting the chromatin-bound pool of MDM2 since
Nutlins cannot inhibit MDM2 function as an E3 ubiquitin ligase [50].
Rather, to date, peptide mimetics that bind to the MDM2 acidic
domain provide a lead for inhibiting MDM2 function as a E3 ubiquitin
ligase [50]. Additional research has highlighted novel molecular
functions of MDM2. A cellular function was assigned to the RNA-
binding activity of MDM2 [12, 21, 24], which involves (4) an
interaction of MDM2 with p53 mRNA at ribosomes to stimulate p53
protein synthesis [7]. A function was also assigned to the ATP-binding
motif of MDM2 [35], which involves (5) the ability of MDM2 to
exhibit the property of a molecular chaperone by catalyzing the ATP-
dependent folding of the p53 tetramer to enhance p53 function as a
transcription factor [41, 51]
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the known biochemical functions of MDM2 is also
summarized in Fig. 1. The MDM2 oncoprotein is known
to have diverse molecular functions in (1) transcriptional
repression of p53, (2) ubiquitination and degradation of
p53, (3) synthesis of p53 protein, and (4) ATP-dependent
molecular chaperone functions on p53 protein (Fig. 1). It is
not known if these four functions are integrated, function in
parallel, or are coordinately switched on or off. However,
human and mouse genetic studies have established a
specific role for the RING domain and hydrophobic pocket
in the control of MDM2 function as a transrepressor and as
an E3 ubiquitin ligase [2, 44].
In order to dissect further the dual-site model of MDM2-
mediated ubiquitination of p53, we focused our analysis on
the effects of the pseudo-substrate motif (Fig. 2a) on the in
vitro E3 ubiquitin ligase function of MDM2. An NMR
study of the unliganded apo-form of the N-terminal domain
of MDM2 revealed the pseudo-substrate motif to be largely
unstructured and in a dynamic equilibrium (Fig. 2b).
Further, ligands that occupy the hydrophobic pocket can
alter the conformation of MDM2 [25, 37, 40, 45],
highlighting the conformational flexibility of MDM2.
However, ligands such as Nultin or a p53 peptide (BOX-I
domain peptide) do not inhibit MDM2-mediated ubiquiti-
nation (Fig. 2c and d), while peptides that bind to the acidic
domain of MDM2 (BOX-V domain homology peptides) can
inhibit MDM2 function (Fig. 2e; as in [33, 50, 52]). As the
conformational flexibility of this N-terminal pseudo-
substrate motif of MDM2 could have significant regulatory
effects on MDM2 conformation, this motif also provides a
novel tool with which to evaluate how perturbation of the
hydrophobic pocket of MDM2 might regulate allosterically
the E3 ubiquitin ligase function of MDM2.
To define a role for this flexible pseudo-substrate motif or
lid, purified untagged wild-type MDM2 and MDM2
mutants were generated, including one with an N-terminal
flexible pseudo-substrate motif deletion (MDM2!LID;
Fig. 3a). A titration of MDM2 (Fig. 3b, lanes 1–5) or
MDM2!LID (Fig. 3b, lanes 6–10) in ubiquitination
reactions demonstrated that MDM2!LID has a lower
specific activity, although it can still catalyze ubiquitina-
tion. The lowered specific activity of MDM2!LID suggests
the pseudo-substrate motif normally has an intrinsic
positive regulatory effect on MDM2 function.
The pseudo-substrate motif also has a SQ phospho-
acceptor site whose phospho-mimetic mutation (S to D)
induces a conformational change in the N-terminal domain of
MDM2 as defined using NMR [25] (Fig. 2a and b). This
mutation was predicted to stabilize the lid equilibrium into a
position that partially occludes ligands like p53 and that this
mutation might therefore block the MDM2:p53 complex.
However, the biochemical effects of this mutation on
MDM2 function in vitro and in vivo have not actually been
defined experimentally. As such, we also evaluated the
effect of the phospho-mimetic pseudo-substrate motif
mutant (MDM2S17D; Fig. 3a) on MDM2:p53 interactions.
Three possibilities include (1) that the phospho-mimetic
motif could act like a lid and partially cover the
hydrophobic pocket, thus destabilizing the MDM2–p53
interaction [25]; (2) the phospho-mimetic motif could act
like a lid and partially cover the hydrophobic pocket, thus
stabilizing MDM2 acid domain interactions with p53 via
the dual site allosteric model [50]; and (3) the phospho-
mimetic mutation might stabilize the lid in equilibrium in
a distinct conformation and “open” the hydrophobic
pocket (Fig. 2b). The phospho-mimetic mutation in
MDM2 in fact did not inhibit the ubiquitination function
of MDM2; rather, the Asp17 mutation increased the
specific activity of MDM2 as an E3 ubiquitin ligase
(Fig. 3c, lanes 5–7 vs 2–4 and d).
These data are consistent with the lid functioning as a
positive rather than as a negative regulatory motif.
Regulatory motifs often alter the thermostability of an
enzyme or protein [11], and we evaluated whether the
pseudo-substrate motif deletion alters thermostability of
MDM2. The preincubation of MDM2!LID at the indicated
temperatures completely inactivated the E3 ubiquitin ligase
function of the protein (Fig. 3e, lanes 8–12 vs 7). MDM2S17D
was not thermosensitive when preincubated at elevated
temperatures compared to MDM2!LID (Fig. 3f). These data
suggest that the pseudo-substrate motif contributes positively
to maintaining the thermostability of MDM2 protein.
Consistent with this, transfection of the plasmid encoding
MDM2!LID into cells destabilizes the protein and accord-
ingly reduces its specific activity as an E3 ubiquitin ligase
toward p53 (Fig. 3g, lanes 6–8 vs 3–5).
A phospho-mimetic mutation in the pseudo-substrate motif
stabilizes MDM2:p53 interactions
We next analyzed whether the elevated specific activity of
MDM2S17D as a E3 ubiquitin ligase could be attributed to
enhanced binding of MDM2 to p53 protein resulting in a
more stable MDM2:p53 protein complex. This enhanced
stability of the MDM2:p53 complex would in turn translate to
enhanced p53 ubiquitination. A titration of MDM2S17D, wt-
MDM2, or MDM2!LID provided a correlation between
specific activity of an E3 ubiquitin ligase and enhanced
stability of the MDM2:p53 protein complex (Fig. 4b).
Although MDM2!LID was essentially unable to form a stable
contact with the p53 tetramer presumably as a result of
pseudo-substrate motif deletion, MDM2S17D exhibited a
striking increase in its binding for p53 protein as defined by
the stability of the MDM2:p53 complex (Fig. 4b). The
preincubation of MDM2S17D, wt-MDM2, or MDM2!LID at
distinct temperatures had no effect in altering wt-MDM2
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protein or MDM2S17D interactions with p53 (Fig. 4c). This
elevated stability of the MDM2:p53 complex as a result of the
Asp17 mutation in MDM2 is consistent with the enhanced E3
ubiquitin ligase activity of MDM2S17D (Fig. 3). However,
these data are not compatible with the hypothesis that this
phospho-mimetic substitution would destabilize the MDM2:
p53 interactions [25].
The data presented above showing that the phospho-
mimetic S17D substitution of MDM2 stabilizes the MDM2:
p53 interaction could be explained by two models consistent















































































Fig. 2 The N-terminal pseudo-
substrate motif of MDM2.
a Conservation of amino acids
1–44, including the pseudo-
substrate motif (aka, the lid)
within MDM2 homologues and
absence of the pseudo-substrate
motif in the orthologue MDM4.
The pseudo-substrate motif is
surrounded by a box, and the
phosphorylation site at Ser17 is
highlighted with a green circle.
b The NMR structure of the
non-liganded N-terminal p53
binding domain of MDM2
(PDB ID 1Z1M, residues
10–109; apo-MDM2 [45])
reveals a large degree of
conformational heterogeneity
in the N-terminal 20 residues
(colored from blue (N-terminal)
to red (C-terminal)). Pseudo-
substrate motif conformations
acting like a lid to cover the
MDM2 hydrophobic pocket are
highlighted with arrows, and
conformations with the pseudo-
substrate motif interacting with
the MDM2 surface are high-
lighted with asterisks. c–e The
effects of small ligands on
MDM2 function as an E3 ubiq-
uitin ligase. A ubiquitination
assay was assembled with puri-
fied E1, E2, MDM2, and p53
proteins without or with in-
creasing concentrations of
c Nutlin, d BOX-I peptide
derived from the N-terminus
of p53, or e BOX-V homology
peptides derived from Rb
(BOX-Vb) and p53 DNA
binding domain (BOX-Va).
Ubiquitination was assayed as
indicated in the “Materials and
methods”. The position of the
un-ubiquitinated p53 substrate is
highlighted with arrows and
p53-ubiquitin adducts with
brackets
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with the dual site docking model of MDM2 function [50]; (1)
the phospho-mimicking pseudo-substrate motif is indeed
partially occluding the hydrophobic binding pocket [25], but
is acting in a positive auto-allosteric manner (i.e., like Nutlin
[50]), or (2) the S17D mutation orientates the pseudo-
substrate motif in a position that stabilizes the N-terminal
domain of MDM2 in an open conformation with the pseudo-
substrate motif in equilibrium at a position outwith the
hydrophobic pocket (Fig. 2b, asterisks). The striking
conformational flexibility of MDM2 when peptide ligands
of differing length occupy the pocket [37] or when the lid is
in distinct conformations [40] is consistent with either of
these two models. We carried out further biochemical
characterization of MDM2S17D in order to distinguish
between these two models.
One method to examine whether the Asp17 mutation
stabilizes the pseudo-substrate motif over the hydrophobic
pocket of MDM2 or whether the mutation opens the
hydrophobic pocket by shifting lid equilibrium would be
to determine whether MDM2S17D is sensitive or resistant to
Nutlin. It could be predicted that MDM2S17D cannot
interact with Nutlin (or the BOX-I domain of p53) if the
Asp17 modified pseudo-substrate motif is stabilized over
the hydrophobic pocket. However, Nutlin destabilizes the
MDM2S17D:p53 complex as well as the wt-MDM2:p53
complex (Fig. 5b and c). Although these data might not be
compatible with the model that the Asp17 substituted
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Fig. 3 A phospho-mimetic substitution in the MDM2 lid stimulates the
E3 ubiquitin ligase function of MDM2. a Diagram of the functional
domains of MDM2, including (1) wt-MDM2; (2) MDM2!LID, which
has a deletion of the flexible motif; and (3) MDM2S17D, which has a
phospho-mimetic aspartate mutation at Ser17 (S17D). b MDM2-pseudo-
substrate motif deletion reduces the specific activity of MDM2. Purified
wt-MDM2 or MDM2!LID was titrated directly into ubiquitination
reactions using p53 as a substrate. After 10 min, the reactions were
stopped and processed for immunoblotting to measure extents of p53
ubiquitination. c The S17D mutation in the MDM2 pseudo-substrate
motif stimulates its E3 ubiquitin ligase function. Purified wt-MDM2
(lanes 2–4) or MDM2S17D (lanes 5–7) were titrated directly into
ubiquitination reactions using p53 as a substrate. After 10 min, the
reactions were stopped and processed for immunoblotting to measure
extents of p53 ubiquitination, which is quantified in d. eMDM2-pseudo-
substrate motif deletion promotes thermoinstability in MDM2. Purified
wt-MDM2 or MDM2!LID was added directly to ubiquitination reactions
(lanes 1 and 7) or was preincubated at increasing temperatures (0–50°C)
in ubiquitination buffer (lanes 2–6 and 8–12) followed by titration in
ubiquitination reactions using p53 as a substrate. After 10 min, the
reactions were stopped and processed for immunoblotting to measure
extents of p53 ubiquitination. f S17D mutation in the MDM2 pseudo-
substrate motif does not destabilize MDM2. Purified MDM2S17D was
preincubated at increasing temperatures (0–50°C) in ubiquitination
buffer followed by titration in ubiquitination reactions using p53 as a
substrate. After 10 min, the reactions were stopped and processed for
immunoblotting to measure extents of p53 ubiquitination. g MDM2-
pseudo-substrate motif deletion promotes MDM2 instability in cells. P53
was co-transfected into cells with his-tagged ubiquitin and vector control
(lane 2) or increasing amounts of MDM2 (lanes 3–5) or MDM2!LID
(lanes 6–8). The reactions were processed to measure p53 ubiquitination
as indicated [39]
!
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hydrophobic pocket of MDM2, modeling data have shown
that if the phospho-mimetic lid does occlude the hydropho-
bic pocket, it does so only in the entry region of the N-
terminal p53 peptide [40]. Thus, we evaluated whether the
MDM2S17D has a higher or lower binding activity for the
p53 peptide itself derived from the BOX-I domain.
As seen with the full-length p53 tetramers, MDM2S17D
also binds more stably to the BOX-I peptides, relative to wt-
MDM2 (Fig. 6c and d). The BOX-I peptide “a” is the
naturally occurring peptide from p53, while BOX-I peptide
“b” is the optimized higher affinity peptide named 12.1
identified using combinatorial peptide libraries [4]. This
enhanced binding of MDM2S17D to the BOX-I peptide from
p53 again is not compatible with the model that the Asp17
pseudo-substrate motif is stabilized over the hydrophobic
pocket, and if this were the case, then MDM2S17D should
have a lower binding activity for the p53 BOX-I peptide. As
a control, MDM2!LID cannot form a stable complex with the
BOX-I peptide (Fig. 6c and d), although MDM2!LID can
form a stable complex with the ubiquitination signal within
the BOX-V peptide from p53 (Fig. 6f and g). These latter
data indicate that the integrity of the acidic domain of
MDM2 is maintained to a significant degree in MDM2!LID.
Furthermore, the MDM2S17D is also more active in binding
to the BOX-V peptide that wt-MDM2 (Fig. 6f and g), which
together explains in part why MDM2S17D binds better to the
p53 tetramer (Fig. 4b and c). These data also suggest that
conformational changes in the N-terminal hydrophobic
pocket of MDM2 as a result of the phospho-mimetic lid
mutation are transferred to the acidic domain of MDM2,
which is consistent with the dual-site model of MDM2-
mediated ubiquitination of p53.
A single missense mutation of the RING domain of
MDM2 changes the conformation of both the hydrophobic
pocket and the acidic domain [52]. We evaluated further
this intra/interdomain allosteric interaction in MDM2S17D
protein by examining its binding activity for BOX-I- and
BOX-V-derived p53 peptides in the absence and presence of
Nutlin. A Nutlin titration into reactions containing wt-
MDM2 or MDM2S17D indicated that Nutlin is able to
compete with MDM2 binding to the BOX-I-derived peptide
(Fig. 7b and c), as expected. However, quantitative differ-
ences are observed in this reaction. MDM2S17D protein is
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Fig. 4 A phospho-mimetic substitution in the MDM2 lid stabilizes
MDM2:p53 tetramer complex formation. a Strategy for measuring the
stability of the MDM2:p53 complex. Tetrameric forms of p53 protein
were adsorbed onto the solid phase (in red) followed by MDM2
titration (gray). The stability of MDM2 bound to p53 tetramers was
measured using a monoclonal antibody specific for MDM2 by
chemiluminescence. b The S17D mutation in the MDM2 pseudo-
substrate motif stabilizes the MDM2:p53 tetrameric complex. Increas-
ing amounts of the indicated MDM2 protein (wt-MDM2, MDM2!LID,
or MDM2S17D) were titrated into reactions where fixed amounts of
tetrameric p53 were on solid phase as described previously [38]. The
extent of MDM2 binding was quantified using an anti-MDM2
monoclonal antibody and binding stability depicted using enhanced
chemiluminescence in relative light units (RLU). c Elevated temper-
ature does not alter the activating effect of S17D mutation on MDM2:
p53 complex stability. MDM2 was preincubated at distinct temper-
atures, as indicated, and binding activity to the p53 tetramer was
measured as described above in RLU
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presence of Nutlin relative to wt-MDM2, consistent with
the model that the phospho-mimetic mutation opens the
hydrophobic pocket. Another prediction of this allosteric
model would be that Nutlin would alter the binding activity
of MDM2S17D to the BOX-V-domain-derived peptides. This
is observed experimentally; although the BOX-I peptide can
partially destabilize MDM2S17D:BOX-V peptide complexes
(Fig. 7e), Nutlin completely destabilizes this interaction
(Fig. 7f). The acute sensitivity of the MDM2:p53 tetrameric
complex to Nutlin (Fig. 5) can therefore be explained
because not only does Nutlin destabilize the MDM2:BOX-I
peptide complex by direct competition but it can also
destabilize the MDM2:BOX-V peptide complex by alloste-
ric effects as suggested previously [52].
Mutation of basic residues in the hydrophobic domain
is dominant over Asp17 and inactivates MDM2S17D
Together, the data allow the formation of a model, whereby
the Asp17 substitution does change the conformation of
MDM2 [25], but it does so by “opening” the hydrophobic
pocket. One model to explain why the phospho-mimetic
mutation in the MDM2 lid stabilizes MDM2:p53 interac-
tions is that the phospho-amino acid is stabilized by
interactions with a second binding site on MDM2 (as in
Fig. 2b, asterisks). NMR analysis shows that, in compar-
ison to the peptide bound form, the N-terminal domain of
apo-MDM2 is more unstructured and flexible, especially
the regions surrounding the peptide binding cleft [45]. The
unliganded structure shows a narrow, shallow binding
groove as a result of the closer association of the two sub-
domains. As suggested previously [25], some conformers
show MDM2 residues 18–24 can have helical character and
partially occlude the shallow end of the p53 binding cleft
(Fig. 8b). The remainder of the binding pocket, however, is
not occupied by the remainder of the pseudo-substrate
motif [25], and further, conformers show this region
unwound and more displaced from the binding pocket
(Fig. 2b, asterisks). This conformational heterogeneity of
the pseudo-substrate motif eludes to a dynamic equilibrium
between more structured conformations occupying part of
the binding groove and less ordered states removed from
binding pocket. The mutual occupancy of the p53 peptide








Fig. 5 Nutlin destabilizes the MDM2S17D:p53 tetramer complex. a
Strategy for measuring the stability of the MDM2:p53 complex in the
presence of small ligands. Tetrameric forms of p53 protein were
adsorbed onto the solid phase (in red) followed by MDM2 titration
(gray) in the absence or presence of the indicated inhibitors, including
(1) Nutlin-3, (2) BOX-Ia peptides, (3) BOX-Va or BOX-Vb peptides,
and (4) DMSO carrier. The stability of MDM2 bound to p53 tetramers
was measured using a monoclonal antibody specific for MDM2 by
chemiluminescence. b and c MDM2S17D binding to p53 is not
inhibited by Nutlin. MDM2 (b) or MDM2S17D (c) was assembled
into reactions containing the indicated ligand: BOX-I peptide, BOX-V
peptides, or Nutlin. The mixture was added to tetrameric p53 protein
on the solid phase, and the amount of MDM2 bound stably to p53 was
quantified using an MDM2 monoclonal antibody. The stability of the
MDM2:p53 complex is depicted in relative light units
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p53 would preferentially bind to the N-terminal domain of
MDM2 when the D17-pseudo-substrate domain was dis-
placed from the binding site (Fig. 8c and d).
The increased ligand binding activity of MDM2S17D
could thus be explained by the mutation causing a shift in
equilibrium toward a more open conformation primed for
peptide binding. In fact, the phospho-pseudo-substrate
motif peptide of MDM2S17D has a higher binding activity
for MDM2 compared to wild-type peptide [25], and the
phospho-mimetic mutation may preferentially bind to a
cationic region on the MDM2 surface. Inspection of the















































































































































Fig. 6 Phospho-mimetic substi-
tution in the MDM2 lid motif
enhances MDM2 binding activity
for BOX-I and BOX-V peptide
ligands. a The domain structure
of MDM2 minidomains, relative
to p53 minidomains containing
the BOX-I and BOX-V docking
regions is highlighted. The panel
highlights (a) an interaction be-
tween the N-terminal MDM2
domain (N) and the p53 BOX-I
motif (I) and (b) an interaction
between the acid domain of
MDM2 (AD) and the BOX-V
motif of p53 (V). b The assay
was designed to measure the
interaction between the N-
terminal domain of full-length
MDM2 and the BOX-I-derived
p53 peptide. c and d MDM2S17D
has an enhanced binding activity
for the BOX-I domain of p53.
wt-MDM2, MDM2!LID, or
MDM2S17D proteins were titrated
into reaction buffer and incubat-
ed onto the solid phase contain-
ing BOX-I a peptide (left panel)
and BOX-I b peptide (right
panel). The amount of MDM2
bound stably to the p53 peptides
was quantified using an MDM2
monoclonal antibody. The stabil-
ity of the MDM2:p53 complex is
depicted in relative light units.
e The assay was designed to
measure the interaction between
the central acidic domain of
full-length MDM2 and the BOX-
V-derived peptides. f and
g MDM2S17D has an enhanced
binding activity for the BOX-V
domain of p53. wt-MDM2,
MDM2!LID, or MDM2S17D
proteins were titrated into
reaction buffer and incubated
onto the solid phase containing
BOX-V a peptide (left panel) and
BOX-V b peptide (right panel).
The amount of MDM2 bound
stably to the p53 peptides was
quantified using an MDM2
monoclonal antibody. The
stability of the MDM2:p53
complex is depicted in relative
light units
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conformationally heterogeneous pseudo-substrate motif can
be in proximity to a positively charged region at the N-
terminal part of helix "2! composed of His96, Arg97, and
Lys98, which could complex acidic residues (Fig. 8c and d).
Binding of Asp17 to this positively charged region may help
stabilize the pseudo-substrate motif away from the binding
groove and shift the equilibrium toward a conformation
favorable for peptide binding by MDM2.
In regard to this equilibrium model, it is interesting to note
that the His96, Arg97, and Lys98 equivalent residues of
MDM4 are altered, thus removing a potentially cationic
interface (Fig. 9a). This might give clues to residues that
have co-evolved with the MDM2 pseudo-substrate motif,
which is also absent in MDM4. To disrupt this positively
charged patch (Fig. 9a), we created an MDM2 mutant which
contains the Arg97Lys98 mutated to the MDM4 equivalent of
Ser97Pro98 (Fig. 8a). MDM4 has been shown to have a
conserved structure with MDM2 and bind p53 peptides in
the same manner and with comparable affinities [34]. A
titration of the wt-MDM2 and MDM2R97S:K98P demonstrated
that the basic substitutions maintain an equivalent ability of
MDM2 to bind to tetrameric p53 (Fig. 8e), reduced
interactions with the p53 BOX-I peptide (Fig. 8f), and
maintain equivalent binding activity of MDM2 for the p53
BOX-V peptide (Fig. 8g). These data indicate that the
Ser97Pro98 substitutions do not disrupt fundamentally the
core folding of the hydrophobic domain, not the allosteric
interactions with the acidic domain of MDM2.
By contrast, the enhanced binding ofMDM2S17D to the p53
tetramer is completely eliminated in the MDM2S17D:R97S:K98P
triple mutant (Fig. 9c). Further, the MDM2S17D:R97S:K98P triple
mutant is unable to form a stable complex with the p53 BOX-I
peptide (Fig. 9d), but can still bind to the BOX-V peptide
(Fig. 9e). Thus, the R97S:K98P double mutations can convert
MDM2S17D protein from an activated to an inhibited form,
under conditions where the MDM2 R97S:K98P double
mutant remains active. This inactivated triple mutant is
consistent with the model that mutation of the basic patch
stabilizes the phospho-mimetic lid over the hydrophobic
pocket, which is not compatible with p53 binding (Fig. 9b).
MDM2 bound to BOXVb MDM2 bound to BOXVb
MDM2 bound to BOXIb MDM2 bound to BOXIb
a b c
d e f
Fig. 7 Nutlin destabilizes the MDM2:p53 BOX-I and BOX-V peptide
complex. a Strategy for measuring the stability of the MDM2:p53
BOX-I peptide complex in the presence of small ligands. The
biotinylated BOX-Ib peptide was adsorbed onto the streptavidin-
coated solid phase followed by wt-MDM2, MDM2!LID, or
MDM2S17D proteins titration in the absence or presence of the
indicated inhibitors, including b the BOX-Ib peptide and c Nutlin-3.
The stability of MDM2 bound to the BOX-I peptide was measured
using a monoclonal antibody specific for MDM2 by chemilumines-
cence and is depicted in relative light units. d Strategy for measuring
the stability of the MDM2:p53 BOX-V peptide complex in the
presence of small ligands. The biotinylated BOX-Vb peptide was
adsorbed onto the streptavidin-coated solid phase followed by wt-
MDM2, MDM2!LID, or MDM2S17D proteins titration in the absence
or presence of the indicated inhibitors, including e the BOX-Ib peptide
and f Nutlin-3. The stability of MDM2 bound to the BOX-V peptide
was measured using a monoclonal antibody specific for MDM2 by
chemiluminescence and is depicted in relative light units
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Discussion
MDM2 is a multidomain E3 RING-finger ubiquitin ligase and
represents a model protein with which to define mechanisms of
substrate ubiquitination. The recent dual-site model forMDM2-
mediated ubiquitination of p53 suggested an allosteric compo-
nent to the E3 ubiquitin ligase function, which invokes MDM2
docking to two distinct sites on p53: the BOX-I transactivation
domain and a conformationally flexible motif in the BOX-V
domain of p53. The allostery in the N-terminal domain that
operates toward the acidic domain [50] can be propagated
presumably via the striking conformational flexibility of the
N-terminal domain of MDM2 as defined by NMR [25, 37,
45]. The unexpected feature of the dual site model was that
the N-terminal hydrophobic pocket of MDM2 can act as an
allosteric ligand binding site and that ligands like Nutlin can
prime MDM2 and “activate” the E3 ubiquitin ligase function
of MDM2 [50]. The allosteric interactions have been further
linked to the RING domain, as certain mutation in the RING
can induce conformational changes in both the hydrophobic
pocket and the central acidic domain [52].
A novel model can be developed that incorporates the
various biochemical and biophysical studies of the flexible
N-terminal domain of MDM2 and which supports an
equilibrium model for pseudo-substrate motif function. As
originally suggested [25] and later confirmed in the NMR
structure of apo-MDM2 [40, 45], the N-terminal segment
of MDM2 can partially occlude the shallow end of the p53-
binding cleft (Fig. 8b); however, this motif is not well
structured, and the remainder of the binding pocket remains
empty, at least in the non-phosphorylated state. In this
conformation, Ile19 occupies much of the space taken up by
Pro27 of the p53 peptide chain [20] and as such excludes
the mutual occupancy of the pseudo-substrate motif and
p53. Interestingly, Ile19 is the only residue in the N-terminal
region that exhibits any significant interaction with the rest
of apo-MDM2 [45], forming hydrophobic contacts with
His96, Arg97, and Tyr100 in the N-terminal part of "2!. In
some NMR conformers, Ile19 is displaced from the site
occupied by Pro27, forming a more intimate association
with the N-terminal region of helix "2!. Based on this, we
have proposed that the pseudo-substrate motif exists in
dynamic equilibrium between states that are incompatible
with or compatible with p53 peptide binding; p53 can only
bind when the pseudo-substrate motif has dissociated from
the hydrophobic binding site. In favor of this equilibrium,
both NMR studies indicated several residues within the
pseudo-substrate domain and the region surrounding helix
"2! that behaved as though in slow conformational
exchange [25, 45]. Furthermore, it is interesting to note
that the shorter p53 peptide, lacking residues 27–29, which
share an overlapping binding site with the pseudo-substrate
motif, binds to MDM2 with a ten-fold higher affinity [37].
Thus, in order for p53 to bind to MDM2, the following
events need to occur possibly in a concerted fashion;
residues 19–25 forming the pseudo-substrate motif must
dissociate from one end of the groove and be replaced by
segments 27–29 of the incoming p53; the two MDM2
subdomains swing apart from one another by 3–4Å; during
the process of binding, strand #3! is formed, completing the
terminal (#1, #2, #3!) sheet that caps one end of the groove
and helps to hold the two subdomains in their new more
rigid conformation. However, deletion of the flexible lid
destabilizes the N-terminal domain of MDM2 (this study),
so this motif also has a positive role to play in the MDM2-
p53 interaction. In addition to these ordered and sequential
changes in MDM2-substrate binding, our current study
suggests an activating model for the function of the flexible
pseudo-substrate motif upon phosphorylation, which
enhances displacement of the pseudo-substrate domain by
altering its equilibrium, thus opening the groove to stabilize
p53-peptide binding to MDM2 (Fig. 10). This conforma-
tional change upon hydrophobic pocket occupation by its
ligand then appears to be propagated to the central acidic
domain of MDM2 that results in enhanced MDM2
interactions with p53 (Fig. 10).
MDM2 regulation in cis by a pseudo-substrate peptide
motif highlights the growing realization that many signal
transduction events are modulated by relatively small and
unstructured polypeptide motifs [27–29]. Although there
are many well-defined globular protein domains that form
folded independent compact structures, these globular
domains represent only a fraction of the cellular polypep-
tide sequence repertoire. The remaining peptide sequences
are intrinsically disordered and comprise linear motifs with
weaker binding kinetics. Thus, signal transduction among
many components interacting via linear peptide motifs with
weaker binding kinetics can provide specific and sensitive
regulation of cellular signal transduction processes. The
regulation of MDM2 by such a flexible motif highlights
how these motifs can impact signal transduction. Further
perturbations in these linear interaction motifs, for example
by covalent modifications like phosphorylation, have the
potential to drive signaling changes that mediate changes in
the protein–protein interaction dynamics central to signal
transduction. The ability of MDM2 to be modulated by a
flexible peptide motif opens the door to identify the
physiological signals that regulate this conformational
switch in MDM2 as well as potentially novel pathways
that respond to such an activated MDM2 conformation. For
example, if the MDM2-lid kinase were to be identified, it is
possible that this would promote p53 protein ubiquitination
and degradation in cells, and this lid-kinase pathway would
therefore function as a pro-oncogenic signal in cancers. By
contrast, protein phosphatases that antagonize this kinase
would be predicted to function as co-tumor suppressor of
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p53 function by attenuating MDM2-mediated ubiquitina-
tion of p53.
Conclusions: perspectives on potential drug leads
in the MDM2 pathway based on protein–protein
interactions in the ubiquitination system
The molecular and structural mechanisms of MDM3 E3-
RING domain-E2-mediated ubiquitination of p53 are only
beginning to be defined. Complex and dynamic protein–
protein interactions can be anticipated a priori. These include
firstly the allosteric intradomain interactions in MDM2 itself,
for example, highlighted by the fact that the RING domain
plays a role in regulating the conformation of the N-terminal
hydrophobic domain and the acidic domain [52]. It is striking
that specific mutations in the RING domain appear to open
the conformation of the acidic domain of MDM2 based on
elevated intrinsic tryptophan fluorescence. This suggests that
ligands that bind to the RING domain (like RNA, ATP, and
E2 ubiquitin–conjugating protein) would regulate the inter-
conversion between open and closed conformations of
MDM2 within the acidic domain. This might in turn modify
the type of small molecules acquired in screens for ligands
that bind to the acidic domain of MDM2 and inhibit p53
ubiquitination, i.e., reconstitution of the complete E2–E3–
p53 tetramer ubiquitination reaction using highly purified
proteins and with specific RING-domain co-factors will
likely affect the dynamics of the acidic domain conformation.
The ability of the phospho-mimetic MDM2 lid to stabilize
the MDM2:BOX-V peptide interaction (Fig. 10) further puts
focus on the acidic domain as a key site for developing small
ligands that disrupt MDM2 ubiquitination of p53.
The second protein–protein interaction to consider is the
undefined effect of E3-RING domain on the E2-mediated
enzymatic transfer of ubiquitin to the p53 substrate. Small
molecule first generation leads have already been identified
that disrupt substrate ubiquitination possibly by effecting E2
activity as well as E3 functions [54]. We do not know how E2
protein conformation is altered by E3-RING domain binding
and in turn how ligand binding at the RING domain of
MDM2 would alter the catalytic function of the E2 proteins.
The definition of E2–E3 interfaces using purified minido-
mains and then using the reconstituted ubiquitination system
would likely shed light on novel allosteric stages in this
multicomponent ubiquitination reaction. The third protein–
protein dynamic is the fact that the p53 protein is tetrameric,
and although it has at least two main binding sites for
MDM2, it is not clear how quaternary structure of p53
contributes to the valency of the MDM2:p53 interaction and
in turn what changes occur in p53 tetramers that allow E2-
dependent ubiquitination transfer to p53.
Although the N-terminal hydrophobic pocket of MDM2 is
a drug binding site, drug occupation at this site does not
inhibit p53 ubiquitination due to the allosteric nature of the
E3 ubiquitin ligase function of MDM2. However, the three
scenarios reviewed above provide biochemical approaches
with which to develop peptide-mimetic leads for disrupting
protein–protein interactions in the p53 substrate–E3–E2
enzymatic ubiquitination system. Additionally, if phosphor-
ylation in vivo of the MDM2 lid will be proven to stabilize
the interaction between the acidic domain of MDM2 and the
BOX-V peptide in the p53 DNA-binding domain, this would
drive p53 protein ubiquitination and degradation in cells.
The lid-kinase pathway itself would in turn provide a novel
approach for developing drug leads that attenuate MDM2-
mediated ubiquitination and degradation of p53 protein.
Fig. 8 A model of lid function through stabilization of the phospho-
mimetic motif on the surface of MDM2. a Multiple sequence
alignment of MDM2 and MDM4 highlighting the evolutionary
divergence between MDM2 and MDM4 at the potential pseudo-
substrate motif basic docking site for acidic residues (i.e., Asp,
phosphate) at amino acid residues 97–98. b The C-terminal region of
the pseudo-substrate domain (residues 18–24; colored yellow) can
have helical character and occupy the shallow end of the hydrophobic
binding pocket as reported previously [25]. The p53 peptide from
PDB structure 1YCR [20] is shown for comparison (colored orange).
The N-terminal p53 peptide sequence and the lid cannot occupy the
hydrophobic pocket simultaneously. c The pseudo-substrate motif can
also exist displaced from the binding pocket with Ser17 (S17D
mutation shown for illustration) in proximity to a basic region (see
d) at the N-terminal of helix "2! composed of Arg97/Lys98. Based on
this, it is postulated that the S17D (mimicking phosphorylation of
Ser17) mutation could stabilize the N-terminal domain of MDM2 in a
conformation primed for p53 binding by forming electrostatic
interactions with residues Arg97/Lys98. e–g Effects of Arg97/Lys98
mutation on wild-type MDM2 activity. e MDM2 codon 97–98 residue
mutation to the MDM4 equivalent does not destabilize the MDM2:
p53 tetramer complex. Increasing amounts of the indicated MDM2
protein (wt-MDM2 or MDM2R97S:K98P) were titrated into reactions
where fixed amounts of tetrameric p53 were on solid phase as
described previously above. The extent of MDM2 binding was
quantified using an anti-MDM2 monoclonal antibody and binding
stability depicted using enhanced chemiluminescence in relative light
units (RLU). f The effects of MDM2 codon 97–98 residue mutation to
the MDM4 equivalent on MDM2:BOX-I peptide complex stability.
Increasing amounts of MDM2 protein (wt-MDM2 or the double mutant
MDM2R97S:K98P) were titrated into reactions with fixed amounts of the
BOX-I peptide on solid phase, as described previously above. The
extent of MDM2 binding was quantified using an anti-MDM2
monoclonal antibody and binding stability depicted using enhanced
chemiluminescence in relative light units (RLU). g The effects of
MDM2 codon 97–98 residue mutation to the MDM4 equivalent
on MDM2:BOX-V peptide complex stability. Increasing amounts of
MDM2 protein (wt-MDM2 or the double mutant MDM2R97S:K98P) were
titrated into reactions with fixed amounts of the BOX-V peptide on solid
phase, as described previously above. The extent of MDM2 binding
was quantified using an anti-MDM2 monoclonal antibody and binding
stability depicted using enhanced chemiluminescence in relative light
units (RLU)
b
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Materials and methods
Plasmids and site-directed mutagenesis
MDM2WT and MDM2!Lid were cloned into the Invitrogen
Gateway system entry vector pDONR221 (Invitrogen)
using the following primers: full-length MDM2 Fwd 5!-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGA
AGGAGATAGAACCAT GTGCAATACCAACATGT
CTGTACCTACT-3! and Rev 5!-GGGGACCACTTTGTA
CAAGAAAGCTGGGTCCTAGGGGAAATAAGTTAG
CACAATCAT-3!: lid deletion MDM2 Fwd 5!- GGGGACA
AGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATA
GAACCATGACCCTGGTTAGACCAAAGCCATTGCTT-
3! and Rev—same as full length MDM2. This vector was
used as a template to perform site-directed mutagenesis
using the in vitro mutagenesis system QuikChange
(Stratagene) as directed by the manufacturer. MDM2
serine 17 was mutated to an aspartic acid using the
following primers (bases which introduce amino acid
change are in bold): amino acid 17 S>D Fwd 5!-
GGTGCTGTAACCACCGACCAGATTCCAGCTTCG-3!
and Rev 5!CGAAGCTGGA ATCTGGTCGGTGGTTA-
CAGCACC-3!. For native expression of protein in Escher-
ichia coli, pDONR221-MDM2 vectors were recombined with
the pDEST14 vector (Invitrogen) as recommended by the
manufacturer. For expression in mammalian cells, the
pDONR-MDM2 vectors were recombined with the
pDEST3.2 vector (Invitrogen). pDONR221-MDM2 was used
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EcoR1 and Xho1 restriction sites. EcoR1 Fwd primer 5!-
GCCTCGAATTCATGACCCTGGTTAGAC CAAAGC-
CATTGCTT-3 ! and Xho1 Rev 5 ! - GCCTCGA
GCTCCTAGGGGAAATAAGTTAGCACAATCAT-3!.
pCDNA3.1 full length MDM2 was subjected to site-directed
mutagenesis as described before to introduce mutation at
serine 17 (S>D).
Protein expression and purification
pDEST14-MDM2 constructs were overexpressed in BL-21
arabinose-inducible E. coli for 3 h at room temperature.
Cells were harvested by centrifugation at 6,000!g for
10 min and frozen in liquid nitrogen. Bacterial pellet was
lysed in 10% sucrose, 50 mM Tris–HCl (pH8), 150 mM
NaCl, and 150$g/ml lysozyme and left on ice for 45 min
before sonication. After sonication, 2 mM Pefabloc, 5 mM
DTT, and 1 mM benzamidine was added to lysate before
centrifugation at 30,000!g for 20 min. Lysate was loaded
onto a fast flow SP column (GE Healthcare) equilibrated
with buffer A (25 mM Hepes, pH7.5, 10% glycerol, 1 mM
benzamidine, 5 mM DTT, 50 mM KCl, and 2 mM
Pefabloc). Bound protein was eluted with increasing salt
concentration using buffer B (same as buffer A but 1M
KCl) and MDM2 function measured in E3 ubiquitin ligase
assays.
MDM2-peptide and p53 protein binding activity assays
Recombinant human MDM2 protein, ubiquitination assays,
and p53 protein binding assays were developed as
described previously [38, 50]. For p53-peptide binding
assays, the plate was adsorbed with streptavidin overnight
and washed six times with PBS-T, and biotinylated peptides
were added for 1 h followed by titrating increasing amounts
of MDM2 (from 3 to 200 ng). Following further washes for
six times with PBS-T, wells were incubated with secondary
rabbit anti-mouse horseradish peroxidase antibodies fol-
lowed by further washing and ECL. The results were
quantified using Fluoroskan Ascent FL equipment (Lab-
systems) and analyzed with Ascent Software version 2.4.1
(Labsystems). Peptides BOXIa, BOXIb, BOXVa, and
BOXVb were from Chiron Mimetopes and Nutlin3a from
Alexis Biochemicals. Peptide sequences are as follows:




In vitro ubiquitination assay
Reactions contained 25 mM HEPES (pH8.0), 10 mM
MgCl2, 4 mM ATP, 0.5 mM DTT, 0.05% (v/v) Triton X-
Fig. 8 (continued)
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100, 0.25 mM benzamidine, 10 mM creatine phosphate,
3.5 units/ml creatine kinase, ubiquitin (2$g), E1 (100 nM),
E2 (1$M), and p53 (0.5$g). Reactions were assembled on
ice by adding, last, purified MDM2, MDM2!lid, or
MDM2S17D at various concentrations (3–200 ng), followed
by incubations for 15 min at 30°C, and analyzed with 4–
12% NuPAGE gels in a MOPS buffer system (Invitrogen)
followed by immunoblot. For temperature gradient, MDM2
was subjected to heat treatment for 5 min prior to addition
to ubiquitination reaction.
Cell culture and purification of his-ubiquitin conjugates
H1299 cells were grown at 37°C in RPMI with 10% FBS and
5%CO2. p53
!/!MDM2!/! mouse embryonic fibroblasts were






Fig. 9 Inactivation of MDM2S17D by mutation of surface basic residues
of MDM2. a Electrostatic potential mapped onto the solvent accessible
surface. Positive- and negative-charged regions colored blue and red,
respectively. Alignment figure generated with ESPript [14]. Structural
figures generated with PyMol (www.pymol.org). The electrostatic
calculations were performed with APBS [3] and highlighted is (left)
wild-type MDM2 and (right) MDM2 with R97/K98 residues substituted
with the S97/P98 MDM4 residues. bWhen the basic patch on MDM2 is
mutated to Ser97/Pro98, the phospho-mimetic pseudo-substrate motif
may bind other basic regions of the MDM2 surface such as Lys94/His96,
which line the hydrophobic binding pocket and explain why the MDM2
triple mutant (MDM2S17D:R97S:K98P) binds p53 with a substantially
lower activity than does the MDM2 double mutant (MDM2R97S:K98P;
see c–e). c MDM2 codon 97–98 residue mutation to the MDM4
equivalent inactivates MDM2S17D as a p53 binding protein. Increasing
amounts of the indicated MDM2 protein (MDM2S17D or the triple
mutant MDM2S17D:R97S:K98P) were titrated into reactions where fixed
amounts of tetrameric p53 were on solid phase as described previously
above. The extent of MDM2 binding was quantified using an anti-
MDM2 monoclonal antibody and binding stability depicted using
enhanced chemiluminescence in relative light units (RLU). d The effects
of MDM2 codon 97–98 residue mutation to the MDM4 equivalent on
MDM2S17D:BOX-I peptide complex stability. Increasing amounts of
MDM2 protein (MDM2S17D or the triple mutant MDM2S17D:R97S:K98P)
were titrated into reactions with fixed amounts of the BOX-I peptide on
solid phase, as described previously above. The extent of MDM2
binding was quantified using an anti-MDM2 monoclonal antibody and
binding stability depicted using enhanced chemiluminescence in relative
light units (RLU). e The effects of MDM2 codon 97–98 residue
mutation to the MDM4 equivalent on MDM2S17D:BOX-V peptide
complex stability. Increasing amounts of MDM2 protein (MDM2S17D or
the triple mutant MDM2S17D:R97S:K98P) were titrated into reactions with
fixed amounts of the BOX-V peptide on solid phase, as described
previously above. The extent of MDM2 binding was quantified using an
anti-MDM2 monoclonal antibody and binding stability depicted using
enhanced chemiluminescence in relative light units (RLU)
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Transient transfections were carried out as described [10].
Cells were lysed in NP40 buffer (25 mM HEPES, pH7.5,
0.1% NP40, 150 mM KCl, 5 mM DTT, and 50 mM NaF)
and analyzed by 4–12% NuPAGE/immunoblot. His-ubiquitin
conjugates were purified as previously described [53].
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